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One in three men and one in four women will develop cancer prior to 75 years of age,1 
as will one in every four dogs during its lifetime.2 It goes without saying that cancer is 
an important cause of death. Indeed, cancer kills 31.5% of men and 23.6% of women in 
Flanders,1 whereas nearly half of pet dogs over the age of 10 die from the consequences 
of cancer.2  
Not only does cancer have a great social and emotional impact on patients and their 
environment, it also has a substantial financial impact on society. In 2006, the Belgian 
Health Fund reimbursed a total of 336 million euro for cancer, which is without doubt 
a considerable underestimation of the actual cost.1 
 
Surgery, chemo- and radiotherapy are the current standard cancer treatment options in 
human and canine patients.3 Yet often a small amount of cancer cells persists after 
therapy, causing relapse. This instigated the search for treatment options that 
complement standard therapies. Several alternative treatments have seen the light of 
day, e.g. hormone or endocrine therapy,1 hyperthermia, photodynamic therapy, 
targeted therapy and immunotherapy.4 Of these new avenues of research, especially 
immunotherapy has shown to be very promising in prevention of cancer recurrence.  
Antitumoral immunotherapy is a therapeutic treatment option that stimulates the 
immune system of the cancer-bearing patient against the patient’s cancer cells. 
Successes in immunotherapy for humans include among others increase in survival 
demonstrated by sipuleucel-T for prostate cancer,5 ipilimumab for melanoma6 and 
regression of high-grade premalignant lesions of the vulva through the therapeutic 
HPV16-vaccine.7 Cancer immunotherapy has also been successfully applied in 
veterinary medicine. For cancer-bearing dogs, novel immunotherapeutics such as a 
melanoma vaccine (Oncept®) and a monocloncal antibody against canine B-cell 
lymphoma (AT-004) and T-cell lymphoma (AT-005) were developed.  
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1 Cancer animal models in the search for novel therapeutic 
alternatives 
Mouse cancer models are a standard research tool for cancer in human cancer patients 
and offer a well-known platform to perform basic tests to evaluate the toxicity, potency 
and therapeutic efficacy of antitumoral drugs.8 Their popularity is due to the various 
facilities available for research in mice. For example, many research tools are accessible 
for mice; the inbred mouse strains offer high standardization of experiment design as 
well as the ability to grow tumors from cancer cells derived from mice of the same 
strain. Furthermore, mice are easy to house as they do not require much space, food or 
maintenance. However, the translation of cancer research from mouse to man is far 
from optimal. Only one-third of highly cited animal research enters into clinical trials.9, 
10 Despite successful pre-clinical testing in rodent models, 85% of early clinical trials for 
novel drugs fail. The largest proportion of these failures occurs in trials for cancer 
drugs.11 
It was postulated that most of the cancer vaccine trials in humans have failed due to 
elevated levels of circulating immunosuppressive cytokines and various immunological 
checkpoints in humans that may not be present in rodents.12 Furthermore, it is true that 
human and mouse immune systems differ in the properties of both innate and adaptive 
immunity. These include discrepancies in leukocyte subsets, Toll-like receptors, natural 
killer (NK) cell inhibitory and activating receptors, Fc-receptors (FcR), 
immunoglobulin (Ig) subsets, some B cell and T cell signaling pathway components, γδ 
T cells, cytokines and cytokine receptors, Th1/Th2 differentiation, stimulatory 
molecule expression and function, antigen-presenting function of endothelial cells as 
well as in chemokine and chemokine receptor expression.13 Moreover, in most of the 
rodent models, tumors are either artificially induced through injection of chemicals or 
through inoculation of a great number of cultured cancer cells, whereas tumor 
formation in humans is a long and complex process. Inbred rodents are not fully 
immune competent and therefore the complexity of spontaneously arising tumors in 
humans cannot be approximated with these models. Indeed, due to inherent differences 
in cancer development between rodent cancer models and human patients, rodent 
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models fail to faithfully mirror the extremely complex process of human 
carcinogenesis.10 Consequently, rodent models result in a very low predictive power for 
antitumoral treatment efficacy in humans. 14, 15, 16 This leads to poorly efficient and 
expensive human phase I trials, prompting the need for an alternative intermediate 
animal model for human oncology patients. It is therefore recommended that 
therapeutic agents should be further evaluated in higher animal species after initial 
evaluation and positive results in rodents.8 In addition, experiments should be designed 
in both genders and in different age groups of animals.17 Since 1976,18 diverse clinical 
trials have been conducted in dogs with spontaneous cancer and complemented the 
information obtained from more traditional research tools as murine cancer models 
and human clinical trials. Canine clinical trials have enabled researchers to collect 
information that would otherwise have been difficult or impossible to gather in either 
mice or humans alone.19 There are obvious biological, practical and regulatory 
arguments for the use of spontaneous tumors in pet dogs as intermediate model in 
human cancer research. 
 
From a biological point of view, canine clinical trials offer many advantages for human 
cancer research. Not only do dogs develop tumors in a syngeneic environment and in 
the presence of an intact immune system, they also share a similar histologic, biologic, 
and genetic cancer background significantly closer than the relationship between 
mouse and man.20 In more detail, since cancer in dogs occurs naturally, a similar 
development and interaction between tumor, host and tumor microenvironment as in 
humans is evident.19 For example, the spectrum of canine cancer is as diverse as in 
human patients and its initiation and progression are influenced by similar factors 
including age, nutrition, sex, reproductive status and environmental exposures.21, 22, 23  
Histological analogy was found to be present in melanoma, non-Hodgkin lymphoma, 
leukaemia, osteosarcoma, soft tissue sarcomas, and prostate, mammary, lung, head and 
neck, and bladder carcinomas.19 Moreover, the intratumoral (cell-to-cell) heterogeneity 
in these cancers result in the same deadly features of human cancers (including 
acquired resistance to therapy, recurrence and metastasis).19 Likewise, responses to 
treatment in dogs are analogous to men.19 Furthermore, genetic molecular alterations 
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that drive cancers in dogs and humans are nearly identical.20, 19 This is especially true 
for lymphoma, osteosarcoma, melanoma, glioma and soft tissue sarcoma.19, 24, 25 These 
findings were possible through advances in technology and the release of a high-quality 
sequence covering 99% of the canine genome enabling the application of the same high-
throughput methodologies in dogs that are used to examine human cancer.20  
Although it has been argued that dog populations are more inbred than men, it has 
been demonstrated that the genetic diversity in both populations for a certain tumor 
type are similar.14 
 
From a practical point of view, similar diagnosis and treatment options are available for 
dogs and humans. Indeed, adequate body size allows surgical interventions, medical 
imaging and tissue/blood sampling much like in human patients.15, 24 The scientific 
climate today is very favorable for canine clinical trials with rapidly increasing species-
specific research tools15,, 24, 26 and veterinary infrastructure that meets the standards of 
good clinical practice.26 
Trials in pet dogs also prove to be time-efficient. Some tumor types (e.g. osteosarcoma 
and brain tumors) occur much more in dogs than in humans. The higher the 
occurrence of certain tumor types, the more patients with these tumor types can be 
recruited for clinical trials and the faster this will lead to results. Furthermore, 
progression of cancer in companion animals is, on the one hand, slow enough to be 
able to compare responses to therapies and, on the other hand, fast enough to obtain 
results within a reasonable period of time.15, 24 Since overall survival is the golden 
standard in evaluation of immunotherapeutic trials, the compressed course of cancer 
progression in pet dogs allows an effective and timely assessment of new cancer 
therapies.19, 27 Indeed, whereas the assessment of disease-free interval or survival in 
human clinical trials usually takes several years, getting similar information from 
clinical trials in dogs generally takes much less time, just a few months in some cases.28 
These factors increase the feasibility of conducting clinical trials with sufficient 
statistical power.24, 25 Moreover, the associated costs are lower than in human clinical 
trials.24, 27  
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The advantages of trials in pet dogs are not limited to cancer-bearing human patients. 
For the time being, the treatment options in veterinary oncology are limited. Pet dog 
owners seek the best possible care and are open to participation in clinical trials. Their 
contribution to the benefit of veterinary and human medicine is generally considered as 
positive. For these reasons, compliance with treatment, control visits and autopsy are 
exceptional.24 
 
From a regulatory point of view, pet dogs have a broader access to clinical trials than 
humans. In human medicine, access to clinical trials is restricted to those refractory to 
standard treatment options. In veterinary medicine, this is not the case and any patient 
can participate as long as this is based on an informed owner’s consent, approved by an 
ethical and deontological committee. This allows for evaluation of new therapeutic 
approaches in early stages of disease and in the setting of minimal residual disease after, 
for example, surgery or chemotherapy.24 Research translation can be facilitated through 
collaboration between veterinary and human medicine and thus expensive phase I trials 
in humans optimized or even avoided. As a result, the present scientific and public 
climate is very favorable for implementing clinical trials with dogs as treatment models 
for humans. Close collaboration between veterinary and human clinical trials has led in 
the past to the development of a vaccine comprising of an adenoviral vector targeted to 
dendritic cells (DCs),29 novel limb-sparing techniques in patients with osteosarcoma,19 
inhaled cytokine immunotherapy approaches in treatment of human patients with 
pulmonary metastases19 and a DNA vaccine for melanoma in dogs (Oncept®), whose 
efficacy and safety led to ongoing clinical trials in patients with melanoma.28 
Not only can pet dogs with spontaneous tumors aid in the development of new cancer 
therapeutics, they can also contribute to the study of environmental risk factors, as well 
as cancer biology, cancer progression and identification of cancer-associated genes.19  
 
Future clinical studies in pet dogs are facilitated thanks to the completion of the canine 
genome, development of reagents for immunologic tests and flow cytometry and 
consortia such as LUPA (a European initiative taking advantage of the canine genome 
architecture for unravelling complex disorders in both human and dog), the US 
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National Cancer Institute’s Center for Cancer Research’s Comparative Oncology 
Program,30 Zoobiquity‘s integrated and interdisciplinary approach to physical and 
behavioral health31 and the Comparative Oncology Trials Consortium.32  
2 Interactions between the immune system and cancer 
A link between the immune system and cancer was observed by William Coley in 1890. 
He observed a significant reduction in tumor growth in cancer-bearing people 
diagnosed with erysipelas, a bacterial skin infection. Intrigued by this finding, Coley 
initiated the first immunotherapy trial in cancer-bearing patients by injecting live 
bacteria into the patient’s tumor. Although a reduction in tumor size was apparent, 
fatal sepsis occurred in a number of patients.33 Meanwhile chemo- and radiotherapy 
were introduced and the concept that the immune system has powerful antitumoral 
properties was unfortunately neglected for 80 years. In 1970, Bacillus Calmette-Guerin 
(BCG), an attenuated bacterium, proved to be an efficacious treatment option for 
bladder cancer.34 In 1990, this treatment received an approval from the Food and Drug 
Administration (FDA) as a first-line therapy for superficial bladder cancer and it is still 
used today for the same indications.35 Due to the narrow application possibilities of 
BCG-treatment (mainly suitable for superficial tumor types such as superficial bladder 
cancer), the research in cancer immunotherapy further concentrated on target-based 
therapy, may it be tumor-associated antigens or checkpoint inhibitors. This has led to 
FDA-approved immunotherapeutics such as Sipuleucel-T®, a dendritic cell-based 
cancer vaccine and Aldesleukin®, an interleukin-2 therapy for renal cancer.36 
 
It is clear that the immune system is very closely involved in cancer development and 
plays a dual role. On the one hand, it can suppress tumor growth by killing cancer cells 
or inhibiting further expansion. On the other hand, it provides selective pressure by 
killing the cancer cells that are sensitive to the antitumoral immune response, thereby 
selecting for immune-resistant cancer cells. In addition, the immune system can 
facilitate conditions within the tumor microenvironment favorable for tumor 
outgrowth.37 Whereas foreign organisms such as viruses and bacteria are easily 
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recognized by the immune system as foreign and induce a quick immune response, this 
is not the case for cancer cells, as they greatly resemble normal body cells. Thus, cancer 
cells can profit from this similarity to multiply as the immune system has no incentive 
for killing its own body cells. Since cancer cells greatly resemble normal body cells at 
the start of their development, which do not initiate an immune response due to self-
tolerance, the tumor is initially invisible to the immune system. Yet, the more the 
cancer cells evolve into malignant cells, the more tumor-associated antigens are present 
and the more they become recognizable to the immune system.37 Unfortunately, as 
cancer cells evolve, they also acquire immunoevasive mechanisms. Some of these 
mechanisms include hiding antigens necessary to initiate an immune response or 
secretion or presentation of immunosuppressive proteins that will neutralize the 
antitumoral efforts of the immune system. As a result, an uninhibited growth of these 
malignant cells ensues. The gradual interaction between the immune system and cancer 
cells is hypothesized to occur in three phases: immunosurveillance, immunoediting and 
immunoescape.37   
2.1 Immunosurveillance 
The ability of the immune system to discriminate between cancer cells and normal cells 
is referred to as tumor immunosurveillance.37, 38 Indeed, cancer cells express antigens 
that differentiate them from their nontransformed counterparts, leading to their 
elimination by both the innate and the adaptive immune system.37 Initially, in the stage 
of immunosurveillance, the immune system will efficiently recognize and kill aberrant 
cells.  
The existence of immunosurveillance was first demonstrated when mice, immunized 
with chemically induced tumors, were protected against a subsequent rechallenge with 
the same tumor.39 Nowadays this finding is supported by strong evidence, in both 
animal cancer and in human’s.37, 38 Chen and colleagues40 proposed a step-by-step cycle 
of the generation of immunity to cancer. This whole step-by-step cycle can be divided 
into seven major steps: (1) release of antigens from the cancer cell, (2) cancer antigen 
presentation, (3) priming and activation of T cells, (4) trafficking of T cells to tumors, 
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(5) infiltration of T cells into tumors, (6) recognition of cancer cells by T cells and (7) 
killing of cancer cells.40 Normally, a legitimate stimulus for the immune system is self-
propagating at each step of the step-by-step cycle and leads to a broad T cell response. 
2.2 Immunoediting 
Swann and colleagues41 hypothesized that, if the initial elimination of cancer cells by 
host immunity is not complete, cancer cells accumulate different genomic mutations 
and become more immune-resistant. Tumoral variants are selected after the cancer 
cells that were easily recognizable to the immune system have been eliminated. Such 
variant cancer cells are able to avoid or suppress the immunogical response and 
constitute the edited cancer.38 Although host immunity cannot completely control these 
variant cancer cells, the adaptive immune system will have enough influence on the 
cancer cells to achieve a steady state situation. Thus, a type of tumor dormancy is 
evoked during the immunoediting phase.37 However, for each step of the step-by-step 
cycle of the generation of immunity to cancer, cancer cells or tumor 
microenvironmental factors can develop inhibitory factors. These inhibitory factors are 
able to halt the development or limit the antitumoral immune response and lead to 
tumor escape.40  
2.3 Immunoescape 
Through continuous adaptation of cancer cells in response to the immune system or 
due to immune system deterioration, cancer cells become invisible to the immune 
system and are able to escape its control. These events finally tip the balance in favor of 
tumor growth and spread. In more detail, immunoevasion is mainly accomplished 
through lack of antigen presentation and creation of an immunosuppressive 
microenvironment (through production of immunosuppressive cytokines or 
recruitment of immunosuppressive regulatory immune cells).42 Tumors can thus create 
a tolerogenic environment which spreads to draining lymph nodes (LN) and can 
enhance regulatory T cell (Treg) activity. These immunoevasive mechanisms lead to the 
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clonal expansion of less immunogenic cancer cells (by loss of tumor antigen) and 
prevention of apoptosis of cancer cells.43 
3 Arms of the antitumor immune response  
Cancer can be targeted through various arms of the immune system. In the design of an 
antitumoral immunotherapeutic treatment, it is important to target specifically rather 
than induce overall non-specific activation of the immune system.40 However, it should 
be borne in mind that immunity results from a complex interplay between the innate 
(which is antigen-nonspecific) and the adaptive immune system (which is antigen-
specific).44 Furthermore, the antitumoral immune response can be abrogated by the 
immunosuppressive environment of the tumor. Therefore, the immunosuppressive 
tumor microenvironment should be tackled to allow for an effective antitumor 
response.45  
The three principal arms of the immune system; the innate immune system, the 
adaptive immune system and the immunosuppressive arm of the immune system will 
be discussed in general. Then, immunotherapeutic targets for each arm will be reviewed 
as well as their application in canine clinical trials. 
3.1 The adaptive arm of the antitumoral immune response 
When the immune system is exposed to certain pathogens, it develops an immune 
protection against them. It is well-known that foreign entities such as viral or bacterial 
material are easily recognized by the immune system, resulting in their eradication. 
Alike, rodent models immunized with irradiated cancer cells were found to be able to 
resist tumor challenge when challenged with live cancer cells. This discovery led to the 
finding that cancer cells can also express antigens unknown to the host, that can be 
recognized by the immune system.46 However, since cancer cells can also overexpress 
self-antigens, antitumoral immunotherapy delicately balances between non-self 
recognition and prevention of autoimmunity.40 In general, the patient must be 
immunosufficient to elicit an effective antitumoral immune response.47 
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3.1.1 The general principle of adaptive antitumoral immune responses 
The first step in the adaptive antitumor cellular immune response is the recognition 
and capture of tumor antigens by immature DCs (iDCs). The DCs subsequently 
degrade and cleave the tumor antigens into peptides, which are processed into the 
MHC class I or II pathways to be (cross-) presented on their cell surface. When a 
damage-associated molecular pattern (DAMP) or a pathogen-associated molecular 
pattern is present, the iDCs undergo maturation. This process is characterized by an 
increased secretion of cytokines, an increased expression of costimulatory molecules 
CD80 and CD86, as well as chemokine receptor 7 by the DCs, which induce their 
migration into the LN. When the antigen-loaded DC arrives in the LN, it undergoes an 
additional activation step called ‘licensing’, mediated either by direct interaction of 
CD40 on the DC with the CD40 ligand on the CD4+ T cell or by cytokines.48 Both 
CD4+ and CD8+ T cells require a minimal number of MHC–peptide T-cell receptor 
(TCR) interactions with the mature DCs (mDCs) to become activated49 and for optimal 
activation, interactions between additional ligands on the mDCs (4-1BBL, OX40L, 
ICOSL) and the respective receptors on the CD4+ and CD8+ T cells (4-1BB, OX40, 
ICOS) are required.  
The activation of CD4+ T cells is essential for many more features of the adaptive 
immunity besides activating and maintaining CD8+ T cells.50, 51, 52 Lack of properly 
activated DCs in the absence of CD4+ T cells can induce tolerance rather than 
activation of CD8+ T cells.53 Activated CD4+ T cells can develop into Th1 or Th2 cells, 
of which the former will produce cytokines to activate a Th1 response and the latter a 
Th2 response (generally characterized by a mainly pro-inflammatory and cellular 
immune response versus an anti-inflammatory and humoral response, respectively). 
CD4+ T cells also assist in the infiltration of CD8+ T cells in the tumoral mass. They 
recruit macrophages, granulocytes and NK cells to directly kill cancer cells and enhance 
angiogenesis. CD4+ T cells are additionally fundamental for the induction of long-term 
memory CD8+ T cells.54 Therefore, CD4+ T cells determine the nature of the immune 
response.49, 52, 55, 56  
The CD8+ T cell is crucial in the cellular immune response, particularly the CD8+ 
cytotoxic T lymphocyte (CTL).44 They provide the strongest antitumor immune 
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response by directly killing cancer cells that present peptide–MHC class I complexes. 
Interaction of CD80 or CD86 on the DC with CD28 on the CD8+ T cell causes 
activation of the CD8+ T cells, which results in IL-2 release and proliferation of T cells 
(Figure 1). 
 
FIGURE 1. Principle of the adaptive immune response. Adapted from Melero 2014 57 
DCs are not only critical for cellular responses but also have an important role in 
controlling humoral immunity. They do so both directly by interacting with B cells and 
indirectly by inducing the expansion and differentiation of CD4+ helper T cells.44 The 
humoral immune response is characterized by the production of antibodies by B 
lymphocytes. Antibodies bind onto the surface of a foreign antigen, marking it for 
other cells of the immune system. For instance, when NK cells recognize antibody-
coated cells, they will destroy these cells through antibody-dependent cell-mediated 
cytotoxicity (ADCC).58 Furthermore, the complement system consists of a collection of 
proteins capable of binding antibodies, whereafter these proteins initiate a proteolytic 
cascade. This cascade results in lysis of the antibody-bound cell. Moreover, antibodies 
are capable of blocking signal transfer of for instance growth factors.58 In turn, the lysis 
of cancer cells through ADCC and/or the complement system induces cancer cell 
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fragments and thus the release of tumor antigens, which can be presented by antigen-
presenting cells (APCs). B cells themselves can function as an APC and when activated, 
B cells produce cytokines that direct the differentiation of naive CD4+ T cells into 
effector CD4+ T cells.58  
3.1.2 Antitumoral application of the adaptive arm of the immune system 
via cancer vaccines 
The adaptive immune system is able to eliminate cancer cells. Cancer cells express new 
foreign antigens and/or overexpress self-antigens while the adaptive immune system is 
able to specifically target cancer cells. Considering the immune system can be taught to 
specifically recognize and eliminate foreign material through vaccination, cancer 
antigens can be assembled into a vaccine and used to immunize the patient against its 
own cancer cells. Most cancer vaccines so far are used as (experimental) therapeutic 
vaccines, although some are deployed prophylactically (e.g. HPV-vaccine Gardasil®). In 
many phase I/II studies, cancer vaccines have shown clinical benefit in all species, in 
particular extended overall or disease-free survival. In contrast, objective durable 
regressions of the type associated with targeted or immunomodulatory monoclonal 
antibody therapy or chimeric antigen receptor (CAR) adoptive T cell therapy were 
rarely seen.59 Although both active (cancer vaccines) and passive (adoptive T cell 
transfer) approaches have the ability to be extremely specific for an antigen of interest, 
one important difference is the inability of passive approaches to confer memory.60 
Cancer vaccines aim to reeducate the immune system to create an immune memory in 
order to prevent cancer recurrence.61, 62, 63, 64 In addition, cancer vaccines are currently 
the most efficient and cost-effective means of generating tumor specific immunity.65 
3.1.2.1 Cancer vaccine types 
All cancer vaccines deliver tumor antigens, but the form of the antigen can vary 
according to the cancer vaccine type. Antigens can be provided through (whole) cancer 
cell vaccines, genetic vaccines and peptide or protein vaccines.66 Whole cancer cell 
vaccines possess several advantages over the other cancer vaccine types. When cancer 
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cells are administered, all relevant antigens to evoke an antitumoral immune response 
are present. There is no need, in contrast to genetic vaccines or peptide and protein 
vaccines, to identify tumor antigens or to select immunodominant epitopes on the 
tumor antigens. The antigens present on the cancer cells in whole cancer cell vaccines 
are varied and evoke an MHC independent broad-ranged anticancer response. 
Furthermore, both CD8+ and CD4+ T cells will be stimulated, as the antigens provided 
by whole cancer cell vaccines contain epitopes for presentation to both cell types. This 
delivery method thus generates a varied and broad immune cell activation which 
greatly diminishes the chance of tumor escape. In contrast, non-mutated self-antigens 
have often been selected for peptide/protein or genetic vaccines. However, when self-
antigens are not mutated, they are likely to induce a less efficient antitumoral immune 
response. Indeed, there is a small chance that they will generate high-avidity clones and 
if memory T cells (Tmem) exist toward them, they will often include Tregs.44 
Autologous cancer cells will contain both non-mutated and unique mutated self-
antigens, thus maximizing the chance of immune recognition.66 In contrast, peptide 
and protein vaccines are more limited in their generation of broad antitumoral immune 
responses as their response is MHC-restricted and limited to the selected epitopes.66 For 
genetic vaccines, the antigens will mainly be channeled into the MHC class I 
presentation pathway, resulting in a less broad immune activation than whole cancer 
cell vaccines.67 However, recently DNA vaccines have been constructed that produce 
antigens that are secreted, thus being able to access the MHC II pathway.68 Whole 
cancer cell vaccines showed a higher objective clinical response rate than peptide, 
protein or genetic vaccines.66, 69, 70, 71
3.1.2.1.1 Peptide and protein cancer vaccines 
The successful induction of a T cell response requires stable presentation of T cell 
epitopes on MHC complexes. The antigen of interest can be introduced by vaccination 
with the whole protein, or with short or long synthetic peptides derived from this 
protein.72  
Cancer cells express peptide antigens recognized by CD8+ CTLs, which are typically 8-
10 amino acids long and are presented in association with MHC I. The peptides 
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recognized by CD4+ T cells are presented in association with MHC II and are usually 
longer (13-18 amino acids in length).73 Peptide vaccines have several benefits, including 
easy synthesis and administration, target specificity, convenient storage, their safety (as 
demonstrated in many trials) and effective induction of T cell responses.73 Although 
MHC-restriction of individual peptides limits their use to a subset of patients, it was 
observed that mixtures of a dozen of differently MHC-restricted peptides can induce 
immune responses in the 85% of patients with melanoma who express one or more of 
those MHC molecules.73 An increase of the antigen dosage directly correlated with 
immunological response rates and frequency of circulating, peptide-specific CD8+ T 
cells; however, plateau responses have been observed.72 Since most short peptide 
vaccines are injected in non-physiologically high amounts, they are likely to clog up the 
appropriate MHC class I molecules of non-professional APCs in the absence of 
costimulatory molecules.59 This interaction can result in tolerance toward the bound 
peptides.73, 59 Moreover, these short peptides have little or no tertiary structure and thus 
are subject to rapid degradation by tissue and serum peptidases. Furthermore, the 
stability of the peptide-MHC interaction on the DC is probably lower than the stability 
of processed whole protein and thus less likely immunogenic.73 Indeed, peptide cancer 
vaccines resulted in overall clinical response rates of only about 2.9%.62 Thus, these 
vaccines are not yet optimized and require more research on antigen and adjuvant 
improvement.73  
Whole tumor proteins are uptaken and processed by APCs into MHC-associated 
peptides. The advantage of vaccination with whole tumor proteins is not only that they 
could provide peptides for binding to a large array of MHC molecules (therefore 
available to virtually all patients) but also that no prior knowledge of T cell epitopes is 
required.72 However, a shortcoming with the use of protein-based therapeutic vaccines 
is that they mainly induce responses to dominant epitopes, resulting in a rather narrow 
T cell response.72 
A compromise between the advantages of peptide and protein vaccines is the use of 
longer peptides. Various studies suggested that longer peptides induce better CTL 
responses, presumably because they are more easily endocytosed, processed and 
presented by APCs than whole proteins.72 The advantage of using long synthetic 
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peptides is that they have the capacity to induce immune responses to subdominant 
epitopes, which are not induced when vaccinating with short peptides (covering exact 
epitopes) or with proteins. Indeed, T cells specific to subdominant epitopes also 
contribute in anti-tumor immune responses. Therefore, the broadest variety of T cell 
specificities and the best anti-tumor immunity is probably generated when vaccinating 
with a pool of long synthetic peptides covering the entire protein sequence.72 
3.1.2.1.2 Genetic vaccines 
Genetic vaccines utilize DNA (as plasmids (pDNA)) or RNA (as messenger RNA 
(mRNA)) to deliver an expression cassette carrying the coding region of the antigen(s) 
of choice in vivo. Cells that have uptaken the pDNA or mRNA translate the constructs 
into protein, which results in the production of the selected antigen.2, 74 Transfection 
can be mediated through simple injection of “naked” pDNA or mRNA, or its delivery 
enhanced through gene-gun delivery, electroporation or association with liposomes or 
other particles.74, 75 
DNA vaccines are bacterial plasmids constructed to express an encoded protein 
following in vivo administration and subsequent transfection of cells.75 DNA delivery 
vehicles contain a gene expression cassette usually controlled by a strong constitutive 
promoter. DNA inoculation must be followed by cell uptake and localization inside the 
cell nucleus to give rise to a transcriptionally active form.2 DNA vaccination elicits cell- 
and antibody-mediated responses to a variety of antigens. The amount of proteins 
expressed, its persistence and the kind of antigen presentation are key variables that 
determine the efficacy of the protection thus elicited.76 Overall, various studies have 
shown DNA vaccines to be safe, with fever and pain, redness, and swelling at the 
injection sites the most common adverse events reported.77 
Besides DNA, the naturally transient and cytosolically active mRNA is seen as a 
possibly safer and more potent alternative to DNA for gene vaccination.75 Similar to 
DNA vaccines, they are constructed to express an encoded protein following in vivo 
administration and subsequent transfection of cells.75 Self-replicating mRNA vaccines 
are potentially more potent than DNA vaccines because double-string (ds)RNA is 
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formed during mRNA replication which is very immunogenic as it resembles viral 
dsRNA.78 
Many advantages have been attributed to RNA vaccines compared to DNA vaccines. 
RNA vaccines elicit a transient effect, require only cytoplasmic expression (DNA needs 
to cross the cell and nucleus membrane to be functional) and there is no risk for 
genome integration. Yet the above-listed advantages are not black and white and mostly 
theoretical. DNA vaccines do not induce a life-long expression. Their effect is mostly 
transient as well, due to cell replication, loss or inactivation of the plasmid.79 
Integration of pDNA into the genome following intramuscular injection is at least three 
orders of magnitude below the spontaneous mutation rate. This suggests that the risk 
for mutation due to integration of plasmid DNA vaccines is negligible after 
intramuscular injection.80 Electroporation increases the risk for chromosomal 
integration, yet still at a lower rate than spontaneous mutations.81 Furthermore, while 
mRNA only needs to cross one cell membrane to be functional, pDNA-mediated 
protein expression greatly surpasses mRNA-mediated expression after 
electroporation.82 On the other hand, clear advantages of mRNA are that, unlike 
pDNA, RNA can be produced by a cell-free enzymatic transcription reaction, thus 
avoiding the use of micro-organisms or cultured cells in manufacturing, with associated 
quality and safety issues. This method enables simple downstream purification and very 
rapid and cost-effective manufacturing.75 
Although mRNA is known to be less stable than pDNA vaccines, lyophilization studies 
have shown that RNA vaccines are not less stable than conventional vaccines that 
require a cold chain to be effective. Therefore, mRNA can be produced in large 
amounts and with good manufacturing practice (GMP) quality, thus allowing further 
development of mRNA-based therapies.75 
As new cancer antigens come to the forefront with novel RNA encapsulation and 
targeting techniques, RNA vaccines may prove to be a vital, safe and robust method to 
initiate patient-specific anti-tumor efficacy.78 Replicon mRNA (self-amplifying mRNA) 
possibly fills the gap between RNA and DNA vaccine structures as it combines a 
prolonged expression and a better transfection efficiency.75 
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3.1.2.1.3 Dendritic cell vaccines 
DCs are rare leukocytes that are uniquely potent in their ability to present antigens to T 
cells and form a link between innate and adaptive immunity. These properties have 
prompted their application to therapeutic cancer vaccines.44, 83 DC vaccines consist of 
DCs loaded with tumor-specific antigens. This can be achieved either by culturing 
ex vivo autologous DCs with an adjuvant that induces DC maturation and the tumor-
specific antigen followed by injecting these cells back into the patient, or by inducing 
DCs to take up the tumor-specific antigen in vivo.44 DCs that are generated ex vivo by 
culturing haematopoietic progenitor cells or monocytes with cytokine combinations 
have been tested as therapeutic vaccines in canine and human cancer patients for more 
than a decade. These studies concluded that DC-based vaccines are safe and can induce 
the expansion of circulating CD4+ T cells and CD8+ T cells that are specific for tumor 
antigens.44, 83 However, apart from the results with sipuleucel-T (Provenge®), no 
successful phase III trial results have been reported for DC-based cancer vaccines.59  
3.1.2.1.4 Whole cancer cell vaccines  
The source and the characteristics of cancer cells will have an important impact on the 
efficacy of whole cancer cell vaccines. Additionally, whole cancer cell vaccines can be 
manufactured and administered in different ways, resulting in diverse effects on the 
immune response. In this section, we will discuss these aspects in more detail.  
CANCER CELL SOURCE FOR WHOLE CANCER CELL VACCINES  
For the preparation of whole cancer cell vaccines, cancer cells derived from cell lines or 
from primary tumors can be used.84 Furthermore, cancer cells can be provided by the 
patient (autologous) or by a donor (allogeneic).85  
In theory, primary cancer cells are preferred over tumor cell lines. The antigen 
spectrum of tumor cell lines can change after long-term culture86, 87, whereas primary 
cancer cells are counterselected by the immune system and potentially provide 
additional tumor antigens.87 However, in practice and depending on the tumor type, 
only a minority of primary cancer cells can be maintained in culture,88 limiting their use 
in whole cancer cell vaccines. Cancer stem cells (CSCs) are considered superior to the 
General Introduction 
20 
unselected cancer cells as an antigen source.84, 89 It has been hypothesized that CSCs 
drive both local cancer recurrence and systemic relapse, which makes specific targeting 
of CSCs very attractive.89 In experimental mice, CSC vaccines elicited humoral as well 
as cellular immune responses against CSCs90 resulting in an efficient protective 
anticancer immunity.89  
Autologous cancer cells are a better antigen source than allogeneic cells when only the 
raised anticancer immune response is taken into account.91 The autologous vaccine will 
contain unique tumor antigens encoded by gene mutations specific to that individual 
tumor. These antigens might be more immunogenic than commonly shared tumor 
antigens and result in stimulating effective and long-lasting anticancer responses in the 
canine and human patient.91 In contrast, the complexity of vaccine manufacturing for 
individual patients (such as the need for a sufficient amount of cancer cells, the 
collection of these cells, problems concerning standardization, quality control) and its 
usefulness limited to a single patient has led to the use of allogeneic cancer cells.66 The 
development of cancer vaccines based on allogeneic cancer cells is possible through the 
use of cell lines, which are preferred over allogeneic primary cells as they harbor most 
of the same production complexities as autologous primary cells. These cell lines are 
selected to provide a limitless source of multiple tumor-specific antigens and a broad 
range of MHC expression.56 Allogeneic vaccines can, however, only achieve clinical 
effectiveness if they adequately represent the characteristic tumor antigens of the 
patient’s cancer cells.70 Alas, allogeneic cancer cells will seldom contain the same tumor 
antigens as autologous tumors, even when combining multiple allogeneic cell lines.85 
The most efficient response will probably be provided by autologous cancer cells that 
express an allogeneic molecule. Allogeneic MHC molecules could hereby act as an 
adjuvant, without overwhelming the cancer-specific CTL response.92 However, it 
should be borne in mind that adding allogeneic elements in vaccines will potentially 
decrease their efficacy after repeated vaccination through alloreaction, which destroys 
the vaccine before it even has the chance to generate the desired response.93 
EFFECT OF IMMUNOGENIC CELL DEATH OF CANCER CELLS IN CANCER CELL VACCINES 
When a cell dies, it can be cleared with (immunogenic) or without (nonimmunogenic) 
stimulating an immune response against its dead cell antigens.47 In cancer cell vaccine 
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manufacture, immunogenic cell death (ICD) is the objective. An immunogenic death 
depends on the ICD-inducing stimulus.47 Multiple ICD-inducing stimuli have been 
described and their main characteristic is the ability to induce expression and release of 
DAMPs from the cells they have killed. The DAMPs that are expressed and released by 
the cancer cells after ICD can interact with pattern recognition receptors on many 
immune cells according to a defined spatiotemporal pattern. Binding of DAMPs to 
pattern recognition receptors results in the release of cytokines and chemokines by the 
immune cell. As a result, APCs are stimulated to efficiently take up and process tumor 
antigens and cross-prime T cells94 (Figure 2). Multiple factors can influence the efficacy 
of DAMPs.87 The immunogenicity of the whole cancer cell vaccine is influenced by the 
death-inducing stimulus, the produced DAMPs themselves, the DAMP location, and 
the combination of cancer- and host-associated factors.50, 95, 96, 97, 98 The cancer cell has 
to be able to express the DAMPs, which in turn should bind immune cells and not 
cancer cells.87 Indeed, binding of DAMPs to toll-like receptors (TLRs) expressed on 
cancer cells can promote cell survival and chemoresistance.87  
 
FIGURE 2. Principle of immunogenic cell death (ICD). Legend: CTL: Cytotoxic T cell, HMGB1: 
High Mobility Group Box 1, HSP70: Heat Shock Protein 70, MHC: Major Histocompatibilty, 
TLR: Toll-like Receptor. Adapted from Green 2009 99. 
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APPLICATION OF CANCER CELL VACCINES  
Antigen dosage of cancer cell vaccines  
Despite observed tumor eradication in experimental animal studies, limited success has 
been obtained so far in clinical trials for whole cancer cell vaccines in humans.100, 101 
However, it is possible that the antigen dosage generally used in vaccine studies is 
inadequate to initiate an optimal anticancer response in humans. The amount of cancer 
cells, DCs or cancer cell–DC fusion cells generally used for the vaccination of humans 
was comparable to the amounts used in mice (mamma cancer mouse102, 103, 104, 105, 106 / 
human107, 108, 109,110; melanoma mouse111, 112, 113, 114, 115/human116, 117, 118). Although the 
minimal antigen dose for antibody responses is independent of the body size,119 this is 
not true for cellular responses.120 T cells are highly dose-responsive and when the mice 
doses of antigen are used in humans, they are likely ineffective at raising T cell 
responses.120 The marked difference in the biology of secondary lymphoid tissue 
between mice and humans adds to this inappropriate extrapolation of doses. The 
average volume of a human LN is larger and the local draining lymphoid tissue is far 
more diffuse than in the mouse. This dilution of antigen may result in a local 
concentration of antigen insufficient to initiate effective T cell priming.120 The optimal 
quantity of the antigen in human whole cancer cell vaccines remains to be determined 
and undoubtedly depends on the antigen properties, the adjuvant and target species, 
and should ideally be determined for each antigen.121  
Administration route of cancer cell vaccines  
It is not clear which method of administration is most immunogenic for cancer 
vaccines.71 DCs injected intravenously (IV) primarily accumulate in the lungs and 
subsequently redistribute to the liver, spleen and bone marrow in human cancer-
bearing patients. Those injected intradermally (ID) or subcutaneously (SC) migrate to 
the regional LNs.122 The content of an intraperitoneal (IP) injection is distributed to the 
mediastinal LNs and the liver.123 Activated DCs can prime cellular immunity regardless 
of the route, yet the quality of this response and the induction of the humoral response 
may be affected by the route of administration.123 Cancer type and location, timing of 
vaccination and location of injection relative to the tumor will also be related to the 
evoked responses.71 In humans, it has been reported that ID administration is superior 
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to IV vaccination55 or IP vaccination.71 Although some researchers challenged the 
superiority of intranodal (IN) vaccination,124 many researchers claimed IN vaccination 
to be superior to IV,55, 125, 126 ID,127 SC or IP vaccination.125 However, IN injection of 
vaccines is difficult.128 Technical problems might explain the observed inferiority of IN 
vaccination in the study of Engell-Noerregaard and colleagues.124 
Location of vaccination relative to the tumor 
The location of vaccination relative to the tumor has an important influence on the 
effectiveness of cancer vaccines.71 Peritumoral vaccination will activate T cells centered 
in tumor-draining LNs (TDLNs), a location favorable for T cell trafficking into the 
tumor, and elicits anticancer effects more rapidly than distal vaccination.129 However, 
TDLNs are often actively tolerogenic as these LNs contain locally secreted cytokines 
such as transforming growth factor (TGF) β, PgE2 and IL-10.45 On top of that, they 
harbor immunosuppressive cells such as Tregs, iDCs, mDCs expressing PDL1 and 
indoleamine 2,3-dioxygenase (IDO). All of these elements are responsible for a potent 
immunosuppressive environment, leading to a tolerizing cross-presentation of tumor-
derived antigens by the host cells present in the TDLN. The increased levels of Treg 
activity are localized to TDLNs and do not occur in the other LNs of the same host.45 
Subsequently, peritumoral vaccination is not preferred when the tumor has already 
established immunosuppressive features. This has been documented by Ohlfest and 
colleagues who observed in an experimental setup that immune responses decreased as 
the vaccine was administered closer to the tumor, whereas a significantly higher site-
specific immune response was observed in tumor-free mice.130 Furthermore, tumor 
antigen administration does not need to take the location of DC types in the body into 
consideration, as DC location is not a limiting factor in the generation of an effective 
anticancer immune response. Indeed, the study of Ali and colleagues demonstrates that 
it is possible to attract DCs which are typically localized to secondary lymphoid 
structures toward a subcutaneous vaccine site in mice.131 These DCs also proved to be 
necessary for an efficient immune response, despite the fact that tissue-specialized DCs 
impart tissue-specific homing properties to CD8+ T cells.71 
General Introduction 
24 
Administration schedule of cancer cell vaccines 
The current consensus dictates weekly, biweekly or monthly boosters,67, 71 yet daily 
exogenous antigen immunization with peptide/protein cancer vaccines for several 
consecutive days (socalled cluster immunization) has proven to be clearly superior to 
booster immunization with greater intervals.132 When previously immunized mice were 
boosted with cluster immunization of peptide/protein cancer vaccines, it resulted in a 
CD8+ T cell peak response that surpassed the primary immunization level. This was 
not the case when a single second immunization was conducted after a single primary 
immunization.132 Interestingly, an adjuvant is needed to obtain the superior effect of 
cluster immunization. Indeed, Wick and colleagues found that immunization of mice 
with four consecutive daily doses of exogenous antigen without an adjuvant failed to 
evoke any antigen-specific T cell response.132 However, depending on the administered 
adjuvant, daily vaccination is not always possible as, for example, daily CpG exposure 
causes damage to secondary lymphoid organs and diminishes CD8+ T cell responses, 
while poly I:C does not.133 There is little known about how the timing of whole cancer 
cell vaccine administration may change clinical efficacy. Daily vaccination is probably 
not needed when using cancer cell–DC fusion cancer vaccines, as the fusion cells will 
produce, process and present tumor antigens for several days after the fusion.49  
CONCLUSION OF APPLICATION OF WHOLE CANCER CELL VACCINES 
Despite high expectations in whole cancer cell vaccination trials, thus far reported 
clinical responses have been rather disappointing. Many variables in the vaccine 
manufacture require optimization. Until today, the optimal dosage of the cancer 
vaccines remains to be elucidated; there is evidence that the current dose of antigens is 
too low for the treatment in humans. The therapeutic design should take the properties 
of immune response phases into account.48 Ideally, first the specificities not only of the 
cancer but also of the patient should be identified.134, 135 Afterward, tolerance should be 
suppressed, followed by the delivery of the adjuvanted cancer vaccine and 
accompanying therapies to enhance antigen presentation and to boost T cell priming. 
This treatment plan is ultimately completed with strategies that augment T cell efficacy 
and memory.48 
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3.1.2.2 Adjuvants in cancer vaccines 
The immune response induced by cancer cell vaccines can be significantly enhanced by 
the use of the appropriate adjuvants.136 There are effector adjuvants on one hand and 
memory-inducing adjuvants on the other hand. Eradication of cancer cells and the 
simultaneous buildup of immune memory are not easily generated by one single 
adjuvant type. IL-12 and type I interferon (IFN) are known to induce potent 
differentiation of T cells into effector cells.120 Tumor necrosis factor receptor (TNFR) 
ligands (such as OX-40, 4-1BB and CD27) activate protein kinase B which directs T cell 
differentiation more toward Tmem than toward primary effector T cells.120 The primary 
and secondary CD8+ T cell responses rely more on CD27 than OX40 for their 
generation and vice versa for the CD4+ T cell response.120 Dosage is the key to success 
for effector as well as memory-inducing adjuvants.120 An excess of effector adjuvants 
can drive responding cells into terminal differentiation and thus become a weak point 
for the generation of immune memory.137, 138 Moreover, Burchill and colleagues also 
demonstrated that overstimulation of CD27 has a negative effect on the development of 
competent CD8+ T cell memory.120 It is important that the dosage is tailored to the 
individual adjuvant. 
3.1.2.2.1 Persistence of antigens by adjuvants that generate a depot effect  
Antigens should be presented long enough to enable a robust immune response, yet 
short enough to enable an efficient memory response.52, 131 In the search for an ideal 
vaccine, it was long assumed that an antigen depot is necessary to provide a sufficiently 
long antigen contact. However, although depots provide a longer presence of antigens 
and thus a longer possibility for the immune system to interact with these antigens, not 
all depots provide the aspired immune stimulating effect. It has been demonstrated that 
an antigen depot formation can trap T cells generated by the vaccine, and hence pre-
vent them from reaching the desired target cancer site.120, 139 Therefore, Hailemichael 
and colleagues suggested that cancer vaccines with a short-lived depot effect might 
result in enhanced therapeutic efficacy.139 In some adjuvants an unwanted depot effect 
is created by their formulation, such as those based on saponin, MF59, Montanide ISA 
51 or QS21, which require an emulsion for the formulation of the adjuvant. Adjuvants 
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such as the TLR-based adjuvants poly I:C, monophosphoryllipid or CpG do not require 
an emulsion formulation120 and are therefore suitable for cancer vaccination. 
3.1.2.2.2 Timing of adjuvant administration 
An efficient and durable T cell response depends on signals that are either received in 
the first few days of antigen recognition by naive T cells or later, when memory cells 
come across this antigen once more.140 TNF/TNFR family members are induced hours 
to days after TCR affiliation.134 Several adjuvant vaccination schemes might sufficiently 
skew the anticancer immune response in the desired direction. One option is 
alternating priming for several consecutive days with an effector and a memory 
adjuvant, followed by a boost with a memory adjuvant. Alternatively, priming with an 
effector adjuvant only, followed by a well-timed secondary boost with a memory 
adjuvant. It is important to administer the memory adjuvant when the memory cells 
start to develop and require maintenance through sustained protein kinase B activation. 
3.1.2.3 Limitations in cancer vaccines  
3.1.2.3.1 Genetic defects in cancer cells and patients 
The efficacy of a cancer vaccine treatment depends on the possibility of the patient 
and/or the patient’s cancer to respond to the vaccine. Certain genetic defects in patients 
or tumors may compromise the efficacy of cancer vaccines or adjuvants.141, 142 For 
example, it has been demonstrated that TLR4 is essential for efficient tumor antigen 
cross-presentation.143 However, 12% of Caucasians are TLR4 deficient which may imply 
an inefficient cross-presentation of tumor antigen in these patients.143 Compensatory 
treatments have been developed to specifically tackle TLR4 deficiency.47 It is therefore 
important to assess the immunogenic characteristics of cancer patients and adapt the 
vaccine manufacture where needed. Furthermore, tumor immunogenicity varies greatly 
between different types of cancer and even between cancers of the same type (in 
different individuals).144 A cancer type can differ in specific transduction pathways95, 97 
or in the expression of endogenous cytokines or the amount of MHC class I 
molecules.100 Additionally, certain tumors can expose (e.g., CRT) or release 
General Introduction 
27 
immunogenic signals (e.g., ATP and HMGB1) in response to a death-inducing 
stimulus, whereas others do not.95, 97 These deficiencies can be compensated for via the 
addition of, for example, recombinant CRT, ATP agonists and TLR4 agonists to cancer 
cells that do not express CRT or release ATP and HMGB1, respectively.143 The 
development of a scanning assay for missing ICD pathway factors in a cancer patient is 
the future to optimized patient-specific cancer cell vaccines. Nowadays, not all relevant 
missing factors are known yet47 and running an elaborate checklist for each possible 
missing factor in every single cancer patient would further increase the vaccine 
production costs. 
3.1.2.3.2 Heterogeneity in patient selection and tumor size 
The large variety in reported clinical success of DC-based cancer vaccines in humans 
might be partially explained by the selection of the enrolled cancer patients. Most 
eligible are patients with early-stage cancer and patients who had a successful first-line 
therapy and had minimal prior chemotherapy. Moreover, the tumor is preferably not 
very aggressive in order to allow the patient enough time to receive multiple rounds of 
vaccination.145 In current trials, often advanced-stage patients with high tumor burdens 
and/or patients who need more time than granted to respond to the treatment are 
assessed.145 Tumor size has a great impact on the efficiency of anticancer vaccines. 
Decreasing the tumor burden prior to vaccine treatment allows a higher cure rate since 
smaller tumors are more effectively eradicated than large ones.129 Unfortunately, most 
current mice models provide a proof of concept for the immunogenicity of the vaccine 
in a rather prophylactic than therapeutic setting. In the majority of preclinical studies 
with mice, cancer vaccination is performed a few days after inoculation, not taking into 
account the impact that slowly progressing tumors have on the adaptive immune 
system.63 In many studies, the cancer vaccine is given even before the inoculation of the 
cancer cells.62 
3.1.2.4 Cancer vaccines in dogs (peptide, protein, genetic and cell vaccines) 
Successful cancer vaccine results in companion animals can often be translated to 
human medicine.16 Prior to clinical trials in cancer-bearing pet dogs, several cancer 
General Introduction 
28 
vaccines were evaluated in healthy laboratory dogs. Three important conclusions were 
drawn from preclinical vaccination studies in healthy laboratory dogs. First, it was 
confirmed that cancer vaccines generate an antitumor immune response. Second, no 
autoimmune or other serious adverse effects were detected. Third, clinical efficacy of 
DC vaccines and DNA vaccines was demonstrated in dogs with transmissible venereal 
tumor (TVT) .146  
Cancer vaccines in dogs have been applied for several tumor types and generated a 
range of treatment results (Table 1, Table 2, Table 3). Melanoma and lymphoma are the 
most popular tumor types studied so far. For melanoma, the best results were obtained 
in the study of Finocchiaro and colleagues.147 Melanoma’s were completely or partially 
excised and the tumor bed or tumor tissue respectively were co-injected with lipoplexes 
bearing Herpes simplex virus (HSV)-thymidine kinase and IFNβ genes and ganciclovir 
at the time of surgery. This approach was combined with the periodic administration 
(concurrent with the surgery) of a SC genetic vaccine composed by tumor extracts and 
lipoplexes carrying the genes of human IL-2 and human granulocyte-macrophage 
colony-stimulating factor. The control group consisted of patients in which melanoma 
was completely or partially excised. Overall survival of the group with complete 
excision and immunotherapy was 7 times higher than in the control group that had 
complete excision only (704 (99-2251) versus 101 (11-568) days). Overall survival of the 
group with partial excision and immunotherapy was 4 times higher than in the control 
group that had partial excision only (323 (46-1321) days versus 78 (29-206) days),147 
thus potentially indicating the impact of tumor load on immunotherapeutic approaches 
(Table 1).147 
 
Also for lymphoma, a significant increase in overall survival was obtained with a cancer 
cell vaccine (unspecified lymphoma,18  B cell lymphoma148) and a DNA vaccine (B cell 
lymphoma).149 All studies had concurrent control groups that indicated a significant 
survival. Already in 1976, Benjamini and colleagues administered an IM autologous 
tumor cell lysate, admixed with Freund’s complete adjuvant to 11 canine lymphoma 
patients in complete remission after chemotherapy. The control group consisted of 
patients having received chemotherapy and a placebo vaccine (vitamin B12) only (n= 
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9). A median survival time of over 348 days was obtained in the vaccinated group, 
which was significantly higher than the 197.5 days in the chemotherapy only group.18 
Thirty-eight years later, similar results were obtained by administrating an ID 
autologous tumor cell lysate, admixed with hydroxylapatite on top of chemotherapy in 
12 lymphoma patients.148 The control group (n= 7) received chemotherapy and a 
placebo only (the same amount of hydroxylapatite without the tumor proteins). A 
lymphoma-specific survival of 505 days was obtained in the vaccinated group, whereas 
only a median of 159 days was reached in the control group.148 Gavazza and colleagues 
administered IM and subsequently electroporated a telomerase reverse transcriptase 
DNA vaccine to 21 dogs with lymphoma combined with chemotherapy, whereas the 
control group (n= 21) received chemotherapy only. A significant increase in overall 
survival ensued (532 days vs 205 days) (Table 2).149 
Besides melanoma and lymphoma, other tumor types have been treated with cancer 
vaccines. For haemangiosarcoma, fibrosarcoma, osteosarcoma, mammary gland 
tumors, glioma, meningioma, astrocytoma or bronchoalveolar adenocarcinoma, no 
concurrent control groups were included, thus preventing sound conclusions (Table 3). 
  
The absence of concurrent randomized control groups complicates comparisons 
between cancer vaccine trials conducted in cancer-bearing pet dogs. Many published 
trials use different treatment schedules, tumor antigens, delivery systems, patient 
selection criteria and a low patient number.  
Boston and colleagues conducted a retrospective study in 151 dogs with melanoma and 
found no survival benefit with any systemic adjuvant therapy compared to surgery 
only.150 Yet, the authors emphasize that this is possibly due to the low number of dogs 
in each treatment group in their study. Indeed, together with the inherent study 
limitations including lack of randomization and treatment protocol standardization, it 
was made impossible to detect any differences in survival times provided by the various 
systemic adjuvant therapies. They claimed it could be due to a type II error, or it may be 
that there was no difference in survival times between the treatment groups. Post hoc 
power analysis revealed an exceedingly low statistical power (13.5%) to detect the 
observed difference based on the sample size. To detect the same difference with 80% 
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power, inclusion of at least 1,530 dogs would have been required, depending on the 
allocation ratio between the 2 groups.150 Bergman stated that immunotherapy, like any 
form of anticancer treatment, seems to work best in a minimal residual disease setting, 
suggesting its most appropriate use will be in an adjuvant setting with local tumor 
therapies, such as surgery and/or radiation.60 
 
TABLE 1. Cancer vaccines for melanoma in canine clinical trials 
Patients  
Control 
group 
Vaccine type Outcome Adverse effects Ref 
10 No 
Cancer cell 
vaccine 
4/10 response Minimal or absent 151 
3 No DC vaccine 1/3 response Minimal or absent 152 
34 No 
Cancer cell 
vaccine 
12/34 response 
Minimal or 
absent; vitiligo 
was observed in 1 
dog  
153 
31 Concurrent 
Cancer cell 
vaccine  
OS: 370 vs 76 days Minimal or absent 154 
58 
Published 
data  
DNA vaccine MST: 464 vs 156 days Minimal or absent 155 
58 
Published 
data  
DNA vaccine OS: 476 vs 365 days Minimal or absent 156 
24 
Retrospective 
data  
DNA vaccine 
No difference in survival 
time 
None  150  
14 Concurrent  DNA vaccine 
Survival %  at 12m 64.3 vs 
15.3  
Minimal or absent 30 
301 Concurrent 
DNA and cancer 
cell vaccine   
OS 7x higher for complete 
tumor removal, 4x higher for 
partial removal 
Minimal or absent  147 
Minimal adverse effects: mild induration, erythema, pruritis at injection site; MST: median 
survival time; OS: overall survival; response: complete response, partial response and/or stable 
disease (several response options valid as response within same study). 
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TABLE 2. Cancer vaccines for lymphoma in canine clinical trials 
Patients  Control group Vaccine type Outcome Adverse effects Ref 
11 
Concurrent, 
placebo-
controlled 
Cancer cell vaccine 
OS >348 vs 
197.5 days 
Abscedations in 50% of 
patients during 4-6 
weeks 
18 
58 
Concurrent, 
randomized 
Cancer cell vaccine 
No survival 
benefit 
No adverse effects  157 
26 
Concurrent, 
randomized, 
placebo-
controlled 
Cancer cell vaccine 
No survival 
benefit 
No adverse effects 158 
7 No Cancer  cell vaccine 
OS suggestive 
for 2-3x 
increase in 
survival  
No adverse effects  159 
14 
Recent historical 
cases from same 
institution 
DNA vaccine 
(TERT) 
OS 403 vs 182 
days 
No adverse effects 
elicited by vaccination 
regimen 
160 
15 
Recent published 
data 
Tumor antigen-
coated microbeads 
No survival 
benefit 
No or mild adverse 
effects  
161 
19 
Recent historical 
cases from same 
institution 
Tumor RNA-loaded 
B-cell vaccine 
No survival 
benefit 
Acute manageable 
systemic reaction in one 
dog. No or mild adverse 
effects in other dogs.  
162 
21 Concurrent DNA vaccine (TERT) 
OS 205.1 vs 
42.7 days 
No adverse effects 149 
19 
Concurrent, 
randomized, 
placebo-
controlled 
Cancer  cell-based 
vaccine (autologous 
tumor lysate with 
hydroxylapatite + 
chemotherapy) 
Lymphoma-
specific 
survival 505 vs 
159 days  
No adverse effects 148 
AI: auto-immune response; mild adverse effects: mild induration, erythema, pruritis at 
injection site; OS: overall survival; response: complete response, partial response and/or stable 
disease (several response options valid as response within same study); TERT: telomerase reverse 
transcriptase.  
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TABLE 3. Cancer vaccines for various other tumor types in canine clinical trials 
Tumor type Patients  
Control 
group 
Vaccine type Outcome 
Adverse 
effects 
Ref 
Hemangio-
sarcoma  
28 
Recent 
historical 
cases  
Cancer cell vaccine 
OS 182 vs 133 
days 
No or mild 
adverse effects 
163 
Fibrosarcoma 3 No Cancer cell vaccine 2/3 response 
No or mild 
adverse effects 
151 
Fibrosarcoma 1 No DC vaccine 1/1 response TLS: DIC 164 
Fibrosarcoma 8 No Cancer cell vaccine 
OS >1459 vs 
184 days 
No adverse 
effects 
165 
Osteosarcoma 2 No Cancer cell vaccine No response 
No or mild 
adverse effects 
151 
Osteosarcoma 5 No Cancer cell vaccine 
OS >386 vs 96 
days 
No adverse 
effects 
165 
Mammary 
gland tumor 
4 No DC-vaccine 4/4 response 
TLS: cachexia 
in 1 patient 
164 
Mammary 
gland tumor 
7 No  
DNA vaccine 
(p62) 
7/7 response  
No adverse 
effects 
28 
Mammary 
gland tumor 
21 No  
Cancer cell-based 
vaccine 
(Autologous lysate + 
biotin + 
streptavidin) 
15/21  
exceeded 
expected 
survival time 
by 2 weeks to 
22 months 
No or mild 
adverse effects  
166 
Peripheral 
nerve sheath 
tumor 
9 No 
Peptide vaccine 
(VEGF)  
3/9 response 
No adverse 
effects 
167 
Broncho-
alveolar 
adeno-
carcinoma 
1 
(case 
report) 
Cancer cell vaccine 
(autologous HSP-
rich lysate 
+Imiquimod + BcG) 
1/1 exceeded 
expected 
survival time 
by 40 weeks 
No adverse 
effects 
168 
Glioma  10 
Con-
current 
DNA vaccine (TetOn 
Flt3L and herpes 
simplex virus type I 
thymidine kinase 
OS 341 vs 117 
days 
No adverse 
effects 
27 
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(HSV-tk)) 
Glioma  Ongoing  Ongoing  
Cancer cell vaccine 
(autologous tumor 
lysate) 
Ongoing  
No severe 
adverse effects 
27 
Gemistocytic 
astrocytoma 
12 
Con-
current 
Cancer cell vaccine 
(autologous tumor 
lysate) 
No survival 
benefit for 
addition of 
IFNγ 
Temporary left 
hemiparesis 
and left 
blindness after 
vaccination 
27 
Meningioma 11  Historical  
Cancer cell vaccine 
(autologous tumor 
lysate) 
OS 645 vs 222 
days 
(historical) 
No or mild 
adverse effects 
169 
DIC: disseminated intravascular clotting; mild adverse effects: mild induration, erythema, 
pruritis at injection site; OS: overall survival, response: complete response, partial response 
and/or stable disease (several response options valid as response within same study); TLS: Tumor 
lysis syndrome.  
3.2 The innate arm of the antitumoral immune response  
3.2.1 The general principle of innate antitumoral immune responses 
In contrast to the adaptive immune system, the innate immunity is rapidly reacting to 
aberrant cells or organisms but its activity is typically not very specific. Although the 
innate immune system is capable of effectively eradicating cancer cells, it can be 
manipulated by the cancer to contribute to its progression. The innate immunity 
includes physicochemical barriers (skin and mucosa), blood proteins (such as 
complement), antigen-presenting and effector cells (DCs, macrophages, neutrophils, γδ 
T cells (T cells expressing γδ TCRs) and NK cells), and cytokines, which coordinate and 
regulate the cells involved in innate immunity.60, 170 Prominent players of the innate 
immune system will be discussed further in the upcoming sections. 
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3.2.1.1 Cellular components of the innate immune system  
The cellular component of the innate immune system consists of effector cells as well as 
antigen-presenting cells. The major effector cells of the innate immune system that 
target cancer cells are NK cells, macrophages, neutrophils and mast cells.171 NK cells, 
NKT cells, and γδ T cells can sense malignant transformation and contribute to 
immune responses at an early stage. All three populations can be activated via NKG2D, 
through MICA/B and other ligands expressed by cancer cells.170 The major APCs 
include DCs and macrophages.171 Above-mentioned cells are discussed below. 
 
NK cells have the ability to contribute to host control of hematologic cancers as well as 
solid cancers.172 NK cells have 3 modes of antitumoral action. (1) They can recognize 
and kill non-MHC expressing cancer cells171, 173 and this process depends on 2 
functional types of receptors on the NK cell surface: stimulatory receptors and 
inhibitory receptors. NKG2D, a stimulatory receptor on NK cells, specifically 
recognizes MICA/B on cancer cells which stimulates cell killing.172 KIR, an inhibitory 
receptor on NK cells, detects the presence of MHC class I on cancer cells. Whereas 
normal cells always carry MHC class I molecules, this is not generally true for cancer 
cells. When MHC class I is present, KIR will prevent NK cell cytotoxicity.171 When the 
MHC class I molecule is not detected, NK cell cytotoxicity is allowed.171 The final action 
of a NK cell depends on the activation status of the stimulatory and inhibitory receptor. 
When the activating signals received by NK cells dominate the inhibitory signals, 
activated NK cells kill cancer cells directly by releasing perforin and granzymes from 
cytoplasmic granules, expressing Fas antigen ligand (FasL) or TNF-related, apoptosis-
inducing ligand (TRAIL).174 (2) The second mode of action of NK cells involves 
interaction with antibodies. When a cancer cell is coated with antibodies against cell-
surface antigens, it will bind to the Fc receptor (FcR) present on the NK cell and induce 
its destruction through ADCC.171 (3) Finally, the NK cell can contribute to the adaptive 
arm of the antitumoral immune response by releasing immunostimulatory cytokines 
and contributing to the release of tumor antigens. In more detail, by secreting IFNγ, 
activated NK cells can indirectly contribute to CTL activation as well as promote 
differentiation of Th1 CD4+ T cells.175 NK cell–mediated cancer cell lysis releases tumor 
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antigens to DCs and induces DC activation and maturation, for cross-priming of 
specific T cells.176, 177  
NK cells can infiltrate the solid tumor microenvironment, and this infiltration has been 
associated with prolongation of overall survival in cancer patients.178, 179 Unfortunately, 
despite the broad array of antitumoral activities of NK cells, cancer cells are able to 
evade immune surveillance by NK cells through selective survival of NKG2D-ligand-
deficient cancer cells. Many cancer cells release soluble NKG2D ligands, which induce 
anergic or hyporesponsive NK cells as a result of repeated and persistent activation.170 
 
NKT cells can be classified into two major functional types: the antitumoral cytotoxic 
NKT cells and the protumoral immunoregulatory NKT cells. The exerted activity 
depends on the immunologic context and perhaps on the TCR being used.172 Cytotoxic 
NKT cells can be activated directly or indirectly by (recognition of glycolipid antigens 
presented in CD1d molecules on) cancer cells or IL-12 producing DCs (that express 
CD1d-associated self-antigens), respectively. Activated  cytotoxic NKT cells rapidly 
produce cytokines (including IL-2, IL-4, and IFNγ) and cytotoxic granules, such as 
perforins and granzymes that result in antitumoral immune activation and cancer cell 
death respectively.170 Similar to NK cells, NKT cells’ production of IFNγ indirectly 
contributes to CTL activation.  
In contrast to the antitumoral activity that has been implicated for cytotoxic NKT cells, 
an immunosuppressive role for immunoregulatory NKT cells has been suggested. The 
immunosuppressive activity appears to be mediated through production of IL-13 and 
activation of signal transducer and activator of transcription 6 (STAT6) pathways.170  
 
γδ T cells have been implicated in immunomodulation of the tumor micro-
environment. Antitumor effects of cytotoxic γδ T cells have been reported, as well as 
immunosuppressive effects of regulatory γδ T cells.172 Similar to NK cells and cytotoxic 
NKT cells, activated cytotoxic γδ T cells can exert cytolytic death of cancer cells through 
release of cytotoxic granules (containing perforin and granzymes) and effector 
cytokines (IFNγ and TNFα). Additionally, they express apoptosis-inducing ligands 
FasL and TRAIL thereby inducing cancer cell death after binding of these ligands to the 
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cancer cell. Furthermore, as γδ T cells express the CD16-FcR, they can facilitate ADCC. 
γδ T cells contribute to DC activation, which indirectly supports αβ T cell activation. 
The antitumoral activity of γδ T cells is suppressed by prostaglandin (Pg)E2 (produced 
by mesenchymal stem cells), Tregs as well as immunosuppressive factors produced in 
the tumor microenvironment (TGFβ, PgE2, IDO, soluble NKG2D ligands).170 
 
DCs are known as potent professional APCs and form a bridge between the innate and 
adaptive immune system.171 The presence of a high number of DCs in the tumor, 
peritumoral area and/or draining LNs, has been shown to correlate with better disease-
specific survival in various solid cancers.173 DC subsets will not react in a standard 
predetermined manner, but rather according to the nature of the challenge and/or the 
form of the antigen or the adjuvant and inflammatory signals.120, 180 Most importantly, 
the maturation stage of DCs has an influence on the generated immune response 
against cancer cells. Immature DCs induce immunosuppression by skewing the 
patient’s T cell response toward a Th2 response type and secreting tolerance-inducing 
IL-10. On the other hand, mDCs contribute to an antitumoral response by secreting IL-
12 and skewing the αβ T cell response toward a Th1 response and prime αβ T cells to 
the presented antigens.49 Additionally, mDCs reduce tolerance or expansion of 
regulatory cells. 
 
Macrophages infiltrating the tumor often participate to local chronic inflammation 
thus favoring tumor formation and progression.171, 181 Macrophages are recruited by 
cancer and stromal cells through the release of various cytokines and chemokines 
(VEGF, TGFβ, bFGF, M-CSF/CSF-1, uPa, b-defensin-3, Reg3b, oxysterols, CXCL1, 
CXCL2, CXCL3, CXCL5, CXCL8) whereafter the tumor microenvironment induces a 
proangiogenic profile in the tumor-associated macrophages (TAM).181 Under normal 
circumstances in the tumor environment, the interaction between apoptotic cancer 
cells and macrophages leads to immune tolerance without provoking significant 
proinflammatory cytokines.171 However, tumor-infiltrating macrophages are able to 
exhibit two contrasting functions, namely antitumoral (TAM1) and protumoral 
(TAM2) activity. TAM1 produce high amounts of IL-12 and low amounts of IL-10 and 
General Introduction 
37 
they release chemokines (CXCL9, CXCL10) that attract Th1 cells, whereas TAM2 
produce high amounts of IL-10 and low amounts of IL-12 and release chemokines 
(CXCL17, CCL22) involved in the recruitment of Tregs and Th2 cells.181, 170 
Interestingly, exposure of TAM2 to Th1 cytokines such as IFNγ can induce reeducation 
into TAM1 cells and abrogate their immunosuppressive abilities.170, 181  
 
It is suggested that mast cells may be critical players in tumor progression, promoting 
angiogenesis and immunosuppression.182 However, contradictory findings on the role 
of mast cells in cancer development have been reported. Depending on the immune 
context, mast cells may have divergent proinflammatory or immunosuppressive 
effects.183 Ryan and colleagues reported that many tumor types recruit mast cells and 
intratumoral mast cells are associated with tumor growth and decreased host survival, 
possibly through Treg recruitment.182 In contrast, Heijmans and colleagues observed 
that dense mast cell infiltration was associated with a favorable outcome in patients 
with colon cancer.184 Antitumoral effects of mast cells could be the result of their 
interaction with antibody-coated cancer cells through the activating and inhibiting 
FcγR on the mast cell’s surface.171 
 
As many other immune cells described above, the antitumoral activity of tumor-
infiltrated neutrophils depends on its microenvironment.181 Although neutrophil 
infiltration is associated with poor clinical outcome, tumor-associated neutrophils 
(TAN) in early-stage tumors display a more cytotoxic profile toward cancer cells and 
produce higher levels of TNFα, NO and H2O2 than neutrophils in established late-stage 
tumors. In advanced tumors, these functions are down-regulated and neutrophils 
acquire a more protumoral phenotype by actively recruiting Tregs and promoting 
angiogenesis.181 
 
Unlike the innate immune cells mentioned above, not much is known about the 
intratumoral activity of eosinophils and basophils. Eosinophilia is regularly observed 
during immunotherapy protocols.185 Additionally, tumor-associated tissue eosinophilia 
was detected in several types of cancer and linked with a generally good prognostic 
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value.185 Eosinophils do often exhibit a state of degranulation when in close proximity 
to the tumor.185 
Basophils respond to various IgE-dependent or -independent stimuli, and are engaged 
in a complex cross-talk with a number of immunocompetent cells.186 In cancer-bearing 
patients, the absolute number of circulating basophils is decreased. This appears to be 
due to the presence of the tumor, since after successful excision of the primary tumor, 
blood basophil number and blood histamine levels are normal.187 In general, basophils 
are able to quickly produce Th2 cytokines (IL-4, IL-13) and express CD40L and 
chemokine receptors (CCR3).188 Moreover, basophils are thought to have important 
regulatory functions in innate as well as adaptive immunity through their contribution 
to immunoglobulin synthesis and class switching, angiogenesis, autoimmunity and 
tumor immunity via production of cytokines such as IL-6, VEGF, GM-CSF and IL-3.186  
3.2.1.2 Non-cellular components of the innate immune system 
3.2.1.2.1 Damage-Associated Molecular Patterns (DAMP) 
In addition to the direct cancer/innate immune system interactions, a large number of 
molecules, released as a reaction to cancer cell death, may function as DAMP and 
interact with innate immune cells (Table 4) (see 3.1.2.1.4). 
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TABLE 4. Principal damage-associated molecular patterns (DAMPs) 
DAMP on plasma 
membrane 
Effect Ref 
CRT Stimulates antigen-uptake 
87, 141, 
189 
HSP70  
Induces DC maturation (upregulation CD86 and CD40), activates NK cells, 
attracts monocytes and neutrophils, stimulates antigen uptake 
87, 97, 141, 
190 
HSP90 
Induces DC maturation (upregulation CD86 and CD40), activates NK cells, 
attracts monocytes and neutrophils 
 87, 190 
NKg2D-ligand 
Stimulates NK cells, NKT cells and CD8+ T cells to destroy cancer cells that 
express NKG2D-ligands 
97, 141, 
191 
Secreted 
HMGB1 
Induces DC maturation, facilitates processing and presentation of tumor 
derived antigens, attracts various immune cells 
87, 141, 
143,, 190 
HSP90 Can inhibit activation of TGFβ 87 
End-stage degradation products 
ATP 
Acts in low concentration as chemoattractant for iDC, induces DC 
maturation, causes IL-1β release from DC 
87, 192  
DNA Stimulates DC and macrophage 141 
RNA Activates innate immune system through TLR3 binding 87 
CRT: Calreticulin; DC: Dendritic cell; HMGB1: High-mobility group box-1; HSP70: Heat shock 
protein 70; HSP90: Heat shock protein 90; iDC: Immature dendritic cell; NKG2D: Natural killer 
group 2 member D; TLR3: Toll-like receptor 3. 
3.2.1.2.2 Complement 
Complement is a collective term for a system comprising over 50 proteins that function 
as enzymes, substrates, or regulators of pathway activation. The main functions of the 
complement are to bridge innate and adaptive immunity, defend the host against 
bacteria, and bind to immune complexes for complement-mediated cell lysis.193 
Complement can induce cell death by binding antibody complexes, which ultimately 
leads to cell perforation. There are different mechanisms of complement activation that 
General Introduction 
40 
differ in their initial steps; yet all lead to the formation of the membrane attack complex 
(MAC), which ultimately induces chemokines (C3a, C5a) with important inflammatory 
and chemoattractant functions.194 Recognition of cancer cells by the complement 
system is presumed to contribute to immune-mediated elimination of cancer cells.170  
3.2.1.2.3 Host microbiota 
Microbiota can actively contribute to the development of the host’s immune response. 
Indeed, different commensal bacteria can shape a pro- or anti-inflammatory milieu in 
the intestine. Commensal bacteria can have an antitumoral impact on the systemic 
immunity.170 For instance, commensal microbiota will lower the activation threshold 
for APCs.170 Furthermore, microbiota can indirectly contribute to an immune-
mediated antitumoral response. Cyclophosphamide (CP) causes dysbiosis and 
translocation of bacteria to LNs, leading to the generation of anti-commensal Th17 cells 
that, in turn, contribute to the therapeutic efficacy of the drug. When no or few gut 
bacteria are present, this will impair the generation of Th17 cells and thus the 
antitumoral effect of CP.170, 195 Thus, commensals can control various aspects of 
immunity associated with antitumoral responses.195 However, the presence of certain 
microbiota is not always advantageous to the host. An example of tumor progression 
due to gut microbes includes the development of gastric cancer due to Helicobacter 
pylori.170  
3.2.2 Antitumoral application of the innate arm of the immune system via 
interleukin 12 
3.2.2.1 The principles of interleukin 12 
IL-12 is an immunostimulatory cytokine, produced by DCs, with a key role in the 
regulation of inflammation by linking innate and adaptive immune responses.196 In 
addition, it has powerful antitumoral properties.196 The sensing of IL-12 is mediated 
through the heterodimeric IL-12 receptor (IL-12R) composed of IL-12Rβ1 and IL-
12Rβ2.196 The IL-12R complex is found on NK cells, NKT cells, activated T cells, 
granulocytes, monocytes and B cells.197 IL-12Rβ1 is constitutively expressed on naive T 
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cells, whereas IL-12Rβ2 is only expressed on activated T cells. Co-expression of both 
receptor subunits is required for the generation of high-affinity binding sites for IL-12. 
Since naive T cells express IL-12Rβ1 but not IL-12Rβ2 they will not  be able to induce 
antitumoral activity as expression of both receptor subunits is critical for the signal 
transduction downstream of the receptor complex.197 As a consequence, IL-12 only 
stimulates activated T cells,198, 199 making IL-12 a useful booster of a pre-existing 
immune response. Subsequent to binding to the IL-12R complex, IL-12 leads to 
activation and proliferation of T cells and NK cells200, 201, 202 and is able to recruit NK 
cells and polymorphonuclear (PMN) cells.198, 199 In turn, activated T cells produce IFNγ, 
which induces a positive feedback loop on IL-12 secretion by APCs.197 Not only can IL-
12 engender instant activation of (antitumoral) effector cells, it can also program 
effector T cells for optimal generation of effector memory T cells and T follicular helper 
cells.203, 204 Furthermore, IL-12 inhibits differentiation to and the expansion of Tregs205, 
206 and decreases the suppressive function of myeloid-derived suppressor cells 
(MDSC).207 An additional antitumoral mechanism of IL-12 is the inhibition of 
angiogenesis through mechanisms such as the inhibition of new blood vessel formation 
by Inducible Protein (IP) 10 and Monokine Induced by Gamma interferon (MIG), 
cascade products of IFNγ208 (Figure 3). As a result, the production of factors that 
facilitate new blood vessel formation such as vascular endothelial growth factor (VEGF) 
and metalloproteinase-9 is decreased.208, 209, 210, 211, 212 
IL-12 has intriguing antitumoral features, yet grave toxicity has been shown when 
recombinant IL-12 was administered systemically to human cancer patients.213 This 
toxicity has urged the need to find alternatives for systemic IL-12 treatment and led to 
the evaluation of tumor-specific delivery methods of IL-12. Intratumoral IL-12 
production after IL-12 plasmid DNA (pDNA) gene transfer can be accomplished 
through various ways, one of which is electroporation (EP), a reproducible and highly 
efficient method to deliver pDNA.214 Electroporation is the short administration of 
electrical pulses to ensure the formation of transient pores into the plasma membrane 
of the cancer cells thereby facilitating intracellular delivery215 of IL-12 pDNA.216, 217 By 
this route, a high intracellular level of IL-12 pDNA can be obtained, leading to 
production of IL-12 encoded by the plasmid.216, 217 Electroporation does not cause any 
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severe adverse events,218 and several veterinary and human clinical trials showed the 
safety and clinical efficacy of EP-mediated intratumoral IL-12 pDNA treatments.219, 220, 
221, 222 These results present evidence that it is possible to overcome local suppressor 
pathways and tip the balance in favor of an antitumor immune response, even with 
inhibiting effects on non-treated metastases. Regression of primary tumors222 and 
metastases219, 222, 223 has been observed for small tumors after intratumoral IL-12 gene 
therapy, but successes were present in only a subset of patients.219, 221, 222, 146  
 
 
FIGURE 3. Antitumoral mechanisms of IL-12. Adapted from Cemazar 2010 214 
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3.2.2.2 Interleukin 12 in cancer-bearing dogs 
3.2.2.2.1 Safety of IL-12 electrogene transfer 
So far, 1 intratumoral IL-12 pDNA electrogene transfer (EGT) study was conducted in 
healthy laboratory dogs  with induced tumors146 and 5 intratumoral IL-12 EGT clinical 
trials in pet dogs with spontaneous tumors220, 221, 222, 224, 225, 226 were performed to 
evaluate the effects of IL-12 EGT and are listed in Table 5. No adverse effects were listed 
for IL-12 EGT in these trials and studies, but fever, anemia, thrombocytopenia, 
lethargy, poor appetite, cytokine-induced acute vasculitis and subsequent peripheral 
edema with pleural effusion, and disseminated coagulopathy were reported in dogs 
treated with a SC injection of an IL-12 immunocytokine (a construct with IL-12 bound 
to an antibody with specificity for necrotic tissue).227 These side effects are similar to 
those reported for early IL-12 clinical trials in human patients, where pure IL-12 was 
administered IV.213 IL-12 toxicity is partly explained by the induction of IFNγ through 
IL-12, resulting in haematologic suppression and gastrointestinal toxicity.213 Paoloni 
and colleagues found adverse effects in all dogs with IFNγ serum concentrations of 
>100 pg/mL.227 However, the adverse effects may be unrelated to the IFNγ serum 
concentration as in the IL-12 EGT studies performed so far in dogs, the IFNγ serum 
concentrations varied between 2.15 -815.6 pg/mL and no serious adverse effects were 
observed. 
No or mild adverse effects for IL-12 EGT were seen in dogs, which is similar to the IL-
12 pDNA electroporation trial in humans with metastatic melanoma.219 The mild 
adverse events included transient pain during the electroporation procedure and 
bleeding around the treatment site. In none of the 24 human patients 219 nor 38 canine 
patients220, 221, 222, 224, 225, 226 hematologic abnormalities were observed. 
In murine melanoma and squamous cell carcinoma tumor models, the toxicity of IL-12 
pDNA EGT was evaluated.228, 229 In the melanoma group, no clinically detectable 
adverse effects or changes in laboratory parameters were observed. Although no 
changes in kidney function or biochemical indicators were present, histopathological 
analysis revealed a focal inflammation and glomerulosclerosis of the kidneys was found 
1 month after the procedure.228 In the squamous cell carcinoma group, a statistically 
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relevant transient increase of liver enzyme alanine transferase was noticed, as well as a 
trend in transient decrease in total white blood cell count within 7 days after therapy.229 
In canine patients, only a transient decrease in total white blood cell count was present 
during 14 days after therapy.222
3.2.2.2.2 Clinical responses to intratumoral IL-12 electrogene transfer  
Good responses (significant inhibition canine TVT growth followed by complete 
response) were obtained in the study of Chuang and colleagues in which healthy 
Beagles were inoculated with canine TVT cells and treated with hIL-12 pDNA when the 
tumors reached the size of 1-2 cm (after 2-3 weeks).146 However, such experimental 
approach does not take into account the effects that slowly growing tumors have on the 
immune system and, as the authors stated,146 canine TVT is a more immunogenic 
tumor than other spontaneous cancers. Indeed, in the later clinical trials in dogs with 
spontaneous cancer, the responses were less impressive. In Pavlin and colleagues, 8 
dogs with mastocytoma’s were treated with hIL-12 pDNA electroporation, of which 6 
dogs with additional chemotherapy or surgery.221 The 2 dogs (with mastocytoma) that 
were treated with solely hIL-12 pDNA demonstrated a stable disease (follow-up time 36 
and 44 months respectively), which signifies according to RECIST criteria a response 
characterized as either an increase or a decrease in tumor burden insufficient in 
magnitude to qualify as partial regression or progressive disease.230 Six cancer-bearing 
dogs with various tumors were treated with hIL-12 pDNA225 of which 5 dogs with 
additional antitumoral therapies. The one dog treated with only IL-12 pDNA had an 
osteosarcoma and IL-12 treatment induced a stable disease (follow-up 5.5 months),225 
whereas median survival for osteosarcoma was 2.6 months after combination of surgery 
and chemotherapy and 4.3 months after chemotherapy and palliative radiation.165 
Cutrera and colleagues treated 4 cancer-bearing dogs with hIL-12 pDNA as a sole 
therapy.222 The response was not measurable in 2 dogs, but partial regression was 
present in the remaining 2 dogs. In one dog with multiple SCC nodules, 5 nodules were 
treated intratumorally and a mixed response ensued: 2 partial responses, 1 stable 
disease and 2 progressive diseases. In the second dog, with an oral melanoma, a 
transient partial regression was obtained.222 In a later case series published by the same 
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research group, 7 cancer-bearing dogs received EGT with only tumor-targeted canine 
IL-12 pDNA which led to a stable disease (3/7) or partial regression (4/7). Importantly, 
tumor growth did eventually resume in all patients that were treated with only cIL-12 
pDNA, indicating that the antitumor immune response induced by IL-12 is only 
transient.224 Recently, 18 dogs with melanoma were treated with subcutaneously 
injected NHS-IL-12, which led to 2 partial regressions, 5 stable diseases, 8 progressive 
diseases and 3 euthanasias due to adverse affects.227 
3.2.2.2.3 Differences in trial design in IL-12 pDNA trials in dogs 
The obtained clinical responses are difficult to compare between studies, since different 
doses or types of IL-12 pDNA, electroporation parameters, treatment frequencies or 
tumor types were evaluated (Table 5). All mentioned parameters can impact the 
treatment efficiency and will be briefly discussed. 
IL-12 of 3 different species has been evaluated in cancer-bearing dogs so far: feline, 
human and canine IL-12. Human or feline IL-12 pDNA were used in clinical trials due 
to lack of canine IL-12 pDNA availability. Feline and human IL-12 are both capable of 
activating canine leukocytes.220, 231, 232 IL-12 pDNA trials have been conducted with 
human, feline and canine IL-12 pDNA in dogs with SCC. The outcomes were similar 
and no serious adverse events were recorded.220, 222, 224  
Different doses of IL-12 pDNA (between 200 μg and 2 mg) have been evaluated in 
intratumoral IL-12 pDNA clinical trials in cancer-bearing dogs. For human IL-12 
pDNA the best results were observed at 1 mg IL-12 pDNA/tumor (which was the 
highest dose used in that stud y).146 Since responses were evident and no adverse effects 
were recorded with 1 mg of IL-12 pDNA in the preclinical study of Chuang and 
colleagues, most clinical trials opted to maintain this dose.  
The electroporation protocol used to transfect the IL-12 pDNA into the cancer cells can 
have a significant impact on the transfection efficiency.233 In a study conducted by 
Cemazar and colleagues, an electroporation protocol with low voltages and a long 
duration of pulses resulted in an almost 20 times higher transfection efficiency than a 
protocol with high voltages and a short duration of pulses.233 The administration route 
of IL-12 pDNA significantly impacts the efficacy of the IL-12 treatment. Li and 
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colleagues claimed that IT but not IM electroporation of the IL-12 gene induces CD8+ 
T cell infiltration, CTL activity, and tumor eradication.234 Despite this finding, the 
effects of IM administration of IL-12 pDNA EGT were still evaluated after this study, as 
IT IL-12 pDNA administration is not always feasible.225  
The tumor type has a significant impact on the transfection efficiency as well.233 In 
mouse models, melanoma was found to be more easily transfected than carcinoma, 
followed by carcinosarcoma and sarcoma.233 The specific properties of the 
electroporated tumor tissue could elicit different responses to treatment. These 
properties include differences in tissue organisation, extracellular matrix, presence or 
absence of necrosis, overall tissue conductivity, the ability of cells to express transfected 
genes, cell density, and cell size.233 This could explain why the observed transfection 
efficiency in vivo (1-3%) was significantly lower than in vitro (60%).233 In dogs with 
cancer, a better clinical effect was found for squamous cell carcinoma (SCC) and 
acanthomatous ameloblastoma (AA) than sarcoma’s,235 but, due to the small sample 
size, no statistical significance could be attributed to these findings. The apparently 
superior effects of IL-12 pDNA in SCC and AA could be pure coincidence, since only 5 
SCC’s and 2 sarcoma’s were treated (Table 6).224 
 
TABLE 5. Characteristics of IL-12 trials in dogs 
Tumor type 
IL-12 
type 
IL-12 
admini-
stration 
IL-12 dose 
Electroporation 
parameters 
Treatment 
frequency 
Ref 
Mastocytoma  H IT EP 
0.5-1 mg/cm3/session 
(tumor volume <2.5 
cm3); 
1 mg (tumor volume 
>2.5 cm3)  
1200 V/cm  
100 μs 1x 
140 V/cm 
8x50ms 
Weekly (max 
4 sessions) 
221 
Mastocytoma H IM EP 1 mg per tumor 
600 V/cm 1x 100 
μs, 1 s in 
between, 80 
V/cm 4x 100 ms 
Once 225 
Mastocytoma* H ID EP 
1-2 mg per treatment 
session 
1200 V/cm 1x 
100 μs, 140 
V/cm 1x 400 μs 
Once 236 
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Transmissible 
Venereal Tumor 
H IT EP 
0.1 mg, 0.3 mg or 1 
mg per tumor 
200 V/cm 10x 
50 ms 
Once 146 
Squameus Cell 
Carcinoma 
F IT EP 
150 μg/cm2 (total 
amount between 150 
and 400 μg) 
400V/cm 2x 
20 ms 
1-3 sessions, 
10-day 
interval  
220 
Squameus Cell 
Carcinoma   
C IT EP Not specified 
350 V/cm, 2x 20 
ms, 100 ms-
interval 
Variable 
(depending on 
results) 
224 
Squameus Cell 
Carcinoma   
H 
PT or  
IT EP 
0.2 mg, 0.4 mg, 0.75 
mg, 2 mg per 
treatment session 
350 V/cm 2x 20 
ms, 100 ms-
interval 
Day 1 and 7; 
day 1/7/15; 
day 
1/15/22/29, 
day 
1/8/15/29/35; 
“multiple” 
222 
Melanoma H 
SC 
injection, 
no EP 
0.8 mg/m 2 body 
surface, 1.6 mg/m2 
and 2.4 mg/m2 
NA Monthly  227  
Melanoma H IT EP 
0.2 mg, 0.4 mg, 0.75 
mg, 2 mg per 
treatment session 
350 V/cm 2x 20 
ms, 100 ms 
interval 
Day 1 and 7; 
day 1/7/15; 
day 
1/15/22/29, 
day 
1/8/15/29/35; 
“multiple” 
222 
Melanoma F IT EP 
150 μg/cm2 (total 
amount between 150 
and 400 μg) 
400V/cm 2x 
20 ms 
1-3 sessions, 
10-day interval  
220 
Sarcoma  C IT EP Not specified 
350 V/cm, 2x 20 
ms, 100 ms 
interval 
Variable 
(depending 
on results) 
224 
Sarcoma F IT EP 
150 μg/cm2 (total 
amount between 150 
and 400 μg) 
400V/cm 2x 
20 ms 
1-3 sessions, 
10-day interval  
220 
Ameloblastoma F IT EP 
150 μg/cm2 (total 
amount between 150 
and 400 μg) 
400V/cm 2x 
20 ms 
1-3 sessions, 
10-day 
interval  
220  
Osteosarcoma H IM EP 1 mg per tumor 600 V/cm 1x 100 Once  225  
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μs, 1 s in 
between, 80 
V/cm 4x 100 ms 
Pulmonary 
histiosarcoma 
 
H IM EP 1 mg per tumor 
600 V/cm 1x 
100 μs, 1 s in 
between, 80 
V/cm 4x 100 ms 
Once  225  
Mammary 
adenocarcinoma 
(1) 
H IM EP 1 mg per tumor 
600 V/cm 1x 100 
μs, 1 s in 
between, 80 
V/cm 4x 100 ms 
Once  225  
C: canine; EP: electroporation; F: feline; H: human, ID: intradermal; IM: intramuscular; IT: 
intratumoral; ms: millisecond; PT: peritumoral. 
TABLE 6. Outcome in canine IL-12 trials 
Tumor type Patients  
Control 
group 
IL-
12 
type 
IL-12 
admini-
stration 
Outcome Adverse effects Ref 
Mastocytoma°  8 (2) No H IT EP 2/2 response 
No adverse 
effects 
221 
Mastocytoma 6 No H IM EP 3/6 response 
No adverse 
effects 
225 
Mastocytoma* 18 No H ID EP 16/18 response 
No adverse 
effects 
236 
Transmissible 
Venereal Tumor 
16 
(purpose-
bred) 
Yes  H IT EP 16/16 response 
No adverse 
effects 
146 
SCC*° 6 (0) No F IT EP 3/6 response 
Minimal side 
effects (loss in 
appetite, 1 day 
lethargy) 
220 
SCC  5 Yes C IT EP 
5/5 transient 
response  
No adverse 
effects 
224 
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SCC  3 No  H 
PT or IT 
EP 
1/3 response of 
primary tumor 
and anti-
metastatic effects  
(2/3 not 
evaluable) 
No adverse 
effects 
222  
Melanoma 18 No H 
Injection 
SC, no 
EP 
7/18 response, 8/1 
progressive 
disease,  
3/18 fatal AE 
Thrombo-
cytopenia, liver 
enzymopathies, 
fever, vasculitis 
227  
Melanoma 1 No  H IT EP 1/1 response 
No adverse 
effects 
224 
Melanoma*° 1(0) No F IT EP 1/1 response 
No or minimal 
adverse effects 
220 
Sarcoma  2 Yes C IT EP 2/2 response 
No adverse 
effects 
224 
Sarcoma*° 2 (0) No F IT EP 2/2 response 
Joint 
enlargement in 1 
dog 
220 
Ameloblastoma*° 1 (0) No F IT EP 1/1 response 
No adverse 
effects 
220 
Osteosarcoma 1 No H IM EP 1/1 response 
No adverse 
effects 
225  
Pulmonary 
histiosarcoma 
1 No H IM EP 1/1 response 
No adverse 
effects 
225  
Mammary 
adenocarcinoma  
1 No H IM EP 1/1 response 
No adverse 
effects 
225  
AE: adverse effects, C: canine, EP: electroporation, F: feline, H: human, IM: intramuscular, IT: 
intratumoral, PT: peritumoral, response: complete response, partial response and/or stable 
disease. 
° Dogs between brackets indicate number treated with IL-12 electrogene therapy (EGT) only 
* Dogs treated with a mixture of IL-12 pDNA and Bleomycin
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3.3 Cancer-related immunosuppression  
3.3.1 The general principles of the immunosuppressive tumor 
microenvironment 
Cancer cells or host cells in the tumor environment can produce immunosuppressive 
modulators that abrogate the development of an efficient anticancer immune response. 
Unfortunately for the host, suppressor pathways in cancer immunology generally have 
a dominant effect over activating stimuli.45 In this way, a general tolerance toward 
tumor antigens will be generated when tumor antigens are simultaneously presented by 
immune-stimulating and by tolerizing APCs.45 However, exposure of 
immunosuppressive cells to Th1 cytokines can reeducate immunosuppressive cells and 
abrogate their immunosuppressive abilities, suggesting that immunosuppression in the 
whole may be reversible.172, 181 This is particularly important to cells of the innate 
immune system, which express stimulatory or regulatory characteristics depending on 
the immune context. In order to achieve maximal effect of any immunotherapy, the 
immunosuppressive environment of the tumor has to be tackled.45, 237 
Two different situations in the tumor microenvironment should be considered. 
Immunosuppressive mechanisms, such as Treg inhibition or CTLA4 blockage, can 
address the pre-treatment immunosuppressive burden.135 Agents such as anti-PDL1-
specific monoclonal antibodies, on the other hand, are better suited in the case of post-
treatment immunosuppression caused by the stressed patient’s cancer cells.135 
Immunotherapy can, via the induction of IFNγ secretion, induce PD-L1 expression on 
the host’s cancer cells and this will suppress the activity of PD1+ T cells.135 
Not only immunosuppressive cytokines and cancer cells, but also the tumoral stroma 
actively contributes to a decreased antitumoral immune response. The solid tumor 
stroma consists of fibroblasts, macrophage-lineage cells and vascular endothelial cells, 
with variable amounts of extracellular matrix.238 Cancer cells manipulate the tumor 
stroma by releasing profibrotic growth factors, such as TGFβ, that inhibit T cell 
activation, proliferation and differentiation239 and activate tumor stroma fibroblasts.240 
In turn, the activated fibroblasts induce a shift of the tumor stroma from a defensive to 
a permissive microenvironment. Indeed, these stromal cells produce growth factors, 
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such as TGFβ and VEGF, to enhance local tissue growth and further inhibit 
antitumoral T cell function.240  
 
Since multiple factors inhibiting T cell effector functions are present in the tumor 
microenvironment, blockade of two or more pathways should be considered for 
optimal therapeutic efficacy of treatments that stimulate the formation of antitumoral 
effector T cells.172 Combinations such as blockade of CTLA-4 plus PD-L1 or dual 
inhibition of LAG-3 and PD-L1 have shown to be synergistic in mouse models.241, 242 
For immunotherapy, the main focus now lies on therapies that enable antitumoral T 
cell efficacy: ipilimumab is an anti-CTLA-4 antibody that inhibits T cell suppression, 
pembrolizumab is an anti-PDL1 antibody that inhibits apoptosis of effector T cells by 
cancer cells and indoximod is small-molecule indoleamine 2,3-dioxygenase (IDO) 
pathway inhibitor which results in the provision of tryptophan, necessary for effector T 
cells to function.243 
Different targeted therapies to challenge the immunosuppressive elements of tumors 
have been described and they are listed in Table 7. 
 
TABLE 7. Immunosuppressive elements in cancer and therapeutic agents that affect their 
production or function  
Target Means Ref 
Cytokines 
IL-10 
Low-dose cyclophosphamide, anti-IL-10/IL-10R-blocking antibodies, 
anti-IL-10 antisense oligonucleotides 
244 
Epigenetic modification of DNA and histones 
DNMT 
HDAC 
DNMT-inhibitors (5- azacitidine) 
HDAC inhibitors (Vorinostat) 
64, 245, 246 
Growth factors 
EGFR mAb (Cetuximab, 7A7 mAb) 48, 87, 247 
VEGF mAb (Bevacizumab) 48  
TGFβ mAb, antisense oligonucleotide 137  
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Homing receptors 
CCR5 CCR5-antagonists (maraviroc, vicriviroc) 248  
Immune checkpoints 
4-1BB 4-1BB agonistic antibody (BMS-663513) 48, 134, 249 
CD40 
CD40-agonistic antibody (CP-870,893, SGN-40 (Dacetuzumab), 
HCD 122) 
69, 134, 249, 250 
GITR DTA-1 agonistic mAb 249 
ICOS-L ICOS-L-IgG fusion protein 134 
OX40 OX40 agonistic antibody 249 
TRAIL rhTRAIL, Apomab, Mapatumumab 53 
Immunosuppressive cells 
Treg 
Anti-CTLA4/LAG3 /PD1 (CT-011, BMS-936558)/PDL1 (MDX-
1105), CD25 Ab (Ontak), low doses cyclophosphamide, agonistic 
OX40/GITR (DTA1) Ab, Bcl-2 inhibitor, tyrosine kinase inhibitor 
(sunitinib)  
70, 251, 249 
MDSC 
Formalin-inactivated HSV, chemotherapy, PDL1, stimulation with 
activated NKT cells 
250, 252, 253 
Immune system down-regulating enzymes 
Arginase 
Arginase-inhibitors (shRNA directed against arginase I, S-(2-
boronoethyl)-L-cysteine  (BEC), NG-hydroxy-L-arginine (NOHA)) 
70, 254, 255 
IDO 
Methyltryptophan/anti-IDO siRNA, small-molecule IDO pathway  
inhibitor indoximod  
70, 254, 256 
Melanoma B-raf 
enzyme 
B-raf enzyme inhibitor vemurafenib 70, 254 
Tyrosine kinase Tyrosine kinase inhibitors (imatinib/sunitinib) 70, 254 
Immune system downregulating protein receptors 
A2aR A2aR mAb, adenosine analogues 135 
BTLA BTLA mAb 135 
CTLA-4 Anti CTLA-4-specific mAb (ipilimumab) 70, 135, 250, 257 
KIR KIR-specific mAb 258 
LAG3 
Anti LAG3-specific mAb (IMP701) 
LAG3–Ig fusion protein (IMP321) 
70, 135, 250, 257 
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PD-1 Anti PD1-specific mAb (MDX-1106, CT-011) 70, 134, 135, 250, 257  
PD-L1 Anti PDL1-specific mAb (MDX-1105) 70, 135, 250, 257 
TIM3 TIM3 mAb 135 
Inhibition of apoptosis 
cIAP1 Small molecule antagonists GDC-0152 259 
Survivin 
Anti-sense oligonucleotide LY2181308, ribozymes, siRNA, small 
molecule antagonists YM155, chemotargeting with silibinin and 
NSAID, vaccination with survivin-2B80-88 
64, 260 
Interaction block 
HVEM and 
BTLA/CD160 
Glycoprotein D 
Anti-CD160 mAb (CL1-R2) 
63, 134 
Pathways 
JAK2 ATP competitive inhibitor of JAK2-kinase (AZD1480) 48, 261 
mTOR mTOR inhibitor (aspirin) 251 
STAT3 JAK2-inhibitor (AZD1480) 261  
Wnt/β-catenin 
signaling  
Wnt/β-catenin signaling inhibitor (Salinomycin)  262 
Prostaglandin PgE2 
PgE2 COX2-inhibitor (aspirin, celecoxib, rofecoxib) 137 
4-1BB: Cluster of differentiation 137; A2aR: A2 adenosine receptor; Bcl-2: B cell lymphoma 2; 
BTLA: B and T lymphocyte attenuator; CCR5: Chemokine receptor 5; cIAP1: Cellular inhibitor 
of apoptosis 1; CTLA-4: Cytotoxic T lymphocyte-associated antigen 4; DNMT: DNA 
methyltransferase; EGFR: EGF receptor; GITR: Glucocorticoid-induced TNF receptor; HDAC: 
Histone deacetylase; HVEM: Herpes virus entry mediator; ICOS L: Inducible co-stimulatory 
molecule ligand; IDO: Indoleamine 2,3-dioxygenase; Ig: Immunoglobulin; JAK2: Janus kinase 2; 
KIR: Killer inhibitory receptor; LAG3: Lymphocyte activation gene 3; mAb: Monoclonal 
antibody; MDSC: Myeloid-derived suppressor cells; OX40: Cluster of differentiation 134; PD1: 
Programmed death 1; shRNA: Short hairpin RNA; STAT3: Signal transducer and activator of 
transcription 3; TGF-b: Tumor growth factor b; TIM3: T-cell membrane protein 3; TRAIL: 
TNF-Related Apoptosis-Inducing Ligand; Wnt/b-catenin: Wingless-type mouse mammary 
tumor virus integration site family member/b-catenin 
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3.3.2 Suppression of the immunosuppressive arm via metronomic 
chemotherapy 
3.3.2.1 The principles of metronomic chemotherapy 
Classic chemotherapy is a cytotoxic treatment designed to kill rapidly multiplying cells, 
such as cancer cells. Unfortunately, due to this rather unspecific approach, this 
treatment option is accompanied by many side effects.263 Because of toxicity-issues, the 
cancer patient requires recuperation time in between treatments, offering the cancer 
cells the chance to develop escape mechanisms and multiply.263 An alternative approach 
for classic chemotherapy is metronomic chemotherapy: administration of 
chemotherapeutics in small regular doses.263, 264 Administration of small doses of 
chemotherapeutics results in very low toxicity allowing uninterrupted administration. 
In contrast to classic chemotherapy, continuous low doses of certain chemotherapeutics 
are able to specifically decrease a number of immunosuppressive cells. For instance, low 
doses of cyclophosphamide and 5-fluoro-uracil can specifically target Tregs and 
MDSCs respectively.265, 266 Moreover, both chemotherapeutics have anti-angiogenic 
effects.267, 268 This continuous treatment results in persistent suppression of the targeted 
immune cells and/or tumor vasculature and thus less opportunities for the cancer and 
endothelial cells to adapt.267, 269 Whereas rapidly multiplying cancer cells are the target 
of classic cytotoxic chemotherapy, the immunosuppressive tumor microenvironment is 
the target of metronomic chemotherapy and thus the intrinsic sensitivity or acquired 
resistance of the cancer cells to the cytotoxic action of the drug is irrelevant.263 
Additionally, metronomic chemotherapy is very well tolerated and the versatile 
possibilities of oral intake (and thus at home treatment) contribute to a relatively low 
treatment-related cost.270 Although preclinical research and also preliminary clinical 
results with metronomic chemotherapy are promising, conclusive phase III trials are 
not yet completed.263 
Cyclophosphamide is an alkylating prodrug that is activated in vivo by liver enzymes to 
4-hydroperoxy cyclophosphamide (4-HC).271 4-HC induces Treg cell death, due to low 
intracellular ATP-amount of Tregs, which results in a decreased glutathione synthesis 
and thus a reduced capacity to detoxify 4-HC.265 Moreover, 4-HC causes apoptosis of 
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capillary endothelial cells by up-regulating the endogenous angiogenesis inhibitor 
thrombospondin (TSP)-1.272 In turn, TSP-1 binds to the CD36R on endothelial cells 
inducing apoptosis.273 Furthermore, TSP-1 binds to the CD47-part of the VEGFR, thus 
blocking the proangiogenic effects of VEGF on endothelial cells.274 Metronomic 
cyclophosphamide has also shown to restore NK cell function and inhibit tumor 
stromal cells.275 Chlorambucil and lomustine are both alkylating agents. Similar anti-
angiogenic activities as cyclophosphamide have been attributed to low-dose 
administration of chlorambucil276 and are so far unknown for lomustine. Toceranib is a 
tyrosine kinase inhibitor with an antitumoral (targeting tyrosine kinase) as well as anti-
angiogenic (targeting VEGFR2 and platelet-derived growth factor receptor (PDGFR)) 
activity.277, 278 
3.3.2.2 Metronomic chemotherapy in dogs 
3.3.2.2.1 Safety of metronomic chemotherapy in cancer-bearing dogs 
Metronomic chemotherapy offers a high tolerability and active modulation of the 
tumor microenvironment.279, 280 The most evaluated metronomic chemotherapeutic 
drug in human and canine patients is cyclophosphamide.278 Various doses of sustained 
metronomic cyclophosphamide treatment have been associated with the development 
of sterile hemorrhagic cystitis in a subset of treated dogs.278, 281, 282 Cystitis developed as 
an adverse effect of metronomic cyclophosphamide reported so far was apparent after a 
minimal treatment duration of 18 weeks.281 Alternatives for cyclophosphamide 
evaluated in cancer-bearing dogs include chlorambucil, lomustine and toceranib. It was 
demonstrated that metronomic toceranib is also capable of specifically targeting 
Tregs.280 No cystitis has been attributed to metronomic therapy with chlorambucil, 
lomustine or toceranib, only mild gastro-intestinal and hematologic effects similar to 
cyclophosphamide treatment were reported. However, long-term administration (> 12 
months) of metronomic chlorambucil or lomustine has led to grave hematologic 
adverse effects.283, 284 To summarize, 10 clinical trials evaluating the effects of 
metronomic chemotherapy have been performed so far. Of those 10 trials, 4 had a 
control group of which 2 were randomized.278, 285 The 6 remaining trials did not include 
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a control group. Seven trials were conducted with metronomic cyclophosphamide, of 
which 1 was complemented with toceranib280 and 4 with standard dosing of an NSAID 
and/or etoposide281 or toceranib.278 Treatment was well tolerated, although long-term 
treatment led to sterile hemorrhagic cystitis in a subgroup of patients. Two trials 
evaluated metronomic chlorambucil and 1 trial metronomic lomustine. Both 
metronomic chlorambucil and lomustine were well tolerated with only mild adverse 
effects. Long-term treatment (over 1 year) did, however, cause grave hematologic 
adverse effects for both chemotherapeutics (Table 8).283, 284  
3.3.2.2.2 Clinical response of metronomic chemotherapy in cancer-bearing dogs  
Significant increases in survival time have been reported after metronomic 
cyclophosphamide chemotherapy in hemangiosarcoma’s or soft tissue sarcoma’s,281, 282, 
289 whereas no increase in survival time was found for osteosarcoma’s.278 The effects of 
metronomic chemotherapy are difficult to evaluate since, in contrast to cytotoxic 
maximum tolerated dose (MTD) chemotherapy, the objective of metronomic 
chemotherapy is to offer disease stabilization through modulation of the tumor 
microenvironment.286 However, stable disease is a vague parameter for success in 
immunotherapeutic trials as tumor growth is not constant and has various plateau 
phases during its progression.287 These plateau phases are easily confused with stable 
disease. Therefore, it is difficult to interpret what the true antitumoral value of 
metronomic chemotherapy is. As a result, other parameters for evaluation of 
therapeutic success than stable disease might be more appropriate. Since the 
antitumoral activity of metronomic chemotherapy mainly depends on its anti-
angiogenic effects, it has been suggested that angiogenesis markers should be 
monitored to evaluate treatment efficacy and thus optimal dosing.286 Various 
angiogenesis markers have been proposed, including TSP-1, VEGF and circulating 
endothelial progenitor (CEP) cells.  
 
Metronomic chemotherapy has much potential in combinatorial treatments263 and 
possibly synergizes with other immunomodulatory or anti-angiogenic antitumoral 
therapies.286 Metronomic chemotherapy may sensitize cancer (stem) cells to classic 
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cytotoxic chemotherapy.282 As a consequence, dogs receiving continuous metronomic 
chemotherapy may benefit from pulses of conventional high-dose chemotherapy.282 It 
may not be opportune to continue metronomic chemotherapy during classic cytotoxic 
chemotherapy, as metronomic chemotherapy during classic cytotoxic chemotherapy 
did not result in specific decrease of Tregs.275 However, specific decrease of Tregs 
represents only one of the effects associated with metronomic chemotherapy and lack 
thereof during classic cytotoxic chemotherapy does not exclude its other antitumoral 
effects (such as anti-angiogenesis, restoration of NK cell effector functions and 
inhibition of normal stromal cells that support the growth of cancer cells).275 
 
 
TABLE 8. Metronomic chemotherapy trials in dogs with spontaneous cancer 
Tumor type Patients  
Control 
group 
Treatment 
protocol 
Outcome Adverse effects Ref 
Stage II 
splenic 
hemangio-
sarcoma 
9 
3 
randomized 
+ 21 
historical 
doxorubicin 
treated dogs 
Surgery followed 
by CP 12.5-
25mg/m2 + 
etoposide 
50mg/m2+ 
piroxicam 
0.3mg/kg 
MST 178 
days vs 
133 days* 
2/9 sterile 
haemorrhagic 
cystitis, mild 
unspecified 
gastro-intestinal 
or hematologic 
adverse effects 
281 
Incomplete 
resected soft 
tissue sarcoma 
30 
Concurrent 
non-
randomized 
dogs 
CP 
10mg/m2+piroxica
m 0.3mg/kg 
Median 
DFI 410 
vs 211 
days* 
3/30 sterile 
haemorrhagic 
cystitis, mild 
gastro-intestinal or 
renal adverse 
effects 
282 
Soft tissue 
sarcoma 
11 No 
CP 12.5mg/m2 or 
CP 15mg/m2 
MVD 
and Treg 
decreased 
(15mg/m
2) 
No adverse effects 279 
Various 
metastasized 
cancers 
15 No 
CP 25mg/m2 + 
celexocib 2mg/kg 
6/15 
response 
(MST 102 
days) 
No adverse effects 288 
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Various 
advanced 
stage cancers 
15 No 
Toceranib 
2.75mg/m2 + CP 
15mg/m2 
Treg 
decreased
, serum 
IFNγ 
increased 
Mild gastro-
intestinal or bone 
marrow-related 
adverse effects 
280 
Macroscopic 
soft tissue 
sarcoma 
20 
Historic non-
randomized 
dogs   
Surgery followed by 
radiotherapy 
followed by 1-2 
mg/kg/day 
thalidomide + 
piroxicam 0.3 
mg/kg/day + 7 
mg/m2 CP/ 2 days 
OS 757 vs 
286 days* 
No or mild adverse 
effects  
289 
Various 
cancers 
30 
Concurrent 
randomized   
CP 12.5 mg/m2,  
TMZ 6.6 mg/m2, 
CP 12.5+ TMZ 6.6 
mg/m2 
Treg 
decrease 
for  CP 
12.5 
mg/m2 
and its 
combinat
ion  
2/30 sterile 
haemorrhagic 
cystitis 
285  
Osteosarcoma 126 
Concurrent 
randomized 
surgery 
followed by 
carboplatin 
followed by 
CP+PI, 
historic 
surgery and 
carboplatin 
only 
Surgery followed by  
carboplatin 
treatment followed 
by CP 10 mg/m2 + 
0.3 mg/kg 
piroxicam + 2.75 
mg/kg toceranib 
OS no 
significant 
difference 
7/126 sterile 
haemorrhagic 
cystitis, mild 
gastro-intestinal, 
hematologic 
adverse effects 
278 
Various 
cancers 
81 No 
Lomustine 
2.84mg/m2 
29/81 
response 
22/81 
discontinued 
treatment due to 
mild hematologic, 
gastrointestinal, 
and/or moderate 
biochemical 
negative effects  
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Various 
cancers 
36 No 
Chlorambucil 
4mg/m2 
18/36 
response 
Mild 
gastrointestinal 
toxicity in 4 dogs 
290 
Transitional 
cell 
carcinoma 
31 No 
Chlorambucil 
4mg/m2 
21/31 
response 
(MST 221 
days) 
Mild gastro-
intestinal adverse 
effects, mild 
lethargy. 1/20 mild 
anemia, mild 
neutropenia, 
severe 
thrombocytopenia 
after 20 months  
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CP: cyclophosphamide, DFI: disease-free interval, MST: median survival time, MTTE: median 
time to terminal event, MVD: mean vascular density, TMZ: temozolomide. Mild adverse 
effects: anorexia, nausea or diarrhoea 
* indicates a significant difference 
3.4 Combinatorial immunotherapy against cancer   
Two major tumor microenvironments exist: T cell infiltrated and non-T cell 
infiltrated.170, 172 The T cell infiltrated tumor indicates that the tumor did induce an 
immune response, allowing antitumoral T cells to infiltrate the tumor. Unfortunately, 
the antitumoral effect of the infiltrated T cells is neutralized through inhibitory 
mechanisms of the tumor (such as secretion of immunosuppressive cytokines by cancer 
cells or immunosuppressive immune cells). On the other hand, tumors that are not 
infiltrated by T cells never evoked an antitumoral immune response.170, 172 One could 
adapt an antitumoral treatment strategy according to the patient’s tumor T cell 
infiltration status. For patients with a T cell infiltrated microenvironment, it could be 
sufficient to merely reactivate the immune response, whereas the immune response in 
patients with the non-T cell infiltrated microenvironment remains to be generated.170 
The differences in tumor microenvironment may explain why in most 
immunotherapeutic trials only a subset of patients responds to the treatment.165, 219, 220 
Indeed, most trials evaluate the effects of one immunotherapeutic treatment regimen 
wherein only one arm of the antitumoral immune system is stimulated, which is likely 
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insufficient for most cancer patients. It is unrealistic to expect significant results from 
one type of immunotherapy as the immune system and the tumor microenvironment 
interact in a very complex way. Most successful immune therapies are (just as in MTD 
chemotherapy291) combinatorial in nature. To treat against both T cell infiltrated and 
non-T cell infiltrated tumor microenvironments, a combinatorial approach targeting 
immune activation, immune enhancement and inhibitors of effector T cells might be 
most appropriate.170, 292 Since immunotherapy is only effective if the cancer 
microenvironment is restructured,59 depletion of Tregs and/or MDSCs from the tumor 
microenvironment could allow cancer vaccines not only to induce proper systemic 
effector and memory T cell populations, but also allow these effector cells to migrate to 
the cancer sites and exert their antitumoral activity.59 
The most effective cancer therapies probably consist of combinations of various 
immunotherapeutic strategies with rational combinations of other standard therapies 
(such as surgery, radiotherapy and conventional chemotherapy).292 For cancer vaccines 
in dogs, the best results so far were obtained by combining surgery with a cancer 
vaccine and antitumoral cytokines.147  
4 Conclusion 
The interaction between the immune system and the tumor microenvironment is very 
complex. In cancer patients, many aspects of the immune system contribute to the final 
therapeutic outcome which may be to the advantage or disadvantage of the cancer 
patient. Since the immune context is very important for the behavior of tumor-
infiltrating immune cells, efforts should be directed toward the manipulation of the 
protumoral microenvironment into an antitumoral environment capable of activating 
immune cells toward the tumor. It is therefore interesting to improve our knowledge 
on the most important aspects of the immune system in immunotherapeutic 
treatments: the innate immune system, the adaptive immune system and the 
immunosuppressive regulators of the immune system.  
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The general aim of this thesis was to explore the efficacy and tolerability of an 
antitumoral combination immunotherapy in cancer-bearing pet dogs.  
In the Laboratory of Gene Therapy, a preclinical combinatorial immunotherapeutic 
study was successfully performed in mice by Denies and colleagues.293 The combination 
of intratumoral murine (m)IL-12 pDNA administration with metronomic 
cyclophosphamide and a tyrosinase vaccine resulted in a higher cure rate and survival 
of cancer-bearing mice than only intratumoral mIL-12 pDNA administration or the 
combination of intratumoral mIL-12 pDNA with metronomic cyclophosphamide. We 
wanted to evaluate the safety and efficacy of each component in a more appropriate 
cancer model for humans, namely cancer-bearing pet dogs, prior to combination 
therapy. 
Chapter 1. Since the tyrosinase vaccine would only be applicable to dogs with 
melanoma, a vaccine vehicle for all tumor types (cancer cell vaccines based on 
immunogenically killed cancer cells) was first researched in mice. Immunogenically 
killed cancer cells are cancer cells that are killed with immunogenic cell death-inducers, 
which cause the cancer cells to evoke an immune response upon their death as opposed 
to a tolerance response.  
Afterward, the aim was to evaluate the effects of each component of the 
aforementioned combination treatment in cancer-bearing pet dogs.293  
Chapter 2. The safety and efficacy of only intratumoral IL-12 pDNA administration 
were evaluated in cancer-bearing pet dogs.  
Chapter 3. The effects of administration of only metronomic cyclophosphamide in 
cancer-bearing pet dogs were already assessed by Denies and colleagues293 prior to the 
studies described in this thesis. The results from this study indicated that the used 
metronomic cyclophosphamide protocol was safe and effective at reducing the amount 
of circulating Tregs. Therefore, this metronomic cyclophosphamide protocol was 
selected for our combination treatment of intratumoral IL-12 pDNA administration 
with metronomic cyclophosphamide in cancer-bearing pet dogs and the safety and 
efficacy of this combination were assessed.  
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1 Abstract 
Immunogenic cell death offers interesting opportunities in cancer cell vaccine 
manufacture, as it increases the immunogenicity of the dead cancer cell. Furthermore, 
fusion of cancer cells with dendritic cells is considered a superior method for 
generating whole cancer cell vaccines. Therefore, in this work, we determined in naive 
mice whether immunogenically killed cancer cells per se (cancer cell vaccine) elicit an 
antitumoral immune response different from the response observed when 
immunogenically killed cancer cells are associated with dendritic cells through fusion 
(fusion vaccine) or through co-incubation (co-incubation vaccine). After tumor 
inoculation, the type of immune response in the prophylactically vaccinated mice 
differed between the groups. In more detail, fusion vaccines elicited a humoral 
anticancer response, whereas the co-incubation and cancer cell vaccine mainly induced 
a cellular response. Despite these differences, all three approaches offered prophylactic 
protection against tumor development in the murine mammary carcinoma model 
tested. 
In summary, it can be concluded that whole cancer cell vaccines based on 
immunogenically killed cancer cells may not necessarily require association with 
dendritic cells to elicit a protective anticancer immune response. If this finding can be 
endorsed in other cancer models, the manufacture of cancer cell vaccines would greatly 
benefit from this new insight, as production of dendritic cell-based vaccines is 
laborious, time-consuming and expensive. 
2 Introduction 
Cancer vaccines have emerged as a new therapeutic modality for cancer.3 Cancer 
vaccines aim to reeducate the immune system to recognize and eliminate cancer cells.63 
An additional aim of cancer vaccines is to create an immune memory in order to 
prevent cancer recurrence. As a single modality, cancer vaccines will in most cases not 
be able to eradicate established tumors.145 However, they can reduce the risk of cancer 
recurrence,294 increase survival time154, 295 and induce regression of metastases.151, 296 
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One can divide cancer vaccines into (whole) cancer cell vaccines, genetic vaccines and 
peptide or protein vaccines.297 There are some strong arguments to consider whole 
cancer cell vaccines as superior to most other cancer vaccine types.297 First of all, there is 
no need to identify tumor antigens or select immunodominant epitopes on the tumor 
antigens for vaccine generation. Furthermore, a great variety of antigens is offered by 
whole cancer cells which evoke a Major Histocompatibility Complex (MHC)-
independent broad-ranged anticancer response. Additionally, the cancer cells contain 
epitopes for parallel presentation to both CD8+ and CD4+ T cells, which greatly 
diminishes the risk of tumor escape. Autologous cancer cells have the added advantage 
of containing patient-specific unique mutated antigens. Whole cancer cell vaccines 
have shown a higher objective clinical response ratio than peptide, protein or genetic 
vaccines.66, 69, 70, 71 Despite observed tumor eradication in experimental animal studies, 
limited success has been obtained so far in clinical trials for whole cancer cell vaccines 
in humans.71, 100 
 
Various forms of cancer cell vaccines exist and those loaded ex vivo with dendritic cells 
(DC) (DC-based vaccines) have been considered superior to non-DC-based vaccines in 
stimulating anticancer immunity in vivo101 as antigen presentation is facilitated in the 
former.67 DC-based vaccines can be generated through various techniques. DCs can be 
loaded through co-incubation with different types of tumor antigens, namely, whole 
cancer cells, tumor lysate, apoptotic cancer cells, peptides, transfection of RNA or 
DNA68 or, alternatively, they can be fused with cancer cells.298 DCs fused to cancer cells 
elicit levels of DC maturation and tumor-specific T cell activation that are superior to 
the levels obtained by DCs co-incubated or pulsed with cancer cells or tumor lysate, 
respectively.296, 298 In spite of these advantages, fusion vaccines are not common 
practice, since fusion is the most complicated method of loading DCs with cancer cells 
and has a low production efficiency.296 
 
The immunogenicity of whole cancer cells in vaccines can be increased through 
immunogenic cell death (ICD).299 In analogy, vaccines based on DCs pulsed with 
apoptotic cells are considered superior to those pulsed with whole cell lysate or necrotic 
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cells.298, 300 ICD can be induced by chemical agents such as anthracyclines (eg. 
Mitoxantrone (MTX)) or by physical stimuli (eg. UV light or γ-irradiation). The main 
characteristic of ICD-inducing stimuli is their ability to induce the expression or release 
of Danger (or damage)-Associated Molecular Patterns (DAMPs) from the killed cells. 
The DAMPs that are expressed or released by the cancer cells after ICD can interact 
with Pattern Recognition Receptors (PRRs) present on immune cells. Binding of 
DAMPs to PRRs results in the release of immunostimulatory cytokines and chemokines 
by the immune cell. As a result, antigen presenting cells (APCs) are stimulated to 
efficiently take up and process tumor antigens and cross-prime T cells.299 
 
In this article, we examined the in vivo effects of vaccines based on immunogenically 
killed cancer cells, induced by MTX, and whether the protective anticancer effects could 
be augmented through association with DCs (through co-incubation or fusion of DCs 
with immunogenically killed cancer cells). 
3 Materials and Methods 
3.1 Animals 
Female C57BL/6 mice, aged 6-8 weeks, were purchased from Janvier Labs (Janvier 
Breeding Center, 2013-06-ENG-RM-20) and housed at the Laboratory for Gene 
Therapy at the University of Ghent. Experiments were conducted at age 16-52 weeks. 
This experiment was approved by the Ethical Committee (approval number 
EC2013/123). 
3.2 Media and cell culture 
Complete medium consisted of Dulbecco’s modified Eagle’s medium (DMEM) 
(Invitrogen, 21041-033), supplemented with 100 IU/ml penicillin (Invitrogen, 15140-
122) and 10% heat-inactivated fetal bovine serum (Thermoscientific, SV30160.03). 
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EO771 cells, an aggressive estrogen receptor-positive poorly immunogenic mamma 
adenocarcinoma cell line (a kind gift from professor Jo Van Ginderachter), were grown 
in culture medium (CM). Stable transduction with luciferase of these cells with a 
luciferase gene was performed as described earlier by Van Impe.301 Briefly, retrovirus 
was produced in HEK293T cells by calcium phosphate transfection, harvested after 48 
and 72 h, filtered and concentrated by ultracentrifugation. Retroviral transduction was 
performed in the presence of 8 μg/ml polybrene and the efficiency was evaluated by 
bioluminescence. These cells were grown in DMEM, supplemented with 10% fetal 
bovine serum, 100 mg/ml streptomycin, 100 IU/ml penicillin and 1 mmol/ml L-
glutamine (Invitrogen, 25030-081). 
Monocyte-derived DCs were generated as described by Lutz.302 Briefly, bone marrow 
cells were harvested from the femur and tibia of sacrificed mice and seeded at 2x106 
cells per 100 mm dish in 10 ml DC-CM (ie. CM with 20 ng/ml recombinant murine 
GM-CSF (Peprotech, 315-03) and 50 μM beta-mercaptoethanol (Sigma-Aldrich, 
M3148-25ML)). Five ml of DC-CM was added on day 3 and on days 6 and 8 collected, 
centrifuged after which the cell pellet was resuspended in 5 ml of fresh DC-CM and 
given back to the original plate. On day 10, non-adherent DCs were harvested by gentle 
pipetting. 
3.3 In vitro evaluation of immunogenic cell death 
Induction of ICD. EO771 cells were incubated for 2 h in SFM (DMEM, supplemented 
with 100 IU/ml penicillin) containing various concentrations of MTX (Sigma, M6545) 
(1, 10 or 20 μM). Afterwards the MTX-treated EO771 cells were immediately analyzed 
for expression of the ICD markers CRT (Millipore, MABT145) and HSP70 (Abcam, 
ab45133) through Anti-Rabbit Antibody (Invitrogen, A-11008), or further incubated 
during 22 h in the same MTX-containing medium or in SFM. As controls, EO771 cells 
were incubated either in SFM or in CM during 2 or 24 h (n= 4 for each condition 
tested). Expression of ICD markers on cells was analyzed by flow cytometry (Accuri C6, 
BD Biosciences). To generate the cell suspension for flow cytometry we compared 
forceful pipetting with trypsinization, and we found that cells harvested via 
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trypsinization had a significantly lower expression of surface associated DAMPs than 
cells harvested via forceful pipetting (data not shown). Hence, all further cell harvesting 
was done through forceful pipetting. 
Evaluation of cell death after Mitoxantrone treatment. Vaccines based on cancer 
cells should be free of multiplying cancer cells to eliminate the risk of inducing cancer 
after in vivo administration. For this purpose, cell death after MTX-treatment was 
evaluated in vitro. Luciferase-positive EO771 cells (1x104) were treated with 1 μM MTX 
in 100 μl CM or left untreated in 100 μl CM in a black 96-well plate. After 24 h, 48 h 
and 72 h of incubation 10 μl of D-luciferin (Gold Biotechnology, LUCK-1G) was added 
per well and the plate was incubated at 37°C and 5% CO2  and 95% relative humidity 
for 15 min. The expression of luciferase (as identification of living EO771 cells) was 
measured with an IVIS Lumina II (Perkin-Elmer, Zaventem). 
Preparation of vaccines. Cancer cell-DC fusion hybrids were prepared as follows. 
Bone marrow-derived DCs and MTX-treated EO771 cells were mixed before fusion at 
DC:CC ratio (2:1) using 50% polyethylene glycol (PEG) (Sigma, P7306), as previously 
described.303 Briefly, the DCs and MTX-treated EO771 cells were washed with DMEM 
and mixed before fusion at DC:CC ratio (2:1). The cell mix was spun for 5 min at 1300 
rpm after which the supernatant was removed. The pellet was broken by a 2 min 
pipetting in 1 ml of prewarmed PEG (37˚C). Then, 1 ml of prewarmed DMEM was 
slowly added over 1 min followed by slow addition of 3 ml of DMEM over a period of 3 
min. This was followed by slow addition of 10 ml DMEM over a period of 1 min. The 
mixture was afterwards incubated for 5 min at 37˚C in a 15 ml final volume of DMEM, 
followed by centrifugation for 5 min at 1500 rpm. The cell pellet of the fusion products 
was resuspended in 30 ml CM, unless otherwise specified, and plated in 3 100 mm Petri 
dishes for 1 h. After 1 h of incubation, (fused) DCs were magnetically separated from 
the MTX-treated EO771 cells in the CC-DC mix according to the manufacturer’s 
instructions. Briefly, DCs were targeted with an antibody complex recognizing CD11c 
and dextran-coated magnetic particles (Stemcell Technologies, 18780). Labeled cells 
were subsequently separated using an EasySepTM magnet (Stemcell Technologies, 
18000). 
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Cancer cell-DC hybrids were also generated via co-incubation of MTX-treated EO771 
cells with DCs (co-incubation vaccine). In more detail, non-PEG-treated DCs and 
EO771 cells were co-cultured at the same DC:TC ratio (2:1). Unless otherwise stated, 
co-incubated cells were harvested 24 h after co-incubation. Like the fusion CC-DC 
hybrids the co-incubated CC-DC hybrids were magnetically separated from the CC-DC 
mix prior to further use. 
Confirmation of hybrid formation. Before fusion or co-incubation the DCs and 
MTX-treated EO771 cells were fluorescently labeled using respectively the PKH67-
Green Fluorescent Cell Linker Kit (Sigma, mini67 1 kit) and the CellVue® Claret Far 
Red Fluorescent Cell linker Kit (Sigma, MINCLARET-1KT). After labeling, the DCs 
and EO771 cells were mixed (DC:CC ratio 2:1) and were fused with 50% PEG or co-
incubated as described above. 
The fusion and phagocytosis efficiency (during co-incubation) was evaluated by 
assessing the percent of double-stained cells using flow cytometry and an inverted 
fluorescence microscopy (Ti-S/L100). Prior to vaccine administration, the amount of 
hybrids was determined through flow cytometry. A gate was placed on CD11c-PE-FL2 
positive cells and within this gate the number of MTX-FL4 positive cells was 
determined. 
Influence of fusion or co-incubation on DC maturation. After staining with CD11c 
antibody (Biolegend, 117307), the phenotypical maturation markers CD40 
(eBioscience, 11-0402) and CD86 (eBioscience, 11-0862-81) and the functional 
maturation marker IL-12p70 (eBioscience, 53-7123-80) were used to stain naive DCs, 
DCs co-incubated with LPS (Sigma, L4391-1MG) (100 ng/ml for 22 h), DCs co-
incubated with MTX-treated EO771 cells and DCs fused to MTX-treated EO771 cells. 
In the latter 2 conditions the amount of maturation markers was determined after 
magnetic separation of the CC-DC hybrids. For IL-12 measurement, the cells were 
permeabilized. Briefly, the cells were incubated during 4 h with Brefeldin A (Biolegend, 
420601) to block secretion of cytokines and then stained with CD11c prior to fixation. 
Afterwards the cells were permeabilized and stained with anti-IL-12 antibody in 
permeabilization buffer for 30 min at 4°C, and then analyzed by flow cytometry. 
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In vivo experimental setup. In the vaccine groups, mice were SC vaccinated on day 0 
in the left flank with 2x106 MTX-treated EO771 cells (cancer cell vaccine group), with 
2x106 MTX-treated EO771-DC hybrids obtained through co-incubation (co-incubation 
vaccine group), or with 2x106 MTX-treated EO771-DC hybrids obtained through 
fusion (fusion vaccine group). On day 35, a second vaccine was given in the right flank. 
The control group consisted of mice injected with a phosphate buffered saline solution 
(DPBS) (Invitrogen, 14190250) on days 0 and 35 (SC) in the flanks (left and right flank, 
respectively). The injections were performed with a hypodermic needle. Three mice in 
each group were euthanized on day 40 to characterize the cellular as well as the 
humoral response. Tumor inoculation was performed on day 42 with 5x105 EO771 cells 
in the right mammary fat pad of the fourth mammary gland with a hypodermic needle. 
Eight mice in each group were euthanized on day 142 (or earlier if the tumor would 
reach 1 cm2) for the memory cellular and humoral response. After euthanasia, spleen 
and serum were harvested (Figure 8). 
Cellular response: tumor-specific cytotoxicity. Splenocytes (2x105) from every 
mouse from every treatment group were co-incubated with luciferase-positive EO771 
cells (1x104) in 100 μl CM in a black 96-well plate. After 24 h of co-incubation, 10 μl of 
D-luciferin (Gold Biotechnology, LUCK-1G) was added per well and incubated during 
15 min at 37°C, 5% CO2 and 95% relative humidity. The expression of luciferase was 
measured with an IVIS Lumina II (Perkin-Elmer) and compared between the different 
treatment groups. The expression of luciferase is inversely correlated to cancer cell 
death caused by tumor-specific cytotoxicity. 
Cellular response: activation of Th1 or Th2 effector T cells. The ability of 
splenocytes of vaccinated mice to produce IFNγ (marker for activated CTLs and Th1 
cells) or IL-4 (marker for activated Th2 cells) when stimulated with EO771 whole cell 
lysate was evaluated. In detail, whole cell lysate of EO771 cells was developed as follows: 
cells were harvested with a scraper and re-suspended in a DPBS solution, at a final 
concentration of 8x107 cells/ml. A tablet cOmplete Mini (Roche, 5892970001) was 
added to the cells and the mixture was frozen quickly in a -154°C freezer for 10 min 
followed by rapid thawing in a 37°C water bath for 5 min. The quick freeze/thaw 
process was performed 5 times. 
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Subsequently, splenocytes were harvested and 1x107 splenocytes per mouse were 
incubated in 100 μl CM with 50 μl tumor lysate (the equivalent of 4x106 tumor cells) or 
without tumor lysate. After 18 h of incubation, Brefeldin A (1/1000 dilution) was added 
to block secretion of cytokines and the splenocytes were further incubated during 4 h. 
Afterwards, the splenocytes were harvested, washed and resuspended in FACS Buffer 
(BD Biosciences, 554656). Cell-surface staining with CD8 antibody (Biolegend, 100705) 
or CD4 antibody (Biolegend, 100509) was followed by fixation, permabilization and 
intracellular staining with IL-4 antibody (Biolegend, 504103) and IFNγ antibody 
(Biolegend, 17-7311-81). The cells were analyzed with a flow cytometer and events in 
the lymphocyte gate were selected. Control for specificity of the cytokine response was 
evaluated by assessing non-stimulated splenocytes. 
Humoral response. The presence of tumor-specific antibodies was determined as 
previously described 293. Briefly, serum of each mouse was 1/8 diluted in FACS Buffer. 
Washed EO771 cells (1.25x105) were resuspended in 50 μl of this diluted serum and 
incubated for 1 h at 37°C, 5% CO2 and 95% relative humidity. Subsequently, the cells 
were washed and stained with anti-mouse IgG antibodies (Biolegend, 405308) and the 
number of positive cells was analyzed via flow cytometry. Control for specificity of 
staining included EO771 cells that were not incubated with serum before being stained 
with the secondary antibodies. 
3.4 Statistical Analysis 
All data were analyzed with the statistical software program SPSS (version 19.0). The 
parametric data were analyzed with one-way ANOVA, the non-parametric data with 
the Kruskall-Wallis test with Bonferroni correction. Proportion data were analyzed 
with Fisher’s exact test. Statistical significance was determined at p≤ 0.05. 
4 Results 
In vitro optimization. Different MTX concentrations and incubation conditions were 
tested to induce ICD of the EO771 cells. The most optimal protocol for this purpose 
Chapter 1: Can dendritic cells improve whole cancer cell vaccines  
based on immunogenically killed cancer cells? 
79 
was 2 h of incubation in a 1 μM MTX-containing serum-free medium (SFM) followed 
by 22 h of incubation in SFM. This protocol yielded the highest expression of 
Calreticulin (CRT) (35.39% ±16.7) and Heat Shock Protein 70 (HSP70) (50.64% 
±20.74) on the surface of the immunogenically killed cancer cells. These MTX-treated 
cells also expressed significantly more CRT and HSP70 than the mildly stressed cells 
that were incubated in SFM (14.87% ±9.63, p=0.01 and 23.44% ±12.12, p= 0.012 
respectively) and than the unstressed control cells that were incubated in culture 
medium (CM) (12.1% ±3.2, p= 0.003 and 17.49% ±12.02, p=0.003 respectively). 
Mitoxantrone-treated EO771 cells are not able to induce tumors, since it was confirmed 
in vitro that EO771 cells treated with MTX do no longer multiply and die over a period 
of 3-4 days, whereas untreated EO771 cells continue to multiply. 
We demonstrated that immunogenic cell death has a positive influence on 
phagocytosis. We followed the phagocytosis of untreated and MTX-treated EO771 cells 
by DCs during 12 h. MTX-treated EO771 cells were much faster phagocytized by DCs 
than untreated EO771 cells. Depending on the time point, 2- 2.5 times more cancer 
cells (CC)-DC hybrids were formed after co-incubation of DCs with MTX-treated 
EO771 cells than with untreated EO771 cells (Figure 4). 
 
Subsequently, CC-DC hybrid formation via fusion or co-incubation of 
immunogenically killed cancer cells with DCs was compared and followed over 72 h. 
Thirty min after fusion or co-incubation, a significantly higher percentage of double-
fluorescent (hybrids) cells was observed after fusion (p= 0.002). The instant formation 
of hybrids after fusion was confirmed by the observation that the generation of hybrids 
after co-incubation occurred much slower. Indeed, the percentage of hybrids in the co-
incubation group gradually increased as a function of time and after 24 h, the 
percentage of hybrids was the same as in the fusion group (Figure 5). 
 
Chapter 1: Can dendritic cells improve whole cancer cell vaccines 
based on immunogenically killed cancer cells? 
80 
 
FIGURE 4. Phagocytosis of MTX-treated and untreated EO771 cells. Phagocytosis of MTX-treated 
(dash line) EO771 cells and untreated (solid line) EO771 cells by DCs during 12 h of co-
incubation (n= 4, error bars ± 1 SD) 
 
FIGURE 5. Formation and characterization of CC-DC hybrids. Hybrid formation between MTX-
treated EO771 cells fused to DCs (dash line) or co-incubated with DCs (solid line) (n= 4, error 
bars ±1 SD). 
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To ensure that real hybrids were measured and not merely aggregated cells, the 
formation of hybrids was also confirmed through fluorescence microscope imaging 
(data not shown). 
One can expect DCs to mature after fusion or co-incubation with immunogenically 
killed cancer cells.87,97,141,190 However, maturation markers such as CD40 and CD86 can 
also be expressed by cancer cells.304 Therefore, to unambiguously confirm DC 
maturation, the expression of CD40, CD86 and IL-12 by MTX-treated and untreated 
EO771 cells was measured. CD40 was highly expressed by MTX-treated and untreated 
EO771 cells, while CD86 and IL-12 were barely expressed by treated as well as 
untreated EO771 cells. Interestingly, MTX-treatment seemed to increase the expression 
of CD40, although statistical significance could not be reached (p=0.053), while it did 
not affect the expression of CD86 and IL-12 (p= 0.318 and p= 0.912, respectively). 
Since it was observed that the maturation marker CD40 was highly expressed on MTX-
treated cancer cells, this marker was not optimal to evaluate maturation of CC-DC 
hybrids. Hence CD86 and IL-12 were used as maturation markers (Figure 6 and Figure 
7). Twenty-four h after fusion or co-incubation with immunogenically killed EO771 
cells, CD86 expression as well as IL-12 production in DCs were not significantly higher 
than in naive DCs and did not reach the CD86 and IL-12 levels observed in LPS treated 
DCs. After 48 h, the CD86 expression remained not significantly higher and, 
interestingly, the level of IL-12 expression dropped in DCs fused with immunogenically 
killed cancer cells or treated with LPS and even returned to the levels close to those of 
naive DCs. In contrast, the level of IL-12 production in DCs co-incubated with 
immunogenically killed cancer cells was significantly higher than in naive DCs and 
similar to the IL-12 level 24 h after co-incubation (Figure 6 and Figure 7). 
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FIGURE 6. Characterization of CC-DC hybrids. Influence of fusion or co-incubation of EO771 
cells with DCs on functional DC maturation (IL-12 production) (n= 3, error bars ± 1 SD). 
 
FIGURE 7. Characterization of CC-DC hybrids. Influence of fusion or co-incubation of EO771 
cells with DCs on phenotypical DC maturation (CD86 surface expression) (n= 3, error bars ± 1 
SD). 
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In vivo effects of whole cancer cell vaccines based on immunogenically killed 
cancer cells followed by tumor inoculation. Three groups of 11 mice were vaccinated 
with either immunogenically killed EO771 cells (cancer cell vaccine group), 
immunogenically killed EO771 cells co-incubated with DCs (co-incubation vaccine 
group) or fused with DCs (fusion vaccine group). A fourth group of 11 mice served as 
control and was treated with a saline solution (negative control group). The vaccination 
and sample collection schedule is shown in Figure 8. The effect of immunogenically 
killed EO771 cells and co-incubation or fusion of immunogenically killed EO771 cells 
with DCs on the elicited immune response in mice was evaluated. 
 
FIGURE 8. In vivo experimental setup. All mice received on days 0 and 35 in the flanks (left and 
right flank, respectively) a subcutaneous injection of phosphate buffered saline (control group) or 
1 of the 3 vaccines (cancer cell vaccine, co-incubation vaccine or fusion vaccine). Three mice in 
each group were euthanized on day 40 and spleen and serum were collected to characterize the 
cellular and humoral response (tumor-specific cytotoxicity, activation of Th1 or Th2 effector T 
cells, production of tumor-specific antibodies). Tumor inoculation was performed on day 42. 
Eight mice in each group were euthanized on day 142 (or earlier if the tumor would reach 1 cm2) 
and spleen and serum were collected for the characterization of the memory cellular and humoral 
response (tumor-specific cytotoxicity, activation of Th1 or Th2 memory T cells, production of 
tumor-specific antibodies). 
Five days after the second vaccination, cellular and humoral responses were evaluated 
in the mice of all 4 groups. The percentages of activated tumor specific T helper (Th)2 
CD4+ and CD8+ T cells were significantly higher in the co-incubation vaccine group 
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than in the control group and the other vaccine groups. The latter vaccine groups did 
not generate more activated Th2 T cells than the control group (Figure 9). 
 
FIGURE 9. In vivo evaluation of vaccines based on immunogenically killed EO771 cells. Activation 
of Th2 effector cells (IL-4 positive CD4+ and CD8+ T cells) 5 days after the second vaccination 
(n=3, ± 1 SD). Abbreviations: Control, control group; CCV, cancer cell vaccine group; CIV, co-
incubation vaccine group; FV, fusion vaccine group; Pre, 2 days prior to tumor inoculation or 5 
days after the second vaccination. 
The percentages of activated tumor specific Th1 or cytotoxic T lymphocyte (CTL) CD4+ 
and CD8+ T cells in the vaccinated groups were not significantly higher than in the 
control group. The cellular response was also characterized by measuring tumor-
specific cytotoxicity (in vitro cancer cell killing capacity of isolated splenocytes). 
Splenocytes from the cancer cell vaccine group resulted in a significantly higher cancer 
cell killing than splenocytes collected from the fusion vaccine or control group (Figure 
10), while those of the co-incubation vaccine group only differed significantly from the 
control group. 
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FIGURE 10. In vivo evaluation of vaccines based on immunogenically killed EO771 cells. The 
humoral response (presence of antibodies against EO771 cells) (Pre n=3, Post n=8, ± 1 SD). 
Abbreviations: Control, control group; CCV, cancer cell vaccine group; CIV, co-incubation 
vaccine group; FV, fusion vaccine group; Pre, 2 days prior to tumor inoculation or 5 days after 
the second vaccination; Post, 100 days post tumor inoculation or 102 days after the second 
vaccination. 
Five days after the second vaccination, the humoral response (presence of antibodies 
against EO771 cells) was confirmed in all vaccinated groups, yet only the co-incubation 
and fusion vaccine group had, compared to the control group, significantly higher 
levels of IgG antibody directed against the EO771 cells. The highest antibody levels 
were measured in the co-incubation vaccine group, which parallels the high percentage 
of activated Th2 T cells in this group (Figure 11). 
 
Six of 8 mice in the control group developed a tumor after the tumor inoculation, 
which differed significantly from 1 in 8 mice in the cancer cell vaccine group (p= 0.041) 
and none in the co-incubation and fusion vaccine group (p= 0.015). 
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Hundred days after the tumor challenge, significant differences in the type of immune 
response were observed between the different treatment groups at the time of necropsy. 
The percentages of activated tumor specific T helper (Th)2 CD4+ and CD8+ T cells in 
any vaccine group were not significantly higher than in the control group. The 
percentages of activated tumor specific Th1 T cells and CTL in mice of the cancer cell 
and the co-incubation vaccine groups were significantly higher than in the control 
group (Figure 12), indicating a clear memory T cell response. 
 
 
FIGURE 11. In vivo evaluation of vaccines based on immunogenically killed EO771 cells. The 
cellular response for tumor-specific cytotoxicity (in vitro cancer cell killing capacity of isolated 
splenocytes. In this cytotoxicity assay, the percentage of live EO771 cells inversely correlates with 
the efficacy of the vaccine/group (Pre n=3, Post n=8, ± 1 SD). Abbreviations: Control, control 
group; CCV, cancer cell vaccine group; CIV, co-incubation vaccine group; FV, fusion vaccine 
group; Pre, 2 days prior to tumor inoculation or 5 days after the second vaccination; Post, 100 
days post tumor inoculation or 102 days after the second vaccination. 
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FIGURE 12. In vivo evaluation of vaccines based on immunogenically killed EO771 cells. 
Activation of Th1 and CTL effector cells (IFNγ-positive CD4+ and CD8+ T cells) 102 days after 
the second vaccination (n=8, ± 1 SD). Abbreviations: Control, control group; CCV, cancer cell 
vaccine group; CIV, co-incubation vaccine group; FV, fusion vaccine group; Post, 100 days post 
tumor inoculation or 102 days after the second vaccination. 
The tumor-specific cytotoxic effect of the isolated splenocytes was also higher in these 
groups than in the control group, but did just not reach the significance level (p=0.064 
and 0.085 respectively) (Figure 10). On the other hand, no indications of a cellular 
memory could be found in the fusion vaccine group. Hundred days after the tumor 
challenge, the level of tumor-specific antibodies was, compared to the control group, 
significantly higher in the cancer cell and fusion vaccine groups, but not in the co-
incubation group (Figure 11). Thus, a clear humoral memory was established in the 
cancer cell and fusion vaccine group, but not in the co-incubation vaccine group. 
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5 Discussion 
Association of cancer cells with DCs and ICD of cancer cells both improve the 
immunogenicity of whole cancer cell vaccines. We examined whether the 
immunogenicity of immunogenically killed cancer cells could be further enhanced 
through association with DCs. The impact of these constructs was monitored by 
measuring cellular and humoral (memory) responses of all included mice groups 
(Table 9). 
 
TABLE 9. Cellular and humoral responses in the different vaccine groups 
Vaccine 
groups 
Cellular Humoral 
IFNγ (%) IL-4 (%) Cytotoxicity (%) IgG (%) 
Pre Post Pre Post Pre Post Pre Post 
Control 0.97 ± 0.28 0.46 ± 0.41 2.03 ± 0.47 
16.26 ± 
32.75 
0.75 ± 0.05 0.82 ±  0.19 2.43 ± 1.66 
15.26 ± 
24.87 
CCV 0.58 ± 0.23 1.08 ± 0.43 6.12 ± 3.47 4.96 ± 4.92 0.35 ± 0.10 0.61 ± 0.26 4.67 ± 3.23 
41.32 ± 
12.22 
CIV 1.19 ± 0.22 1.00 ± 0.33 
29.42 ± 
17.49 
2.22 ± 0.43 0.41 ± 0.31 0.68 ± 0.07 
19.79 ± 
14.13 
19.34 ± 9.83 
FV 0.87 ± 0.16 0.50 ± 0.19 3.99 ± 0.96 1.50 ± 0.78 0.63 ± 0.08 0.74 ± 0.17 
10.53 ± 
7.35 
52.22 ± 
20.35 
Control: control group; CCV: cancer cell vaccine group; CIV: co-incubation vaccine group; FV: 
fusion vaccine group; Pre: 2 days prior to tumor inoculation or 5 days after the second 
vaccination; Post: 100 days post tumor inoculation or 102 days after the second vaccination; 
IFNγ: IFNγ produced by CD4+ and CD8+ T cells stimulated with EO771 cell lysate (marker for 
CTL and Th1 activation); IL-4: IL-4 produced by CD4+ and CD8+ T cells stimulated with EO771 
cell lysate (marker for Th2 activation); Cytotoxicity: in vitro efficacy of isolated splenocytes to 
kill EO771 cells; IgG: presence of IgG-antibodies on EO771 cells. Mean data with 1x standard 
deviation per group are represented, significant results are marked in bold. 
Although cancer cells used in whole cancer cell vaccines are often irradiated prior to 
use299, 305, 306 and irradiation is able to cause ICD,50 we cannot assume the antitumoral 
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effects of these vaccines arise from immunogenically killed cancer cells. Indeed, the 
question remains whether irradiation can specifically and efficiently induce ICD.307 To 
unambiguously evaluate the effects of ICD, MTX, a well-known ICD inducing agent, 
was used as the ICD inducing stimulus. 
 
None of the mice vaccinated with immunogenically killed cancer cells fused (fusion 
vaccine) or co-incubated (co-incubation vaccine) with DCs developed a tumor after 
tumor challenge. In the group that received only the immunogenically killed cancer 
cells one mouse developed a tumor after tumor challenge. In contrast, 75% of the mice 
of the control group did develop a tumor after tumor challenge (Figure 13). 
 
 
FIGURE 13. Kaplan–Meier survival curve after tumor challenge of prophylactically vaccinated 
mice (n=8/group). Abbreviations: CCV, cancer cell vaccine group; CIV, co-incubation vaccine 
group; Control, control group; FV, fusion vaccine group. 
Therefore, it is sound to conclude that all tested vaccines induced a protective effect 
against cancer growth. Although all vaccinated groups were protected against tumor 
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development, our experiments indicated that the immunological responses accountable 
for this protection were different between the different vaccine groups. 
In the co-incubation vaccine group, tumor-specific cytotoxicity and humoral responses 
were present shortly after the second vaccination. Surprisingly, hundred days later, a 
significant cellular memory response for CTL and Th1 activation was present but only a 
trend towards increased tumor-specific cytotoxicity and humoral response was 
observed. This decline in cellular and humoral response in time could potentially be 
explained by the fact that the co-incubation vaccine induced such a powerful effector 
effect that the responding lymphocytes were driven into terminal differentiation and 
did not have the opportunity to develop a memory response.137 
In the fusion vaccine group, no cellular response was induced after vaccination and the 
observed humoral response appeared relatively weak. Hundred days after the tumor 
challenge, the humoral memory response demonstrated a 5-fold increase compared to 
the response before challenge, while a cellular response remained absent. The fact that 
none of the mice in this group developed a tumor suggests that a sole humoral response 
has protective effects against tumor development. The observed protection is 
potentially mediated through Th2-cytokine IL-24.308 Indeed, although Th2 cells have 
been associated in the past with a contribution to tumor growth,309 large numbers of 
tumor-infiltrating Th2 cells are associated with significantly improved disease-free 
survival in human patients with classical Hodgkin lymphoma.310 
Vaccination with immunogenically killed cancer cells only induced a strong tumor-
specific cytotoxicity response, but no humoral response. After the tumor challenge, 
there was a significant humoral and cellular memory response (for CTL and Th1 
activation and a trend for tumor-specific cytotoxicity). 
It is noteworthy that the initial cellular immune responses in the vaccinated groups 
seem to originate from CTLs with lytic activity that secrete no or low amounts of IFNγ, 
as we did not observe significantly higher amounts of IFNγ positive cells within 5 days 
after the second vaccination compared to the control group. Likewise, CTLs with lytic 
activity that do not secrete IFNγ have been reported by several other research groups.311, 
312 Indeed, IFNγ and cytotoxicity are regulated independently in CD8+ T cells.311 
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Many previous studies with CC-DC fusion vaccines mentioned an overnight incubation 
of the fusion mixture.105, 306, 313-316 Yet our in vitro data revealed that during overnight 
incubation of the fusion mixture, CC-DC hybrids are also formed via phagocytosis of 
unfused cancer cells by unfused DCs. Therefore, it is very likely that in overnight 
incubated fusion mixtures, two types of CC-DC hybrids are present: on the one hand 
hybrids that are formed via fusion, on the other hand hybrids that occur after 
phagocytosis of cancer cells by DCs. In our study, the CC-DC hybrids were purified 
shortly after fusion and hence the formation of hybrids through phagocytosis was 
prohibited. In the literature, humoral as well as cellular responses have been reported 
after vaccination with “unpurified” CC-DC fusion vaccines.317 Our data documented 
that the fusion vaccine mainly operated through a humoral response, suggesting that 
the cellular response induced by unpurified fusion vaccines with overnight incubation 
most likely originates from CC-DC hybrids formed via phagocytosis and not via fusion. 
The lower immunogenicity of our fusion vaccine compared with the other fusion 
vaccines reported in the literature could be accredited to the use of pure CC-DC fusion 
hybrids. However, there are two other possible reasons that may explain why our fusion 
vaccine did not elicit a significant cellular response. First, it has been reported that in 
some CC-DC fusion hybrids based on mature DCs, like in this study, the anti-
inflammatory cytokine IL-10 is produced, which tempers the cellular immune response 
and skews it toward a Th2 response.318 Second, O’Connor et al319 described reversal of 
mature DCs to an immature state after fusion319 that is less capable of homing toward 
the lymph node. Therefore, cellular responses might not be induced, as they are highly 
dose responsive,120 whereas for antibody responses the minimal antigen threshold is 
relatively low.119 
 
The cancer cell and the co-incubation vaccine group both did induce cellular as well as 
humoral immune responses. It has been shown that primarily the lymph node residing 
CD11c+ macrophages are essential for the cross-presentation of dead cell antigens.320 
However, a small contribution of migratory DCs, as present in the co-incubation 
group, cannot be ruled out320 and might explain the differences in timing and intensity 
of the immune reactions observed between these two vaccine groups. 
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Although it has been reported that SC injection of EO771 cells near the fat pad of the 
fourth mammary gland into C57BL/6 mice resulted in tumor development in 97% of 
the inoculated mice,321 gross tumor growth was only present in 75% of the non-
vaccinated mice. Yet, the number of affected mice in the control group versus any of 
the vaccine groups was significantly different. 
Since the fusion process can reverse the maturation state of DCs, preferably immature 
DCs should be harvested for vaccination with fusion-based vaccines.319 Dendritic cells 
in this work were selected through their expression for CD11c in order to remove non-
hybridized MTX-treated EO771 cells from the CC-DC mix. Since mature DCs express 
more CD11c than immature DCs,322 mature DCs were more likely selected prior to 
fusion. Consequently, the obtained response in the fusion vaccine group is possibly 
lower than it could have been. A possible solution for fusion-based DC vaccines could 
be selection of DCs based on DC immaturity markers CCR1, CCR2 or CCR5319 after 
negative selection of DCs. 
6 Conclusion 
In conclusion, based on our findings, we stipulate that vaccination with 
immunogenically killed cancer cells alone or with CC-DC hybrids obtained via co-
incubation or fusion of immunogenically killed cancer cells with DCs, results in the 
protection of vaccinated mice against tumor development when challenged 5 days after 
the second vaccination. However, the immune responses responsible for this protection 
differ between the vaccine types. The immunogenically killed cancer cells without DCs 
protect the mice against tumor development via a cellular response only. The pre-
inoculation protection in the fusion vaccine occurs mainly via a humoral response, 
whereas the co-incubation vaccine protects the mice via a cellular as well as a humoral 
immune response. 
The current study indicates that vaccination with immunogenically killed cancer cells 
(with or without DCs) may be a useful prophylactic strategy for cancer growth. Based 
on the finding that a non DC-based cancer cell vaccine provided protection when using 
immunogenically killed cancer cells, the manufacture of cancer cell vaccines can 
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potentially be simplified as the production of DC-based vaccines is laborious, time-
consuming and expensive. Further research should be performed to confirm the 
advantages of ICD in cancer cell vaccines. Additional cancer models should be tested to 
document whether other cancer types will reveal similar results. 
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1 Abstract 
Interleukin 12 (IL-12) is a powerful immunostimulatory cytokine with a strong 
antitumoral activity. In this work, the immunological, anti-angiogenic and clinical 
effects of 3 consecutive intratumoral IL-12 electrogene therapy (EGT) treatments were 
evaluated in 9 dogs with spontaneous cancer. In all dogs, tumor biopsies and blood 
samples were taken prior, during and after the intratumoral IL-12 EGT (on day 1, 8, 35 
and 1, 3, 8, 15, 35 respectively). An initial decrease in immune cells was followed by an 
increase above baseline 1-3 weeks after treatment initiation. Interestingly, the decrease 
in peripheral leukocytes 2 days after intratumoral IL-12 EGT coincided with erythema 
and tumor swelling. Transient increases of IL-12 and IFN-γ were measured in the 
serum and the tumor tissue, whereas IL-10 transiently increased only in the serum. The 
effect of intratumoral IL-12 EGT on the levels of IL-24 and vascular endothelial growth 
factor in the sera and tumor biopsies differed per dog. Via contrast-enhanced 
ultrasound (on day 1, 8 and 35), we demonstrated that intratumoral IL-12 EGT resulted 
in a significant decrease of the relative blood volume and blood flow speed in the tumor 
compared to baseline. Metastases were present in 2 dogs. In 1 of these dogs, IL-12 EGT 
of the primary tumor was associated with a transient partial regression of the 
metastases, but not of the primary tumor. The second dog with metastases did not 
survive long enough to complete the entire treatment cycle.  
Despite encouraging immunostimulatory and anti-angiogenic effects after intratumoral 
IL-12 EGT, no clinically relevant outcomes were observed in this study, since persistent 
tumor regression could not be obtained. On the other hand, the laboratory and 
ultrasound results hold great promise for combinatorial strategies of intratumoral IL-12 
EGT with conventional antitumor (immuno)therapies. 
2 Introduction 
During the last decennia, our knowledge on how cancer cells interact with the cancer 
patient’s immune system has exponentially increased. This has resulted in the belief 
that immunotherapy can play an important role in the treatment of cancer. In 
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principle, the immune system is able to recognize and kill cancer cells. Yet the tumor 
and its microenvironment are capable of creating a protective immunosuppressive 
shield.45 Unfortunately for the host, suppressor pathways in cancer immunology 
generally have a dominant effect over activating stimuli.45 In this way, a general 
tolerance toward tumor antigens will be generated when tumor antigens are 
simultaneously presented by immune-stimulating and by tolerizing antigen presenting 
cells (APCs). Therefore, part of the treatment strategy in cancer patients should aim at 
tackling the protumoral microenvironment, allowing the immune system to exert its 
antitumoral effects.45, 237 
Interleukin 12 (IL-12) is an immunostimulatory cytokine, produced by different 
immune cells like dendritic cells (DCs). It plays a key role in the regulation of 
inflammation by linking innate and adaptive immune responses. In addition, it has 
powerful antitumoral properties. Interleukin 12 leads to activation and proliferation of 
T cells and Natural Killer (NK) cells.200, 201, 202 It is able to recruit NK cells, activated T 
cells and polymorphonuclear (PMN) cells,198, 199 making IL-12 a useful booster of a pre-
existing immune response. In turn, activated T cells produce interferon (IFN) γ, which 
induces a positive feedback loop on IL-12 secretion by APCs.197 Not only can IL-12 
engender instant activation of (antitumoral) effector cells, it can also program effector 
T cells for optimal generation of effector memory T cells and T follicular helper cells.203, 
204 Furthermore, IL-12 decreases the suppressive function of myeloid-derived 
suppressor cells (MDSC)207 and inhibits the differentiation of T cells to regulatory T 
cells (Tregs) as well as the expansion of Tregs.205, 206 An additional antitumoral 
mechanism of IL-12 is the inhibition of angiogenesis through the induction of IFNγ-
Inducible Protein (IP) 10 and Monokine Induced by Gamma IFN (MIG). These two 
cascade products of IFNγ inhibit the formation of new blood vessels208 by i.a. decreasing 
the production of angiogenic factors such as vascular endothelial growth factor (VEGF) 
and metalloproteinase (MMP) 9.208, 209, 210, 211, 212  
Interleukin 12 has intriguing antitumoral features; yet grave toxicity has been shown 
when recombinant IL-12 protein was administered intravenously (IV) to human cancer 
patients.213 This toxicity has urged the need to find alternatives for systemic IL-12 
treatment and led to the evaluation of tumor-specific delivery methods of IL-12. A 
Chapter 2: Intratumoral interleukin 12 gene therapy stimulates the immune system  
and decreases angiogenesis in dogs with spontaneous cancer 
99 
simple and often used approach to target IL-12 to the tumor consists out of 
intratumoral IL-12 gene therapy. This can be accomplished through various ways and 
one of which is electroporation, a reproducible and highly efficient method to deliver 
plasmid (p)DNA.214 Electroporation is the short administration of electrical pulses to 
ensure the formation of transient pores into the plasma membrane of cells, thereby 
facilitating the intracellular delivery of large molecules such as pDNA.215 Once the 
pDNA reaches the cell’s nucleus, the production of the protein encoded by the plasmid 
ensues.216, 217 In vivo electroporation does not cause any severe adverse events,218 and 
several canine and human clinical trials showed the safety and clinical efficacy of 
electroporation-mediated intratumoral delivery of a pDNA encoding IL-12.235, 219, 220, 221 
Those studies present evidence that it is possible to overcome local suppressor 
pathways in tumors and tip the balance in favor of an antitumor immune response. 
Regression of electroporated primary tumors223, 221, 146, 235 and distant non-treated 
metastases219, 222, 223  has been observed when small tumors of human and canine cancer 
patients were treated with intratumoral IL-12 gene therapy. However, in these studies 
successes were present in only a subset of patients, whereas others patients seemed 
refractory to such approach.146, 219, 221, 222  
 
Given the above, we wanted to investigate whether the effects of IL-12 therapy on the 
immune system are comparable in every dog with spontaneous cancer. To this end, we 
aimed to examine in more detail the immunological and anti-angiogenic effects of 
intratumoral IL-12 EGT in canine cancer patients with different tumor types by serial 
tissue biopsies and blood samples. The immunological effects were studied by 
monitoring the blood levels of lymphocytes, monocytes and granulocytes. Also the 
serum and intratumoral levels of key Th1 and Th2 cytokines were studied. The anti-
angiogenic effect of the IL-12 gene therapy treatment was studied by monitoring local 
and systemic VEGF levels as well as by contrast-enhanced ultrasound. Contrast-
enhanced ultrasound is a technique that has recently been validated to measure the 
efficacy of anti-angiogenic treatments in clinical trials.323 To detect possible side effects 
of IL-12 gene therapy, we monitored the dogs by regular physical examinations and by 
analyses of selected hematology and biochemistry parameters. 
Chapter 2: Intratumoral interleukin 12 gene therapy stimulates the immune system 
and decreases angiogenesis in dogs with spontaneous cancer 
100 
3 Materials and methods 
3.1 Animal selection 
Client-owned dogs with spontaneous malignant neoplasms were enrolled at the Faculty 
of Veterinary Medicine of Ghent University between October 2014 and April 2015 if 
they met the following inclusion criteria: a histologically confirmed neoplasia accessible 
for application of electrodes, normal cardiovascular function, good general health 
status and a biochemistry profile within reference range. Patients included in the study 
were not eligible for surgery, either due to recurrent disease for which conventional 
surgery was already exhausted, or due to impractical location of the tumor. Baseline 
bloodwork consisted of a complete blood count (CBC) with differential white blood cell 
count, which was performed using an automated laser hematology analyzer (Procyte, 
Idexx, The Netherlands) with species-specific software (Vetlab Station). The automated 
chemistry analyzer Technicon RA-XT (Catalyst, Idexx, The Netherlands) was used for 
the determination of the following biochemical parameters: blood urea nitrogen 
(BUN), creatinine, serum alkaline phosphatase (SAP), alanine aminotransferase (ALT), 
glucose, total protein, and globulins. 
The study cohort consisted of 9 dogs, 5 castrated males and 4 spayed females of 8 
different breeds (Golden Retrievers (n=2), Malinois, Bouvier, Maltese, Labrador 
Retriever, Bichon Frisé, French Bulldog and Bordeaux Dog); their age ranging from 2.9 
to 13.7 years (mean 9.5 ± 4.1years) (Table 10).  
In all animals, screening for metastatic disease was accomplished by thoracic 
radiographs and/or computer tomography (CT) and/or abdominal ultrasonography. 
Other conventional therapies such as chemotherapy or radiation were not given prior 
to intratumoral hIL-12 EGT, except in dog 3 (radiotherapy and metronomic 
chemotherapy were discontinued 6 weeks and 1 month respectively prior to study 
entry) and dog 8 (chemotherapy was discontinued 2 weeks prior to study entry). 
Animals were free of non-steroidal anti-inflammatory drugs (NSAID) at least 1 week 
before and during the entire study period. All animal handling and treatment 
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procedures were approved by the Ethical Committee (approval number 2013/166) of 
the Faculty of Veterinary Medicine of Ghent University, Belgium. 
 
 
 
TABLE 10. Signalment, tumor type, tumor size, presence of metastases and IL-12 EGT 
treatment regimen for each dog 
Dog Breed Sex Age 
Tumor type 
(localization) 
Metastases 
Treatment 
frequency  
Tumor 
size 
1 
Golden 
Retriever 
Mn 
13y 
7m 
Schwannoma 
(dorsal to carpus) 
Regional lymph 
node cytology and 
thoracic X-rays 
negative 
Day 1, 3, 5 314 cm3 
2 
Golden 
Retriever 
Mn 
5y 
10m 
Fibrosarcoma 
(rostromaxillar) 
Regional lymph 
node cytology and 
thoracic X-rays 
negative 
Day 1, 3, 5 2.9 cm3 
3 
Bichon 
Frisé° 
Mn 
2y 
11m 
Osteosarcoma (left 
maxillary, 
zygomatic arch and 
bone, sphenoid and 
ventral part of the 
nasal conchae)  
Regional lymph 
node cytology and 
thoracic CT 
negative 
Day 1, 3, 5* 
Extensive 
skull 
invasion, 
approx. 
13% 
4 Malinois Fn 6y 9m 
Tubulopapillar 
complex carcinoma 
(mammary glands) 
Regional lymph 
node cytology 
positive, thoracic X-
rays negative 
Day 1, 8, 15 
58.6 cm3 
1.8 cm3 
7.1 cm3 
15.7 cm3 
5 Bouvier Fn 
12y 
9m 
Fibrosarcoma 
(right maxillary, 
palatine and 
sphenopalatine 
bone, and invasion 
of the 
nasopharynx) 
Regional lymph 
node cytology and 
thoracic CT 
negative 
Day 1, 8, 15 
Extensive 
skull 
invasion, 
approx. 
15% 
6 Maltese Fn 
12y 
7m 
Adenocarcinoma 
(perianal) 
Regional lymph 
nodes ultrasound 
positive 
Day 1, 8, 15 10.2 cm3 
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7 
Labrador 
Retriever 
Mn 
11y 
9m 
Schwannoma 
(dorsal to carpus) 
Regional lymph 
node cytology and 
thoracic X-rays 
negative 
Day 1, 8, 15 12.5 cm3 
8 
French 
Bulldog° 
Mn 
13y 
7m 
Mastocytoma 
(interocular) 
Regional lymph 
node cytology and 
thoracic X-rays 
negative 
Day 1, 8* 
25.1 cm3 
and 2.4 cm3 
9 
Bordeaux 
Dog 
Fn 6y 1m 
Squameus Cell 
Carcinoma (right 
maxillary) 
Regional lymph 
node 
histopathology 
positive, thoracic X-
rays negative 
Day 1, 8* 75.4 cm3 
F: female; Fn: female neutered; M: male; Mn: male neutered.  
* patient did not survive long enough to finish the entire treatment cycle 
° patient received chemotherapy or radiation therapy prior to IL-12 EGT 
3.2 Plasmid 
An IL-12 plasmid encoding human IL-12 (hIL-12) was obtained via Celsion-EGEN, 
Inc. (Huntsville, AL, USA). It was produced under GMP conditions by Eurogentec 
(Seraing, Belgium). The hIL-12 plasmid contains consecutively an immediate early 
enhancer and a promoter derived from cytomegalovirus (CMV), a 5' untranslated 
region (UTR), a synthetic intron, the human p35 gene, the human growth hormone 
(hGH) 3' UTR and polyadenylation signal sequence, a CMV promoter, a 5' UTR, a 
synthetic intron, the human p40 gene, the hGH 3' UTR and polyadenylation signal 
sequence. Of note is the fact that both the hIL-12 subunits are individually expressed 
under the control of 2 separate CMV promoters. The sequences of the p35 and p40 
cDNAs are identical to the sequences found in GenBank with the exception of a single 
base mutation in the second codon of the p35 cDNA. The change was made to insert a 
KOZAK sequence for proper translation initiation and also created an Nco I restriction 
digest site. The mutation changed the second amino acid of the p35 signal sequence 
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from a cytosine (CYS) to a glycine (GLY). A similar change was made to the second 
codon of the p40 cDNA. 
3.3 Ultrasound and contrast-enhanced ultrasound  
Prior to lL-12 treatment, B-mode ultrasound (US) of all tumors was performed with a 
linear 12-5 MHz or 17-5 MHz transducer (Philips, iU22 xMATRIX, Philips Medical 
systems, Bothell, Washington, USA) to determine the echogenicity, to assess the 
presence of mineralization within the tumor and to measure the tumor dimensions.  
Following conventional US examination, tumor perfusion measurements with 
contrast-enhanced ultrasound (CEUS) were performed with a dedicated machine 
(Philips, iU22 xMATRIX, Philips Medical systems, Bothell, Washington, USA) 
equipped with contrast-specific imaging technology using a linear 12-5 MHz probe. To 
evaluate the tumor perfusion, dogs were imaged with manual restraint or, in 1 dog, 
under mild sedation with butorphanol (Dolorex® 0.2 mg/kg), a drug that is known not 
to influence the CEUS.324 Prior to injection of microbubbles (MB), several imaging 
parameters were adjusted to decrease early destruction of the injected MBs by the US 
beam. Mechanical index was decreased (0.09), persistence was switched off and a single 
focal spot was placed under the tumor.  
MB contrast agent (Sonovue®, Bracco, Milan, Italy), consisting of lipid-stabilized MBs 
with a sulfur hexafluoride gas core, was injected intravenously as a bolus (0.04 mL/kg), 
immediately followed by a 1 mL flush of sterile saline (Mini-Plasco NaCl 0.9%, Braun) 
via a peripheral venous catheter inserted in the cephalic vein. Between the boluses, the 
remaining MBs were destructed by increasing the acoustic power in the imaging plane 
for several minutes.  
During CEUS, areas that should be avoided during injection of the IL-12 pDNA 
solution, such as main tumor vessels or necrotic tissue, were identified. All CEUS 
studies were digitally registered as a movie clip at a rate of 10 frames/sec for 90 sec after 
bolus injection. These clips were analyzed using integrated dedicated specialized 
computer software (VUEBOX, Bracco) for objective quantitative analysis. Tumor 
regions-of-interest (ROIs) were manually drawn and mean pixel intensities and time-
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intensity curves created per ROI. These curves were analyzed for Radius Basis Function 
parameters representing blood volume (area-under-curve) and blood velocity (wash-in 
rate). A B-mode image was projected simultaneously with CEUS imaging (Figure 19), 
and (CE)US was repeated for comparison at the same tumor location at day 8 and 35. 
3.4 Electrogene therapy  
One mg of IL-12 plasmid per session was diluted with calcium and magnesium free 
phosphate-buffered saline (DPBS) (14040-174, Invitrogen). The injection volume was 
1/6 of the tumor volume that was calculated with the following formula: L*H*Wπ/6 (L: 
length, H: height, W: width). The injection volume was administered intratumorally 
throughout the whole tumor mass. An 8-needle array electrode connected to an 
electroporator (Agile Pulse generator, BTX® Harvard Apparatus) was inserted within 2 
min after injection around the injection site. Two pulses of 450 V/cm were given (pulse 
duration was 0.05 msec and the interval between the pulses 0.2 msec). After 50 msec, 
those 2 pulses were followed by 8 pulses of 100 V/cm (pulse duration was 10 msec and 
the interval between pulses 20 msec). 
3.5 Clinical trial design 
A written informed consent was obtained from each dog owner. Prior to each 
treatment session, the dog owner was interviewed and each dog was physically 
examined. Blood was collected to assess the patient’s hematology and biochemistry. 
When all values were within reference range, a peripheral venous catheter was placed. 
Hair overlying tumor nodules was clipped prior to (CE)US. After a general US 
examination of the region of the tumor, the patients received IV contrast agent for 
CEUS evaluation of tumor perfusion. Afterward, the subject was anesthesized for the 
electroporation of the hIL-12 pDNA. For this purpose, the dog was premedicated with 
IV buprenorphine (Vetergesic® 10 μg/kg) followed 15 min later by IV dexmedetomidine 
(Dexdomitor® 5 μg/kg). After another 15 min, induction with IV propofol (Propovet 
multidose® 1 mg/kg) followed and was, if necessary, maintained with isoflurane. 
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A sterile IL-12 pDNA solution was injected directly into the tumoral tissue. The tumor 
volume treated was restricted by the needle length of the electrodes. Since the 
maximum length of the electrodes was 25 mm, tumor tissue at a depth greater than 25 
mm could not be electroporated. After electroporation of the IL-12 pDNA into the 
tumor, 3 punch biopsies of 2 mm (Bap Medical, 33-31) were taken from different 
locations within the neoplasm to factor in intratumoral heterogeneity;325 biopsies were 
taken after electroporation to avoid leakage of the diluted pDNA from the tumor. After 
the biopsy taking, the subjects were antidoted with IM atipamezole (Revertor®, 25 
μg/kg). No (N)SAIDs were administered, to avoid interference with the development of 
an inflammatory response to the treatment. The non-anti-inflammatory pain killer 
Tramadol (Tramadol EG®, 2 mg/kg) was offered per os as alternative.  
The occurrence of local side effects was evaluated at each follow-up with physical 
examination of the patient and careful assessment of the appearance of the 
electroporated area for signs of local inflammation (erythema, swelling, pain), 
secretions, necrosis, etc. Additionally, the occurrence of systemic effects was evaluated 
by measuring the amount of IL-12, IFNγ, IL-10, VEGF and IL-24 in serum and by 
screening for aberrations in CBC and/or the biochemistry profile. The response to 
therapy was assessed with repeated measurements of tumor size and perfusion through 
(CE)US and measurement of the amount of IL-12, IFNγ, IL-10, VEGF and IL-24 in 
tumor tissue.  
The first 3 dogs (dogs 1, 2 and 3) were treated with a 1-day interval between treatments, 
but 1 of these dogs developed transient immune-mediated anemia and another fatal 
thrombocytopenia. Since both side effects could be attributed to IL-12 toxicity,146 the 
treatment regimen was altered to a 1-week interval between treatments for all following 
patients (Figure 14).  
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FIGURE 14. Initial hIL-12 EGT regimen (top) and adapted regimen (bottom) after the observation 
of severe side effects in 2 of the 3 patients treated with the initial regimen. Blood: complete blood 
count and biochemistry analysis, CEUS: contrast-enhanced ultrasound, IL-12: intratumoral 
injection of 1 mg hIL-12 plasmid DNA and electroporation, Biopsy: collection of 3 small tumor 
biopsy samples. 
3.6 Tumor tissue analysis 
The biopsies were immediately kept on dry ice and stored in a -150°C freezer 
(Panasonic, TCPS) until further use. A day prior to ELISA analysis biopsies were 
thawed in a 500 μL mixture of DPBS (Invitrogen) and protease-inhibitor cocktail 
(cOmplex Mini, Roche, 5892970001). Biopsy samples were disrupted with a tissue 
disruptor (TissueRuptor®, Qiagen, Germany) during 30 sec to lyse the cells. The lysed 
cells were centrifuged at 12,000xg during 10 min at 4°C. Afterward, the supernatant was 
removed and stored at 4°C until use the following day. 
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3.7 ELISA of local and systemic cytokines during intratumoral hIL-12 
EGT 
The presence of canine IFNγ, VEGF, IL-10 and IL-24 in serum and tumor tissue was 
determined using ELISA kits (Canine IFN-γ/VEGF/IL-10 Duoset ELISA Kit, R&D 
Systems, DY781B/DY1603/DY735, USA and Interleukin 24 ELISA Kit, MyBiosource, 
ABIN2088813 respectively) and human IL-12 with human IL-12 (p70) ELISA MAXTM 
Standard (Biolegend, 431701). In order to assess if the intratumoral IL-12 EGT was 
successful, the amount of human IL-12 in tumor tissue was compared for each dog on 
day 1, 8 and 35 of the treatment. The stimulatory effects of human IL-12 were 
determined by analysis of the amount of canine IFNγ, anti-angiogenic effects by VEGF 
analysis, anti-immunosuppressive effects by IL-10 analysis and antitumoral Th2 
responses by IL-24 analysis. Intratumoral cytokines were assessed on day 1, 8 and 35, 
while the serum cytokine levels were measured on day 1, 3, 8, 15 and 35 for each dog. 
The Bradford test (Pierce™ Coomassie (Bradford) Protein Assay Kit, Invitrogen, 23200) 
was performed to take into account the differences in the amount of protein between 
samples. 
3.8 Statistical Analysis 
All data were analyzed with the statistical software program SPSS (version 19.0). The 
parametric data were analyzed with the paired sample t-test, the non-parametric data 
with the Wilcoxon rank-sum test with Bonferroni correction. Statistical significance 
was determined at p≤ 0.05. No statistical analysis could be performed on the ELISA 
data, since in some samples the cytokine levels were below the standard curve.  
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4 Results 
4.1 Intratumoral and systemic release of cytokines in dogs that 
completed a whole IL-12 treatment cycle 
To monitor the effects of IL-12 treatment, the levels of cytokines were analyzed at day 1 
(baseline level), 8 and 35 in tumor biopsies and at day 1 (baseline level), 3, 8, 15 and 35 
in blood samples. After intratumoral electroporation of the pDNA encoding hIL-12 
(hIL-12 electrogene therapy (EGT)), a transient intratumoral increase of hIL-12 was 
observed in 4 out of the 6 dogs that completed the treatment regimen. One of the 2 
dogs that did not have elevated hIL-12 levels in the tumor had increased hIL-12 levels 
in the serum. A clear, although transient, release of hIL-12 in the serum was only 
observed in 2 dogs (Figure 15 and Supplementary table 1). Similarly, a transient 
increase of IFNγ in the tumor was measured in 1 out of 6 dogs and none of the dogs 
showed a clear increase of IFNγ in the serum (Figure 15 and Supplementary table 1). 
The IL-12 treatment did not cause change of the IL-10 levels in the tumor, whereas 
mild increases in the serum were measured in 3 out of 6 dogs (Figure 15 and 
Supplementary table 1). An intratumoral decrease of VEGF was measured in 2 out of 6 
dogs; serum VEGF-levels remained unchanged in all 6 (Supplementary table 1). Due to 
technical issues, IL-24 measurements were only performed in 5 of the 6 dogs. An 
intratumoral decrease of IL-24 was measured in 3 out of 5 dogs, an increase in 1 dog 
and no change in the remaining dog. A serum increase of IL-24 was apparent in 5 out of 
5 dogs, but started at different days (3 out of 5 at day 8, 1 out of 5 at day 15 and 1 out of 
5 at day 35) (Supplementary table 1). 
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FIGURE 15. Intratumoral and serum absorbance values of IL-12 (A, B resp), IFNγ (C, D resp), IL-
10 (E, F resp) prior, during and after intratumoral IL-12 EGT. The top rows represent the 
intratumoral values, the bottom rows the serum values. The Bradford test indicated similar 
amounts of protein between samples. Since several values were beneath the standard curve, 
significance could not be indicated and measurements are displayed in optical density (OD). 
4.2 Complete blood count and biochemistry in dogs that completed 
a whole treatment cycle 
After the first intratumoral hIL-12 EGT, a similar temporary decrease in peripheral 
leukocytes was observed in all 9 patients. Below, only the results of the 6 dogs that 
completed the whole treatment cycle are represented. The amount of lymphocytes, 
eosinophils and basophils initially decreased in each patient, but recovered above 
baseline in each patient as well (Figure 16). These effects were irrespective of their 
treatment regimen (Supplementary figure 1). A temporary increase in monocytes was 
observed between days 1-5 of treatment (Figure 17 and Supplementary figure 1). The 
amount of red blood cells initially decreased in each patient (Figure 16), irrespective of 
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their treatment regimen (Supplementary figure 1). Subsequent intratumoral hIL-12 
EGT did not further decrease the hematocrit. In contrast, a steady increase of 
hematocrit values was observed, and at day 35, the hematocrit values almost reached 
their baseline levels. Two out of 3 dogs in the early 1-day regimen experienced clinically 
relevant decreases in hematocrit (dog 1) or thrombocyte count (dog 3). The hematocrit 
of dog 1 recovered spontaneously, the thrombocytopenia of dog 3 did not despite 3 
blood transfusions. No clinically relevant effects for hematology and biochemistry were 
observed in the remaining 6 dogs that were treated with the 1-week regimen. 
 
 
FIGURE 16. Temporary decrease in hematocrit (day 1-3) (A) and amount of peripheral 
eosinophils (day 1-5) (B), lymphocytes (day 1-3) (C), and basophils (day 1-3) (D) following 
intratumoral hIL-12 EGT. *, p≤ 0.05 between groups. 
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FIGURE 17. Temporary increase in amount of peripheral monocytes (day 3-15) and neutrophils 
following intratumoral hIL-12 EGT. *, p≤ 0.05 between groups. 
All biochemical parameters remained within reference range and no significant 
changes were detected throughout the treatment cycle. 
4.3 Physical examination findings and side effects after intratumoral 
hIL-12 EGT 
During electroporation, clear muscle contractions occurred which required appropriate 
sedation. To assess possible side effects of the procedure, physical examinations 
(Supplementary Data 1), complete blood counts and biochemical parameters were 
performed at least on day 1, 3, 8, 15 and 35 of the treatment cycle. The VCOG-CTCAE 
criteria for adverse effects326 associated with IL-12 toxicity were used to evaluate the 
findings of these examinations and are listed in Table 11. Generally, erythema and 
swelling were apparent 2-3 days after the first intratumoral hIL-12 EGT (Figure 18). 
Two dogs (dogs 1 and 3), treated with the 1-day regimen, developed systemic toxicities. 
Dog 1 developed immune-mediated anemia (Coomb’s positive for IgG (H+L)) and dog 
3 thrombocytopenia (the platelet amount was too low to establish an immune-mediated 
cause). Following adaptation of the regimen to a 1-week interval in the remaining 6 
dogs, local or systemic side effects were not observed after intratumoral hIL-12 EGT in 
any of those patients. 
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TABLE 11. VCOG-CTCAE criteria for adverse effects326 associated with IL-12 toxicity 
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1 
Grade 1 
(possible) 
- - - 1 - 1 1 - - 1 
2 - - - - - - - - - - - 
3 
No 
confirmation 
possible 
- - 5 1 2 1 - - - - 
4 - - - - 1 1 - 1 - - 1 
5 - - - - 1 - 1 2 1 - 1 
6 - - - - 1 - 1 1 - - 1 
7 - - - - 1 - - - - - 1 
8 - - - - 2 - 3 2 - - 1 
9 - - - - 3 - 1 2 - - 1 
Auto-immune disorder grade 1 indicates a mild auto-immune reaction. Thrombocytopenia grade 
1 indicates mild thrombocytopenia; grade 5 indicates death as a consequence of 
thrombocytopenia. Fatigue grade 1 indicates mild lethargy; grade 5 indicates death as a 
consequence of lethargy. Fever grade 1 indicates 39.5–40.0ƕ C; grade 5 indicates death as a 
consequence of fever. Weight loss grade 1 indicates <10% from baseline; grade 5 indicates death 
as a consequence of weight loss. Anorexia grade 1 indicates coaxing or dietary change required to 
maintain appetite; grade 5 indicates death as a consequence of anorexia. Diarrhea grade 1 
indicates increase of up to 2 stools per day over baseline; grade 5 indicates death as a consequence 
of diarrhea. Tumor pain grade 1 indicates mild pain not interfering with function; grade 4 
indicates disabling or uncontrollable pain. 
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FIGURE 18. Representative tumor inflammation after intratumoral hIL-12 EGT in a schwannoma 
dorsal to the carpus (dog 1). The tumor inflammation is recognized by erythema on day 3 and 
swelling on day 8. Day 1: before treatment, day 3, 8, 15: after treatment initiation (1-day 
regimen).  
4.4 Effects of intratumoral hIL-12 EGT on primary and metastatic 
tumor progression 
Despite 3 intratumoral hIL-12 EGT treatments, all primary tumors continued to 
enlarge. Two of the included dogs (dog 6 and 9) had metastases before the start of the 
study. Dog 9 did not survive long enough to evaluate the anti-metastatic effects of the 
treatment. The abdominal metastases in the left and right medial iliac lymph nodes 
(LN) of dog 6 did show a transient response to treatment. The left medial iliac LN 
demonstrated a slow growth initially (size of 0.359 cm2 on day 8, 0.591 cm2 on day 35), 
but a rapid progression (3.050 cm2) on day 90. The right medial iliac LN exhibited a 
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transient decrease in size (2.401 cm2 on day 8, 1.840 cm2 on day 35), but growth had 
resumed (2.121 cm2) on day 90. 
4.5 Effects of intratumoral hIL-12 EGT on neoangiogenesis 
The anti-angiogenic properties of intratumoral hIL-12 EGT were measured via CEUS 
of the tumor (Figure 19 and Figure 20) and via VEGF-analysis of serum and tumor 
tissue in all dogs. In total, 9 malignant tumors were evaluated in 9 dogs. With CEUS, 
sarcomas were less well-vascularized than (adeno)carcinomas. Despite the lower 
vascularization of sarcomas, a difference in flow pattern could be observed in all tumor 
types after intratumoral hIL-12 EGT. A significant decrease in tumor blood volume 
(characterized by the wash-in area under the curve (WiAU)) and blood flow speed 
(characterized by the wash-in rate (WiR)) was present in all dogs after intratumoral 
hIL-12 EGT (Figure 20). The blood flow speed showed a decreasing trend between days 
1 and 8 (p= 0.071) and a significant decrease was apparent between days 8 and 35 of 
treatment (p= 0.04) (Figure 20). A significant decrease of relative blood volume was 
present between days 1 and 8 (p= 0.018) (Figure 20). A remarkable decrease in 
intratumoral VEGF was present in 2 dogs at day 35, but no clear decreases in VEGF 
amounts could be detected in the other treated dogs. Nevertheless, the CEUS findings 
did demonstrate an anti-angiogenic effect in all treated dogs. 
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FIGURE 19. Follow-up of tumor vascularization of an interocular mastocytoma (dog 8) on day 1 
(top) and 8 (bottom) of intratumoral hIL-12 EGT. The left side of the image corresponds to the 
CEUS-image of the tumor, the right side to the US B-mode. The decrease in orange speckling 
(contrast-uptake) is marked enough to be discernable with the naked eye. 
 
FIGURE 20. Follow-up of tumor perfusion (WiR) and relative blood volume (WiAU) as measured 
by CEUS. Mean values ± standard deviations are shown. ° indicates a mild outlier. *, p≤ 0.05 
between groups. 
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5 Discussion 
In this article, we evaluated intratumoral as well as systemic responses to intratumoral 
hIL-12 EGT in dogs with various tumor types. Immune stimulation was apparent in all 
treated dogs through either serum IFNγ release or local inflammatory responses within 
1 week after hIL-12 pDNA administration. CEUS documented the anti-angiogenic 
effects of IL-12 therapy in all dogs. In 5 out of 6 dogs, increased hIL-12 levels were 
measured either in the tumor or serum after intratumoral hIL-12 EGT. In 2 dogs (dog 4 
and 7), the tumor biopsy samples did not demonstrate increased hIL-12 levels. For dog 
4 this was most likely due to the thin layer of viable tumor tissue present and in dog 7 
because the second tumor biopsy was exceptionally taken on day 15 instead of day 8, 
thereby probably missing the peak of intratumoral hIL-12 production. The peak 
production of hIL-12 is most likely situated at day 2, as the highest amounts of serum 
hIL-12 were measured on day 3 after intratumoral hIL-12 EGT.  
 
The first pillar of IL-12 immunotherapy is immune stimulation through activation and 
recruitment of NK cells, T cells and PMN cells toward the tumor. As local IL-12 pDNA 
immunotherapy can result in systemic immune activation, changes in pro- and anti-
inflammatory cytokines and immune cells were analyzed in the patients’ blood samples. 
Three days after the first intratumoral hIL-12 EGT, a transient decrease in lymphocytes, 
eosinophils and basophils concurred with a serum increase in IL-12, IFNγ or IL-10. 
Transient increases of IFNγ (an immunostimulatory cytokine) and IL-10 (an 
immunosuppressive cytokine) serum levels have been previously described after IL-12 
treatment327, 328 and represent its positive and negative feedback loop, respectively.329 
The balance between the level of IL-12, with IFNγ production and T cell expansion on 
the one hand, and the level of IL-10, with effector T cell suppression on the other hand, 
may dictate the end result of the immune response.329 Interestingly, IL-10 causes 
significant suppression of IFNγ production in resting peripheral blood mononuclear 
cells (PBMC), whereas once PBMCs are activated, IL-10 no longer has the ability to 
suppress their IFNγ production.330 Therefore, when a pre-existing antitumoral immune 
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response exists, IL-12 is highly suited to enhance this pre-existing immune response,331 
unhindered by the IL-10 feedback response.  
The transient decrease in number of lymphocytes, eosinophils and basophils after the 
first intratumoral hIL-12 EGT is likely related to their quick recruitment into the 
tumoral tissue as a result of IL-12- and IFNγ-mediated upregulation of intratumoral 
vascular adhesion molecules.213, 327, 332, 333, 334 Indeed, infiltration of CD4+ and CD8+ T 
cells,146, 219, 221, 234, 335, 336 NK cells,334 macrophages334 and plasma cells221, 328 has been 
described following intratumoral IL-12 treatment. Unfortunately, histopathologic 
confirmation of lymphocytic and/or eosinophilic tumor infiltration has not been 
performed in our study since this would entail supplementary sedation and trauma to 
the patients. Nevertheless, the fact that the observed drop in immune cells coincided 
with the appearance of intratumoral inflammatory symptoms (erythema and swelling) 
supports the hypothesis that the intratumorally produced hIL-12 recruited immune 
cells into the tumor. Although electroporation is known to cause swelling, such 
electroporation-induced swelling subsides within 48 h after electroporation,226, 337 
whereas in our patients the inflammatory symptoms only became apparent after 48 h. 
An alternative explanation for the transient drop in leukocytes after the first treatment, 
could be the IFNγ-mediated induction of nitric oxide production from macrophages.338 
Nitric oxide induces suppression of T cell mitogenic responses,338 possibly clarifying the 
initial decrease in leukocytes and lag in lymphocyte recovery. Furthermore, the initial 
decrease in leukocytes could be attributed to an anesthesia-induced stress response,339 
although no further decrease was observed after the first treatment and the dogs were 
anesthetized for each treatment according to the same protocol.  
Although IL-12 initiates a period of immunosuppression, an enhanced protective 
antitumor immunity develops afterward.338 Indeed, the initial drop in immune cells was 
followed by an increase in all treated dogs. Monocytes recovered quickly and briefly 
demonstrated a peak amount during days 5-8 after intratumoral hIL-12 EGT, whereas 
recovery above baseline was present at days 15 and 35 for lymphocytes and eosinophils 
respectively. Since activated T cells340 and eosinophils341 express IL-12 receptors, the 
initial drop in these immune cells followed by their increase above baseline might 
indicate a continued attraction toward the tumor. Eosinophilia is regularly observed 
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during immunotherapy protocols185 and tumor-associated eosinophilia has been linked 
with a generally good prognostic value.185 Eosinophils do often exhibit a state of 
degranulation when in close proximity to tumors.185 The induced IFNγ may have 
stimulated enhanced eosinophilic superoxide generation and degranulation.342 
Alternatively, plasmid IL-12 gene therapy has shown to induce a significant amount of 
cancer cell death146 and necrosis induces eosinophilic migration.185 No significant 
changes for neutrophils were detected, in contrast to a decrease in circulating 
neutrophils during IL-12 therapy described before.327 A transient decrease in 
hematocrit was observed in all dogs throughout the study. The decrease in hematocrit is 
most likely linked to a slight increase in serum IFNγ, since IFNγ suppresses human 
erythroid colony-forming units.343, 344   
 
The effects of intratumoral hIL-12 EGT on the levels of pro- and anti-inflammatory 
cytokines in the tumors were also analyzed. Considering IL-12 is a promoter of the Th1 
response, the intratumoral Th2 response was likely inhibited, which in turn induced a 
Th2 serum feedback response. As such, IL-12 probably induced an intratumoral 
decrease of IL-24, a Th2-cytokine able to selectively kill different cancer cells,308 while a 
serum increase of IL-24 was present 3, 8, 15 or 35 days after the first intratumoral hIL-
12 EGT and a transient increase of serum IL-10 was present 3 and 8 days after the first 
intratumoral hIL-12 EGT. 
 
The second pillar of IL-12 antitumoral immunotherapy is anti-angiogenesis, which is 
induced through the down-regulation of the pro-angiogenic stimulus VEGF208, 210 and 
the prevention of development of new vasculature as well as induction of involution of 
nascent vessels through IP-10 and MIG.208, 210 The amount of VEGF was measured 
through ELISA in serum and in tumoral tissue, whereas the effects of IP-10 and MIG 
were monitored with CEUS. Only 2 dogs demonstrated a remarkable decrease in 
intratumoral VEGF levels, while the CEUS findings indicated a significant decrease in 
relative blood volume and blood flow speed in all dogs after treatment. Malignant and 
benign tumors are characterized by a rapid and slow increase of contrast uptake, 
respectively.345 In similar terms, the observed decrease in blood flow speed could 
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indicate a less aggressive behavior of the tumor after IL-12 treatment. A similar 
decrease in angiogenesis parameters was also observed after an anti-angiogenic 
treatment in rats.346 Although the anti-angiogenic effects of IL-12 can be monitored in 
various ways (decrease in intratumoral VEGF and microvessel density (MVD),333, 347 
apoptosis of endothelial cells348), CEUS provides an excellent non-invasive quantitative 
and qualitative alternative for biopsies. CEUS has proven to be a more sensitive 
technique for angiogenesis monitoring than immunohistopathology,346 as small 
biopsies are not likely representative for the whole tumor.227 Moreover, histological 
follow-up entails invasive and repetitive biopsies within short time spans, which is not 
required for CEUS.346  
 
In this study, hIL-12 was used instead of canine IL-12. Belgian legislation requires all 
new drugs that are evaluated in clinical trials with canine patients to be of GMP-grade, 
therefore human IL-12 pDNA was chosen for 2 reasons. First, a GMP grade pDNA 
encoding canine IL-12 was not available at the time and second, human IL-12 is 
recognized by canine immune cells231 without causing a cross-reaction toward canine 
IL-12.349 Indeed, canine and human IL-12 share 90% genetic identity based on amino 
acid sequence analysis349 and human IL-12 activates proliferation of canine PBMCs in 
in vitro setting and triggers immune responses in canine PBMCs.231, 232 And, last but not 
least, intratumoral EGT with a pDNA encoding hIL-12 has yielded antitumoral 
responses in a subset of treated dogs.146, 221, 222 
Even though IL-12 transfection was successful and IL-12 was produced by all treated 
dogs, this did not prohibit further growth of the primary tumors in any of the dogs. 
However, the consistency of the primary tumors did change after the first or second 
intratumoral hIL-12 EGT. As ischaemic necrosis often leads to softening of the 
tumor,350 the observed softening is likely the result of the anti-angiogenic effects of the 
IL-12 treatment.  
Three owners reported an improvement of quality of life after the third treatment 
session. Their dog exhibited a more energetic and happier behavior despite progression 
of the primary tumor. A positive association between immune stimulation and 
improvement of quality of life has been described in previous immunotherapy trials.292 
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A decrease in well-being is associated with a Th2 profile.351, 352 Since IL-12 elicits a Th1 
response and Th1 and Th2 responses are mutually inhibitory,352 it is possible that the 
induced Th1 immune stimulation contributed to the improvement in welfare of several 
IL-12 treated dogs. 
Despite the absence of a clear effect of intratumoral hIL-12 EGT on the primary tumor, 
we observed in 1 of the 2 patients with LN metastases a transient decrease in size of 
these metastases. The other patient with LN metastases did not complete the study; 
therefore the putative anti-metastatic effect of IL-12 could not be evaluated in this dog. 
A transient decrease in size of LN metastases after intratumoral IL-12 EGT has been 
previously described by Cutrera et al..222  
A growth of a primary tumor concurrent with a reduction of its metastases seems 
paradoxal, but for complete tumor eradication, tumor infiltration with CD8+ T cells is 
required, whereas prevention of growth of metastases is also regulated by NK cells, B 
cells and the IFNγ-mediated anti-angiogenesis.214  
Although remarkable cure rates have been described with intratumoral IL-12 pDNA 
administration in rodent cancer models,293, 331, 333 similar successes can thus far not be 
claimed in dogs and men with spontaneous cancer.219, 218 In the majority of preclinical 
studies with mice, the impact that slowly progressing tumors exert on the adaptive 
immune system is not taken into account.63 This underscores the importance of 
evaluating immunotherapeutic treatments in appropriate cancer models such as pet 
dogs with spontaneous cancer. 
 
So far, the effects of IL-12 therapy in dogs have been evaluated on relatively small 
tumors of 0.05 to 25.4 cm3 146, 221, 222 and intratumoral IL-12 production after IL-12 EGT 
has proven to be a safe treatment option in humans and pet dogs. 218, 219 However, IL-12 
induced cell death could potentially induce tumor lysis syndrome in large tumors (such 
as those of dogs 1, 3, 4, 5 and 9). It is also possible that, if a large amount of cancer cells 
produce IL-12, this could lead to high systemic IL-12 values. Grave toxicity has been 
shown when pure IL-12 was administered systemically to human cancer patients.213 To 
this end, possible side effects of the procedure were monitored by regular clinical 
examination and measurements of selected hematology and biochemistry parameters. 
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Surprisingly, 2 of the 3 dogs that were treated with IL-12 EGT on day 1, 3 and 5 
developed side effects (immune-mediated anemia and thrombocytopenia, dogs 1 and 7 
respectively) that could be attributed to IL-12 toxicity. Since Chuang et al. saw a peak 
level of IL-12 on day 7 following intratumoral electroporation with 1 mg of human IL-
12 pDNA in dogs,146 the precautionary measure was taken to change the treatment 
regimen and spread the interval between treatments from 1 day to 1 week to avoid IL-
12 accumulation in the serum and its possible associated side effects. Although no 
further adverse effects were observed after the changes in administration schedule, we 
believe the initial IL-12 EGT regimen was not responsible for the observed adverse 
effects. Similar or higher serum amounts of IL-12 or IFNγ (the cytokine responsible for 
IL-12 toxicity) were detected in the dogs receiving IL-12 EGT once a week; yet none of 
them developed any adverse effects. A more satisfactory explanation takes account of 
the impact cancer has on the immune system. Cancers can induce auto-immunity 
through disruption of central tolerance, peripheral immune dysregulation, and 
alteration of self-antigens. Cancer-induced auto-immune complications 
(paraneoplastic syndrome) occur in many tumor types. For instance, 10 to 25% of 
patients with chronic lymphocytic leukemia will develop auto-immune complications, 
of which auto-immune hemolytic anemia and immune thrombocytopenia are the most 
common types.353 It is therefore possible that the observed adverse effects were not a 
direct consequence of IL-12 toxicity, but represented an aggravation of a pre-existing 
subclinical paraneoplastic syndrome that was further stimulated by the intratumoral 
hIL-12 EGT. A 22-fold increase in IL-10 serum levels was measured in 1 dog (dog 3), 
possibly in an attempt to control the auto-immune response. Any other adverse effects 
were more likely related to tumor progression than to IL-12 toxicity. It could be 
interesting to equip pDNA in the future with a regulatory element that enables the 
control of IL-12 expression in case of doubt.  
 
Although electroporation is a very effective way to acquire gene transfer, the technique 
has some limitations. First, an adequate electrical conduction, which is crucial for 
effective perforation of cell membranes, is not always achievable in all tumors. Indeed, 
some tumors did not demonstrate necrosis on US, but their core exhibited a tissue 
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resistance below 50 Ohm, inhibiting effective electroporation. In dog 4, for example, 
only a minimal layer of viable tissue (4-6 mm) could be electroporated. Furthermore, 
oral tumors are more prone to shearing when injecting the pDNA solution followed by 
insertion of electrodes. The injected pDNA solution is also prone to leakage in 
ulcerated tumors. As a consequence, strict application of the calculated injection 
volume is not always possible, which lowers the treatment efficiency since the extent of 
gene expression is proportional to the amount of transduced cells and of intact plasmid 
copies entering the nucleus.354 Additionally, the induction of an intratumoral electric 
field is perceived as quite painful and requires adequate analgesia and complete 
sedation in dogs. Unfortunately, sedation is detrimental to the contemplated immune 
response as it induces a stress response resulting in immune suppression.355 Moreover, 
the anesthesia and adjustment of the intratumoral placement of the electrodes to 
acquire a feasible electrical tissue resistance (in our hands a minimal of 65 Ohm) are 
time-consuming. The difficulty in proper electrical conduction and the 
immunosuppressive and time-consuming anesthesia could be avoided through the use 
of alternative gene delivery methods such as sonoporation, where US waves are applied 
to create cell membrane pores. However, this technique requires further technological, 
biological and medical studies before it can be translated into routine clinical 
practice.356 
 
In our study, a similar haematologic effect of hIL-12 is seen in the 1-day interval and 1-
week interval regimen. Numerous explanations are possible, such as IFNγ-induced 
inhibition of transgene expression of the cytomegaloviral (CMV) promotor of the IL-12 
pDNA construct.357 As IL-12 pDNA induces IFNγ production, this could explain the 
similar results seen between the dogs treated with a 1-day interval and a 1-week 
interval. In both groups IFNγ was induced after hIL-12 EGT in the tumoral tissue and 
in both groups further treatments did not seem to induce an additional decrease in 
immune cells. This argument is further supported by enhanced transgene expression 
seen in vivo after administration of neutralizing anti-IFNγ antibodies.338, 357 
Furthermore, a biopsy taken on day 15 from dog 7 did not show the presence of IL-12, 
whereas a clear increase in serum IL-12 was measured on day 3. An attenuation 
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response due to formation of antibodies against hIL-12 is also feasible since Paoloni et 
al. found in 8 out of 12 canine melanoma patients production of antibodies against 
human IL-12 2 to 4 weeks after administration of NHS-IL-12, an immunocytokine 
consisting of an antibody linked to human IL-12. The host antibody responses were 
directed mainly against the human IgG part of the molecule, but 5 out of 14 dogs tested 
also developed antibodies against the human IL-12 portion.227 Other possible causes 
include a dilution effect due to the loss of non-integrated DNA after cancer cell 
multiplication or destruction by endonucleases present in the cancer cells,357 but then a 
similar haematologic effect would be expected after a second treatment.  
6 Conclusion 
In conclusion, tumor biology is extremely complex and various factors influence the 
process of carcinogenesis and progression. Although the immune system is capable of 
mounting an immune response against cancer cells, this response is often not robust 
enough to eliminate them. To enhance the efficacy of the immune response toward the 
tumor, immunostimulatory cytokines can be administered.331 Interleukin 12 is a 
cytokine that enhances a pre-existing antitumor immune response through stimulation 
of NK and T cells331 and also targets various aspects of tumor angiogenesis through 
induction of IFNγ and its cascade effects.208 In this article, immune stimulation was 
apparent in all treated dogs through local inflammatory responses within 1 week after 
the first intratumoral hIL-12 EGT and anti-angiogenic effects were documented 
through CEUS in all treated dogs. Although intratumoral IL-12 EGT has shown to be 
able to cure human patients without having a negative impact on the host (in contrast 
to cytotoxic treatments such as chemotherapy),219 IL-12 monotherapy of spontaneous 
(large) tumors has not yielded clinically relevant results in the pet dogs of this study. As 
a monotherapy, this therapy offers cytostatic rather than cytotoxic results. Interleukin 
12 is especially useful as adjuvant therapy in metastatic cancer or prevention of 
metastases. For eradication of established tumors through IL-12, the presence of a pre-
existing antitumoral T cell response is required. In cancer-bearing patients, only a 
limited number dispose of a pre-existing immunity.331 This provides a rationale to 
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believe that the effectiveness of IL-12 therapy could be enhanced by vaccinating the 
patient against his own cancer cells prior to IL-12 therapy.331 As an alternative, the 
efficacy of IL-12 therapy could be enhanced by combining it with metronomic 
cyclophosphamide to selectively decrease the amount of Tregs,285 since IL-12 effects are 
transient and induce a rebound in Tregs.358 Furthermore, immunotherapy generally has 
a more powerful effect in a minimal residual disease setting,147 thus IL-12 therapy could 
benefit from a combinatorial strategy with surgery. 
  
Chapter 2: Intratumoral interleukin 12 gene therapy stimulates the immune system  
and decreases angiogenesis in dogs with spontaneous cancer 
125 
7 Supplements 
7.1 Supplementary table 1 
Intratumoral and serum absorbance (OD) values of IL-12, IFNγ, IL-10, IL-24 and 
VEGF prior, during and after intratumoral IL-12 pDNA treatment. 
Intratumoral IL-12 absorbance 
 Day 1 Day 8 Day 35 
Dog 1* 0.109 0.352 0.106 
Dog 2* 0.112 1.087 0.153 
Dog 4 0.126 0.106 0.090 
Dog 5 0.108 0.209 0.111 
Dog 6 0.109 0.349 0.096  
Dog 7° 0.087 0.074 0.082 
 
 Serum IL-12 absorbance 
 Day 1 Day 3 Day 8 Day 15 Day 35 
Dog 1* 0.129 0.371 0.212 0.091 0.089 
Dog 2* 0.128 0.161 0.127 0.122 0.128 
Dog 4 0.110 0.134 0.114 0.108 0.105 
Dog 5 0.108 0.113 0.118 0.125 0.111 
Dog 6 0.117 0.169 0.146 0.149 0.125 
Dog 7° 0.080 0.934 0.236 0.106 0.121 
Intratumoral IFNγ absorbance 
 Day 1 Day 8 Day 35 
Dog 1* 0.072 0.101 0.083 
Dog 2* 0.066 0.279 0.065 
Dog 4 0.065 0.077 0.071 
Dog 5 0.063 0.077 0.063 
Dog 6 0.070 0.083 0.080 
Dog 7° 0.053 0.042 0.049 
 
 Serum IFNγ absorbance 
 Day 1 Day 3 Day 8 Day 15 Day 35 
Dog 1* 0.039 0.077 0.038 0.030 0.031 
Dog 2* 0.039 0.048 0.040 0.042 0.041 
Dog 4 0.034 0.043 0.049 0.029 0.033 
Dog 5 0.048 0.039 0.039 0.038 0.035 
Dog 6 0.031 0.035 0.040 0.063 0.041 
Dog 7° 0.017 0.055 0.015 0.015 0.016 
Intratumoral IL-10 absorbance 
Day 1 Day 8 Day 35 
Dog 1* 0.022 0.016 0.023 
Dog 2* 0.016 0.016 0.017 
Dog 4 0.018 0.010 0.011 
Dog 5 0.013 0.013 0.009 
Dog 6 0.036 0.028 0.037 
Dog 7° 0.033 0.023 0.028 
 
 
 
 Serum IL-10 absorbance 
 Day 1 Day 3 Day 8 Day 15 Day 35 
Dog 1* 0.041 0.054 0.096 0.039 0.038 
Dog 2* 0.012 0.086 0.078 0.026 0.021 
Dog 4 0.017 0.016 0.036 0.012 0.038 
Dog 5 0.044 0.056 0.022 0.016 0.015 
Dog 6 0.044 0.056 0.040 0.036 0.040 
Dog 7° 0.010 0.076 0.012 0.025 0.010 
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Intratumoral IL-24 absorbance 
 Day 1 Day 8 Day 35 
Dog 1* 1.185 0.867 0.862 
Dog 2* 0.932 0.937 0.924 
Dog 4 0.944 1.101 0.981 
Dog 5 0.939 0.911 0.877 
Dog 6 1.228 1.072 0.958 
 
 Serum IL-24 absorbance 
  Day 1 Day 3 Day 8 Day 15 Day 35 
Dog 1* 0.997 1.184 1.141 0.783 1.163 
Dog 2* 0.891 0.943 1.194 0.974 0.971 
Dog 4 1.238 1.107 1.080 1.365 1.607 
Dog 5 1.037 1.030 1.022 1.042 1.121 
Dog 6 1.001 1.122 1.144 1.034 1.016 
Intratumoral VEGF absorbance 
 Day 1 Day 8 Day 35 
Dog 1* 0.044 0.054 0.043 
Dog 2* 0.051 0.080 0.060 
Dog 4 0.524 0.535 0.217 
Dog 5 0.060 0.053 0.210 
Dog 6 0.068 0.042 0.049 
Dog 7° 0.140 0.104 0.044 
 
 Serum VEGF absorbance 
 Day 1 Day 3 Day 8 Day 15 Day 35 
Dog 1* 0.033 0.042 0.032 0.031 0.040 
Dog 2* 0.039 0.057 0.022 0.019 0.020 
Dog 4 0.030 0.034 0.034 0.032 0.026 
Dog 5 0.023 0.016 0.025 0.022 0.022 
Dog 6 0.024 0.026 0.028 0.027 0.030 
Dog 7° 0.018 0.025 0.018 0.016 0.018 
Values in italic represent values below the standard curve, underlined values within the standard 
curve, *: 1-day regimen; °: dog 7 was analyzed on a different ELISA plate. A change in OD with t 
0.05 was considered as a decrease or increase of that cytokine. 
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7.2 Supplementary figure 1  
Complete blood count in dogs that completed a whole 1-day or 1-week interval 
regimen 
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Complete blood count in dogs that completed a whole 1-day interval regimen (n= 2) and 1-week 
interval regimen (n= 4). Temporary decrease in hematocrit and amount of peripheral 
lymphocytes (day 1-3), eosinophils (day 1-5) and basophils (day 1-3) following intratumoral hIL-
12 EGT. Temporary increase in amount of peripheral monocytes (day 3-15) and neutrophils (day 
1-5) following intratumoral hIL-12 EGT. 
7.3 Supplementary data 1: Response to treatment 
Despite hIL-12 EGT, all primary tumors continued to grow. A decrease in tissue 
resistance (Ohm) as measured by the electroporator was observed in 7 out of 8 dogs (all 
but dog 3). Due to extreme tumor heterogeneity, the tissue resistance in dog 7 could not 
be evaluated. Further tumor specifics are discussed per patient that received a whole 
treatment cycle.  
 
Dog 1: The soft tissue sarcoma was firm before treatment, but softened by day 8. 
Erythema and swelling were present 2 days after the first intratumoral hIL-12 EGT 
(Figure 18). The consistency of the tumor remained soft and elastic thereafter. Prior to 
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treatment, the owners reported the dog was excessively licking the tumor. The dog 
discontinued this behavior 20 days after his third intratumoral hIL-12 EGT to date (16 
months of follow-up to date). The owners reported that the dog showed an ameliorated 
appetite, and increased weight and a general increase in well-being. 
 
Dog 2: The intra-oral fibrosarcoma did not demonstrate a discernable change in 
consistency after IL-12 treatment. The mass remained stable in size for 1 month after 
treatment, after which growth resumed. The dog was in generally good shape and no 
clinically relevant changes occurred for 8 months. After 9 months, occasional nose 
bleedings became apparent and the dog was euthanized.  
 
Dog 4: The very aggressive mammary carcinoma had a promising response to the IL-12 
treatment, since, 2-3 days after each treatment, impressive signs of local inflammation 
were present (Figure 21). By day 8, all nodules had become softer. At day 9, the skin 
between tumor nodules sheared and released tumor exsudate. The tumor exsudate was 
clear and slightly bloody, and the owners reported a necrotic odor. The dog developed a 
fever of 39.8°C at day 10, which spontaneously subsided within 24 hours. From day 12 
on, the openings between the nodules released great amounts of odorless exsudate. The 
openings narrowed by day 20. At day 32, the exsudate was chunky and the necrotic 
odor reappeared. The dog’s well-being regressed from that point on, which led to the 
decision of euthanasia. 
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FIGURE 21. Tumor inflammation after intratumoral hIL-12 EGT in a tubulopapillar complex 
carcinoma of the mammary glands (dog 4). The tumor inflammation is recognized by erythema 
on day 3 and swelling on day 8 and 12. Day 1: before treatment, day 3, 8, 12, 19: after treatment 
initiation (1-week interval regimen). 
 Dog 5: The intra-oral fibrosarcoma did not demonstrate a discernable change in 
consistency after IL-12 treatment. The tumor was associated with bone destruction of 
the right maxilla, palatine and sphenopalatine bone, and invasion of the nasopharynx. 
During treatment, the dog demonstrated loss of appetite, most likely due to tumor 
progression. The dog was euthanized on day 52 due to progressive weakness.  
 
Dog 6: The perianal adenocarcinoma easily bled on day 1, 8 and 15 after rectal toucher. 
At day 15, the tumor was erythematous and swollen (Figure 22). From day 15 on, the 
dog gained weight and experienced fewer difficulties defecating (less straining). On day 
35, no bleeding occurred after rectal toucher. The left medial iliac LN demonstrated 
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slow tumor growth between days 8 and 35, but quintupled in size by day 90. The right 
iliac LN demonstrated partial regression (more than 20% decrease in tumor size) 
between days 8 and 35, but tumor growth resumed by day 90. The dog was euthanized 
on day 210. 
 
FIGURE 22. Tumor inflammation after intratumoral hIL-12 EGT in a perianal adenocarcinoma 
(dog 6). The tumor inflammation is recognized by erythema and swelling on day 15. Day 1: 
before treatment, day 15, 35: after treatment initiation (1-week interval regimen). 
 Dog 7: The schwannoma was firm before treatment, but softened by day 15, although 
less spectacularly than in dog 1. Erythema was present on day 3 and swelling during 
days 5-8 (Figure 23). The dog remained in generally good shape and no further changes 
occurred to date (11 months). 
 
FIGURE 23. Tumor inflammation after intratumoral hIL-12 EGT in a schwannoma dorsal to the 
carpus (dog 7). The tumor inflammation is recognized by erythema and swelling on day 3. Day 1: 
before treatment, day 3, 8, 35: after treatment initiation (1-week interval regimen). 
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1 Abstract 
The immunological, anti-angiogenic and clinical effects of metronomic 
cyclophosphamide and 3 consecutive intratumoral IL-12 gene therapy (EGT) 
treatments were evaluated in 6 dogs with spontaneous cancer. A total of 3 tumor 
biopsies (day 1, 15, 35) and 5 blood samples (day 1, 3, 8, 15, 35) per dog were taken 
prior, during and after intratumoral IL-12 EGT. In all dogs, an initial decrease in blood 
immune cells was followed by an increase 1-3 weeks after treatment initiation. The 
decrease in peripheral leukocytes 2 days after IL-12 EGT coincided with erythema and 
swelling of the tumor. In the tumor, a transient increase in IL-12 levels was measured, 
whereas a continuous increase in interferon γ (IFNγ) and thrombospondin 1 (TSP-1) 
were determined in contrast to a continuous decrease in vascular endothelial growth 
factor (VEGF). In the serum, a transient increase in IL-12 and interleukin 10 (IL-10) 
levels were noted in contrast to a transient decrease in VEGF and TSP-1. There were no 
changes in intratumoral IL-10 levels or serum IFNγ levels. Microbubble contrast-
enhanced ultrasound (CEUS) was performed prior, during and 3 weeks after the last 
intratumoral IL-12 EGT treatment (on day 1, 8 and 35) to establish the anti-angiogenic 
effect of IL-12 EGT. The treatment resulted in a significant decrease of tumor relative 
blood volume and blood flow speed. All primary tumors continued to progress in time, 
but the CEUS indicated that this progression was slower than before treatment. Besides 
the encouraging immunostimulatory and anti-angiogenic effects observed in all dogs 
we also noticed in 4 out of 6 dogs clinically relevant improvements in quality-of-life and 
weight. However, tumor regression could not be obtained. The laboratory and 
ultrasound (US) results hold great promise for combinatorial strategies of IL-12 EGT 
and metronomic chemotherapy with conventional antitumor (immuno)therapies. 
2 Introduction 
The development of cancer is recognized by the body’s immune system as an anomaly. 
On a genetic level, many control mechanisms are in place to detect and destroy 
aberrant cell copies. Similarly, immune surveillance plays an important role in the 
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prevention of neoplastic spread.38 Unfortunately, despite these checkpoints for 
abnormal cell development, cancer cells are able to escape their control resulting in the 
development of a tumor.42 The relationship between cancer and the oncologic patient’s 
immune system is very complex and continuously evolving.359 It is therefore unlikely 
that one immunotherapeutic agent will be powerful enough to produce an effective 
antitumoral immune response. The more cancer promoting pathways that are 
simultaneously targeted, the higher the chances of successfully decreasing tumor 
escape.360 We propose to combine the antitumoral effects of interleukin 12 (IL-12) with 
metronomic cyclophosphamide (CP) as a multi-targeted and complementary approach.  
IL-12 is a powerful immunostimulatory cytokine that links innate and adaptive 
immune responses. By stimulating the immune response, IL-12 is able to activate key 
immune cells such as natural killer (NK) and T cells to recognize and kill cancer cells.197 
Furthermore, IL-12 decreases the suppressive function of myeloid-derived suppressor 
cells (MDSCs)207 and inhibits the differentiation of T cells to regulatory T cells (Tregs) 
as well as the expansion of Tregs.205, 206 
Metronomic chemotherapy, i.e. the continuous administration of low-dose 
chemotherapeutics, has much potential in combinatorial treatments263 and possibly 
synergizes with other immunomodulatory or anti-angiogenic antitumoral therapies.286 
The aim of metronomic chemotherapy is not to kill cancer cells directly but indirectly, 
by influencing the microenvironment of the cancer cells. Cyclophosphamide is a well-
known alkylating chemotherapeutic that has been mainly used in a cytotoxic dose to 
kill rapidly multiplying cells such as cancer cells.263 When given in metronomic doses, 
CP is able to selectively decrease the amount of circulating Tregs and has anti-
angiogenic properties.266  
 
There are multiple advantages to the combination of intratumoral IL-12 EGT and 
metronomic CP as both therapies decrease immunosuppression and angiogenesis. 
Whereas metronomic CP has shown to selectively decrease the amount of Tregs, 293, 279, 
361 IL-12 decreases the suppressive function of immunosuppressive MDSCs,207 which 
could compensate for the CP-induced MDSC expansion.361 The anti-
immunosuppressive effects of metronomic CP restores NK cell effector functions and 
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thus facilitates the generation of innate and eventually adaptive immune responses 
induced by IL-12.362 Indeed, the combination of a low dose of CP and IL-12 induced a 
stronger Th1 response than IL-12 alone in mice.331 Furthermore, multiple 
complementary angiogenesis pathways are simultaneously targeted through this 
combinatory approach. Interleukine 12 inhibits neo-angiogenesis via induction of 
interferon γ (IFNγ) and its cascade products Inducible Protein (IP) 10 and Monokine 
Induced by Gamma interferon (MIG).208 On the other hand, metronomic CP causes 
apoptosis of capillary endothelial cells by up-regulating the endogenous angiogenesis 
inhibitor thrombospondin 1 (TSP-1).272 In turn, TSP-1 binds not only to the CD36R on 
endothelial cells inducing apoptosis,273 but also to the CD47-part of the VEGFR, thus 
blocking the proangiogenic effects of VEGF on endothelial cells.274  
 
Because of severe toxicity, systemic injection of recombinant IL-12 (rIL-12) is not 
recommended.213 Local (intratumoral) injection of rIL-12 has been considered, but 
requires frequent injections due to the short half-life of rIL-12 (12 h).363 Therefore, 
intratumoral IL-12 gene therapy, using plasmid (p)DNA electroporation, has been 
evaluated as it offers a prolonged delivery of IL-12 and resulted in very promising 
(pre)clinical results.219, 220, 221, 222 Electroporation is the short administration of electrical 
pulses to ensure the formation of transient pores into the plasma membrane of cells 
thereby facilitating the intracellular delivery of large molecules such as pDNA.215 Once 
the pDNA reaches the cell’s nucleus, the production of the protein encoded on the 
plasmid ensues.216, 217 In vivo electroporation does not cause any severe adverse 
events,218 and several canine and human clinical trials showed the safety and clinical 
efficacy of electroporation-mediated intratumoral delivery of a pDNA encoding IL-
12.219, 220, 221, 222 
 
In this article, the effects of intratumoral IL-12 EGT in combination with metronomic 
CP on tumor angiogenesis, amount of circulating Tregs and shifts in the tumor 
microenvironment were studied in 6 dogs with various tumor types and sizes. To our 
knowledge, this is the first article that describes the combinatorial effects of 
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intratumoral IL-12 EGT and metronomic CP (IL-12-CP treatment) in dogs with 
spontaneous tumors. 
3 Materials and Methods 
3.1 Animal selection 
Client-owned dogs with spontaneous malignant neoplasms were enrolled between 
April 2015 and October 2015. Patients included in the study were not eligible for 
surgery, either due to recurrent disease for which conventional surgery was already 
exhausted, or due to the impractical location of the tumor. Other conventional 
therapies such as chemotherapy or radiation were not given prior to IL-12-CP 
treatment. 
The study cohort consisted of 6 dogs, 2 intact and 2 castrated males and 2 spayed 
females belonging to 5 different breeds (Golden Retrievers (n=2), Stabyhoun, Malinois, 
French Bulldog and Beagle), their age ranging from 7 to 14.8 years (mean 10.2 years 
±2.6) (Table 12). The following additional inclusion criteria were applied: a 
histologically confirmed neoplasia accessible for application of electrodes, normal 
cardiovascular function, good general health status and a biochemistry profile within 
reference limits. In all animals, screening for metastatic disease was accomplished by 
thoracic radiographs and/or abdominal US.  
Animals were free of non-steroidal anti-inflammatory drugs (NSAID) at least 1 week 
before and during the entire study period, except dog 3 who received NSAIDs during 
the first 3 days of IL-12-CP treatment, since this dog underwent surgical excision of the 
primary tumor and metastases 1 day before onset of the IL-12-CP treatment. All animal 
handling and treatment procedures were approved by the Ethical Committee (approval 
number 2014/81) of the Faculty of Veterinary Medicine of Ghent University, Belgium 
and the Deontological Committee of the Federal Public Service of Health, Food Chain 
Safety and Environment, Belgium. A written informed consent was obtained from each 
dog owner. 
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TABLE 12. Signalment, tumor type, tumor size and metastasis status of the dogs treated by 
intratumoral IL-12 gene therapy and metronomic cyclophosphamide  
Dog Breed Sex Age 
Tumor type 
(localization) 
Tumor 
size 
Metastases 
1 
Golden 
Retriever 
Fn 14y  
Amelanocytic 
melanoma (intra-oral) 
50.24 
cm3 
Lymph node cytology and 
liver ultrasound positive 
2 
Golden 
Retriever 
Mn 14y 10m 
Schwannoma (dorsal 
to carpus) 
360 cm3 
Lymph node cytology and 
thoracic free 
3 Stabyhoun* Fn 7y 
Adenocarcinoma 
(anal sac) NA 
Abdominal metastasized 
lymph nodes resected, 
hypogastric lymph node 
cytology positive, thoracic 
free 
4 Malinois° M 11y  Fibrosarcoma (dorsal 
to carpus) 
43.96 cm3 
Lymph node cytology and 
thoracic free 
5 
French 
Bulldog 
Mn 8y 11m Osteosarcoma (costal) 201 cm3 
No, locally invasive in 
thorax 
6 Beagle M 10y 2m 
Fibrosarcoma 
((rostro)mandibular) 
14.13 cm3 
Lymph node cytology and 
thoracic free 
F: female; Fn: female neutered; M: male; Mn: male neutered.  
* no contrast-enhanced ultrasound was performed in this dog 
° this dog received a second IL-12-CP treatment 5 months after the first IL-12-CP treatment 
cycle.  
3.2 Plasmid 
An IL-12 pDNA encoding human IL-12 (hIL-12) was obtained via Celsion-EGEN, Inc. 
(Huntsville, AL, USA). It was produced under GMP conditions by Eurogentec (Seraing, 
Belgium). The hIL-12 plasmid contains an immediate early enhancer and promoter 
derived from cytomegalovirus (CMV), 5' untranslated region (UTR), synthetic intron, 
human p35 gene, human growth hormone (hGH) 3' UTR and polyadenylation signal 
sequence, CMV promoter, 5' UTR, synthetic intron, human p40 gene, hGH 3' UTR and 
polyadenylation signal sequence. Of note is the fact that both the hIL-12 subunits are 
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individually under the control of 2 separate CMV promoters. The sequences of the p35 
and p40 cDNAs are identical to the sequences found in GenBank with the exception of 
a single base mutation in the second codon of the p35 cDNA. The change was made to 
insert a KOZAK sequence for proper translation initiation and also created an Nco I 
restriction digest site. The mutation changed the second amino acid of the p35 signal 
sequence from a cytosine (CYS) to a glycine (GLY). A similar change was made to the 
second codon of the p40 cDNA. 
3.3 Metronomic cyclophosphamide 
Dogs received 12.5 mg/m2 CP (Endoxan, Baxter, Belgium, Lessines) daily. The dosage 
of CP was based on a previous study with metronomic CP in dogs performed by our 
lab.285 Reformulation of the drugs was done in collaboration with the Faculty of 
Pharmaceutical Sciences of Ghent University.  
3.4 Ultrasound and Contrast-Enhanced Ultrasound 
Prior to lL-12 EGT, B-mode US of all tumors was performed with a linear 12-5 MHz or 
17-5 MHz transducer (Philips, iU22 xMATRIX, Philips Medical systems, Bothell, 
Washington, USA) to determine the echogenicity, to assess the presence of 
mineralization within the tumor and to measure the tumor dimensions.  
Following conventional US examination, tumor perfusion measurements with CEUS 
were performed with the same dedicated machine (iU22 xMATRIX) equipped with 
contrast-specific imaging technology using a linear 12-5 MHz probe. To evaluate the 
tumor perfusion, dogs were imaged with manual restraint or, in one dog, under mild 
sedation with butorphanol (Dolorex® 0.2 mg/kg), a drug that is known not to influence 
the CEUS.324 Prior to injection of microbubbles (MB), several imaging parameters were 
adjusted to decrease early destruction of the injected MBs by the US beam. Mechanical 
index was decreased (0.09), persistence was switched off and a single focal spot was 
placed under the tumor.  
The MB contrast agent (Sonovue®, Bracco, Milan, Italy), consisting of lipid-stabilized 
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MBs with a sulfur hexafluoride gas core, was injected intravenously (IV) as a bolus 
(0.04 mL/kg), immediately followed by a 1 mL flush of sterile saline (Mini-Plasco NaCl 
0.9%, Braun) via a peripheral venous catheter inserted in the cephalic vein. Between the 
boluses, the remaining MBs were destructed by increasing the acoustic power in the 
imaging plane for several minutes.  
During CEUS, areas that should be avoided during injection of the IL-12 pDNA 
solution, such as main tumor vessels or necrotic tissue, were identified. All CEUS 
studies were digitally registered as a movie clip at a rate of 10 frames/sec for 90 sec after 
bolus injection. These clips were analyzed using integrated dedicated specialized 
computer software (VUEBOX, Bracco) for objective quantitative analysis. Tumor 
regions-of-interest (ROIs) were manually drawn and mean pixel intensities and time-
intensity curves created per ROI. These curves were analyzed for Radius Basis Function 
parameters representing blood volume (area-under-curve) and blood velocity (sec). A 
B-mode image was projected simultaneously with CEUS imaging, and (CE)US was 
repeated for comparison at the identical tumor location at day 8 and 35. CEUS imaging 
was performed in all dogs, except dog 3, since the tumor and its metastases were 
surgically removed before IL-12-CP treatment.  
3.5 Interleukin 12 electrogene therapy 
One mg of IL-12 plasmid per session was diluted with calcium and magnesium free 
phosphate-buffered saline (DPBS) (14040-174, Invitrogen). The injection volume was 
1/6 of the tumor volume that was calculated with the following formula: L*H*Wπ/6 (L: 
length, H: height, W: width).  The sterile IL-12 pDNA injection volume was 
administered intratumorally throughout the whole tumor mass. An 8-needle array 
electrode connected to an electroporator (Agile Pulse generator, BTX® Harvard 
Apparatus) was inserted within 2 min after injection around the injection site. Two 
pulses of 450 V/cm were given (pulse duration was 0.05 msec and the interval between 
the pulses 0.2 msec). After 50 msec, those 2 pulses were followed by 8 pulses of 100 
V/cm (pulse duration was 10 msec and the interval between pulses 20 msec). The tumor 
volume treated was restricted by the needle length of the electrodes. Since the 
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maximum length of the electrodes was 25 mm, tumor tissue at a depth greater than 25 
mm could not be electroporated. 
3.6 Clinial trial design 
Prior to each treatment session, subject owners were interviewed and each dog was 
physically examined. Blood was collected to assess the subject’s hematology and 
biochemistry. Baseline bloodwork consisted of a complete blood count (CBC) with 
differential white blood cell count, which was performed using an automated laser 
hematology analyzer (Procyte, Idexx, The Netherlands) with species-specific software 
(Vetlab Station). The automated chemistry analyzer Technicon RA-XT (Catalyst, Idexx, 
The Netherlands) was used for the determination of the following biochemical 
parameters: blood urea nitrogen, creatinine, serum alkaline phosphatase (SAP) and 
alanine aminotransferase, glucose, total protein, and globulines. When all values were 
within reference range, a catheter was placed. Hair overlying tumor nodules was 
clipped prior to (CE)US. After a general US examination of the region of the tumor, 
patients received IV contrast agent for CEUS evaluation of tumor perfusion. Afterward, 
the patient was anesthetized for the electroporation of the IL-12 pDNA. For this 
purpose, patients were premedicated with buprenorphine (Vetergesic® 10 μg/kg) and 
after 15 min dexmedetomidine (Dexdomitor® 5 μg/kg) was administered. After another 
15 min, anesthesia was induced with propofol (Propovet multidose® 1 mg/kg) and was, 
if necessary, maintained with isoflurane.  
Immediately after IL-12 EGT, 3 cylindrical punch biopsies of 2x8 mm (Bap Medical, 
33-31) were taken from different locations within the neoplasm to factor in 
intratumoral heterogeneity.325 The biopsies were taken after electroporation to avoid 
leakage of the injected pDNA from the tumor. After the biopsy taking, the subjects were 
antidoted with atipamezole (Revertor®, 25 μg/kg). No (N)SAIDs were administered, to 
prevent interference with the development of an inflammatory response to the 
treatment. Other non-anti-inflammatory pain medications such as Tramadol 
(Tramadol EG®, 2 mg/kg) were offered as alternative.  
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Oral metronomic CP (12.5 mg/m2, Endoxan, Baxter, Belgium, Lessines) was initiated at 
day 1 and maintained at least until day 35.  
To assess possible side effects of the procedure, physical examinations of patients were 
performed at least on day 1, 3, 8, 15 and 35 of the treatment cycle. During examination, 
the tumor was evaluated for signs of local inflammation (erythema, swelling, pain), 
secretions, necrosis, etc. The production of hIL-12 and the occurrence of systemic 
effects were evaluated by measuring the amount of canine IFNγ, IL-10, VEGF and TSP-
1 in serum and by screening for aberrations in CBC and/or the biochemistry profile. 
The response to therapy was assessed by means of repeated measurements of tumor size 
and perfusion through (CE)US and repeated measurements of the amount of IFNγ, IL-
10, VEGF and TSP-1 in tumor tissue (Figure 24). 
 
FIGURE 24. Schedule of IL-12-CP treatment. Blood: complete blood count and biochemistry 
analysis, CEUS: contrast-enhanced ultrasound, IL-12: intratumoral injection of 1 mg hIL-12 
plasmid DNA and electroporation, Biopsy: collection of 3 small tumor biopsies. 
3.7 Tumor tissue analysis 
The biopsies were immediately kept on dry ice and stored in a -150°C freezer 
(Panasonic, TCPS) until further use. A day prior to ELISA analysis biopsies were 
thawed in a 600 μl mixture of DPBS and protease-inhibitor cocktail (cOmplex Mini, 
Roche, 5892970001). Biopsy samples were disrupted with a tissue disruptor 
(TissueRuptor®, Qiagen) during 30 sec to lyse the cells. The lysed cells were centrifuged 
at 12,000xg during 10 min at 4°C. Afterward, the supernatant was removed and stored 
at 4°C until use the following day. The concentration of the cytokines is shown as pg 
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(IL-12, IFNγ, IL-10, VEGF) or ng (TSP-1) per cm3 of tumor tissue (Figure 25 and 
Figure 33). 
3.8 ELISA of local and systemic cytokines during IL-12-CP treatment 
The presence of canine IFNγ, VEGF, IL-10 and TSP-1 in serum and tumor tissue was 
determined using ELISA kits (Canine IFN-γ/VEGF/IL-10 Quantikine ELISA Kit, R&D 
Systems, CAIF00/CAVE00/CA1000, USA and TSP-1 ELISA Kit, Biotang, CA0214, USA 
respectively) and hIL-12 with Human IL-12 (p70) ELISA MAXTM Standard (Biolegend, 
431701, USA). In order to assess if the IL-12 pDNA transfection was successful, the 
amount of hIL-12 in the tumor was measured for each dog on day 1, 15 and 35 of the 
treatment. The stimulatory effects of hIL-12 were determined by analysis of the amount 
of canine IFNγ, while the anti-angiogenic effects were determined by analysis of the 
pro-angiogenic growth factor VEGF and the anti-angiogenic glycoprotein TSP-1. The 
anti-immunosuppressive effects were determined by analysis of IL-10. Intratumoral 
cytokines were assessed on day 1, 15 and 35, while the serum cytokine levels were 
measured on day 1, 3, 8, 15 and 35 for each dog. 
3.9 Determination of percentage of regulatory T cells 
Blood was collected before treatment, after 2 weeks and 5 weeks of IL-12-CP treatment 
in an EDTA tube. The same day, peripheral blood mononuclear cells (PBMC) were 
isolated using a Ficoll density gradient (GE healthcare Europe, 17-1440-02). The 
isolated PBMCs were dissolved at 107 cells/mL in 40% phosphate buffered saline, 50% 
fetal calf serum and 10% dimethylsulfoxide (Invitrogen, D12345). Vials were placed in a 
cryobox at -80°C overnight and then transferred to -154°C. Upon analysis, vials were 
thawed in a warm water bath and warm medium was gradually added. After 2 wash 
steps cells were stained for Treg. One million cells in a volume of 100 μL of FACS 
staining buffer (BD Biosciences, 554656) were used for immunostaining. Cells were 
stained for the surface antigens CD4 and CD25, using FITC-conjugated anti-dog CD4 
(eBioscience, 11-5040-42) and eFluor 660-conjugated anti-dog CD25 antibodies 
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(eBioscience, 50-0250-42). Surface staining was done at 4°C for 30 min. Intracellular 
staining for FoxP3 was done as described previously,285 with a cross-reactive murine 
PE-conjugated FoxP3 antibody and the permeabilization and fixation/permeabilization 
buffer that accompanies the antibody (foxP3 staining set, clone fjk-16s, eBioscience). 
Briefly, after washing to remove unbound surface antibodies, cells were resuspended in 
fix/perm buffer and incubated at 4°C overnight. The next day, cells were washed twice 
with permeabilization buffer and incubated with the FoxP3 antibody at a concentration 
of 1 μg per 1x106 cells for 30 min at 4°C. Fluorescence Minus One tubes were analyzed 
as controls to determine thresholds and single staining tubes to perform color 
compensation. Flow cytometric analysis was done with a BD Accuri C6 flow cytometer 
and Cflow software (BD, Belgium, Erembodegem). Analysis was performed on the 
permeabilized lymphocyte population based on forward and side scatter characteristics. 
The percentage of Tregs was calculated as the CD4+CD25+FoxP3+ cells in the overall 
CD4+ T cell population. 
3.10 IL-12 receptor activation on peripheral blood mononuclear cells 
No canine antibody for IL-12 receptor β2 (IL-12Rβ2) was available, thus an antibody 
for human IL-12Rβ2 was used instead. Canine IL-12Rβ2 has a high homology with 
human IL-12Rβ2: 85.4% homology at the nucleotide level and 76.8% homology at the 
amino acid level and well conserved structural motifs.364 One hundred thousand 
PBMCs in a volume of 100 μL of FACS staining buffer (BD Biosciences) were used for 
immunostaining. Cells were stained for the surface antigen IL-12Rβ2, using Alexa Fluor 
488-conjugated anti-human IL-12Rβ2 antibodies (R&D Systems, FAB1959G-025, UK). 
Surface staining was done at 4°C for 30 min. Cells were then washed to remove 
unbound surface antibodies. Flow cytometric analysis was done with a BD Accuri C6 
flow cytometer and Cflow software (BD, Belgium, Erembodegem). Unstained canine 
PBMCs served as negative controls, whereas stained human PBMCs served as positive 
controls. 
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3.11 Immunohistopathology 
One cylindrical tumor biopsy of 2x8 mm was taken on day 1, 10 and 15 or 1, 15 and 35 
at the identical area in 2 dogs (dogs 4 and 6 respectively). Samples were fixated for 24 h 
in formol, then rinsed and kept in distillated water until processing. Samples were 
paraffin-embedded and sections were cut longitudinal. Paraffin-embedded sections 
were pretreated for antigen retrieval by heating in a microwave for 30 min in a citrate 
buffer (pH 6.0), and allowed to cool for 20 min. Afterward, endogenous peroxidase 
activity was blocked by resting during 5 min in a 0.03% H2O2 solution (Dako, K4011). 
The section was rinsed with distillated water and washed once with wash buffer. Then, 
the section was incubated during 30 min with a 1/100 dilution (in primary antibody 
diluent Dako, S302283) of cross-reacting primary antibody polyclonal rabbit anti-
human T cell, CD3 (Dako Ref.A0452) or polyclonal rabbit anti-human B cell, CD20 
(Thermo Scientific, RB-9013-P). The section was rinsed again with wash buffer and 
incubated during 30 min with the secondary antibody conjugated with peroxidase 
(Envision Link Rabbit (Dako, K4011)). The section was rinsed twice with wash buffer 
afterward and incubated during 5 min with 3,3ƍ-diaminobenzidine solution (Dako, 
K4011). Then, the section was rinsed with distillated water and counter-coloured with 
hematoxyline, dehydrated and mounted on a slide. Positive controls for CD3 and CD20 
stainings were performed on a LN. Photomicrographs were obtained using a Leica 
microscope DMLB2 with Leica camera type DFC 320 R2 and software program LAS 
(Leica Application Suite) version 4.0.0 (build:877) (Leica, Belgium). 
3.12 Statistical Analysis 
All data were analyzed with the statistical software program SPSS (version 19.0). The 
parametric data were analyzed with the paired sample t-test, the non-parametric data 
with the Wilcoxon rank-sum test with Bonferroni correction. Statistical significance 
was determined at p≤ 0.05. 
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4 Results 
4.1 Local and systemic release of immune activation-linked 
cytokines (ELISA) 
After the IL-12-CP treatment a significant but transient increase of hIL-12 was 
measured in tumor lysate (p= 0.046) and serum (p= 0.028) (Figure 25A, B). No 
significant changes for intratumoral IFNγ or serum IL-10 were measured (Figure 25C, 
D), whereas no changes at all for intratumoral IL-10 or serum IFNγ were measured. 
 
FIGURE 25. Intratumoral levels of IL-12 (A), IFNγ (C) and serum levels of IL-12 (B), IL-10 (D) 
during IL-12-CP treatment. ° indicates a mild outlier, * indicates a strong outlier, an underlined * 
indicates p≤ 0.05 between the different time points (n=6). 
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4.2 Complete blood count and biochemistry 
After the first hIL-12 EGT treatment, no significant changes were observed for 
lymphocytes, eosinophils and monocytes at any of the time points, whereas a significant 
increase in basophils above baseline was noticed at day 8 and 15 (p= 0.043) (Figure 27, 
Figure 28). A significant increase in neutrophil levels was noticed between day 8 and 15 
(p= 0.008), but neutrophil levels did not increase above baseline (Figure 28). No 
significant changes were measured for the amount of red blood cells, but a significant 
increase in reticulocytes was measured at day 8 (p= 0.046) and 15 (p= 0.028) (Figure 
26). All biochemistry values except SAP remained within range and no clinically 
relevant changes were detected throughout the treatment cycle. In 2 dogs with bone-
infiltrating tumors (dogs 5 and 6), the serum SAP levels exceeded reference levels at day 
1 and were decreased at day 3. The level of SAP temporarily decreased after treatment 
in dog 5 and remained decreased in dog 6. 
 
FIGURE 26. Temporary decrease in hematocrit and increase in reticulocyte response during IL-12-
CP treatment. ° indicates a mild outlier, an underlined * indicates p≤ 0.05 between the different 
time points (n=6). 
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FIGURE 27. Temporary decrease in the amount of peripheral lymphocytes (A), eosinophils (B) 
and basophils (C) during IL-12-CP treatment. ° indicates a mild outlier, * indicates a strong 
outlier, an underlined * indicates p≤ 0.05 between the different time points (n=6). 
 
FIGURE 28. Temporary increase in amount of peripheral monocytes and neutrophils during IL-
12-CP treatment. *, p≤ 0.05 between the different time points (n=6). 
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4.3 Physical examination findings and side effects after IL-12-CP 
treatment 
Generally, erythema and swelling were apparent 2-3 days after IL-12 EGT treatment 
(Figure 29). The VCOG-CTCAE criteria for adverse effects326 associated with IL-12 
toxicity were used to evaluate the findings of these examinations and are listed in Table 
13. During electroporation, clear muscle contractions were present which required 
appropriate sedation. Dog 4 received a second IL-12-CP treatment 5 months after the 
first IL-12-CP cycle (Figure 30) and the observed tumor swelling and erythema were 
similar to those after the first IL-12-CP cycle. 
 
FIGURE 29. Tumor inflammation dorsal to carpus during the first IL-12-CP treatment cycle in 
dog 4. The tumor inflammation is recognized by erythema on day 3 and swelling on day 8. 
Photos were taken on day 1 (before treatment) and day 3, 8 and 15 of the IL-12-CP treatment 
cycle. 
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FIGURE 30. Tumor inflammation dorsal to carpus during the second IL-12-CP treatment cycle in 
dog 4. The tumor inflammation is recognized by swelling on day 15 (during). Photos were taken 
3 weeks before treatment and on day 15 and 45 of the second IL-12-CP treatment cycle. 
TABLE 13. VCOG-CTCAE criteria for adverse effects326 associated with IL-12 and/or CP 
toxicity 
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1 - - - - - - - 1* - - - - 
2 - - - - - - - 1* - - - - 
3 - - - - - - - - - - - - 
4 - - - - - - - 1* 1 - - - 
5 - - - - - - - - - - - 2 
6 - - - - - - - 1* - - - - 
Auto-immune disorder grade 1 indicates a mild auto-immune reaction. Cystitis grade 1 indicates 
asymptomatic cystitis; grade 5 indicates death as a consequence of cystitis. Weight loss grade 1 
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indicates <10% from baseline; grade 5 indicates death as a consequence of weight loss. Anorexia 
grade 1 indicates coaxing or dietary change required to maintain appetite; grade 5 indicates death 
as a consequence of anorexia. Tumor pain grade 1 indicates mild pain not interfering with 
function; grade 2 indicates moderate pain manageable with standard oral NSAIDs or opiates; 
grade 4 indicates disabling or uncontrollable pain. * indicates initial weight loss, followed 4 weeks 
later by complete recovery or weight gain. 
4.4 Clinical response to IL-12-CP treatment 
Despite treatment, all primary tumors continued to enlarge. However, the tumor 
progression was visibly slower after treatment than before in 3 out of 6 dogs. Whereas 
before treatment the enrolled dogs gradually lost weight, the body weight of 2 dogs, 
remained stable whereas it increased between 4.2 and 17.4% in the remaining 4 dogs 
(Table 14). 
 
TABLE 14. Effects on patient weight after IL-12-CP treatment. 
Dog Weight (kg) on Day 1 Weight gain (kg) Weight gain (%) 
1 27.3  1.2 (Day 35) + 4.4 
2 31.7  0 (Day 35) 0 (stable weight) 
3 23.2  2.3 (Day 35) + 9.2 
4 32.8  5.7 (Day 90) + 17.4 
5 14.5  0.6 (Day 35) + 4.2 
6 21.6  0 (Day 35) 0 (stable weight) 
4* 35.8  4.7 (Day 60) + 13.1 
* Five months after a first treatment cycle, dog 4 was treated a second time. 
4.5 Effects of IL-12-CP on anti-neoangiogenesis 
The anti-angiogenic properties of IL-12-CP treatment were measured with CEUS of the 
tumor in 5 out of 6 dogs (Figure 31, Figure 32) and the amount of VEGF and TSP-1 was 
measured by ELISA in serum and tumor tissue in all dogs (Figure 33). A significant and 
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persistent decrease in relative blood volume (characterized by the peak enhancement 
(PE)) and blood flow speed (characterized by the time to peak (TTP)) was present at 
day 35 of treatment (p= 0.043 for PE and TTP) in all 5 dogs after IL-12-CP treatment 
(Figure 32). Four out of 5 dogs demonstrated a ≥ 40% decrease in relative blood volume 
(an indicator of increased survival)323 at day 35. A non-significant increase in relative 
blood volume was measured at day 8. A significant increase of intratumoral TSP-1 at 
day 35 (p= 0.046) coincided with a non-significant decrease in intratumoral VEGF. 
Interestingly, serum levels of TSP-1 were significantly decreased at day 8 (p= 0.046), 
which coincided with the lowest amount of serum VEGF. On day 15, serum TSP-1 
levels had again significantly increased (p= 0.043) (Figure 33). 

 
FIGURE 31. Representative time intensity curves after IL-12-CP treatment in dog 2. 
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FIGURE 32. Follow-up of relative blood volume (PE) and blood flow speed (TTP) during IL-12-CP 
treatment.  ° indicates a mild outlier, * indicates a strong outlier, an underlined * indicates p≤ 
0.05 between the different time points (n=5). 
 
FIGURE 33. Intratumoral levels of TSP-1 (A), VEGF (C) and serum levels of TSP-1 (B), VEGF (D) 
during IL-12-CP treatment. ° indicates a mild outlier, * indicates a strong outlier, an underlined * 
indicates p≤ 0.05 between the different time points (n=6). 
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4.6 Effect of IL-12-CP treatment on regulatory T cells 
A significant decrease of Tregs was noted in patients treated for 2 weeks with IL-12-CP 
(3.05 +/-1.52% vs 1.08 +/-0.82%, p=0.046). The percentages of Tregs did slightly 
increase after day 15, but were still significantly below baseline at day 35 (3.05 +/-1.52% 
vs 1.43 +/-0.77%, p=0.043) (Figure 34). 
 
FIGURE 34. Percentages of Tregs during IL-12-CP treatment. ° indicates a mild outlier, an 
underlined * indicates p≤ 0.05 between the different time points (n=6). 
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4.7 Effect of IL-12-CP treatment on IL-12Rȕ2 expression on 
peripheral blood mononuclear cells 
A non-significant decrease of IL-12Rβ2 on PBMCs is noted on day 15 and 35 of the IL-
12-CP treatment cycle (Figure 35). 
 
 
FIGURE 35. Percentages of IL-12Rβ2-positive PBMCs during IL-12-CP treatment. No significant 
differences were present between the different time points (n=6). 
4.8 Effect of IL-12-CP treatment on tumor immune cell infiltration 
Tumor biopsies were taken from 2 dogs (dog 4 and dog 6) to evaluate the presence of 
immune cell infiltration following IL-12-CP treatment. An increase in the amount of T 
cells was noted on day 15 for both dogs. In contrast, whereas a clear increase in B cells 
was present on day 15 in dog 4, this was not present until day 35 in dog 6 (Figure 36). 
 
Chapter 3: Immunological, anti-angiogenic and clinical effects of intratumoral interleukin 12  
electrogene therapy plus metronomic cyclophosphamide in dogs with spontaneous cancer 
157 
 
FIGURE 36. Immunohistochemical stainings for T (CD3) and B cell (CD20) tumor infiltration 
counterstained with haematoxylin (GILL) during IL-12-CP treatment in dog 4. 
5 Discussion 
We evaluated the anti-angiogenic and immunological effects of the combination of 
intratumoral hIL-12 EGT with oral metronomic CP.  
A remarkable increase in intratumoral relative blood volume was noted 1 week after the 
first IL-12-CP treatment, followed by a clear decrease in blood volume below baseline 
on day 35. This transient increase in blood volume may seem paradoxical for an anti-
angiogenic treatment, but is a well-known phenomenon in anti-angiogenic approaches, 
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namely “vascular normalization”. Indeed, anti-angiogenic treatments remold 
intratumoral blood vessels into more mature and functional blood vessels. This 
normalization decreases the intratumoral vascular permeability and thus the interstitial 
fluid pressure, leading to a more homogenous perfusion.365 A decrease in interstitial 
fluid pressure was confirmed in our study, as all the dogs demonstrated a softer tumor 
consistency as from 1 week after the first intratumoral hIL-12 EGT.  
An important advantage of vascular normalization is the restoration of overall 
perfusion which reverses the intratumoral hypoxia and low pH. Since hypoxia and 
decreased pH compromise the cytotoxic functions of immune cells, the improved 
perfusion will not only allow immune cells to reach the entire tumor but also to display 
an improved cytotoxic function.366 The onset of normalization is typically 2 days after 
initiation of an anti-angiogenic treatment.365 The normalization window depends on 
the anti-angiogenic treatment and has been reported to last 2-4367 or even 2-8 days.368 
Erythema and swelling of the tumor was seen in all dogs 2 days after the first 
intratumoral hIL-12 EGT. In 2 dogs, the tumor location was prone to accidental self-
injury. The tumors of these 2 dogs bled very easily during the first 14 days after 
treatment. After these first 14 days, the sensitivity to bleeding after accidental self-
injury was significantly reduced. These findings reinforce the concept of temporary 
normalization of the tumor vascularization, associated with cell influx and 
inflammation, followed by anti-angiogenesis.  
Malignant and benign tumors are characterized by a rapid and slow increase of contrast 
uptake respectively.345 At day 8, the CEUS registered a non-significant decrease in blood 
flow speed, which could indicate a less aggressive behavior of the tumor after IL-12-CP 
treatment. At day 35, the tumor blood flow was significantly slower than on day 1 and 
the relative blood volume had significantly decreased as well. A decrease in tumor 
blood volume does not preclude efficient perfusion. Despite a significant drop in tumor 
blood volume, the delivery of large molecules or immune cells can still be more efficient 
than before treatment through the remaining vessels.369 Additionally, a ≥ 40% decrease 
in relative blood volume was measured in 4 out of 5 dogs. Both tumor vascular 
normalization365 and a ≥ 40% decrease in relative blood volume323 correlated with 
improved patient outcome. Although the tumors of all treated dogs continued to 
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progress, it is thus likely that the IL-12-CP treatment induced a slower tumor 
progression. 
In our study, a clear inflammatory response was present 2 days after treatment 
initiation. As IL-12 upregulates intratumoral vascular adhesion molecules,213, 327, 332, 333, 
334 normalization due to the anti-angiogenic properties of metronomic CP and IL-12 
can greatly enhance the overall immune cell infiltration. The observed inflammatory 
response was probably even further facilitated by the metronomic CP-induced selective 
depletion of circulating immunosuppressive Tregs. The greater decrease in circulating 
Tregs measured in our study on day 15 than on day 35 can be explained by the ability of 
IL-12 to temporarily (minimally 2 weeks) decrease the amount of Tregs.335 
Alternatively, the vascular normalization may have contributed to a more efficient 
intratumoral deposit of CP and thus a greater decrease in Tregs.  
 
Metronomic CP is known to induce TSP-1 in cancer cells and perivascular cells370 and 
TSP-1 inhibits angiogenesis and inflammatory responses in order to suppress tumor 
formation.371 In our study, the intratumoral decrease of VEGF-levels logically 
corresponded with an increase in TSP-1. However, while serum VEGF was lowest on 
day 8, so was serum TSP-1. Interestingly, the effects of TSP-1 can differ according to 
the bound cell type.372 Whereas TSP-1 exerts anti-angiogenic effects on endothelial 
cells, it is a negative regulator of DC activation373 which impedes antitumoral 
immunotherapy. On the one hand, metronomic CP is known to induce TSP-1 and 
TSP-1 suppresses immune cells via interaction with CD47 on immune cells.373 On the 
other hand, metronomic CP has been associated with increased expression of DC 
maturation markers via Treg depletion in mice.374 It is possible that the immune 
activation caused by IL-12-CP treatment induced a negative feedback loop on TSP-1 
serum levels.373 The low amount of serum TSP-1 on day 8 may thus have been the result 
of an overall immune stimulation and beneficial for an effective immune activation of 
monocytes, which were at the highest levels on day 8. A decrease in intratumoral 
VEGF-levels fuels any antitumoral effects even more, as it improves the maturation and 
function of DCs and reduces Treg and MDSC infiltration.375, 376 The decrease in VEGF-
levels observed in our study could be attributed to IFNγ cascade product IP-10 and the 
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metronomic CP TSP-1-induced blocking of CD47.210, 371 Another explanation for the 
decrease in VEGF is through the observed decrease in neutrophils on day 8. 
Neutrophils are able to induce VEGF production in cancer cells and a decrease in 
neutrophils was present on day 8. Although the amount of circulating neutrophils was 
increased on day 15, the anti-angiogenic effects of the IL-12-CP treatment were 
maintained. This persistent anti-angiogenic effect can be the result of a change in the 
neutrophil behavior. Since IL-12 is a powerful stimulator of an antitumoral immune 
response and the antitumoral activity of tumor-infiltrated neutrophils depends on its 
microenvironment,181 it is possible that IL-12 induced a shift in neutrophil behavior. As 
a consequence, the tumor may not have been able to recruit immature protumoral 
neutrophils. Therefore, it would be interesting to characterize the maturity of the 
neutrophils after IL-12 treatments. 
 
Several beneficial developments were noted during IL-12-CP treatment. Most 
remarkable was the apparent anticachectic effect of the IL-12-CP treatment obtained in 
4 out of 6 treated dogs; the body weight remained stable in the 2 remaining cancer-
bearing dogs. What is more, the positive effect on the body weight could be reproduced 
in 1 dog that was treated a second time with intratumoral hIL-12 pDNA after once 
more gradually losing weight 4 months after the first IL-12-CP treatment.after the first 
IL-12-CP treatment. Furthermore, bone destruction was evident in 2 dogs (dogs 5 and 
6) via radiographs and the measurement of SAP, which is an enzyme for bone 
destruction and liver disease.377 The liver function in these 2 dogs was normal and their 
increased levels of SAP were most likely due to bone destruction. The level of SAP 
temporarily decreased after treatment in dog 5 and remained decreased in dog 6, 
possibly indicating a stabilization of bone destruction. Another interesting observation 
made, was the improved healing capacity of the tumors. Whereas tumors are described 
as wounds that do not heal,378 the wounds on the tumors of dogs 2 and 4 did heal after 
IL-12-CP treatment. Finally, before dog 4 received a second treatment cycle, an 
unmistakable necrotic odor and deposit were present, which subsided within 2 weeks 
after the treatment initiation.  
Chapter 3: Immunological, anti-angiogenic and clinical effects of intratumoral interleukin 12  
electrogene therapy plus metronomic cyclophosphamide in dogs with spontaneous cancer 
161 
Overall, the IL-12-CP treatment seemed to induce a less aggressive and more stable 
tumor microenvironment. Similar results were seen for the combination of 
intratumoral IL-12 EGT and oral metronomic CP in cancer-bearing mice.293 The 
combination treatment resulted in a significantly enhanced survival of cancer-bearing 
mice.  
 
To measure the immune activation after IL-12 therapy, one could measure increases in 
IFNγ secretion and/or IL-12Rβ2 expression.227 The non-significant increase in 
intratumoral IFNγ indicates that the hIL-12 was able to stimulate canine immune cells. 
However, IFNγ may not be a good indicator for immune activation. The amount of 
IFNγ produced after stimulation by IL-12 does not correlate with IL-12 efficiency.379 
IFNγ can be produced by NK cells as well as T cells after IL-12 stimulation. In both IL-
12 responsive and unresponsive tumors, NK cells will release the same amount of IFNγ, 
but the T cells in IL-12 responsive tumor types express higher amounts of IL-12Rβ2 
and release more IFNγ when stimulated by IL-12 than unresponsive tumors.379 A non-
significant increase of IFNγ was measured in the tumor lysate in our study, but 
probably none of the tumors were immunogenic. This lack in pre-existing tumor 
immunogenicity seems to be confirmed by the down-regulation of IL-12Rβ2. The IL-
12Rβ2 is expressed in activated (tumor-sensitized), but not naive T cells.380, 381 It is likely 
that tumor-sensitized T cells are primary targets of IL-12 during tumor rejection,379 but 
only a limited number of cancer-bearing patients dispose of a pre-existing immunity.331 
Re-exposure of Th1 cells to IL-12 results in a strong upregulation of the IL-12Rβ2 even 
in the absence of antigen stimulation.382 It has been shown that the combination of CP 
and IL-12 therapy eradicated established large tumors in mice, but only when tumor-
sensitized T cells were present.379 During our study, instead of an upregulation of IL-
12Rβ2, a non-significant down-regulation of IL-12Rβ2 was measured on the patients’ 
PBMCs. This non-significant decrease of IL-12Rβ2 could indicate a lack of reactivation 
of tumor-sensitized T cells, probably signifying that no pre-existing immune response 
was present. Interestingly, a down-regulation of IL-12Rβ2 indirectly stimulates an 
antitumoral immune response by lowering the number and functional maturity of 
Tregs.383 In the IL-12-CP treated dogs, both a decrease in IL-12Rβ2 and circulating 
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Tregs were observed. It is possible that the amount of IL-12 present at the start of the 
treatment led to a higher IL-12Rβ2 down-regulation on the non-tumor-sensitized T 
cells and encouraged a greater decrease in Treg number on day 15 than on day 35 of the 
treatment cycle. 
6 Conclusion 
In conclusion, the combination of intratumoral hIL-12 EGT and metronomic CP is 
associated with a slower tumor progression as well as with an improvement in quality 
of life. Indeed, all dogs experienced weight stabilization or increase during and after the 
IL-12-CP treatment, whereas all dogs progressively lost weight before treatment 
initiation. Anti-angiogenic treatments are ideally suited to be combined with 
immunotherapeutic treatments.375, 384, 385, 386, 387 The temporary normalization as 
observed with the IL-12-CP treatment of the tumor vasculature facilitates not only drug 
delivery (such as CP),359 but also immune cell influx.365  
Despite the significant drop in tumor blood volume at day 35, the primary tumors 
continued to progress. Intrinsic cancer cell resistance to metronomic CP exists, but 
tumor vasculature does not seem to develop resistance to long-term metronomic CP 
therapy.388 Therefore, the tumor progression could be the consequence of adaptation of 
the cancer cells to the anti-angiogenic treatment.389 In order to further improve the IL-
12-CP treatment, a cancer vaccine could be administered prior to IL-12-CP treatment. 
Cancer vaccines elicit specific antitumoral immune responses and are very much suited 
to complement the effects of IL-12-CP treatment, since eradication of established 
tumors through IL-12 requires the presence of a pre-existing antitumoral T cell 
response.331 
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7 Supplementary data on response to treatment per patient 
Despite IL-12 pDNA treatment, all primary tumors continued to grow. A decrease in 
tissue resistance (Ohm) as measured by the electroporator was observed in all dogs. 
Further tumor specifics are discussed per patient.  
 
Dog 1: The intra-oral amelanocytic melanoma was surgically removed a first time 7 
weeks prior to presentation. Within this time the tumor reappeared and had grown to 
the same size before surgery (6x4 cm). The tumor was surgically removed a second time 
and the IL-12-CP treatment initiated 3 days after the surgery. At this time, a new mass 
was present in the parotic gland area and cytology revealed the same cells as the 
primary tumor. On US, a hypovascularized liver nodule was detected (8x8 cm) and 
suspected of metastasis (fine needle aspirate cytology was inconclusive). The accessible 
metastasis and the wound bed of the primary tumor were treated with intratumoral 
hIL-12 EGT. Erythema and swelling were present 2 days after treatment. The primary 
tumor did not resume growth, whereas the metastasis continued to grow. The dog 
maintained a good appetite and although the dog initially lost weight during treatment, 
it was regained by day 35. This dog suddenly died on day 61. A necropsy has not been 
performed.  
 
Dog 2: The soft tissue sarcoma was clearly erythematous and warm by day 3 and 
swollen by day 8.  The inflammation distressed the dog, which led to excessive licking 
and biting in the tumor. Eventually, wounds were present on the tumor, but these 
wounds completely resolved by application of honey-based cream (Melolin®) and 
restriction of access. The mass remained stable in size for 2 months after treatment, 
after which growth slowly resumed. The dog was in generally good shape and no 
clinically relevant changes occurred during a 6-month follow-up.  
 
Dog 3: In this dog, hIL-12 EGT of the wound bed of the anal sac adenocarcinoma was 
initiated the day after surgery. One week after surgical excision of the primary tumor 
and metastectomy this very aggressive adenocarcinoma manifested in the hypogastric 
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lymph node (3.5 x 3.5 cm). Interestingly, the LN size was unaltered during 3 weeks, 
after which it continued to grow. The tumor eventually became so large that it 
compressed the rectum and the urethra which led to euthanasia of the dog on day 120.  
 
Dog 4: This dog beared a fibrosarcoma dorsal to the carpus. Despite a good appetite, the 
dog gradually lost weight in the 6 months prior to IL-12-CP treatment and 
demonstrated a goose step on the tumor-bearing paw. After IL-12 treatment, the dog 
gained 5.7 kg in 3 months and the goose step waned. The fibrosarcoma demonstrated a 
discernable softer consistency after IL-12-CP treatment. The dog remained in generally 
good shape. Five months after the first treatment cycle, the dog’s tumor was treated a 
second time on the owners’ request since he was again after gradually losing weight. 
Once again, a positive effect on weight gain (4.7 kg in 2 months) was observed. A 
discernable decrease in necrotic tissue was observed after the second treatment of the 
second treatment cycle (Figure 30).  
 
Dog 5: After the first intratumoral IL-12 treatment, a mild swelling of the costal 
osteosarcoma was apparent. Alkaline phosphatase, an enzyme that possibly indicates 
bone destruction, exceeded the upper limit at day 1, but remained stable for at least 2 
weeks (values between 900 and 1100 (ref 23-212) U/L). The dog gained weight and 
although the tumor kept progressing, his owners mentioned a clear improvement in 
quality of life. By day 35, the dog gradually weakened and SAP had become 
unmeasurably high (>2000 U/L). On thoracic radiographs, clear invasion of the 
thoracic cavity was present. This resulted in approximately 80% loss of the left lung. 
Due to further deterioration, the dog was euthanized on day 43.  
 
Dog 6: The rostromandibular fibrosarcoma was firm before treatment, but softened by 
day 8. Erythema and swelling were present on day 8. The dog remained in generally 
good shape. Alkaline phosphatase slightly exceeded reference limits at the start of the 
IL-12-CP treatment, but gradually decreased after the first intratumoral hIL-12 EGT 
and was decreased by 46% at day 35. This dog was euthanized on day 60 due to tumor 
progression.
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1 The question is not whether to combine immunotherapeutic 
treatment options or not, but how … 
1.1 Safety, efficacy, practicality and cost of the combination 
treatments 
It is indisputable that the immune system has a major influence on cancer (treatment) 
outcome and that immunotherapy has the potential to safely tilt the cancer/immune 
balance toward a cure for cancer. Yet, the correct application of immunotherapy is still 
a matter of debate. The future of immunotherapy as a major breakthrough in the 
treatment of cancer lies most certainly in combinatorial treatment strategies. 
The overall goal of this PhD was to design a rational combinatorial therapy by targeting 
the 3 major arms of the immune system. Per immune arm, many components are 
available, which allows many possible combinations of components that target a 
different arm of the immune system. A combinatorial treatment with a high likelihood 
of clinical implementation is to be preferred. Therefore, the combinatorial treatment 
chosen should not only effectively manipulate each arm of the immune system, but also 
be safe, practical and cost-effective.  
 
In Chapter 1, autologous whole cancer cell vaccines were investigated as stimulators of 
the adaptive immune arm since, of all cancer vaccine types, only autologous cancer cells 
cover the whole cancer antigen spectrum of the patient. This study was performed in 
mice. Apart from a wide antigenic range, an advantage of using autologous cancer cells 
is the possible incorporation of protumoral stromal cells into the vaccine, thus 
expanding the range of the vaccine from cancer cells to their microenvironment as 
well.172 Whereas DC vaccines are presumed to be the most powerful cancer vaccine 
type,101 they are also laborious, time-consuming and expensive to manufacture. In fact, 
Provenge®, the only FDA-approved DC-based cancer vaccine, costs over 
€77,300/treatment course and is thus (almost) exclusively available to the well-insured 
cancer patients.390 Dendritic cell-based cancer vaccines are also present on the 
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veterinary market and their costs (€2,650 /treatment course) are covered by several 
veterinary health insurance companies in the UK and Germany.391, 392  
Safety. The administered cancer cell vaccines, based solely on immunogenically killed 
cancer cells, were shown to be safe when administered prophylactically. No adverse 
effects were observed besides transient erythema and swelling at the vaccine injection 
site in all vaccinated mouse groups. This is in agreement with previous challenges in 
rodent models. In similarity, early data from canine clinical trials so far confirm the 
safety profile of cancer vaccines. No significant adverse effects were present in any of 
the vaccinated canine patients, except for 2 dogs (on a total of 845 dogs).271, 64  
Efficacy. The administered cancer cell vaccines, based solely on immunogenically killed 
cancer cells, proved to induce an antitumor response that was as effective in preventing 
tumor growth after cancer cell inoculation as immunogenically killed cancer cells that 
were co-incubated or fused to DCs in our prophylactic mouse tumor model. With the 
cancer cell vaccine based on immunogenically killed cancer cells, a cellular immune 
response was induced within 45 days after vaccination. Hundred days after tumor 
inoculation (145 days after the first vaccine), a cellular as well as a humoral immune 
response was present.  
Practical. In the mice, the production of a whole cancer cell vaccine based on 
immunogenically killed cancer cells was relatively easy. Syngeneic cancer cells were 
available through the use of an EO771 cancer cell line. These cancer cells only required 
2 h of incubation in a Mitoxantrone-containing medium and 22 h of rest to become 
immunogenic and ready to inject. During this PhD research, no clinical trial with this 
whole cancer cell vaccine was performed in dogs due to time constraints. The 
manufacture of the vaccine in dogs would entail a sufficient amount of cancer tissue (at 
least 10 gr)117, 393 from which the autologous cancer (and stromal) cells should be 
extracted. The digestion of the tumor tissue to isolate cells present in the tumor tissue 
can be achieved in 4 h394 and ICD of cancer cells in 24 h, thus making it possible to 
incorporate cancer treatment through vaccination in a clinical setting. If insufficient 
tumor tissue is present, the use of an allogeneic cell line for certain tumor types in dogs 
can be considered for vaccine manufacture. However, allogeneic cell-based vaccines 
might be difficult to integrate into non-academic environments, as they require 
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approval from the federal agency for medicines and health products (FAMHP), whereas 
treatments with autologous cells do not.  
Cost. Although very cheap in mice (less than €20), the cost price to produce a canine 
whole cancer cell vaccine based on immunogenically killed cancer cells after surgery is 
probably more than ten times higher, in the range of €200-300 (only taking into 
account the price of a cancer cell isolation kit and the equipment required for the 
induction of ICD). However, this amount is likely acceptable to most dog owners and 
facilitates the incorporation of cancer cell vaccines into routine oncology treatments.  
 
In Chapter 2, IL-12 was investigated as stimulator of the innate immune response arm 
in pet dogs with spontaneous tumors. Intratumoral hIL-12 pDNA was administered 
and electroporated into the cancer cells of cancer-bearing dogs (IL-12 study).  
Safety. The first 3 dogs were treated with a 1-day interval between treatments, but 1 of 
these dogs developed a transient immune-mediated anemia and another a fatal 
thrombocytopenia. Since these symptoms could be related to IL-12 toxicity and peak 
expression of IL-12 pDNA was seen after 7 days in a preclinical study,146 the treatment 
regimen was altered to 3 administrations with a week interval for all later patients. With 
this new regimen, no adverse effects were observed.  
The dosage of IL-12 pDNA used in other intratumoral IL-12 pDNA trials in dogs was 
between 150 μg and 1 mg220, 221, 222 and did not induce any side effects. However, in 
those trials, at least one week interval was left between IL-12 pDNA treatments in dogs 
with spontaneous cancer. 220, 221, 222, 225 In contrast, in a human trial, 1 mg of IL-12 pDNA 
was administered on day 1, 5 and 8 and also did not convey any adverse effects. The 
amount of IL-12 and IFNγ measured in the tumor tissue and serum of IL-12 treated 
dogs in our study showed that the dogs who developed anemia or thrombocytopenia 
did not have the highest amount of IFNγ, the cytokine generally assumed responsible 
for IL-12 toxicity.213 These results likely indicate that the 1-day interval regimen was 
safe. Other reported IL-12 toxicity-related adverse effects include stomatitis, vomiting, 
(bloody) diarrhea, neutropenia, hypoalbuminemia, increase in liver enzymes, increase 
in kidney values and hypoglycemia,395 but none of these effects were observed in any of 
our IL-12 treated patients. Conversely, the observed adverse effects in 2 out of 3 dogs in 
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the 1-day regimen are well-known paraneoplastic symptoms.353, 396 Both dogs that 
developed adverse effects were in a late tumor stage. Both dogs had a low body 
condition score and an elevated neutrophilic count, which is an indication for 
paraneoplastic syndrome.396 It is possible that the observed adverse effects were not the 
result of IL-12 toxicity, but rather represented an aggravation of a subclinical 
paraneoplastic syndrome. Assuming the former, it must be borne in mind that IL-12 
therapy could represent a risk for grave complications in patients with (sub)clinical 
paraneoplastic syndromes.  
Another possible safety issue is inherent to the delivery method of IL-12 pDNA. Since 
IL-12 pDNA electroporation requires thorough sedation of the cancer-bearing dogs 
and most dogs with cancer are older dogs, they are at a higher risk of developing 
anesthesia-related complications.397  
A third concern of administrating hIL-12 pDNA to dogs is the possible development of 
cross-reacting antibodies against cIL-12. In dogs, cross-reacting antibodies between 
human and canine tyrosinase have been described for a xenogeneic tyrosinase 
vaccine.296 In contrast to the tyrosinase vaccine, it was demonstrated that hIL-12 is 
recognized by canine immune cells231 without causing a cross-reaction toward canine 
IL-12.349 When hIL-12 immunocytokines were administered to dogs, 8/12 dogs had 
positive blood samples for antibodies against hIL-12,227 thus indicating that hIL-12 can 
elicit a xenogeneic immune response. During this PhD, 2 cancer-bearing dogs received 
2 hIL-12 treatment cycles with an interval of 6 months between cycles. In both dogs, the 
treatment induced a similar inflammatory response 2 days after hIL-12 pDNA 
treatment. In those dogs, the inflammatory response did not seem to be hindered by the 
capture of hIL-12 by hypothetical canine anti-hIL-12 antibodies.  
Overall, intratumoral administration of hIL-12 pDNA via electroporation to cancer-
bearing pet dogs can be considered safe if pre-existing auto-immune responses that 
might be further stimulated are not present.  
Efficacy. In all dogs treated with hIL-12 pDNA, an immune response and an anti-
angiogenic effect were observed. Although all primary tumors progressed, in 1 dog a 
decrease in the size of the abdominal LN metastases was measured. However, the anti-
metastatic effect, the immune stimulation and anti-angiogenic effects were all transient. 
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Two positive effects of the IL-12 treatment did persist. Three owners reported an 
increase in quality-of-life during the IL-12 study: their dogs showed an increased 
appetite and no longer gnawed or licked their tumor.  
Practical. During this PhD, 16 dogs with various tumor types and sizes were 
anesthetized and treated with hIL-12 pDNA. In human literature, local lidocaine was 
applied and an analgesic was offered to all patients with metastatic melanoma treated 
intratumorally with hIL-12 pDNA electroporation, but no anesthesia was given.219 
However, these tumors were very small, treated with a single electroporation and very 
thin electrodes (0.3 mm needle diameter),219 whereas the dogs treated in this study had 
larger tumors, thus requiring multiple electroporations with sturdy needle electrodes 
(0.7 mm needle diameter). A disadvantage of having to electroporate hIL-12 pDNA 
into the larger tumors was the fact that is was time-consuming. To allow optimal pain 
control and proper sedation prior to intratumoral hIL-12 pDNA injection and 
subsequent electroporation, the dogs needed to be premedicated 30 min prior to the 
first insertion of electrodes. The duration of the hIL-12 pDNA administration into the 
patient’s tumor depended on the size and structure of the tumor. As the maximal 
volume that could be covered with electrodes was approximately 2 cm3, large tumors 
required many electrode insertions thus contributing to increased treatment duration. 
Furthermore, the electroporator could only generate pulses in tumors with a tissue 
resistance above 50 Ohm. While the tissue resistance of the treated tumor’s surface well 
exceeded the 50-Ohm barrier, this was not true for the core of all treated tumors. As a 
consequence, the electrodes had to be gradually retracted after tissue insertion until the 
point where tissue resistance exceeded 50 Ohm. This repositioning of the electrode 
needles added to the procedural time. In conclusion, although electroporation is the 
most efficient non-viral method to transfect cells with pDNA, it is not very practical in 
a clinical setting, especially for large tumors with a heterogenous structure.  
Cost. In order to legally administer hIL-12 pDNA to cancer-bearing pet dogs, the 
construct had to be GMP-grade. The purchase of GMP-grade hIL-12 pDNA is 
extremely costly. The hIL-12 pDNA used in our study was exceptionally available at 
0.7% of the normal minimum price. On average, the total cost of 1 treatment cycle 
consisted of €162 (anesthesia, hIL-12 pDNA and electrode use included). This 
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treatment option could have been cheaper if the pDNA did not have to be GMP-grade. 
In a similar clinical trial in dogs in Slovenia,226 the use of non-GMP-grade pDNA was 
allowed; no adverse effects were observed.  
 
In Chapter 3, the combinatorial effects of intratumoral hIL-12 EGT and metronomic 
cyclophosphamide (IL-12-CP) were evaluated. Cyclophoshamide was chosen as 
chemotherapeutic as our group demonstrated that a dosage of 12.5 mg/m2 was able to 
significantly reduce the amount of circulating Tregs in cancer-bearing dogs.285  
Safety. A previous study conducted in dogs at the Laboratory of Gene Therapy showed 
that metronomic CP (CP treatment) was safe.285 Long-term administration of 
metronomic cyclophosphamide did result in sterile cystitis in 2 out of 30 dogs after 6 
weeks and 10 months. Besides sterile cystitis, none of the adverse effects associated with 
the cytotoxic dose of CP (immunosuppression and gastro-intestinal adverse effects such 
as vomiting, anorexia and diarrhea) were present during the study. 285 The combination 
of IL-12 and metronomic CP did not induce any adverse effects. 
Efficacy. A persistent significant decrease in Tregs was observed for IL-12-CP study, 
which is similar to the results of the CP study performed by Denies and colleagues.285 
Interestingly, a stronger decrease in amount of circulating Tregs was apparent at day 15 
in the IL-12-CP study than in the CP alone study of Denies and colleagues.285 After day 
15, the amount of circulating Tregs increased in the IL-12-CP study, yet remained 
significantly lower than before treatment. These kinetics could be explained by the 
addition of IL-12, since intratumoral IL-12 administration can induce a temporary 
(minimal 2 weeks) elimination of Tregs.335  
The anti-angiogenic effects of IL-12 were enhanced by the addition of metronomic CP: 
a decrease in relative tumor blood volume was still present at day 35, whereas this was 
not the case for IL-12 alone (Table 15). A significant increase in TSP-1 and a non-
significant decrease for VEGF was present in the tumor tissue of dogs treated with the 
IL-12-CP combination. There were no significant differences in serum VEGF kinetics 
after CP or IL-12-CP treatment, but, a significant decrease and increase of TSP-1 was 
present in the IL-12-CP study, which was not the case for the CP study. Interestingly, 
the downregulation of TSP-1 in DCs produces an effective antitumor response that is 
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opposite to the protumor effects of TSP-1 silencing within cancer cells.373 Our results 
suggest that the function of TSP-1 in endothelial cells and DCs may exert opposite 
effects during cancer treatment.  Both the IL-12 and IL-12-CP study induced a transient 
decrease in lymphocytes, eosinophils, basophils and red blood cells, but these decreases 
and increases were more pronounced in the IL-12 study. Nevertheless, tumor 
inflammation after treatment was present in dogs treated with IL-12 and those treated 
with IL-12-CP. Immunohistopathology performed in the IL-12-CP study demonstrated 
immune cell infiltration of B and T cells after the first intratumoral hIL-12 EGT.  
 
TABLE 15. An overview of the anti-angiogenic and immunological effects of the CP study, 
IL-12 study and IL-12-CP study  
Parameter Metronomic CP IL-12 IL-12-CP 
VEGF serum No change No change 
Transient decrease, but 
not significant 
VEGF lysate - 
No change (decrease for 2/6 
dogs) 
Decrease, but not 
significant 
TSP-1 serum No change - 
Significant decrease 
followed by significant 
increase 
TSP-1 lysate - - Significant increase  
Tumor blood volume  - 
Significant, but transient 
decrease 
Significant and 
persistent decrease 
Tumor blood flow 
speed 
- Significant decrease Significant decrease 
Treg 
Significant 
decrease 
- Significant decrease 
Leukocytes - 
Significant decrease and increase 
of lymphocytes, eosinophils and 
basophils 
Decrease, but less 
pronounced (significant 
for neutrophils) 
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Interestingly, in the IL-12-CP study, 1 dog experienced an outspoken anti-cachectic 
effect after his first treatment (from 33.7 kg to 38.5 kg). Thereafter, its body weight was 
stable for about 3 months at what point this dog again started to gradually lose weight. 
When his weight dropped to 35.8 kg, a second IL-12 treatment was administered and 
resulted once more in an increase of appetite and body weight. In the following 6 
weeks, the body weight increased to 39.1 kg.  
Practical. The same practical issues for intratumoral administration of the hIL-12 
pDNA in the IL-12 study applied for the IL-12-CP study. The administration of 
metronomic CP is very practical. Once the Endoxan® tablets are redistributed according 
to the body surface of the patient, the treatment consists of administrating 1 capsule 
once a day orally. None of the dog owners experienced any difficulties with the 
administration of the capsules. Metronomic chemotherapy is already implemented in 
routine veterinary practice today, mostly to patients with no other treatment options 
available (unpublished survey data). The ideal dosage per tumor type still needs to be 
determined, but sufficient scientific evidence indicates that metronomic chemotherapy 
can be beneficial in a subset of patients.281, 282  
Cost. Metronomic CP is a safe antitumoral treatment of which the costs are negligible 
in a combinatorial antitumoral treatment. One box of 50x 50 mg Endoxan® tablets is 
enough to treat a 30 kg dog for 6 months. Should sterile cystitis occur, metronomic 
doses of chlorambucil and lomustine have also shown to be able to induce antitumoral 
responses.283, 284, 290 Chlorambucil can be given as an alternative, but costs 50 times more 
than cyclophosphamide. Lomustine is not commercially available in Belgium.  
1.2 Rational design of combination therapies in immunotherapy 
Many single immunotherapies have given promising results, not least ipilimumab (10-
15% durable response rate in humans). What is more, these treatment results could 
potentially vastly improve when incorporated into well-designed combinatorial 
strategies. However, it is very important to carefully combine immunotherapeutic 
approaches to establish a safe balance between efficacy and toxicity.243 Prior to 
combinatorial treatment all components should be gradually assembled and evaluated.  
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The timing of the administration of immunotherapeutic components is open to 
discussion. For the proposed combinatorial treatment in this PhD, one rationale is to 
administer the intratumoral hIL-12 pDNA after vaccination331 since IL-12 stimulates 
activated T cells and vaccination is able to activate effector T cells. Vaccination itself 
could be rendered more effective through a (1) decrease in immunosuppressive cells 
such as Treg, (2) an optimized administration schedule and (3) appropriate use of 
adjuvants. We have proven that selective and persistent decrease in Tregs after daily 
administration of 12.5 mg/m2 CP to cancer-bearing pet dogs as observed by Denies and 
colleagues285 remains present when combined with intratumoral IL-12 EGT. There is 
little known about how the administration schedule of whole cancer cell vaccines may 
impact their clinical efficacy. Daily exogenous antigen immunization with 
peptide/protein cancer vaccines for several consecutive days (cluster immunization) has 
proven to be clearly superior to booster immunization with greater intervals.132 Cluster 
immunization mimics the kinetics of a viral infection,77, 132 which could explain its 
superior immune stimulation properties compared to immunizations with greater 
intervals. The principle of cluster immunization is likely applicable to whole cancer cell 
vaccines. Interestingly, an adjuvant is needed to obtain the superior effect of cluster 
immunization. The choice of the adjuvant should depend on its potential for toxicity 
and the subset of immune cells it will stimulate. For example, toxicity will be an issue 
after daily exposure to the adjuvant CpG as it causes damage to secondary lymphoid 
organs and diminishes CD8+ T-cell responses, whereas poly I:C does not induce such 
risk.133 Adjuvant schedules that respect the natural phases of immune induction might 
sufficiently skew the anticancer immune response in the desired direction. One option 
is priming with an effector adjuvant such as IL-12 only, followed by a well-timed 
secondary boost with a memory adjuvant such as CDX-1127, a CD27 agonistic 
antibody. It is important to administer the memory adjuvant when the memory cells 
start to develop and require maintenance through sustained protein kinase B 
activation.140 
General Discussion 
178 
 
FIGURE 37. Schematic representation of a rational immune combination treatment. Daily 
metronomic cyclophosphamide is started 1 day prior to the first cluster vaccine (given daily for 4 
consecutive days). On day 10, intratumoral IL-12 electrogene therapy (EGT) is administered. A 
second cluster vaccine is given from day 45-48. On day 55, intratumoral TNFR EGT is 
administered. 
Considering the above, one treatment rationale might be to start metronomic CP 1 day 
prior to cluster vaccination (Figure 37), as low-dose CP given 1 day prior to cancer 
vaccination significantly enhanced vaccine efficacy in mice and humans.374, 398, 399 
Cluster vaccination (vaccination for 4 consecutive days) is then started, to recreate the 
effect of a viral infection and optimally stimulate the immune system.132, 77 Since little 
time is left between administration of metronomic chemotherapy and the whole cancer 
cell vaccine, it is conceivable that this regimen will offer a simultaneous multi-targeted 
approach that inhibits tumor escape. Eight to 15 days after the vaccine administration -
when vaccines generally start to generate an immune response132, 400 this immune 
response can be enhanced through intratumoral hIL-12 pDNA. IL-12 is known to 
induce potent differentiation of T cells into effector T cells.120 Booster vaccinations are 
most effective when administered after the vaccine has generated a peak immune 
response. As the peak immune response after peptide cancer vaccines is generally seen 
4-10 weeks after vaccination,400 a whole cancer cell vaccine booster should not be given 
until 4 to 6 weeks after the first whole cancer cell vaccine cluster vaccination. Cluster 
vaccination should then be repeated to create a booster effect and encourage the 
creation of memory T cells. This could be accompanied by the administration of an 
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immune-memory inducing adjuvant, such as TNFR ligands. TNFR ligands (OX-40, 4-
1BB and CD27) activate protein kinase B which directs T-cell differentiation more 
toward memory T cells than toward primary effector T cells.120 Many different 
combination options are available: combinations of various local or systemic 
immunotherapies as described above, and combinations of local or systemic 
immunotherapy with standard treatments. 
1.3 Influence of biomarkers on the design of combination 
treatments  
Most phase I and II cancer immunotherapy trials in humans have stumbled on 2 crucial 
issues: how to assess the clinical efficacy of the treatment (see 1.6); and how to define 
the correlates (biomarkers) of clinical efficacy.145  
While overall survival might be the only objective parameter of clinical efficacy, clinical 
trials based on overall survival can be exceedingly long and costly, which results in the 
loss of potentially valuable treatments.44 One possible solution could be to evaluate 
overall survival in pet dogs with spontaneous tumors as they have shorter life spans 
than men. Nevertheless, using the cancer-bearing dog as cancer model is not always 
feasible. Thus, immunotherapy is in dire need of reliable biomarkers for treatment 
response, as they could provide information about treatment efficacy during the 
treatment itself and therefore allow grounded decisions on whether or not to adapt the 
installed treatment (schedule). Investigating the cancer cell proteome and secretome 
might lead to the identification of novel biomarkers, which are more effective than the 
so far evaluated candidates.44, 401 This search will be facilitated by the worldwide set-up 
of human (The Cancer Human Biobank from the National Cancer Institute in the US) 
and veterinary (Uppsala University in Sweden, Cornell Veterinary Biobank in the US, 
Fischer Bioservices in Maryland in the US, Oncovet in France) biobanks. These 
biobanks will hopefully help to find appropriate biomarkers for treatment efficiency 
and common denominators for treatments that are so far only effective in a subset of 
patients. The combinatorial treatment rationale we propose in 1.2 could be further fine-
tuned via the use of predictive biomarkers. Since the proposed cancer vaccine – IL-12 – 
General Discussion 
180 
CP approach will function via a wide range of effects, it might be useful to focus on 
these effects to identify potential biomarkers for this approach. Several efficacy 
parameters were examined during the studies of this PhD. Their suitability as possible 
biomarkers for the proposed combinatorial cancer vaccine – IL-12 – CP treatment will 
be discussed below.  
1.3.1 Biomarkers for effectiveness of cancer cell vaccines 
The whole cancer cell vaccine based on immunogenically killed cancer cells from 
Chapter 1 induces a cellular and a humoral antitumoral immune response. Although 
the presence of cancer cell-specific effector T cells or antibodies indicates the ability of 
the vaccine to initiate an immune response, it cannot predict whether the vaccine will 
induce a therapeutic effect.402 However, it has been shown that certain characteristics of 
vaccine-induced CD8+ T cells can predict the efficacy of vaccines during antitumoral 
treatment.402 The formation of (CD62L(-)KLRG1(+) IFNγ+ TNF+) effector-memory T 
cells after vaccination correlated with a superior antitumoral effect of these vaccines in 
a therapeutic setting.402 Thus, if high simultaneous production of IFNγ and TNF by 
memory T cells is shown after administration of our whole cancer cell vaccine, this 
could predict a high degree of therapeutic efficacy. Interestingly, the effects of cancer 
vaccines can be predicted in healthy volunteers,402 allowing a better estimation of the 
efficacy potential of the vaccine before administrating it to cancer-bearing patients. 
An increase of tumor T cell-infiltration after treatment has also been shown to be 
associated to responder tumors, whereas a lack of T cell-infiltration after treatment 
with non-responder tumors.331  
1.3.2 Biomarkers for effectiveness of IL-12 
The main antitumoral activities of IL-12 consist of immune stimulation and anti-
angiogenesis. Therefore, it seems logical to evaluate the efficacy of IL-12 treatment by 
its effect on the immune response (see above) and/or tumor angiogenesis. Although an 
increase of tumoral and/or plasma IFNγ indicates a response to IL-12, it is not a 
predictive biomarker for the efficacy of IL-12 treatment.221, 222, 227 Tumor biopsies for 
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immunohistopathology were taken from 2 dogs during the IL-12-CP treatment. In both 
patients, an increase in T and B cell infiltration was present, yet the tumors continued 
to progress. However, one cannot exclude that these dogs experienced a temporary 
stabilization or a less aggressive tumor progression than would have been the case when 
left untreated.  
For tumor anti-angiogenesis, multiple biomarker options can be considered. The effect 
of IL-12 on important angiogenesis pathways such as VEGF can be explored, the 
perfusion of the treated tumor as well as immune cells with an important role in 
angiogenesis (such as neutrophils).401 So far, no reliable predictive biomarkers for the 
efficacy of anti-angiogenic treatments are available.401, 403 Although promising in pre-
clinical trials, VEGF-inhibition did not yield consistent results in a clinical context.401 
Indeed, many escape mechanisms exist for anti-angiogenic therapy. As a result, a 
decrease in VEGF does not necessarily mean that the treatment is effective, as cancer 
cells can rapidly adapt to a new situation by activating alternative angiogenesis 
pathways to VEGF.388 Alternatively, instead of measuring markers for angiogenesis 
pathways, the overall anti-angiogenic effect of the treatment (such as tumor perfusion) 
can be evaluated through CEUS. CEUS is a new functional validated imaging technique 
for the prediction of tumor progression.323 For all treated dogs in the IL-12 study, a 
transient decrease in relative tumor blood volume was present. This finding might 
indicate a transient treatment efficacy. In contrast, in the IL-12-CP study, a persistent 
decrease (of at least 35 days) in relative blood volume was present in 4 out of 5 dogs. In 
humans, patients treated with several anti-angiogenic agents demonstrated a better 
overall survival and disease stabilization (free from progression) when a greater than 
40% decrease in area under the curve (blood volume) between baseline and day 30 was 
measured.323 Furthermore, normalization is associated with a temporary increase in 
relative blood volume and an improved clinical outcome. In the IL-12-CP study, a 
temporary increase in relative blood volume was measured with CEUS on day 8. In our 
IL-12 study, only 2 dogs demonstrated a clear decrease in tumor VEGF, whereas a 40% 
decrease in area under the curve between baseline and day 35 was present in 7 out of 8 
dogs. In our IL-12-CP study, 4 out of 6 dogs demonstrated a clear decrease in tumor 
VEGF, whereas a 40% decrease in area under the curve between baseline and day 35 
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was present in 4 out of 5 dogs. Although tumor progression was eventually apparent in 
every treated dog, these results indicate a temporary stabilization of the tumor 
progression.  
Neutrophil infiltration in advanced tumors is associated with poor clinical outcome. 
Neutrophils indirectly contribute to tumor progression by inducing VEGF production 
in cancer cells, recruiting Tregs into the tumor and promoting detachment and evasion 
of cancer cells.181 Therefore, the amount of circulating and tumor-infiltrating 
neutrophils during anti-angiogenic treatment could be a valuable prognostic factor for 
treatment efficacy. Indeed, in human patients treated with anti-angiogenic drugs, 
serum neutrophil levels higher than the upper reference limit were shown to be an 
independent predictor of short-term survival.404 More specifically, the quantification of 
circulating immature (TAN2) neutrophils may indicate when the tumor regains its 
capacity to recruit immunosuppressive cells, rendering the therapy no longer effective. 
There is a possible correlation between the proportion of neutrophils and lymphocytes 
and cancer progression.405 It was shown that animals with head and neck tumors had 
high neutrophil/lymphocyte (N/L) proportions in their blood. If treatment was 
successful, a sustained decrease of this proportion was apparent. It is conceivable that 
the N/L proportion reveals when the treatment is no longer effective and this finding 
could aid in the creation of an individualized treatment schedule. In 4 out of 6 dogs in 
the IL-12 study and in half of the dogs in the IL-12-CP study respectively, the N/L 
proportion at day 35 was lower than that at baseline. In those patients, this finding 
might reflect that the tumors progressed more slowly than before treatment, but they 
nevertheless progressed. 
In our IL-12 study, 2 out of 9 dogs were presented with distant metastases. One dog 
died before we were able to evaluate the effect of the treatment on the metastasis, but 
the remaining dog with distant metastases lived for 210 days after treatment initiation. 
This dog (with abdominal metastases) demonstrated a transient partial regression of 
these metastases after administration of hIL-12 pDNA in the primary tumor. In this 
dog, a decreased amount of VEGF was present in the tumor tissue 1 week after IL-12 
treatment and VEGF was still lower than baseline 35 days after the treatment initiation. 
A decreased tumor perfusion could be demonstrated 1 week after IL-12 treatment in 
General Discussion 
183 
this dog, and was still lower than baseline at day 35 after treatment initiation, yet higher 
than at day 8. Circulating neutrophil levels transiently increased during treatment, but 
were lower than baseline at day 35 after treatment initiation. A lower than baseline N/L 
proportion was measured on day 35 after treatment initiation. However, on day 15 the 
N/L proportion was lower than on day 35, thus possibly indicating the transient effect.  
1.3.3 Biomarkers for effectiveness of metronomic cyclophosphamide 
The main antitumoral activity of metronomic CP is to alter the tumor 
microenvironment by selectively decreasing the amount of Tregs and by inducing anti-
angiogenesis by up-regulating TSP-1. Increases in TSP-1 lead to inhibition of the VEGF 
pathway and to induction of endothelial cell apoptosis.272, 274 As discussed above, the 
data on VEGF as a predictive biomarker for benefit and response are not conclusive.  
A clinical trial with 12.5 mg/m2 CP was previously conducted by our lab in cancer-
bearing pet dogs.285 That trial showed that the metronomic treatment did not yield any 
change in the amount of circulating TSP-1 or VEGF in the treated cancer-bearing dogs. 
The lack of effect of 12.5 mg/m2 CP on serum TSP-1 should not preclude this marker 
for evaluation of anti-angiogenic treatment with other doses for metronomic CP or 
other anti-angiogenic treatments. Indeed, in our IL-12-CP study, a significant decrease 
and increase in the amount of serum TSP-1 as well as a significant increase in the 
amount of tumor lysate TSP-1 at day 35 compared to baseline were measured. 
1.3.4 Biomarkers for evaluating the combination of whole cancer cell 
vaccination, intratumoral hIL-12 EGT and metronomic 
cyclophosphamide 
In conclusion, despite promising preliminary results, no general or cancer-specific 
biomarker has yet emerged that could help select patients with a positive prognosis for 
anti-angiogenic therapy.401 Lassau and colleagues demonstrated a significant 
association between a decrease in tumor blood volume and stabilization of tumor 
progression,323 but anti-angiogenic effects do not necessarily predict cure rates. On the 
other hand, if the patient does not have a 40% decrease in tumor blood volume 30 days 
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after anti-angiogenic treatment initiation, this patient should probably switch to 
another treatment option.  
Based on our findings one could propose to evaluate the treatment efficacy of the 
combinatorial treatment by measuring high simultaneous production of IFNγ and TNF 
by cancer-specific memory T cells and a sustained decrease in tumor perfusion and in 
N/L proportion.  
1.4 The influence of patient selection in cancer trials  
An important factor in the success rate of clinical studies is the selection of the patient 
population. In human medicine, only patients who are refractory to established 
antitumoral treatments can participate in clinical trials. As a result, mostly patients with 
a cancer in an advanced stage, that has become resistant to most common therapies, are 
recruited in clinical studies for novel antitumoral approaches. The efficacy of novel 
antitumoral therapeutics is therefore evaluated on a subset of cancer patients who are 
notoriously difficult to cure. The evaluation of such novel therapeutics may therefore 
not result in an objective evaluation of the true potential of the drug. Furthermore, due 
to the advanced stage of the cancer, many patients are weakened and more sensitive to 
adverse effects. Treatment regulations in human oncology are stringent and can be 
quite incapacitating. As such, 1 treatment can be favored over another; even if it is not 
necessarily the best treatment option. For example, ipilimumab has been FDA-
approved since 2011 and is the first-line immunotherapeutic for melanoma patients. 
Nivolumab, an anti-PD-1 antibody, recently received FDA-approval as treatment for 
advanced melanoma that does not respond to other drugs such as ipilimumab, 
although nivolumab offers a more acceptable toxicity, response rate and time to 
response than ipilimumab.243 Despite the many advantages of anti-PD-1 antibodies, 
these antibodies cannot be used as first-line treatment for melanoma patients as they 
are currently approved only as second-line after failure of ipilimumab or BRAF 
inhibitors in melanoma patients.243 Nivolumab is currently under review by the FDA 
for use as a monotherapy for previously untreated patients.406 While these regulations 
do not facilitate initiatives to enroll many human patients in combination trials, they do 
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not apply for canine patients with spontaneous cancer thus highlighting the significant 
role pet dogs can play in cancer research. 
In veterinary medicine, clinical trials in pet dogs are not constrained by traditional 
phase I, phase II, and phase III trial designs.407 Therefore, novel agents can be offered to 
pet dogs before conventional therapies or during the period of minimal residual 
disease407 and allow a more objective evaluation of the potency of the novel agent. Pet 
dogs are able to participate in clinical trials when their owners sign an informed 
consent and the clinical trial was approved by an ethical committee. As antitumoral 
treatments are limited in pets, pet owners are highly motivated to seek novel options for 
management of cancer in their pets. The decision to let their pet participate in a clinical 
trial is often influenced by the risks associated with this therapy compared to 
conventional therapy, as well as their expectations for outcomes and reduced costs for 
care provided by an investigational trial.407 As a result, clinical studies in pet dogs offer 
the much-needed opportunity for immunotherapeutic antitumoral therapies to be 
studied in ideal circumstances.  In our studies, most dogs were presented with a 
recurrent tumor after surgery. It should be noted that for ethical concerns, standard 
antitumoral therapies with good/better chances of survival for the pet dog were always 
advised when the owner was able and willing to pursue these standard treatments. Since 
these pet dogs are patients, the well-being of the pet dog is always the most important 
factor to be considered and therefore the best treatment options should always be 
offered.  
1.5 Combinations of immunotherapy with standard antitumoral 
treatments  
Patients with high tumor burden are likely to benefit less from immunotherapy. 
Continuous exposure of effector T cells to antigen will eventually render them tolerant 
to the antigen. In case of continuous tumor antigen presence, this tolerance results in 
tumor outgrowth. Interestingly, the T cells regain functional capacities when they are 
transferred to an antigen-free environment.408 Elimination of tumor antigen can thus 
enhance the generation of an effective immune response. This effect can be reproduced 
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by performing standard antitumoral therapy prior to immunotherapy. Patients in 
which the tumor burden is reduced or eliminated through surgery or radiotherapy may 
benefit from a combinatorial approach with immunotherapy. Finocchiaro and 
colleagues combined immunotherapy with surgery and observed a remarkable increase 
in efficiency of immunotherapy when applied in a minimal residual disease setting. A 
complete excision is not always possible due to the tumor location, therefore 2 tumor 
burden settings were compared: tumors for which the surgeons were able to obtain 
clean surgical margins, confirmed by histopathology (complete excision) and tumors 
for which no clean surgical margins could be obtained (partial excision). After surgery, 
the cancer had less opportunity to reorganize itself as an impenetrable fortress to the 
immune system. Overall survival of the group with partial excision and 
immunotherapy was 4 times higher than in the control group that had partial excision 
only (323 (46-1321) days versus 78 (29-206) days),147 while overall survival of the group 
with complete excision and immunotherapy was 7 times higher than in the control 
group that had complete excision only (704 (99-2251) versus 101 (11-568) days), thus 
indicating the impact of tumor load.  
Next to surgery, the tumor burden can also be reduced via radiotherapy. Radiotherapy 
combined with immunotherapeutic approaches may increase cancer-cell killing 
compared with either modality alone.409 Promising results were obtained in a phase I 
study of 14 human patients with advanced/metastatic stage hepatoma. Radiation 
therapy was followed by localized cancer vaccination. Only 10 patients had completed 
immunologic response evaluation, which resulted in cancer-specific immune responses 
in 7 out of 10 patients and 2 partial tumor responses.410
The combination of chemotherapy and immunotherapy can be beneficial as well. 
Combinations of chemotherapy and immunotherapy proved to contribute to a better 
patient outcome than either treatment alone. A phase II trial in patients with stage 
IIIb/IV non-small-cell lung cancer or extensive-disease small-cell lung cancer evaluated 
the combination of standard chemotherapy (carboplatin–paclitaxel (CaP)) with 
ipilimumab. The effects of treatment schedules were assessed as well. The results 
showed that this combination was reasonably well tolerated, and that a ‘phased 
regimen’ in which immunotherapy began after chemotherapy resulted in substantially 
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improved progression-free survival compared with CaP alone.411 These results 
underline the importance of the correct sequencing of combinatorial treatments.  
At the moment, various approaches combining immune-checkpoint blockades with 
local standard antitumoral treatments such as focused radiotherapy and ablative 
treatment of hepatic metastases are under investigation. These local standard 
antitumoral approaches induce cancer cell death thus releasing tumor antigens at the 
tumor site and combined with the necrozing action of immune-checkpoint blockade 
can stimulate improved uptake of these tumor antigens by APCs.243  
Combination of several immunotherapies showed synergistic results. For example, 
combination in a mouse model of metastatic colon carcinoma of IL-15 with antibodies 
against CTLA-4 and PD-L1 resulted in a significantly increased antitumor activity 
compared with IL-15 alone or combined with either anti-PD-L1 or anti-CTLA-4.412 
Immunotherapy can be applied locally or systemically. As has been shown, systemic 
therapies are more likely to induce serious adverse effects.213, 413 Much attention goes 
out to local administration of newly developed immunotherapeutics. The aim of local 
delivery is to induce antitumor response while limiting systemic auto-immune toxicity. 
Large-scale clinical trials evaluating these concepts are being considered.243  
No matter which combinatorial strategy will be chosen, the balancing of efficacy and 
toxicity will remain a limiting factor.243  
1.6 Evaluation criteria for immunotherapeutic treatments 
Alongside the need for new biomarkers for assessment of treatment efficacy, new 
clinical evaluation parameters for response to immunotherapeutic treatment are 
necessary to avoid unjustified/premature switches in treatment strategies. The classic 
RECIST criteria describe a standardized way to characterize responses to cancer 
treatment,414 but were proven not to be appropriate for the evaluation of 
immunotherapy.230 Whereas surgery, chemotherapy and radiation offer a quick tumor 
reduction, immunotherapeutic treatments typically require more time to be effective. 
For example, in a subset of human patients treated with ipilimumab immune responses 
were present 12 weeks after treatment230 and in intratumorally IL-12 pDNA-treated 
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human patients several clinical responses were apparent in a span of 6-18 months after 
treatment.219 Thus, responses to immunotherapy may be overlooked as new lesions can 
develop while the immune system is building up an antitumoral immune response.230 
Alternative guidelines to RECIST criteria were developed based on the RECIST criteria 
and propose immune-related response criteria (irRC). In a retrospective study on 
melanoma patients treated with ipililumab, an additional 10% of patients were 
identified to have a favorable prognosis via irRC. According to RECIST criteria, 
(transient appearance of) new lesions or increase in tumor burden represent 
progressive disease (and may wrongfully classify the response to immunotherapy of a 
subgroup of patients as progressive disease). According to the irRC criteria, these 
patterns (response after an increase in total tumor burden and response in the presence 
of new lesions) can be associated with favorable survival. Error of judgement in 
response classification could lead to a possibly inappropriate switch in treatment of 
patients that may benefit from their actual treatment. 
2 Limitations and reflections 
In this PhD, the rationale was to activate the 3 arms of the immune system to induce an 
antitumoral response. In the Laboratory of Gene Therapy, the effect of the 3 arms 
combined was evaluated in mice and considered safe and efficient. Then, our aim was 
to break down this combinatorial therapy to its individual components and test each 
component and combination of components for safety and efficacy in cancer-bearing 
pet dogs. So far, cancer-bearing pet dogs have been treated with metronomic 
chemotherapy, intratumoral hIL-12 pDNA therapy and the combination of the former. 
Each component and combination tested until now was considered safe. A decrease in 
Tregs was present in dogs treated with metronomic CP, immune stimulation and anti-
angiogenic effects were present in dogs treated in the IL-12 study. The IL-12-CP study 
resulted in a significant decrease in Tregs and a persistent decrease in relative tumor 
blood volume. 
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The data obtained in Chapter 1 indicate that vaccination of tumor antigens associated 
with DCs may not be strictly necessary to elicit an effective antitumoral immune 
response. This is obviously a bold statement as we researched these effects in only 1 
prophylactic cancer rodent model. It would be interesting to evaluate if this statement 
still remains true when tested in other cancer models and whether the results in a 
therapeutic setting are similar to those in the prophylactic setting.  
For vaccine manufacturing, CC-DC hybrids were magnetically separated from non-
hybrid cancer cells through selection of CD11c-positive magnetic particles. As a result, 
the hybrid vaccines contained CC-DC hybrids but also unhybridized DCs. This may 
have influenced the results of the hybrid vaccine groups in our study, as administration 
of DCs has been shown by Kayashima and colleagues to be capable of inducing immune 
responses in immunosuppressed cancer-bearing mice.415 The use of a sorter was 
explored to isolate purely hybrids, but resulted in a 50% cell loss. Together with the 
long duration of the sorting process, it was deemed unpractical.  
As the precise antigenic content of cancer cells is unknown, it is possible that 
administration of autologous whole cancer cells could induce an immune response 
mainly targeted against immunodominant non-essential cancer antigens. However, 
there is still a strong rationale to immunize patients with antigen-rich vaccines (such as 
whole cancer cell vaccines) as opposed to a single antigen vaccine to prevent tumor 
escape.416 
For this study, bone marrow from approximately 4 mice had to be harvested to have 
enough DCs to vaccinate 11 mice once. Since the co-incubation and fusion groups were 
vaccinated twice, a minimum of 16 mice had to be sacrificed to enable the vaccination 
protocol of 22 other mice. Fortunately, in dogs and humans this breach into the 3R-
principle is not present. Due to their body size, DCs can be isolated in dogs and humans 
via leukapheresis.  
Electrofusion is known to induce less cell death than PEG-mediated cell fusion,313 but, 
in our hands, it proved difficult to standardize and yielded unsatisfactory results. For a 
reduction in variability, PEG-mediated fusion was chosen. However, the electrofusion 
option probably needed more optimization and, in the end, may have resulted in higher 
fusion percentages and thus a more efficient vaccine manufacture.  
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A potential shortcoming in the design of our whole cancer cell vaccine experiment was 
the use of xenogeneic serum proteins during cancer cell culture. Splenocytes of naive 
mice were capable of killing cancer cells during the cytotoxicity test. Their cytotoxicity 
could be explained by the innate immune response against cancer cells or xenogeneic 
serum proteins attached to the cancer cells. If an immune response was elicited against 
the undesired presence of xenogeneic proteins, this clouds the true effects of the cancer 
cell vaccine itself and the usefulness of the translational study. Therefore, it might have 
been interesting to research what the effects of the vaccines were if the cancer cells were 
grown in serum-free medium. In our study, the EO771 cells were grown in a medium 
containing 10% bovine serum. Bovine serum contains xenogeneic proteins and despite 
several wash steps before administration of the cancer vaccine, their presence in the 
cancer vaccine cannot be excluded. Therefore, it is conceivable that the 
immunogenicity of the cancer vaccines was boosted by the repeated presence of 
xenogeneic protein in the vaccine groups, whereas the control group only came into 
contact with the xenogeneic proteins once, namely during tumor inoculation. A 
possible test could be to twice administer 5x105 non-tumoral cells grown in serum-
containing medium to naive mice, with an interval of 35 days. One week after the last 
“vaccination”, 5x105 EO771 cells are administered to these mice. If the tumor develops, 
this means that the potential presence of serum proteins attached to the vaccine cells 
will have no impact on tumor outgrowth. If no tumor growth is present, the immune 
system of the vaccinated mice was trained to recognize xenogeneic serum proteins and 
killed the inoculated cancer cells in a bystander effect.  
 
In Chapter 2, the antitumoral effects of intratumoral hIL-12 EGT were evaluated in 
cancer-bearing pet dogs. Several alterations could have been made to render the gene 
transfer of intratumoral hIL-12 pDNA more efficient. The hIL-12 pDNA was diluted in 
phosphate-buffered saline, whereas 0.45% NaCl saline is one of the best formulations 
for DNA transfer in muscle cells via electroporation in vivo.417 Furthermore, the 
properties of the DNA itself can significantly impact the gene transfer efficacy. The size 
of the DNA affects transfection rates as smaller DNA enters the transfected cell more 
easily than larger DNA. The pDNA in this study was highly suitable for in vivo 
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transfection. Plasmids can vary in size from 1 to over 200 kbp and the plasmid used in 
this study was between 5-6 kbp, which can be considered as small-sized DNA.418 
Furthermore, its properties were most suited for high transfection efficiency since it 
was demonstrated that a vector system with only a few gene cloning sites, a kanamycin-
resistant gene, a CMV promoter, and a human growth hormone polyadenylation tail 
consistently outperformed the transfection efficiency of vectors with multiple cloning 
sites, an ampicilin-resistant gene, and other types of promoters and polyadenylation 
sites via electroporation. The hIL-12 pDNA used in our research project had a 
kanamycin-resistant gene, two separate CMV promoters and a human growth 
hormone polyadenylation tail. 419 However, a CMV promoter is known to be sensitive 
to IFNγ-induced attenuation.357 Since the IL-12 pDNA will induce production of IFNγ, 
this sensitivity could explain the apparent lack of further expression of hIL-12 after the 
second intratumoral hIL-12 EGT treatment. As our plasmid contained a CMV-
promoter, it is likely that the transgene expression was attenuated once a sufficient 
amount of IFNγ was built up. This argument is further supported by enhanced 
transgene expression seen in vivo after administration of neutralizing anti-IFNγ 
antibodies.338, 357 Another possible but less likely explanation for the relatively short 
expression of hIL-12 in our studies, could be formation of antibodies against hIL-12. 
Two dogs were treated twice with the same plasmid; if anti-human antibodies would 
have been present, the impressive local intratumoral inflammatory responses would not 
have been observed a second time. Furthermore, the choice for use of supercoiled hIL-
12 pDNA may have influenced the duration of the expression as well. Whereas linear 
pDNA is more suited for stable transfection, supercoiled pDNA will induce transient 
transfection.420 A distinct advantage of supercoiled DNA is that it is less vulnerable to 
degradation by exonucleases as is linear DNA. Thus, the non-integration and 
subsequent loss of supercoiled pDNA during cell multiplication is highly likely to cause 
a dilution effect. Finally, the inflammation induced by IL-12 can evoke a compensatory 
action by the immune system. The immune system always seeks homeostasis: if an 
inflammation is too intense or too long, it will induce a regulatory effect to contain it. 
 
During the IL-12 studies, the same electroporation parameters were used for every 
patient. The electroporation protocol used in our IL-12 studies was possibly not 
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optimal for each individual tumor as the best protocol will differ per tumor type and 
even per individual tumor due to intratumoral heterogeneity (amount of necrosis, 
vascularization, …).233 Electroporation requires therefore a lot of optimization that may 
not be possible during clinical studies; in addition, reliable, quantitative conclusions 
can only be derived when a large number of tumors is evaluated.421 As it was not 
possible to optimize delivery for every tumor of every treated dog, our protocol was 
based on BTX’s instructions as well as general guidelines from the literature. Currently 
used field strengths are either high field strength (>700V/cm) or low field strength 
(<700V/cm) with short pulses (microseconds) or long pulses (milliseconds (msec)). The 
combination of these variables depends on the target tissue. Generally cancer cells 
require a low field strength with long pulse, whereas muscle cells require a high field 
strength with short pulse.233, 422 In our protocol, cancer cells were therefore pulsed with 
low field strength and long pulses (2 pulses of 450 V/cm and 8 pulses of 100 V/cm with 
pulse duration 0.05 msec and 10 msec respectively). So far, the ideal protocol has not 
been established and more research is needed to clarify the effects of certain 
electroporation protocols. For example, it is not known why in muscle cells, 1 
moderately high voltage pulse (600 V/cm) followed by 4 low voltage pulses (80 V/cm) 
was found to be more efficient in inducing gene expression than 1 moderately high 
voltage pulse (600 V/cm) followed by 8 low voltage pulses (80 V/cm).226 This difference 
in efficiency could possibly be due to the higher amount of pulses administered in the 
second protocol. Electric resistance of tumors drops after the first few pulses. The 
resistance drop is indicative of the breakdown of the skin barrier and/or tissue cell 
membranes. The less resistance, the more current is evoked by subsequent pulses which 
lead to cell death.421 Cell death defeats the purpose of transfection, as living cells are 
necessary to express the transgene.421 However, a third electroporation protocol in the 
study of Pavlin and colleagues with simply 8 low voltage pulses (200 V/cm) 
demonstrated a gene expression equal to the 1 moderately high voltage pulse followed 
by 4 low voltage pulses. What is more, the administration of 6 lower voltage pulses (100 
V/cm) did not induce any transfection at all.226 Different electric pulse voltages were 
also compared in laboratory dogs with CTVT: 200, 500 and 900 V/cm, the pulse 
duration (50 msec), number of pulses (10 times) and DNA amount (1 mg) were fixed. 
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The highest expression was measured after 200 V/cm.146 Those results demonstrate that 
lower voltages are more likely to induce efficient transgene expression, but it must be 
borne in mind that these studies were performed with transfection markers luciferase 
or green fluorescent protein. These markers may not always be representative of the 
pDNA eventually used in the study, as transfection efficiency also depends on the 
pDNA characteristics.419 Nevertheless, during our studies, hIL-12 was measured in the 
tumor tissue or blood stream of every patient thus indicating that electroporation was 
efficient in inducing transfection of hIL-12 pDNA into the cancer cells. 
Alternatives for electroporation were not explored by our research group, since viral 
vectors are not considered safe42 and electroporation is the most efficient non-viral 
delivery system to date.422 However, the trauma induced by the needle electrodes and 
the repeated anesthesia, necessary to effectuate the treatments, are adverse to the 
patient’s immune system as well.423 The efficiency of other delivery methods may be less 
dependent from the tumor (type) heterogeneity and may also be more time-efficient. 
Anesthesia is not required with non-invasive painless transfection methods such as 
sonoporation, magnetofection or administration of lipoplexes, but so far they 
demonstrated a lower transfection efficiency.356, 421, 422, 424 If the transfection efficiency of 
sonoporation were equivalent to electroporation, sonoporation would have been ideal 
to use in our study, since the treatment efficacy was already evaluated through CEUS 
imaging and sonoporation would have required little extra effort. Sonoporation is a 
safe, noninvasive and flexible site-specific transfection technique. After the 
incorporation of the pDNA within the microbubbles, these microbubbles are 
administered intravenously. At the tumor site, ultrasound waves will temporarily 
permeabilize the cancer cell membranes to allow cellular uptake of pDNA.425 
Sonoporation could also allow targeting of TDLNs and thus reinforcement of the 
antitumoral immune response. Further research on this alternative delivery method 
should definitely be pursued to facilitate the translation of gene transfer to the clinic 
and increase patient compliance. Although upon today lipoplexes represent a less 
efficient transfection method than electroporation, it is highly stimulating that 
significant antitumoral results were obtained through gene therapy with lipoplexes.147  
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Per treatment session, 1 mg of hIL-12 pDNA was administered to every dog in the 
study. The rationale was that efficacy and safety were previously demonstrated with 
that particular dose.146, 221 In our studies, the hIL-12 pDNA solution was diluted 
according to the estimated tumor volume to obtain an even distribution of the hIL-12 
pDNA throughout the tumor. Therefore, 1 mg of hIL-12 pDNA solution was diluted to 
a sixth of the tumor volume prior to administration. However, the dilution of the 
pDNA may have resulted in a relatively much lower amount of IL-12 producing cancer 
cells in dogs with large tumors. Indeed, during the IL-12 and IL-12-CP study, the 
highest intratumoral amounts of hIL-12 were measured in dogs with a relatively small 
tumor.  
It is advisable to evaluate if higher IL-12 pDNA doses are still safe and, if so, to perhaps 
adapt the hIL-12 pDNA dosage to the amount of tumor tissue (same dosage/cm3 tumor 
tissue). However, since differences in tumor organization will impact gene transfer as 
well, one must always take variability in gene transfer between patients into account.233   

In future studies with IL-12, it would be advisable to routinely collect blood samples 
and measure markers of paraneoplastic syndromes, such as auto-immune antibodies, 
prior and during the IL-12 treatment. In our study, the presence of auto-immune 
antibodies was confirmed in only one dog with adverse effects (transient anemia). 
Another dog developed peripheral neuropathy, fatigue and respiratory dysfunction 
(phased breathing). The peripheral neuropathy could have been the consequence of 
tumor swelling on the nearby nerve, but peripheral neuropathy and former symptoms 
have also been described as an expression of a paraneoplastic syndrome such as 
myasthenia gravis.396, 426, Measurement of auto-immune antibodies and metabolic 
imbalances could give us an indication of how likely enrolled patients will develop a 
paraneoplastic syndrome. Unfortunately, the paraneoplastic syndrome represents a 
wide range of cancer-associated anomalies that cannot be detected through the 
presence of one general antibody. One option could be to run a screening test for 
paraneoplastic symptoms most associated with the selected tumor type.396, 426  
 
In Chapter 3, a reduced residual disease setting was studied in 2 dogs, as surgery was 
performed within 4 days prior to the first intratumoral hIL-12 EGT.  
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In the first dog, the intra-oral amelanocytic melanoma was surgically removed a first 
time 7 weeks prior to presentation after which the tumor quickly regrew. The tumor 
was surgically removed a second time and the tumor margins were treated with hIL-12 
EGT 3 days later. Although the tumor margins on histopathology were minimal, the 
resected tumor did not resume growth (whereas it was the case after the first surgery). 
At the time of the first intratumoral hIL-12 EGT, a new tumoral mass was present in 
the parotic gland area and cytology revealed the same cell type as the primary tumor. 
Despite intratumoral hIL-12 EGT, the second mass continued to progress.  
In the second dog, removal of a primary anal sac adenocarcinoma and its abdominal 
LN metastases was followed by hIL-12 EGT of the wound bed of the primary tumor. 
Although the tumor reoccurred in the remaining hypogastric LNs 1 week after surgical 
excision of the primary tumor and the metastectomy, the tumor size then remained 
stable during 3 weeks before it continued to grow.  
These results seem to indicate that a reduced disease setting generates a more 
pronounced and longer equilibrium phase between the immune system and the tumor. 
Unfortunately, a fully minimal residual disease setting could not be obtained for these 
dogs, due to the locations of the metastases and/or the cost of the extra surgery. 
In our IL-12-CP study, intratumoral hIL-12 EGT was complemented by oral intake of 
metronomic CP. Although CP (Endoxan®) is a very cheap chemotherapeutic, it is not 
always easy to implement this treatment option into common veterinary practice. 
During the IL-12-CP study, this was no issue as we redistributed the Endoxan® tablets 
ourselves. However, for owners who wanted to continue the metronomic 
chemotherapy after the IL-12-CP therapy cycle, this proved to be complicated, since 
only a minority of pharmacists was willing to redistribute the Endoxan® tablets 
according to the body surface of the cancer-bearing dog. 
3 Perspectives of combinations in immunotherapy 
Cancer immunotherapy has yielded promising results for a subset of cancer patients. So 
far, success rates were modest, but not illogical as the relation between the immune 
system and cancer is complex and the immune system needs help on multiple fronts to 
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fight the cancer efficiently. Therefore, success rates will most likely increase, as 
combination therapy is the next big step in immunotherapy. However, more 
combination therapy will lead to more possible toxic interactions, thus these 
combinations should be carefully designed and gradually combined to monitor their 
efficacy as well as their safety.  
 
At the Laboratory for Gene Therapy, the effects of combination treatments will be 
further evaluated. Other possible antitumoral research avenues of hIL-12 pDNA could 
include its effects on surgery/anesthesia-induced stress response. As this stress response 
causes immunodepression and tumor progression is largely mediated by reduced NK 
cell-activity, IL-12, as a powerful stimulator of NK cells,427 could potentially inhibit 
surgery-related stress responses and its associated side effects. It would also be 
interesting to further investigate the positive effects of IL-12 on quality of life, such as 
weight gain and the display of a more energetic behavior, in treated patients. 
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As long as there has been life, there has been cancer. Various cases of cancer have been 
detected in fossile remnants of dinosaurs since the Jurassic era.428 Many avenues for the 
treatment of cancer have been explored over thousands of years, yet cancer still 
represents the second leading cause of death in the world after cardiovascular 
diseases.429 In the last 150 years, advancements in cancer therapy have exponentially 
increased as surgery was reinforced by chemotherapy and radiotherapy. Although the 
seeds of immunotherapy were planted at the end of the nineteeth century, 
immunotherapy has never been explored with so much vigor as today,4 as it bears the 
potential to inhibit cancer recurrence. 
 
While several immunomonotherapies have been FDA-approved and seem very 
promising,7 the overall success percentages are low. The interactions between the 
immune system and cancer are numerous and complex. Cancer cells are able to rapidly 
adapt to and escape antitumoral treatment. Therefore, it seems logical that when 
immunotherapy targets only one element in this web of interactions between cancer 
and the immune system, it will not yield significant results.  
Focus should shift from manipulating one to several cancer targets during cancer 
treatment. Therefore, combination therapy is the next big step in immunotherapy. 
Although much knowledge has been gained about the safety of monotherapies, this 
cannot guarantee that combination therapy will not cause toxic or auto-immune 
responses. The chosen combinations should be carefully designed with regard to 
possible interactions and treatment schedules. Then, these therapies can be gradually 
combined, while their efficacy as well as their safety is closely monitored. 
  
For this thesis, several elements of a combination immunotherapy were evaluated for 
safety and efficacy, whereafter these components were gradually combined and re-
evaluated for safety and efficacy. The elements of the combination immunotherapy 
consisted of the 3 arms of the immune system: (1) the adaptive immune system was 
stimulated with a cancer vaccine, (2) the innate immune system with IL-12 and (3) the 
immunosuppressive cancer microenvironment suppressed via metronomic 
cyclophosphamide. The first arm was evaluated in mice, the second and third in dogs.   
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Chapter 1 describes the safety and prophylactic efficacy of 3 different whole cancer cell 
vaccines based on immunogenically killed cancer cells in mice. These 3 different 
vaccine groups were compared for immunological response and survival. Whole cancer 
cell vaccines based on immunogenically killed cancer cells were able to induce an 
antitumoral immune response against tumor outgrowth as effectively as the whole 
cancer cell vaccines combined with DCs (co-incubated or fused). However, the immune 
responses responsible for this protection differed between the vaccine types. The 
immunogenically killed cancer cells without DCs protected the mice against tumor 
development via a cellular response only. The protection against tumor development in 
the fusion vaccine occured mainly via a humoral response, whereas the co-incubation 
vaccine protected the mice via a cellular as well as a humoral immune response. These 
findings indicate that vaccination with immunogenically killed cancer cells (with or 
without DCs) may be a useful prophylactic strategy against (recurrent) cancer growth. 
Furthermore, it proposes that a cancer vaccine design not necessarily has to incorporate 
DCs as whole cancer cell vaccines consisting solely of immunogenically killed cancer 
cells were as effective in inhibiting tumor outgrowth. This finding could greatly 
improve the practicality and cost of cancer vaccines in cancer-bearing pet dogs.  
 
In Chapter 2, the safety and antitumoral effects of intratumoral hIL-12 pDNA on 
spontaneous tumors were evaluated in pet dogs. Whereas immune stimulation and 
anti-angiogenic effects on tumor perfusion were present in every treated dog, no cures 
were obtained. However, 1 dog with metastases of the iliac LNs did experience a 
transient partial regression in the size of these metastases, while the primary tumor 
continued to progress. This makes us hopeful that IL-12 could play an important part 
in anti-metastatic effects. IL-12 is a powerful stimulator of the innate immune system 
and many innate immune cells are very plastic and exert pro- or antitumoral activities 
according to their microenvironment. It is very likely that IL-12 effectively influences 
the transition from a protumoral to an antitumoral microenvironment in less-
established tumors such as metastases and certainly metastatic LNs as they harbor 
immune cells responsive to IL-12.430  
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In Chapter 3, the safety and antitumoral effects of the combination of metronomic 
cyclophosphamide and hIL-12 pDNA with spontaneous tumors were evaluated in pet 
dogs. Inflammatory responses were observed in every dog after treatment as well as a 
clear reduction in tumor perfusion. Whereas in the IL-12 study the blood flow speed 
within the tumors was transiently decreased, it was persistently decreased after IL-12-
CP treatment. Those persistent anti-angiogenic effects indicate that the overall survival 
of the pet dogs was increased after IL-12-CP treatment despite the absence of cures, 
which was similar to the findings in the preclinical mouse study. Furthermore, IL-12-
CP treatment can play a palliative or supporting role for cancer patients as weight gain 
or stabilization after progressive weight loss was seen in all IL-12-CP treated pet dogs.  
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Het ontwikkelen van kanker is van alle tijden. Verschillende gevallen van kanker 
werden ontdekt in de fossiele resten van dinosaurussen sinds het Juratijdperk.428 
Onderzoek naar kankerbehandelingen wordt al duizenden jaren uitgevoerd, maar toch 
blijft kanker de tweede grootste doodsoorzaak na cardiovasculaire aandoeningen.429 
Gedurende de laatste 150 jaar nam de vooruitgang in kankerbehandelingen 
exponentieel toe: zo werd chirurgie vergezeld door chemotherapie en radiotherapie. 
Hoewel de zaden voor immunotherapie reeds gepland werden aan het eind van de 
negentiende eeuw, werd het nog nooit zo verwoed onderzocht als vandaag,4 aangezien 
het het potentieel biedt om kankerherval te voorkomen. 
  
Verschillende immunomonotherapiën werden goedgekeurd door het FDA en lijken erg 
veelbelovend,7 maar de algemene succesratio is laag. Er zijn vele en complexe interacties 
tussen het immuunsysteem en kanker. Daarbovenop zijn kankercellen in staat om zich 
snel aan te passen aan antitumorale behandelingen en zodoende te ontsnappen aan de 
effecten van de kankerbehandeling. Daarom lijkt het logisch dat wanneer slechts één 
element geviseerd wordt binnen het kluwen aan interacties tussen de kanker en het 
immuunsysteem, dit weinig significante resultaten zal opleveren.  
De focus moet daarom verplaatst worden weg van het manipuleren van één 
kankerdoelwit naar het manipuleren van meerdere doelwitten gedurende behandeling. 
Zodoende is combinatietherapie de volgende grote stap in immunotherapie. Hoewel 
veel kennis verworven werd over de veiligheid van monotherapiën, biedt dit geen 
garantie dat combinatiebehandelingen geen toxiciteits- of auto-immuunresponsen 
veroorzaken.  De keuze voor bepaalde combinaties moet logisch zijn en rekening 
houden met mogelijke interacties en behandelingsschema’s. Nadien kunnen deze 
behandelingen gradueel gecombineerd worden, terwijl hun efficiëntie en veiligheid van 
nabij opgevolgd worden. 
  
Voor deze thesis werden verschillende elementen van een combinatie-immunotherapie 
geëvalueerd op veiligheid en efficiëntie, waarna deze componenten gradueel werden 
gecombineerd en opnieuw beoordeeld op veiligheid en efficiëntie. De componenten van 
de combinatietherapie maakten deel uit van de 3 armen van het immuunsysteem: (1) 
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het adaptieve immuunsysteem werd gestimuleerd met een kankervaccin, (2) het 
aangeboren immuunsysteem met IL-12 en (3) de immunosuppressieve kankermicro-
omgeving onderdrukt via metronomische cyclofosfamide. De eerste arm werd 
beoordeeld in muizen, de tweede en derde in honden.   
 
Hoofdstuk 1 beschrijft de veiligheid en profylactische efficiëntie van 3 verschillende 
volledige kankercelvaccins gebaseerd op immunogeen gedode kankercellen bij muizen. 
Deze 3 verschillende vaccingroepen werden vergeleken voor immunologische respons 
en overleving. Volledige kankercelvaccins gebaseerd op immunogeen gedode 
kankercellen waren in staat om een even efficiënte antitumorale immuunrespons op te 
wekken tegen tumoruitgroei als de volledige kankercelvaccins die gecombineerd 
werden met dendritische cellen (gecoïncubeerd of gefusioneerd). De immuunresponsen 
verantwoordelijk voor deze bescherming verschilden tussen de vaccintypes. De 
immunologisch gedode kankercellen zonder dendritische cellen beschermden de 
muizen tegen tumorontwikkeling via enkel een cellulaire respons. De bescherming 
tegen tumorontwikkeling bij het fusievaccin vond plaats via een humorale respons, 
terwijl bij het combinatievaccin dit via een cellulaire en humorale respons gebeurde. 
Deze bevindingen geven aan dat vaccinatie met immunogeen gedode kankercellen (met 
of zonder dendritische cellen) een bruikbare profylactische strategie kunnen zijn tegen 
(recurrente) tumorgroei. Verder geven deze resultaten aan dat een kankercelvaccin niet 
noodzakelijkerwijs dendritische cellen hoeft te bevatten aangezien een volledig 
kankercelvaccin bestaande uit enkel immunogeen afgedode kankercellen even efficiënt 
was in het verhinderen van tumorontwikkeling. Deze bevinding kan een grote 
verbetering betekenen voor de toepasbaarheid en de kost van kankervaccins bij honden 
met spontane tumoren.  
 
In Hoofdstuk 2, werden de veiligheid en antitumorale effecten van intratumorale afgifte 
van plasmide DNA dat codeert voor humaan interleukine 12 beoordeeld bij honden 
met spontane tumoren. Hoewel immuunstimulatie en anti-angiogene effecten op 
tumordoorbloeding meetbaar waren bij elke behandelde hond, werden geen genezingen 
bekomen. Bij één hond met uitzaaiingen in de iliacale lymfeknopen werd echter een 
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tijdelijke partiële regressie gemeten in de grootte van deze uitzaaiingen, terwijl de 
primaire tumor bleef groeien. Dit maakt ons hoopvol dat interleukine 12 een 
belangrijke rol kan spelen in het bestrijden van uitzaaiingen. Interleukine 12 is een 
krachtige stimulator van het aangeboren immuunsysteem en vele aangeboren 
immuuncellen zijn erg plastisch en oefenen pro- of antitumorale activiteiten uit 
naargelang hun micro-omgeving. Het is erg waarschijnlijk dat interleukine 12 de 
overgang van een protumorale naar een antitumorale omgeving erg positief beïnvloedt 
in minder uitgebouwde tumoren zoals uitzaaiingen en zeker uitzaaiingen in 
lymfeknopen aangezien lymfeknopen immuuncellen bevatten die kunnen reageren op 
interleukine 12.430  
 
In Hoofdstuk 3 werden de veiligheid en antitumorale effecten van de combinatie van 
metronomische cyclofosfamide en een plasmide coderend voor humaan  interleukine 
12  (= combinatiebehandeling) beoordeeld in honden et spontane tumoren. 
Inflammatoire responsen werden gemeten bij elke hond na behandeling, evenals een 
duidelijke daling in tumordoorbloeding. Terwijl in de interleukine 12-studie de 
snelheid van de tumordoorbloeding slechts tijdelijk daalde, veroorzaakte de 
combinatiebehandeling echter een voortdurende daling in de snelheid van de 
tumordoorbloeding. Ondanks het gebrek aan genezingen, geven deze aanhoudende 
anti-angiogene effecten aan dat de algemene overleving van deze honden waarschijnlijk 
gestegen was na de combinatiebehandeling, hetgeen gelijkaardig was aan de 
bevindingen in de preklinische muizenstudie. Daarbovenop kan de 
combinatiebehandeling een palliatieve of ondersteunende rol spelen voor 
kankerpatiënten aangezien gewichtstoename of stabilisatie gemeten werd bij alle 
behandelde honden terwijl voor de behandeling progressief gewichtsverlies vastgesteld 
werd.  
 

  
REFERENCES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

References 
213 
1. Jozef Pacolet ADC, Georges Hedebouw, Sofie Cabus, Nele Spruytte. De medische en niet-
medische kosten van kankerpatiënten. In: HIVA, ed.: Vlaamse Liga Tegen Kanker, 2011. 
2. Impellizeri JA, Ciliberto G, Aurisicchio L. Electro-gene-transfer as a new tool for cancer 
immunotherapy in animals. Veterinary and comparative oncology 2014; 12:310-8. 
3. MP Brown, N Burdett. Targeted therapies, aspects of pharmaceutical and oncological 
management. Cancer Forum 2013; 37:70-80. 
4. Arruebo M, Vilaboa N, Saez-Gutierrez B, Lambea J, Tres A, Valladares M, Gonzalez-
Fernandez A. Assessment of the evolution of cancer treatment therapies. Cancers 2011; 
3:3279-330. 
5. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari 
AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant 
prostate cancer. The New England journal of medicine 2010; 363:411-22. 
6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, 
Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients 
with metastatic melanoma. The New England journal of medicine 2010; 363:711-23. 
7. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, 
Essahsah F, Fathers LM, Offringa R, Drijfhout JW, et al. Vaccination against HPV-16 
oncoproteins for vulvar intraepithelial neoplasia. The New England journal of medicine 
2009; 361:1838-47. 
8. Riccardo F, Aurisicchio L, Impellizeri JA, Cavallo F. The importance of comparative 
oncology in translational medicine. Cancer immunology, immunotherapy : CII 2015; 
64:137-48. 
9. Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. 
Jama 2006; 296:1731-2. 
10. Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in 
cancer treatment. American journal of translational research 2014; 6:114-8. 
11. Arrowsmith J. Trial watch: phase III and submission failures: 2007-2010. Nature reviews 
Drug discovery 2011; 10:87. 
12. Yaddanapudi K, Mitchell RA, Eaton JW. Cancer vaccines: Looking to the future. 
Oncoimmunology 2013; 2:e23403. 
13. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human 
immunology. Journal of immunology 2004; 172:2731-8. 
14. Pang LY, Argyle DJ. Using naturally occurring tumours in dogs and cats to study 
telomerase and cancer stem cell biology. Biochimica et biophysica acta 2009; 1792:380-91. 
15. Pinho SS, Carvalho S, Cabral J, Reis CA, Gartner F. Canine tumors: a spontaneous animal 
model of human carcinogenesis. Translational research : the journal of laboratory and 
clinical medicine 2012; 159:165-72. 
16. Denies S, Sanders NN. Recent progress in canine tumor vaccination: potential 
applications for human tumor vaccines. Expert Rev Vaccines 2012; 11:1375-86. 
References 
214 
17. Ledford H. Translational research: 4 ways to fix the clinical trial. Nature 2011; 477:526-8. 
18. Benjamini E, Theilen GH, Torten M, Fong S, Crow S, Henness AM. Tumor vaccines for 
immunotherapy of canine lymphosarcoma. Annals of the New York Academy of Sciences 
1976; 277:305-12. 
19. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. 
Nature reviews Cancer 2008; 8:147-56. 
20. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, 
Chang JL, Kulbokas EJ, 3rd, Zody MC, et al. Genome sequence, comparative analysis and 
haplotype structure of the domestic dog. Nature 2005; 438:803-19. 
21. Hayes HM, Jr., Fraumeni JF, Jr. Epidemiological features of canine renal neoplasms. 
Cancer research 1977; 37:2553-6. 
22. Mukaratirwa S, Chipunza J, Chitanga S, Chimonyo M, Bhebhe E. Canine cutaneous 
neoplasms: prevalence and influence of age, sex and site on the presence and potential 
malignancy of cutaneous neoplasms in dogs from Zimbabwe. Journal of the South 
African Veterinary Association 2005; 76:59-62. 
23. Olson PN. Using the canine genome to cure cancer and other diseases. Theriogenology 
2007; 68:378-81. 
24. Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as 
models for human cancer. Cancer investigation 2000; 18:781-92. 
25. Rankin KS, Starkey M, Lunec J, Gerrand CH, Murphy S, Biswas S. Of dogs and men: 
comparative biology as a tool for the discovery of novel biomarkers and drug 
development targets in osteosarcoma. Pediatric blood & cancer 2012; 58:327-33. 
26. Khanna C, London C, Vail D, Mazcko C, Hirschfeld S. Guiding the optimal translation of 
new cancer treatments from canine to human cancer patients. Clinical cancer research : 
an official journal of the American Association for Cancer Research 2009; 15:5671-7. 
27. Olin MR, Pluhar GE, Andersen BM, Shaver R, Waldron NN, Moertel CL. Victory and 
defeat in the induction of a therapeutic response through vaccine therapy for human and 
canine brain tumors: a review of the state of the art. Critical reviews in immunology 2014; 
34:399-432. 
28. Gabai V, Venanzi FM, Bagashova E, Rud O, Mariotti F, Vullo C, Catone G, Sherman MY, 
Concetti A, Chursov A, et al. Pilot study of p62 DNA vaccine in dogs with mammary 
tumors. Oncotarget 2014; 5:12803-10. 
29. Thacker EE, Nakayama M, Smith BF, Bird RC, Muminova Z, Strong TV, Timares L, 
Korokhov N, O'Neill AM, de Gruijl TD, et al. A genetically engineered adenovirus vector 
targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-
specific immune responses in vivo. Vaccine 2009; 27:7116-24. 
30. Riccardo F, Iussich S, Maniscalco L, Lorda Mayayo S, La Rosa G, Arigoni M, De Maria R, 
Gattino F, Lanzardo S, Lardone E, et al. CSPG4-specific immunity and survival 
prolongation in dogs with oral malignant melanoma immunized with human CSPG4 
References 
215 
DNA. Clinical cancer research : an official journal of the American Association for 
Cancer Research 2014; 20:3753-62. 
31. Natterson-Horowitz B BK. Zoobiquity: A Species-Spanning Approach to Medicine. 
http://www.zoobiquity.com. Accessed 2015/12/17  
32. Comparative Oncology Program 
https://ccrod.cancer.gov/confluence/display/CCRCOPWeb/Comparative+Oncology+Tri
als+Consortium. Accessed 2015/12/17. 
33. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. 
With a report of ten original cases. 1893. Clinical orthopaedics and related research 
1991:3-11. 
34. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue 
sarcomas. The Iowa orthopaedic journal 2006; 26:154-8. 
35. Grossman HB, O'Donnell MA, Cookson MS, Greenberg RE, Keane TE. Bacillus calmette-
guerin failures and beyond: contemporary management of non-muscle-invasive bladder 
cancer. Reviews in urology 2008; 10:281-9. 
36. Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: the first immunotherapy agent 
(vaccine) for hormone-refractory prostate cancer. P & T : a peer-reviewed journal for 
formulary management 2011; 36:197-202. 
37. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in 
cancer suppression and promotion. Science 2011; 331:1565-70. 
38. Nespoli L, Uggeri F, Romano F, Nespoli A, Brivo F, Fumagalli L, Sargenti M, Uggeri F, 
Gianotti L. Modulation of systemic and intestinal immune response by interleukin-2 
therapy in gastrointestinal surgical oncology. Personal experience in the context of 
current knowledge and future perspectives. Anticancer research 2012; 32:989-96. 
39. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from 
immunosurveillance to tumor escape. Nature immunology 2002; 3:991-8. 
40. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. 
Immunity 2013; 39:1-10. 
41. Swann JB, Smyth MJ. Immune surveillance of tumors. The Journal of clinical 
investigation 2007; 117:1137-46. 
42. Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies 
against cancer. Journal of biomedicine & biotechnology 2010; 2010:174378. 
43. Lowe DB, Shearer MH, Jumper CA, Kennedy RC. Towards progress on DNA vaccines for 
cancer. Cellular and molecular life sciences : CMLS 2007; 64:2391-403. 
44. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nature reviews 
Cancer 2012; 12:265-77. 
45. Munn DH, Mellor AL. The tumor-draining lymph node as an immune-privileged site. 
ImmunolRev 2006; 213:146-58. 
References 
216 
46. Boon T, Old LJ. Cancer Tumor antigens. Current opinion in immunology 1997; 9:681-3. 
47. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. 
AnnuRevImmunol 2013; 31:51-72. 
48. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer 
treatment. NatRevCancer 2012; 12:237-51. 
49. Nierkens S, Janssen EM. Harnessing dendritic cells for tumor antigen presentation. 
Cancers(Basel) 2011; 3:2195-213. 
50. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, 
Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependent immunogenicity of 
doxorubicin-induced tumor cell death. JExpMed 2005; 202:1691-701. 
51. Gamrekelashvili J, Kruger C, von WR, Hoffmann M, Huster KM, Busch DH, Manns MP, 
Korangy F, Greten TF. Necrotic tumor cell death in vivo impairs tumor-specific immune 
responses. JImmunol 2007; 178:1573-80. 
52. Boog CJ. Principles of vaccination and possible development strategies for rational 
design. ImmunolLett 2009; 122:104-7. 
53. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-
inducing ligand and TRAIL receptor pathway. Oncogene 2008; 27:6207-15. 
54. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. JImmunol 
2011; 186:1325-31. 
55. Kalos M. Tumor antigen-specific T cells and cancer immunotherapy: current issues and 
future prospects. Vaccine 2003; 21:781-6. 
56. Chang EY, Chen CH, Ji H, Wang TL, Hung K, Lee BP, Huang AY, Kurman RJ, Pardoll 
DM, Wu T. Antigen-specific cancer immunotherapy using a GM-CSF secreting 
allogeneic tumor cell-based vaccine. IntJCancer 2000; 86:725-30. 
57. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, 
Wagstaff J, Zielinski C, Faulkner I, et al. Therapeutic vaccines for cancer: an overview of 
clinical trials. Nature reviews Clinical oncology 2014; 11:509-24. 
58. Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of 
cancer. Seminars in cancer biology 2012; 22:3-13. 
59. Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer 
vaccines. The Journal of clinical investigation 2015; 125:3401-12. 
60. Bergman PJ. Immunotherapy in veterinary oncology. The Veterinary clinics of North 
America Small animal practice 2014; 44:925-39. 
61. Hirschowitz EA, Yannelli JR. Immunotherapy for lung cancer. ProcAmThoracSoc 2009; 
6:224-32. 
62. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current 
vaccines. NatMed 2004; 10:909-15. 
References 
217 
63. Lasaro MO, Ertl HC. Targeting inhibitory pathways in cancer immunotherapy. 
CurrOpinImmunol 2010; 22:385-90. 
64. Aly HA. Cancer therapy and vaccination. JImmunolMethods 2012; 382:1-23. 
65. Regan D, Guth A, Coy J, Dow S. Cancer immunotherapy in veterinary medicine: Current 
options and new developments. Veterinary journal 2015. 
66. Chiang CL, Benencia F, Coukos G. Whole tumor antigen vaccines. SeminImmunol 2010; 
22:132-43. 
67. Gilboa E. DC-based cancer vaccines. JClinInvest 2007; 117:1195-203. 
68. Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, 
Khan AS, Broderick KE, et al. Immunotherapy against HPV16/18 generates potent TH1 
and cytotoxic cellular immune responses. Science translational medicine 2012; 4:155ra38. 
69. Chiang CL, Hagemann AR, Leskowitz R, Mick R, Garrabrant T, Czerniecki BJ, Kandalaft 
LE, Powell DJ, Jr., Coukos G. Day-4 myeloid dendritic cells pulsed with whole tumor 
lysate are highly immunogenic and elicit potent anti-tumor responses. PLoSOne 2011; 
6:e28732. 
70. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 
480:480-9. 
71. Andersen BM, Ohlfest JR. Increasing the efficacy of tumor cell vaccines by enhancing 
cross priming. Cancer Lett 2012; 325:155-64. 
72. Braun M PR, Scholz G, Romero P. Peptide and Protein-Based Cancer Vaccines. New 
York Springer Science+Business Media 2013. 
73. Slingluff CL, Jr. The present and future of peptide vaccines for cancer: single or multiple, 
long or short, alone or in combination? Cancer journal 2011; 17:343-50. 
74. Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: principles, progress 
and prospects. Vaccine 1999; 18:765-77. 
75. Rodriguez-Gascon A, del Pozo-Rodriguez A, Solinis MA. Development of nucleic acid 
vaccines: use of self-amplifying RNA in lipid nanoparticles. International journal of 
nanomedicine 2014; 9:1833-43. 
76. Iezzi M, Quaglino E, Amici A, Lollini PL, Forni G, Cavallo F. DNA vaccination against 
oncoantigens: A promise. Oncoimmunology 2012; 1:316-25. 
77. Colluru VT, Johnson LE, Olson BM, McNeel DG. Preclinical and clinical development of 
DNA vaccines for prostate cancer. Urologic oncology 2013. 
78. Sayour EJ, Sanchez-Perez L, Flores C, Mitchell DA. Bridging infectious disease vaccines 
with cancer immunotherapy: a role for targeted RNA based immunotherapeutics. Journal 
for immunotherapy of cancer 2015; 3:13. 
79. Kim TK, Eberwine JH. Mammalian cell transfection: the present and the future. 
Analytical and bioanalytical chemistry 2010; 397:3173-8. 
References 
218 
80. Ledwith BJ, Manam S, Troilo PJ, Barnum AB, Pauley CJ, Griffiths TG, 2nd, Harper LB, 
Beare CM, Bagdon WJ, Nichols WW. Plasmid DNA vaccines: investigation of integration 
into host cellular DNA following intramuscular injection in mice. Intervirology 2000; 
43:258-72. 
81. Wang Z, Troilo PJ, Wang X, Griffiths TG, Pacchione SJ, Barnum AB, Harper LB, Pauley 
CJ, Niu Z, Denisova L, et al. Detection of integration of plasmid DNA into host genomic 
DNA following intramuscular injection and electroporation. Gene therapy 2004; 11:711-
21. 
82. Johansson DX, Ljungberg K, Kakoulidou M, Liljestrom P. Intradermal electroporation of 
naked replicon RNA elicits strong immune responses. PloS one 2012; 7:e29732. 
83. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annual 
review of medicine 1999; 50:507-29. 
84. Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J, Li M, Ginestier C, Wicha 
MS, Moyer JS, et al. Cancer stem cell vaccination confers significant antitumor immunity. 
Cancer Res 2012; 72:1853-64. 
85. Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K. 
Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor 
responses comparable to autologous tumor cell immunotherapies. ClinImmunol 2009; 
133:184-97. 
86. Zhou J, Weng D, Zhou F, Pan K, Song H, Wang Q, Wang H, Wang H, Li Y, Huang L, et 
al. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit 
anti-tumor activity: in vitro results and clinical responses. Cancer ImmunolImmunother 
2009; 58:1587-97. 
87. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. 
Immunogenic cell death and DAMPs in cancer therapy. NatRevCancer 2012; 12:860-75. 
88. Dillman RO, Beutel LD, De LC, Nayak SK. Short-term tumor cell lines from breast cancer 
for use as autologous tumor cell vaccines in the treatment of breast cancer. Cancer 
BiotherRadiopharm 2001; 16:205-11. 
89. Teitz-Tennenbaum S, Wicha MS, Chang AE, Li Q. Targeting cancer stem cells via 
dendritic-cell vaccination. Oncoimmunology 2012; 1:1401-3. 
90. Pellegatta S, Finocchiaro G. Dendritic cell vaccines for cancer stem cells. Methods 
MolBiol 2009; 568:233-47. 
91. Finn OJ. Cancer vaccines: between the idea and the reality. NatRevImmunol 2003; 3:630-
41. 
92. Toes RE, Blom RJ, van d, V, Offringa R, Melief CJ, Kast WM. Protective antitumor 
immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 
1996; 56:3782-7. 
93. Yasuda T, Kamigaki T, Kawasaki K, Nakamura T, Yamamoto M, Kanemitsu K, Takase S, 
Kuroda D, Kim Y, Ajiki T, et al. Superior anti-tumor protection and therapeutic efficacy 
References 
219 
of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids 
for murine colon adenocarcinoma. Cancer ImmunolImmunother 2007; 56:1025-36. 
94. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, Sukkurwala AQ, 
Menger L, Zitvogel L, Kroemer G. Molecular determinants of immunogenic cell death 
elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011; 30:61-9. 
95. Apetoh L, Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Piacentini M, Kroemer G, 
Zitvogel L. Immunogenic chemotherapy: discovery of a critical protein through 
proteomic analyses of tumor cells. Cancer Genomics Proteomics 2007; 4:65-70. 
96. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, Kroemer G. Cell death 
modalities: classification and pathophysiological implications. Cell DeathDiffer 2007; 
14:1237-43. 
97. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, Kroemer G. 
Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 
2009; 14:364-75. 
98. Korsnes MS. Yessotoxin as a tool to study induction of multiple cell death pathways. 
Toxins(Basel) 2012; 4:568-79. 
99. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. 
Nature reviews Immunology 2009; 9:353-63. 
100. Copier J, Dalgleish A. Overview of tumor cell-based vaccines. IntRevImmunol 2006; 
25:297-319. 
101. Gong J, Koido S, Calderwood SK. Cell fusion: from hybridoma to dendritic cell-based 
vaccine. ExpertRevVaccines 2008; 7:1055-68. 
102. Nanni P, Nicoletti G, De GC, Landuzzi L, Di CE, Cavallo F, Pupa SM, Rossi I, Colombo 
MP, Ricci C, et al. Combined allogeneic tumor cell vaccination and systemic interleukin 
12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. JExpMed 2001; 
194:1195-205. 
103. Koido S, Tanaka Y, Chen D, Kufe D, Gong J. The kinetics of in vivo priming of CD4 and 
CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. JImmunol 2002; 
168:2111-7. 
104. Lindner M, Schirrmacher V. Tumour cell-dendritic cell fusion for cancer 
immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus 
electro-fusion protocols. EurJClinInvest 2002; 32:207-17. 
105. Tamai H, Watanabe S, Zheng R, Deguchi K, Cohen PA, Koski GK, Shu S. Effective 
treatment of spontaneous metastases derived from a poorly immunogenic murine 
mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive 
transfer of sensitized T cells. ClinImmunol 2008; 127:66-77. 
106. Stannard KA, Collins PM, Ito K, Sullivan EM, Scott SA, Gabutero E, Darren G, I, Low P, 
Nilsson UJ, Leffler H, et al. Galectin inhibitory disaccharides promote tumour immunity 
in a breast cancer model. Cancer Lett 2010; 299:95-110. 
References 
220 
107. Ahlert T, Sauerbrei W, Bastert G, Ruhland S, Bartik B, Simiantonaki N, Schumacher J, 
Hacker B, Schumacher M, Schirrmacher V. Tumor-cell number and viability as quality 
and efficacy parameters of autologous virus-modified cancer vaccines in patients with 
breast or ovarian cancer. JClinOncol 1997; 15:1354-66. 
108. Dols A, Smith JW, Meijer SL, Fox BA, Hu HM, Walker E, Rosenheim S, Moudgil T, 
Doran T, Wood W, et al. Vaccination of women with metastatic breast cancer, using a 
costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell 
line: clinical and immunological results. HumGene Ther 2003; 14:1117-23. 
109. Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, 
Smith T, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer 
induces immunological and clinical responses. ClinCancer Res 2004; 10:4699-708. 
110. Homma S, Sagawa Y, Ito M, Ohno T, Toda G. Cancer immunotherapy using 
dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with 
better clinical responses. ClinExpImmunol 2006; 144:41-7. 
111. Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly 
immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. 
JImmunol 1998; 161:5516-24. 
112. van EA, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using 
anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage 
colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of 
subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. 
JExpMed 1999; 190:355-66. 
113. Li J, Holmes LM, Franek KJ, Burgin KE, Wagner TE, Wei Y. Purified hybrid cells from 
dendritic cell and tumor cell fusions are superior activators of antitumor immunity. 
Cancer ImmunolImmunother 2001; 50:456-62. 
114. Siders WM, Vergilis KL, Johnson C, Shields J, Kaplan JM. Induction of specific antitumor 
immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. 
MolTher 2003; 7:498-505. 
115. Prell RA, Gearin L, Simmons A, VanRoey M, Jooss K. The anti-tumor efficacy of a GM-
CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration. Cancer 
ImmunolImmunother 2006; 55:1285-93. 
116. Krause SW, Neumann C, Soruri A, Mayer S, Peters JH, Andreesen R. The treatment of 
patients with disseminated malignant melanoma by vaccination with autologous cell 
hybrids of tumor cells and dendritic cells. Journal of immunotherapy 2002; 25:421-8. 
117. Barbuto JA, Ensina LF, Neves AR, Bergami-Santos P, Leite KR, Marques R, Costa F, 
Martins SC, Camara-Lopes LH, Buzaid AC. Dendritic cell-tumor cell hybrid vaccination 
for metastatic cancer. Cancer ImmunolImmunother 2004; 53:1111-8. 
118. Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, Clift SM, 
Nooijen WJ, Weder P, van de Kasteele WF, et al. Immunogenicity, including vitiligo, and 
References 
221 
feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic 
melanoma patients. JClinOncol 2005; 23:8978-91. 
119. Hurn BA, Chantler SM. Production of reagent antibodies. Methods Enzymol 1980; 
70:104-42. 
120. Burchill MA, Tamburini BA, Pennock ND, White JT, Kurche JS, Kedl RM. T cell 
vaccinology: exploring the known unknowns. Vaccine 2013; 31:297-305. 
121. Hendriksen C HJ. Production of polyclonal and monoclonal antibodies Boca Raton, FL, 
USA: CRC Press, LLC, 2003. 
122. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of 
human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 
1999; 59:56-8. 
123. Widner LA, Teates CD. Distribution of gold Au 198 after intraperitoneal injection in 
animals. SouthMedJ 1975; 68:687-93. 
124. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor SP, Svane IM. Review of clinical 
studies on dendritic cell-based vaccination of patients with malignant melanoma: 
assessment of correlation between clinical response and vaccine parameters. Cancer 
ImmunolImmunother 2009; 58:1-14. 
125. Kjaergaard J, Shimizu K, Shu S. Electrofusion of syngeneic dendritic cells and tumor 
generates potent therapeutic vaccine. Cell Immunol 2003; 225:65-74. 
126. Draube A, Klein-Gonzalez N, Mattheus S, Brillant C, Hellmich M, Engert A, von 
Bergwelt-Baildon M. Dendritic cell based tumor vaccination in prostate and renal cell 
cancer: a systematic review and meta-analysis. PLoSOne 2011; 6:e18801. 
127. Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, Cohen PA, Koski G, 
Czerniecki BJ. Intranodal administration of peptide-pulsed mature dendritic cell vaccines 
results in superior CD8+ T-cell function in melanoma patients. JClinOncol 2003; 
21:3826-35. 
128. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, Oyen 
WJ, Bonenkamp JJ, Boezeman JB, Adema GJ, et al. Magnetic resonance tracking of 
dendritic cells in melanoma patients for monitoring of cellular therapy. NatBiotechnol 
2005; 23:1407-13. 
129. Korbelik M, Stott B, Sun J. Photodynamic therapy-generated vaccines: relevance of 
tumour cell death expression. BrJCancer 2007; 97:1381-7. 
130. Ohlfest JR, Andersen BM, Litterman AJ, Xia J, Pennell CA, Swier LE, Salazar AM, Olin 
MR. Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells 
primed as a function of proximity to the tumor in a murine glioma model. JImmunol 
2013; 190:613-20. 
131. Ali OA, Emerich D, Dranoff G, Mooney DJ. In situ regulation of DC subsets and T cells 
mediates tumor regression in mice. SciTranslMed 2009; 1:8ra19. 
References 
222 
132. Wick DA, Martin SD, Nelson BH, Webb JR. Profound CD8+ T cell immunity elicited by 
sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). 
Vaccine 2011; 29:984-93. 
133. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, Zinkernagel 
R, Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG 
oligodeoxynucleotide administration. NatMed 2004; 10:187-92. 
134. Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E. Targeting costimulatory 
molecules to improve antitumor immunity. JBiomedBiotechnol 2012; 2012:926321. 
135. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. 
NatRevCancer 2012; 12:252-64. 
136. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of 
cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, 
induces the maturation of immunostimulatory dendritic cells. JExpMed 2000; 191:423-
34. 
137. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer 
vaccines and cellular immunotherapy. JClinOncol 2003; 21:2415-32. 
138. Balwit JM, Hwu P, Urba WJ, Marincola FM. The iSBTc/SITC primer on tumor 
immunology and biological therapy of cancer: a summary of the 2010 program. 
JTranslMed 2011; 9:18. 
139. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, 
Greeley NR, Nitti G, Peng W, et al. Persistent antigen at vaccination sites induces tumor-
specific CD8(+) T cell sequestration, dysfunction and deletion. NatMed 2013; 19:465-72. 
140. Song J, Salek-Ardakani S, Rogers PR, Cheng M, Van PL, Croft M. The costimulation-
regulated duration of PKB activation controls T cell longevity. NatImmunol 2004; 5:150-
8. 
141. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. 
Molecular characteristics of immunogenic cancer cell death. Cell DeathDiffer 2008; 15:3-
12. 
142. Vacchelli E, Galluzzi L, Rousseau V, Rigoni A, Tesniere A, Delahaye N, Schlemmer FD, 
Menger L, Sukkurwala AQ, Adjemian S, et al. Loss-of-function alleles of P2RX7 and 
TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. 
Oncoimmunology 2012; 1:271-8. 
143. Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L. Immunogenicity of 
anthracyclines: moving towards more personalized medicine. Trends MolMed 2008; 
14:141-51. 
144. Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour 
immunogenicity. NatRevCancer 2012; 12:307-13. 
145. Schlom J, Gulley JL, Arlen PM. Paradigm shifts in cancer vaccine therapy. 
ExpBiolMed(Maywood) 2008; 233:522-34. 
References 
223 
146. Chuang TF, Lee SC, Liao KW, Hsiao YW, Lo CH, Chiang BL, Lin XZ, Tao MH, Chu RM. 
Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model. 
International journal of cancer Journal international du cancer 2009; 125:698-707. 
147. Finocchiaro LM, Fondello C, Gil-Cardeza ML, Rossi UA, Villaverde MS, Riveros MD, 
Glikin GC. Cytokine-Enhanced Vaccine and Interferon-beta plus Suicide Gene Therapy 
as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma. Human gene 
therapy 2015; 26:367-76. 
148. Marconato L, Frayssinet P, Rouquet N, Comazzi S, Leone VF, Laganga P, Rossi F, Vignoli 
M, Pezzoli L, Aresu L. Randomized, placebo-controlled, double-blinded 
chemoimmunotherapy clinical trial in a pet dog model of diffuse large B-cell lymphoma. 
Clinical cancer research : an official journal of the American Association for Cancer 
Research 2014; 20:668-77. 
149. Gavazza A, Lubas G, Fridman A, Peruzzi D, Impellizeri JA, Luberto L, Marra E, Roscilli 
G, Ciliberto G, Aurisicchio L. Safety and efficacy of a genetic vaccine targeting telomerase 
plus chemotherapy for the therapy of canine B-cell lymphoma. Human gene therapy 
2013; 24:728-38. 
150. Boston SE, Lu X, Culp WT, Montinaro V, Romanelli G, Dudley RM, Liptak JM, 
Mestrinho LA, Buracco P. Efficacy of systemic adjuvant therapies administered to dogs 
after excision of oral malignant melanomas: 151 cases (2001-2012). Journal of the 
American Veterinary Medical Association 2014; 245:401-7. 
151. Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Keller ET, Yang NS, 
MacEwen EG. Development of human granulocyte-macrophage colony-stimulating 
factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. 
HumGene Ther 1998; 9:1851-61. 
152. Gyorffy S, Rodriguez-Lecompte JC, Woods JP, Foley R, Kruth S, Liaw PC, Gauldie J. 
Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring 
melanoma by using human gp100 antigen. Journal of veterinary internal medicine / 
American College of Veterinary Internal Medicine 2005; 19:56-63. 
153. Alexander AN, Huelsmeyer MK, Mitzey A, Dubielzig RR, Kurzman ID, Macewen EG, 
Vail DM. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic 
gp100 and its implementation in a phase II clinical trial in canine patients with malignant 
melanoma. Cancer immunology, immunotherapy : CII 2006; 55:433-42. 
154. Finocchiaro LM, Fiszman GL, Karara AL, Glikin GC. Suicide gene and cytokines 
combined nonviral gene therapy for spontaneous canine melanoma. Cancer Gene Ther 
2008; 15:165-72. 
155. Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S, Hess PR, 
Jankowski MK, Jones PD, Leibman NF, et al. Safety and efficacy of a xenogeneic DNA 
vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant 
melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 2011; 
72:1631-8. 
References 
224 
156. Manley CA, Leibman NF, Wolchok JD, Riviere IC, Bartido S, Craft DM, Bergman PJ. 
Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. 
Journal of veterinary internal medicine / American College of Veterinary Internal 
Medicine 2011; 25:94-9. 
157. Jeglum KA, Young KM, Barnsley K, Whereat A. Chemotherapy versus chemotherapy 
with intralymphatic tumor cell vaccine in canine lymphoma. Cancer 1988; 61:2042-50. 
158. Turek MM, Thamm DH, Mitzey A, Kurzman ID, Huelsmeyer MK, Dubielzig RR, Vail 
DM. Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid 
complexed autologous tumour cell vaccination in the treatment of canine B-cell 
multicentric lymphoma. Veterinary and comparative oncology 2007; 5:219-31. 
159. Lawman M, Eidizadeh, S., Selmon, C., Kane, C., Xigacos, L., Kaufman, L., Shaw, N., 
Lawman, P. Anti-tumor response induced by autologous cancer vaccine in canine 
lymphoma. Cancer Therapy 2008; 6:14. 
160. Peruzzi D, Gavazza A, Mesiti G, Lubas G, Scarselli E, Conforti A, Bendtsen C, Ciliberto 
G, La Monica N, Aurisicchio L. A vaccine targeting telomerase enhances survival of dogs 
affected by B-cell lymphoma. Molecular therapy : the journal of the American Society of 
Gene Therapy 2010; 18:1559-67. 
161. Henson MS, Curtsinger JM, Larson VS, Klausner JS, Modiano JF, Mescher MF, Miller JS. 
Immunotherapy with autologous tumour antigen-coated microbeads (large multivalent 
immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma. Veterinary 
and comparative oncology 2011; 9:95-105. 
162. Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, Vonderheide RH, Mason NJ. 
CD40-activated B cell cancer vaccine improves second clinical remission and survival in 
privately owned dogs with non-Hodgkin's lymphoma. PloS one 2011; 6:e24167. 
163. U'Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW. Evaluation of a novel tumor 
vaccine in dogs with hemangiosarcoma. Journal of veterinary internal medicine / 
American College of Veterinary Internal Medicine 2007; 21:113-20. 
164. Mito K, Sugiura K, Ueda K, Hori T, Akazawa T, Yamate J, Nakagawa H, Hatoya S, Inaba 
M, Inoue N, et al. IFN{gamma} markedly cooperates with intratumoral dendritic cell 
vaccine in dog tumor models. Cancer research 2010; 70:7093-101. 
165. Finocchiaro LM, Villaverde MS, Gil-Cardeza ML, Riveros MD, Glikin GC. Cytokine-
enhanced vaccine and interferon-beta plus suicide gene as combined therapy for 
spontaneous canine sarcomas. Research in veterinary science 2011; 91:230-4. 
166. Weir C, Hudson AL, Moon E, Ross A, Alexander M, Peters L, Langova V, Clarke SJ, 
Pavlakis N, Davey R, et al. Streptavidin: a novel immunostimulant for the selection and 
delivery of autologous and syngeneic tumor vaccines. Cancer immunology research 2014; 
2:469-79. 
167. Kamstock D, Elmslie R, Thamm D, Dow S. Evaluation of a xenogeneic VEGF vaccine in 
dogs with soft tissue sarcoma. Cancer immunology, immunotherapy : CII 2007; 56:1299-
309. 
References 
225 
168. Epple LM, Bemis LT, Cavanaugh RP, Skope A, Mayer-Sonnenfeld T, Frank C, Olver CS, 
Lencioni AM, Dusto NL, Tal A, et al. Prolonged remission of advanced bronchoalveolar 
adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell 
lysate (CRCL) vaccine. International journal of hyperthermia : the official journal of 
European Society for Hyperthermic Oncology, North American Hyperthermia Group 
2013; 29:390-8. 
169. Andersen BM, Pluhar GE, Seiler CE, Goulart MR, SantaCruz KS, Schutten MM, Meints 
JP, O'Sullivan MG, Bentley RT, Packer RA, et al. Vaccination for invasive canine 
meningioma induces in situ production of antibodies capable of antibody-dependent cell-
mediated cytotoxicity. Cancer research 2013; 73:2987-97. 
170. Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annual review 
of immunology 2015; 33:445-74. 
171. Liu Y, Zeng G. Cancer and innate immune system interactions: translational potentials 
for cancer immunotherapy. Journal of immunotherapy 2012; 35:299-308. 
172. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor 
microenvironment. Nature immunology 2013; 14:1014-22. 
173. Al-Shibli K, Al-Saad S, Donnem T, Persson M, Bremnes RM, Busund LT. The prognostic 
value of intraepithelial and stromal innate immune system cells in non-small cell lung 
carcinoma. Histopathology 2009; 55:301-12. 
174. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant 
diseases. Cellular & molecular immunology 2013; 10:230-52. 
175. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. 
Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 
priming. Nature immunology 2004; 5:1260-5. 
176. Mocikat R, Braumuller H, Gumy A, Egeter O, Ziegler H, Reusch U, Bubeck A, Louis J, 
Mailhammer R, Riethmuller G, et al. Natural killer cells activated by MHC class I(low) 
targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003; 
19:561-9. 
177. Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H, Smyth MJ. Induction of 
tumor-specific T cell memory by NK cell-mediated tumor rejection. Nature immunology 
2002; 3:83-90. 
178. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, 
Moreno M. The prognostic significance of intratumoral natural killer cells in patients 
with colorectal carcinoma. Cancer 1997; 79:2320-8. 
179. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S, 
Aikou T. Prognostic value of intratumoral natural killer cells in gastric carcinoma. 
Cancer 2000; 88:577-83. 
180. Nierkens S, Tel J, Janssen E, Adema GJ. Antigen cross-presentation by dendritic cell 
subsets: one general or all sergeants? Trends Immunol 2013; 34:361-70. 
References 
226 
181. Mantovani A. Macrophages, Neutrophils, and Cancer: A Double Edged Sword. New 
Journal of Science 2014:14. 
182. Ryan JJ, Morales JK, Falanga YT, Fernando JF, Macey MR. Mast cell regulation of the 
immune response. The World Allergy Organization journal 2009; 2:224-32. 
183. St John AL, Abraham SN. Innate immunity and its regulation by mast cells. Journal of 
immunology 2013; 190:4458-63. 
184. Heijmans J, Buller NV, Muncan V, van den Brink GR. Role of mast cells in colorectal 
cancer development, the jury is still out. Biochimica et biophysica acta 2012; 1822:9-13. 
185. Gatault S, Legrand F, Delbeke M, Loiseau S, Capron M. Involvement of eosinophils in the 
anti-tumor response. Cancer immunology, immunotherapy : CII 2012; 61:1527-34. 
186. Schneider E, Thieblemont N, De Moraes ML, Dy M. Basophils: new players in the 
cytokine network. European cytokine network 2010; 21:142-53. 
187. Galoppin L, Noirot C, Wastiaux JP, Scheinmann P, Paupe J, Burtin C. Comparison 
between number of basophils, blood histamine, and histamine release in cancer and 
noncancer patients. The Journal of allergy and clinical immunology 1989; 84:501-6. 
188. Falcone FH, Haas H, Gibbs BF. The human basophil: a new appreciation of its role in 
immune responses. Blood 2000; 96:4028-38. 
189. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, 
Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the 
immunogenicity of cancer cell death. NatMed 2007; 13:54-61. 
190. Zitvogel L, Kroemer G. Introduction: the immune response against dying cells. 
CurrOpinImmunol 2008; 20:501-3. 
191. Zafirova B, Wensveen FM, Gulin M, Polic B. Regulation of immune cell function and 
differentiation by the NKG2D receptor. Cell MolLife Sci 2011; 68:3519-29. 
192. la Sala A, Ferrari D, Corinti S, Cavani A, Di VF, Girolomoni G. Extracellular ATP 
induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 
responses. JImmunol 2001; 166:1611-7. 
193. Walport MJ. Complement. First of two parts. The New England journal of medicine 
2001; 344:1058-66. 
194. Markiewski MM, Lambris JD. Is complement good or bad for cancer patients? A new 
perspective on an old dilemma. Trends in immunology 2009; 30:286-92. 
195. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014; 
157:121-41. 
196. Rogge L, Papi A, Presky DH, Biffi M, Minetti LJ, Miotto D, Agostini C, Semenzato G, 
Fabbri LM, Sinigaglia F. Antibodies to the IL-12 receptor beta 2 chain mark human Th1 
but not Th2 cells in vitro and in vivo. Journal of immunology 1999; 162:3926-32. 
References 
227 
197. Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J, Kulig P, Becher 
B. New insights into IL-12-mediated tumor suppression. Cell death and differentiation 
2015; 22:237-46. 
198. Gerber SA, Moran JP, Frelinger JG, Frelinger JA, Fenton BM, Lord EM. Mechanism of 
IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-
tissue mounts. British journal of cancer 2003; 88:1453-61. 
199. Sorensen EW, Gerber SA, Frelinger JG, Lord EM. IL-12 suppresses vascular endothelial 
growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-
dependent mechanisms. Journal of immunology 2010; 184:1858-66. 
200. Perussia B, Chan SH, D'Andrea A, Tsuji K, Santoli D, Pospisil M, Young D, Wolf SF, 
Trinchieri G. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects 
on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK 
cells. Journal of immunology 1992; 149:3495-502. 
201. Salcedo TW, Azzoni L, Wolf SF, Perussia B. Modulation of perforin and granzyme 
messenger RNA expression in human natural killer cells. Journal of immunology 1993; 
151:2511-20. 
202. Aste-Amezaga M, D'Andrea A, Kubin M, Trinchieri G. Cooperation of natural killer cell 
stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and 
cytotoxic cell-associated molecules in human T and NK cells. Cellular immunology 1994; 
156:480-92. 
203. Chowdhury FZ, Ramos HJ, Davis LS, Forman J, Farrar JD. IL-12 selectively programs 
effector pathways that are stably expressed in human CD8+ effector memory T cells in 
vivo. Blood 2011; 118:3890-900. 
204. Schmitt N, Bustamante J, Bourdery L, Bentebibel SE, Boisson-Dupuis S, Hamlin F, Tran 
MV, Blankenship D, Pascual V, Savino DA, et al. IL-12 receptor beta1 deficiency alters in 
vivo T follicular helper cell response in humans. Blood 2013; 121:3375-85. 
205. Cao X, Leonard K, Collins LI, Cai SF, Mayer JC, Payton JE, Walter MJ, Piwnica-Worms 
D, Schreiber RD, Ley TJ. Interleukin 12 stimulates IFN-gamma-mediated inhibition of 
tumor-induced regulatory T-cell proliferation and enhances tumor clearance. Cancer Res 
2009; 69:8700-9. 
206. Prochazkova J, Pokorna K, Holan V. IL-12 inhibits the TGF-beta-dependent T cell 
developmental programs and skews the TGF-beta-induced differentiation into a Th1-like 
direction. Immunobiology 2012; 217:74-82. 
207. Steding CE, Wu ST, Zhang Y, Jeng MH, Elzey BD, Kao C. The role of interleukin-12 on 
modulating myeloid-derived suppressor cells, increasing overall survival and reducing 
metastasis. Immunology 2011; 133:221-38. 
208. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. 
Interleukin-12: biological properties and clinical application. Clinical cancer research : an 
official journal of the American Association for Cancer Research 2007; 13:4677-85. 
References 
228 
209. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is 
mediated by the interferon-inducible protein 10. Blood 1996; 87:3877-82. 
210. Dias S, Boyd R, Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer 
model. International journal of cancer Journal international du cancer 1998; 78:361-5. 
211. Kanegane C, Sgadari C, Kanegane H, Teruya-Feldstein J, Yao L, Gupta G, Farber JM, Liao 
F, Liu L, Tosato G. Contribution of the CXC chemokines IP-10 and Mig to the antitumor 
effects of IL-12. Journal of leukocyte biology 1998; 64:384-92. 
212. Mitola S, Strasly M, Prato M, Ghia P, Bussolino F. IL-12 regulates an endothelial cell-
lymphocyte network: effect on metalloproteinase-9 production. Journal of immunology 
2003; 171:3725-33. 
213. Car BD, Eng VM, Lipman JM, Anderson TD. The toxicology of interleukin-12: a review. 
Toxicologic pathology 1999; 27:58-63. 
214. Cemazar M, Jarm T, Sersa G. Cancer electrogene therapy with interleukin-12. Current 
gene therapy 2010; 10:300-11. 
215. Rosazza C, Buntz A, Riess T, Woll D, Zumbusch A, Rols MP. Intracellular tracking of 
single-plasmid DNA particles after delivery by electroporation. Molecular therapy : the 
journal of the American Society of Gene Therapy 2013; 21:2217-26. 
216. Prud'homme GJ, Glinka Y, Khan AS, Draghia-Akli R. Electroporation-enhanced nonviral 
gene transfer for the prevention or treatment of immunological, endocrine and neoplastic 
diseases. Current gene therapy 2006; 6:243-73. 
217. Cutrera J, Torrero M, Shiomitsu K, Mauldin N, Li S. Intratumoral bleomycin and IL-12 
electrochemogenetherapy for treating head and neck tumors in dogs. Methods in 
molecular biology 2008; 423:319-25. 
218. Pavlin D, Cemazar M, Sersa G, Tozon N. IL-12 based gene therapy in veterinary 
medicine. Journal of translational medicine 2012; 10:234. 
219. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan 
DM, Ugen KE, Messina JL, et al. Phase I trial of interleukin-12 plasmid electroporation in 
patients with metastatic melanoma. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 2008; 26:5896-903. 
220. Reed SD, Fulmer A, Buckholz J, Zhang B, Cutrera J, Shiomitsu K, Li S. 
Bleomycin/interleukin-12 electrochemogenetherapy for treating naturally occurring 
spontaneous neoplasms in dogs. Cancer gene therapy 2010; 17:571-8. 
221. Pavlin D, Cemazar M, Cor A, Sersa G, Pogacnik A, Tozon N. Electrogene therapy with 
interleukin-12 in canine mast cell tumors. Radiology and oncology 2011; 45:31-9. 
222. Cutrera J, King G, Jones P, Kicenuik K, Gumpel E, Xia X, Li S. Safety and efficacy of 
tumor-targeted interleukin 12 gene therapy in treated and non-treated, metastatic lesions. 
Current gene therapy 2015; 15:44-54. 
223. Heinzerling L, Burg G, Dummer R, Maier T, Oberholzer PA, Schultz J, Elzaouk L, 
Pavlovic J, Moelling K. Intratumoral injection of DNA encoding human interleukin 12 
References 
229 
into patients with metastatic melanoma: clinical efficacy. Human gene therapy 2005; 
16:35-48. 
224. Cutrera J, King G, Jones P, Kicenuik K, Gumpel E, Xia X, Li S. Safe and effective 
treatment of spontaneous neoplasms with interleukin 12 electro-chemo-gene therapy. 
Journal of cellular and molecular medicine 2015; 19:664-75. 
225. Cemazar M SG, Pavlin D, Tozon N. Intramuscular IL-12 Electrogene Therapy for 
Treatment of Spontaneous Canine Tumors. Intech, 2011. 
226. Pavlin D, Tozon N, Sersa G, Pogacnik A, Cemazar M. Efficient electrotransfection into 
canine muscle. Technology in cancer research & treatment 2008; 7:45-54. 
227. Paoloni M, Mazcko C, Selting K, Lana S, Barber L, Phillips J, Skorupski K, Vail D, Wilson 
H, Biller B, et al. Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-
IL12 Immunocytokine in Dogs with Malignant Melanoma. PloS one 2015; 10:e0129954. 
228. Heller L, Merkler K, Westover J, Cruz Y, Coppola D, Benson K, Daud A, Heller R. 
Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a 
B16 mouse melanoma model. Clinical cancer research : an official journal of the 
American Association for Cancer Research 2006; 12:3177-83. 
229. Reed SD, Li S. Pre-clinical toxicity assessment of tumor-targeted interleukin-12 low-
intensity electrogenetherapy. Cancer gene therapy 2011; 18:265-74. 
230. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, 
Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in 
solid tumors: immune-related response criteria. Clinical cancer research : an official 
journal of the American Association for Cancer Research 2009; 15:7412-20. 
231. Phillips BS, Padilla ML, Dickerson EB, Lindstrom MJ, Helfand SC. Immunostimulatory 
effects of human recombinant interleukin-12 on peripheral blood mononuclear cells 
from normal dogs. Vet Immunol Immunopathol 1999; 70:189-201. 
232. Yano K, Ide K, Momoi Y, Yamazoe K, Kudo T. Enhancement of reactive oxygen species 
production from canine blood leukocytes by human recombinant interleukin-12. Vet 
Immunol Immunopathol 2003; 93:1-8. 
233. Cemazar M, Sersa G, Wilson J, Tozer GM, Hart SL, Grosel A, Dachs GU. Effective gene 
transfer to solid tumors using different nonviral gene delivery techniques: 
electroporation, liposomes, and integrin-targeted vector. Cancer gene therapy 2002; 
9:399-406. 
234. Li S, Zhang L, Torrero M, Cannon M, Barret R. Administration route- and immune cell 
activation-dependent tumor eradication by IL12 electrotransfer. Molecular therapy : the 
journal of the American Society of Gene Therapy 2005; 12:942-9. 
235. Cutrera J, King G, Jones P, Gumpel E, Xia X, Li S. Managing local swelling following 
intratumoral electro-chemo-gene therapy. Methods in molecular biology 2014; 1121:233-
9. 
References 
230 
236. Cemazar M, Ambrozic Avgustin J, Pavlin D, Sersa G, Poli A, Krhac Levacic A, Tesic N, 
Lampreht Tratar U, Rak M, Tozon N. Efficacy and safety of electrochemotherapy 
combined with peritumoral IL-12 gene electrotransfer of canine mast cell tumours. 
Veterinary and comparative oncology 2016. 
237. Avigan D, Rosenblatt J, Kufe D. Dendritic/tumor fusion cells as cancer vaccines. 
SeminOncol 2012; 39:287-95. 
238. Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, 
Mami-Chouaib F, Donnadieu E. Matrix architecture defines the preferential localization 
and migration of T cells into the stroma of human lung tumors. The Journal of clinical 
investigation 2012; 122:899-910. 
239. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta 
regulation of immune responses. Annual review of immunology 2006; 24:99-146. 
240. Bremnes RM, Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, Camps C, 
Marinez I, Busund LT. The role of tumor stroma in cancer progression and prognosis: 
emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. Journal of 
thoracic oncology : official publication of the International Association for the Study of 
Lung Cancer 2011; 6:209-17. 
241. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade 
expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 
melanoma tumors. Proceedings of the National Academy of Sciences of the United States 
of America 2010; 107:4275-80. 
242. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano 
DM, Vogel P, Liu CL, et al. Immune inhibitory molecules LAG-3 and PD-1 
synergistically regulate T-cell function to promote tumoral immune escape. Cancer 
research 2012; 72:917-27. 
243. Orloff M, Valsecchi ME, Sato T. Successes and setbacks of early investigational drugs for 
melanoma. Expert opinion on investigational drugs 2015; 24:993-7. 
244. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against 
cancer: a counterpoint. JLeukocBiol 2005; 78:1043-51. 
245. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. 
NatBiotechnol 2010; 28:1069-78. 
246. Pratap J, Akech J, Wixted JJ, Szabo G, Hussain S, McGee-Lawrence ME, Li X, Bedard K, 
Dhillon RJ, van Wijnen AJ, et al. The histone deacetylase inhibitor, vorinostat, reduces 
tumor growth at the metastatic bone site and associated osteolysis, but promotes normal 
bone loss. MolCancer Ther 2010; 9:3210-20. 
247. Yong X, Xiao YF, Luo G, He B, Lu MH, Hu CJ, Guo H, Yang SM. Strategies for 
enhancing vaccine-induced CTL antitumor immune responses. JBiomedBiotechnol 2012; 
2012:605045. 
References 
231 
248. Velasco-Velazquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, Pestell 
RG. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 2012; 
72:3839-50. 
249. Postow M, Callahan MK, Wolchok JD. Beyond cancer vaccines: a reason for future 
optimism with immunomodulatory therapy. Cancer J 2011; 17:372-8. 
250. Torabi-Rahvar M, Bozorgmehr M, Jeddi-Tehrani M, Zarnani AH. Potentiation strategies 
of dendritic cell-based antitumor vaccines: combinational therapy takes the front seat. 
Drug DiscovToday 2011; 16:733-40. 
251. Schlom J. Therapeutic cancer vaccines: current status and moving forward. JNatlCancer 
Inst 2012; 104:599-613. 
252. Liu Y, Zeng B, Zhang Z, Zhang Y, Yang R. B7-H1 on myeloid-derived suppressor cells in 
immune suppression by a mouse model of ovarian cancer. ClinImmunol 2008; 129:471-
81. 
253. Ko HJ, Lee JM, Kim YJ, Kim YS, Lee KA, Kang CY. Immunosuppressive myeloid-derived 
suppressor cells can be converted into immunogenic APCs with the help of activated 
NKT cells: an alternative cell-based antitumor vaccine. JImmunol 2009; 182:1818-28. 
254. Munder M. Arginase: an emerging key player in the mammalian immune system. 
BrJPharmacol 2009; 158:638-51. 
255. Morris SM, Jr. Recent advances in arginine metabolism: roles and regulation of the 
arginases. BrJPharmacol 2009; 157:922-30. 
256. Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, Ismail-Khan R, Minton 
S, Vahanian NN, Link C, et al. A first in man phase I trial of the oral immunomodulator, 
indoximod, combined with docetaxel in patients with metastatic solid tumors. 
Oncotarget 2014; 5:8136-46. 
257. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer 
vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. 
Cancer ImmunolImmunother 2008; 57:1569-77. 
258. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and 
natural killer T cells in cancer. NatRevImmunol 2012; 12:239-52. 
259. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, 
inflammation and cancer. NatRevCancer 2010; 10:561-74. 
260. Kameshima H, Tsuruma T, Kutomi G, Shima H, Iwayama Y, Kimura Y, Imamura M, 
Torigoe T, Takahashi A, Hirohashi Y, et al. Immunotherapeutic benefit of alpha-
interferon (IFNalpha) in survivin2B-derived peptide vaccination for advanced pancreatic 
cancer patients. Cancer Sci 2013; 104:124-9. 
261. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia 
D, Kowolik CM, Xin H, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 
signaling and oncogenesis in solid tumors. Cancer Cell 2009; 16:487-97. 
References 
232 
262. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there 
yet? ImmunolRev 2011; 239:27-44. 
263. Nars MS, Kaneno R. Immunomodulatory effects of low dose chemotherapy and 
perspectives of its combination with immunotherapy. International journal of cancer 
Journal international du cancer 2013; 132:2471-8. 
264. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of 
cytotoxic drugs can target tumor angiogenesis in mice. The Journal of clinical 
investigation 2000; 105:1045-7. 
265. Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B. Selective depletion of 
CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by 
reduced intracellular ATP levels. Cancer research 2010; 70:4850-8. 
266. Ghiringhelli F, Bruchard M, Apetoh L. Immune effects of 5-fluorouracil: Ambivalence 
matters. Oncoimmunology 2013; 2:e23139. 
267. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nature 
reviews Cancer 2004; 4:423-36. 
268. Ooyama A, Oka T, Zhao HY, Yamamoto M, Akiyama S, Fukushima M. Anti-angiogenic 
effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. Cancer 
letters 2008; 267:26-36. 
269. Romiti A, Cox MC, Sarcina I, Di Rocco R, D'Antonio C, Barucca V, Marchetti P. 
Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer 
chemotherapy and pharmacology 2013; 72:13-33. 
270. Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Low-dose metronomic 
chemotherapy: a systematic literature analysis. European journal of cancer 2013; 49:3387-
95. 
271. Zhang Q, Kang X, Zhao W. Antiangiogenic effect of low-dose cyclophosphamide 
combined with ginsenoside Rg3 on Lewis lung carcinoma. Biochemical and biophysical 
research communications 2006; 342:824-8. 
272. Scharovsky OG, Mainetti LE, Rozados VR. Metronomic chemotherapy: changing the 
paradigm that more is better. Current oncology 2009; 16:7-15. 
273. Lawler PR, Lawler J. Molecular basis for the regulation of angiogenesis by 
thrombospondin-1 and -2. Cold Spring Harbor perspectives in medicine 2012; 2:a006627. 
274. Kaur S, Chang T, Singh SP, Lim L, Mannan P, Garfield SH, Pendrak ML, Soto-Pantoja 
DR, Rosenberg AZ, Jin S, et al. CD47 signaling regulates the immunosuppressive activity 
of VEGF in T cells. Journal of immunology 2014; 193:3914-24. 
275. Rasmussen RM, Kurzman ID, Biller BJ, Guth A, Vail DM. Phase I lead-in and subsequent 
randomized trial assessing safety and modulation of regulatory T cell numbers following 
a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide 
combination chemotherapy protocol in tumour-bearing dogs. Veterinary and 
comparative oncology 2015. 
References 
233 
276. Schmidt A, Bolck B, Jedig M, Steinritz D, Balszuweit F, Kehe K, Bloch W. Nitrogen 
mustard (Chlorambucil) has a negative influence on early vascular development. 
Toxicology 2009; 263:32-40. 
277. Smith AN. Advances in veterinary oncology. The Veterinary clinics of North America 
Small animal practice 2014; 44:xi-xii. 
278. London CA, Gardner HL, Mathie T, Stingle N, Portela R, Pennell ML, Clifford CA, 
Rosenberg MP, Vail DM, Williams LE, et al. Impact of 
Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs 
with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: 
A Multi-Institutional Study. PloS one 2015; 10:e0124889. 
279. Burton JH, Mitchell L, Thamm DH, Dow SW, Biller BJ. Low-dose cyclophosphamide 
selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue 
sarcoma. Journal of veterinary internal medicine / American College of Veterinary 
Internal Medicine 2011; 25:920-6. 
280. Mitchell L, Thamm DH, Biller BJ. Clinical and immunomodulatory effects of toceranib 
combined with low-dose cyclophosphamide in dogs with cancer. Journal of veterinary 
internal medicine / American College of Veterinary Internal Medicine 2012; 26:355-62. 
281. Lana S, U'Ren L, Plaza S, Elmslie R, Gustafson D, Morley P, Dow S. Continuous low-dose 
oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. Journal of 
veterinary internal medicine / American College of Veterinary Internal Medicine 2007; 
21:764-9. 
282. Elmslie RE, Glawe P, Dow SW. Metronomic therapy with cyclophosphamide and 
piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft 
tissue sarcomas. Journal of veterinary internal medicine / American College of Veterinary 
Internal Medicine 2008; 22:1373-9. 
283. Tripp CD, Fidel J, Anderson CL, Patrick M, Pratt C, Sellon R, Bryan JN. Tolerability of 
metronomic administration of lomustine in dogs with cancer. Journal of veterinary 
internal medicine / American College of Veterinary Internal Medicine 2011; 25:278-84. 
284. Schrempp DR, Childress MO, Stewart JC, Leach TN, Tan KM, Abbo AH, de Gortari AE, 
Bonney PL, Knapp DW. Metronomic administration of chlorambucil for treatment of 
dogs with urinary bladder transitional cell carcinoma. Journal of the American 
Veterinary Medical Association 2013; 242:1534-8. 
285. Denies S, Cicchelero L, de Rooster H, Daminet S, Polis I, Van de Maele I, Sanders NN. 
Evaluation of regulatory T cells and angiogenic markers in canine cancer patients 
compared to a healthy control group and during metronomic chemotherapy. Accepted in 
Veterinary Comparative Oncology 2016. 
286. Biller B. Metronomic chemotherapy in veterinary patients with cancer: rethinking the 
targets and strategies of chemotherapy. The Veterinary clinics of North America Small 
animal practice 2014; 44:817-29. 
References 
234 
287. Pazdur R. Endpoints for assessing drug activity in clinical trials. The oncologist 2008; 13 
Suppl 2:19-21. 
288. Marchetti V, Giorgi M, Fioravanti A, Finotello R, Citi S, Canu B, Orlandi P, Di Desidero 
T, Danesi R, Bocci G. First-line metronomic chemotherapy in a metastatic model of 
spontaneous canine tumours: a pilot study. Investigational new drugs 2012; 30:1725-30. 
289. Cancedda S, Marconato L, Meier V, Laganga P, Roos M, Leone VF, Rossi F, Bley CR. 
Hypofractioned radiotherapy for macroscopic canine soft tissue sarcoma: a retrospective 
study of 50 cases teeated with a 5 x 6 Gy protocol with or without metronomic 
chemotherapy. Veterinary radiology & ultrasound : the official journal of the American 
College of Veterinary Radiology and the International Veterinary Radiology Association 
2015. 
290. Leach TN, Childress MO, Greene SN, Mohamed AS, Moore GE, Schrempp DR, Lahrman 
SR, Knapp DW. Prospective trial of metronomic chlorambucil chemotherapy in dogs 
with naturally occurring cancer. Veterinary and comparative oncology 2012; 10:102-12. 
291. DeVita VT, Jr., Chu E. A history of cancer chemotherapy. Cancer research 2008; 68:8643-
53. 
292. Glikin GC, Finocchiaro LM. Clinical trials of immunogene therapy for spontaneous 
tumors in companion animals. TheScientificWorldJournal 2014; 2014:718520. 
293. Denies S, Cicchelero L, Van Audenhove I, Sanders NN. Combination of interleukin-12 
gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all 
arms of the immune system towards tumor eradication. Journal of controlled release : 
official journal of the Controlled Release Society 2014; 187:175-82. 
294. Vermorken JB, Claessen AM, van TH, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, 
Bloemena E, Ransom JH, et al. Active specific immunotherapy for stage II and stage III 
human colon cancer: a randomised trial. Lancet 1999; 353:345-50. 
295. Raez LE, Cassileth PA, Schlesselman JJ, Sridhar K, Padmanabhan S, Fisher EZ, Baldie PA, 
Podack ER. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma 
cell line in patients with advanced non-small-cell lung cancer. JClinOncol 2004; 22:2800-
7. 
296. Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers 
Y, Sadelain M, Hohenhaus AE, et al. Long-term survival of dogs with advanced malignant 
melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. 
ClinCancer Res 2003; 9:1284-90. 
297. Serhal K, Baillou C, Ghinea N, Fontanges P, Dupuy FP, Lemoine FM, Lacave R. 
Characteristics of hybrid cells obtained by dendritic cell/tumour cell fusion in a T-47D 
breast cancer cell line model indicate their potential as anti-tumour vaccines. IntJOncol 
2007; 31:1357-65. 
298. Fry TJ, Shand JL, Milliron M, Tasian SK, Mackall CL. Antigen loading of DCs with 
irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to 
other approaches. Cancer ImmunolImmunother 2009; 58:1257-64. 
References 
235 
299. Kim TB, Park HK, Chang JH, Choi IH, Kim KH, Yoon SJ, Lee MS, Jung H, Kim CS. The 
establishment of dendritic cell-tumor fusion vaccines for hormone refractory prostate 
cancer cell. Korean JUrol 2010; 51:139-44. 
300. Inzkirweli N, Guckel B, Sohn C, Wallwiener D, Bastert G, Lindner M. Antigen loading of 
dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic 
cells or tumor lysates. Anticancer Res 2007; 27:2121-9. 
301. Van Impe K, Bethuyne J, Cool S, Impens F, Ruano-Gallego D, De WO, Vanloo B, Van 
TM, Lambein K, Boucherie C, et al. A nanobody targeting the F-actin capping protein 
CapG restrains breast cancer metastasis. Breast Cancer Res 2013; 15:R116. 
302. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G. An 
advanced culture method for generating large quantities of highly pure dendritic cells 
from mouse bone marrow. JImmunolMethods 1999; 223:77-92. 
303. Chien-Chun Pai T-FK, Simon J.T. Maoc, Tien-Fu Chuanga, Chen-Si Lina, Rea-Min Chu. 
Immunopathogenic behaviors of canine transmissible venereal tumor in dogs following 
an immunotherapy using dendritic/tumor cell hybrid. Veterinary Immunology and 
Immunopathology 2011; 139:187-99. 
304. Posner MR, Cavacini LA, Upton MP, Tillman KC, Gornstein ER, Norris CM, Jr. Surface 
membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the 
head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. 
ClinCancer Res 1999; 5:2261-70. 
305. Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T 
lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic 
cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based 
vaccination. Cancer ImmunolImmunother 2002; 51:299-310. 
306. Kao JY, Gong Y, Chen CM, Zheng QD, Chen JJ. Tumor-derived TGF-beta reduces the 
efficacy of dendritic cell/tumor fusion vaccine. JImmunol 2003; 170:3806-11. 
307. Golden EB, Pellicciotta I, Demaria S, Barcellos-Hoff MH, Formenti SC. The convergence 
of radiation and immunogenic cell death signaling pathways. Front Oncol 2012; 2:88. 
308. Kreis S, Philippidou D, Margue C, Behrmann I. IL-24: a classic cytokine and/or a 
potential cure for cancer? JCell MolMed 2008; 12:2505-10. 
309. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 
357:539-45. 
310. Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS, Niedobitek G. 
Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin 
lymphoma. HematolOncol 2009; 27:31-9. 
311. Lim DG, Bieganowska BK, Freeman GJ, Hafler DA. Examination of CD8+ T cell function 
in humans using MHC class I tetramers: similar cytotoxicity but variable proliferation 
and cytokine production among different clonal CD8+ T cells specific to a single viral 
epitope. JImmunol 2000; 165:6214-20. 
References 
236 
312. Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, 
Robert C, Prince HM, Grob JJ, et al. Analysis and characterization of antitumor T-cell 
response after administration of dendritic cells loaded with allogeneic tumor lysate to 
metastatic melanoma patients. JImmunother 2008; 31:101-12. 
313. Hayashi T, Tanaka H, Tanaka J, Wang R, Averbook BJ, Cohen PA, Shu S. 
Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by 
electrofusion. ClinImmunol 2002; 104:14-20. 
314. Lee WT, Shimizu K, Kuriyama H, Tanaka H, Kjaergaard J, Shu S. Tumor-dendritic cell 
fusion as a basis for cancer immunotherapy. OtolaryngolHead Neck Surg 2005; 132:755-
64. 
315. Wei YC, Sticca RP, Li J, Holmes LM, Burgin KE, Jakubchak S, Bouton-Verville H, 
Williamson J, Meyer K, Evans L, et al. Combined treatment of dendritoma vaccine and 
low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: 
A pilot study. OncolRep 2007; 18:665-71. 
316. Cho EI, Tan C, Koski GK, Cohen PA, Shu S, Lee WT. Toll-like receptor agonists as third 
signals for dendritic cell-tumor fusion vaccines. Head Neck 2010; 32:700-7. 
317. Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, Joyce RM, 
Wellenstein K, Keefe W, Schickler M, et al. PD-1 blockade by CT-011, anti-PD-1 
antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion 
vaccine. JImmunother 2011; 34:409-18. 
318. Vasir B, Wu Z, Crawford K, Rosenblatt J, Zarwan C, Bissonnette A, Kufe D, Avigan D. 
Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T 
cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-
CD3/CD28 promotes the expansion of activated tumor reactive cells. JImmunol 2008; 
181:808-21. 
319. Branham-O'Connor M, Li J, Kotturi HS, Yu X, Wagner TE, Wei Y. Fusion induced 
reversal of dendritic cell maturation: an altered expression of inflammatory chemokine 
and chemokine receptors in dendritomas. OncolRep 2010; 23:545-50. 
320. Asano K, Nabeyama A, Miyake Y, Qiu CH, Kurita A, Tomura M, Kanagawa O, Fujii S, 
Tanaka M. CD169-positive macrophages dominate antitumor immunity by 
crosspresenting dead cell-associated antigens. Immunity 2011; 34:85-95. 
321. Ewens A, Mihich E, Ehrke MJ. Distant metastasis from subcutaneously grown E0771 
medullary breast adenocarcinoma. Anticancer research 2005; 25:3905-15. 
322. Xing F, Wang J, Hu M, Yu Y, Chen G, Liu J. Comparison of immature and mature bone 
marrow-derived dendritic cells by atomic force microscopy. NanoscaleResLett 2011; 
6:455. 
323. Lassau N, Bonastre J, Kind M, Vilgrain V, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran 
A, Labbe-Devilliers C, et al. Validation of dynamic contrast-enhanced ultrasound in 
predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter 
References 
237 
support for innovative and expensive techniques study. Investigative radiology 2014; 
49:794-800. 
324. Stock E, Vanderperren K, Van der Vekens E, Haers H, Duchateau L, Polis I, Hesta M, 
Saunders JH. The effect of anesthesia with propofol and sedation with butorphanol on 
quantitative contrast-enhanced ultrasonography of the healthy feline kidney. Veterinary 
journal 2014; 202:637-9. 
325. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, 
Matthews N, Stewart A, Tarpey P, et al. Intratumor heterogeneity and branched evolution 
revealed by multiregion sequencing. The New England journal of medicine 2012; 
366:883-92. 
326. Veterinary cooperative oncology group - common terminology criteria for adverse events 
(VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs 
and cats v1.1. Veterinary and comparative oncology 2011. 
327. Portielje JE, Lamers CH, Kruit WH, Sparreboom A, Bolhuis RL, Stoter G, Huber C, 
Gratama JW. Repeated administrations of interleukin (IL)-12 are associated with 
persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis 
factor-alpha, IL-6, and IL-8 responses. Clinical cancer research : an official journal of the 
American Association for Cancer Research 2003; 9:76-83. 
328. van Herpen CM, van der Laak JA, de Vries IJ, van Krieken JH, de Wilde PC, Balvers MG, 
Adema GJ, De Mulder PH. Intratumoral recombinant human interleukin-12 
administration in head and neck squamous cell carcinoma patients modifies locoregional 
lymph node architecture and induces natural killer cell infiltration in the primary tumor. 
Clinical cancer research : an official journal of the American Association for Cancer 
Research 2005; 11:1899-909. 
329. Meyaard L, Hovenkamp E, Otto SA, Miedema F. IL-12-induced IL-10 production by 
human T cells as a negative feedback for IL-12-induced immune responses. Journal of 
immunology 1996; 156:2776-82. 
330. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 
10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing 
natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. The Journal of 
experimental medicine 1993; 178:1041-8. 
331. Le HN, Lee NC, Tsung K, Norton JA. Pre-existing tumor-sensitized T cells are essential 
for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12. Journal 
of immunology 2001; 167:6765-72. 
332. Allavena P, Paganin C, Zhou D, Bianchi G, Sozzani S, Mantovani A. Interleukin-12 is 
chemotactic for natural killer cells and stimulates their interaction with vascular 
endothelium. Blood 1994; 84:2261-8. 
333. Lucas ML, Heller L, Coppola D, Heller R. IL-12 plasmid delivery by in vivo 
electroporation for the successful treatment of established subcutaneous B16.F10 
References 
238 
melanoma. Molecular therapy : the journal of the American Society of Gene Therapy 
2002; 5:668-75. 
334. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ. 
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need 
for prior conditioning. Blood 2012; 119:4133-41. 
335. Kilinc MO, Aulakh KS, Nair RE, Jones SA, Alard P, Kosiewicz MM, Egilmez NK. 
Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-
associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration 
of CD8+ T effectors. Journal of immunology 2006; 177:6962-73. 
336. Muller JM, Wissemann J, Meli ML, Dasen G, Lutz H, Heinzerling L, Feige K. In vivo 
induction of interferon gamma expression in grey horses with metastatic melanoma 
resulting from direct injection of plasmid DNA coding for equine interleukin 12. 
Schweizer Archiv fur Tierheilkunde 2011; 153:509-13. 
337. Kichaev G, Mendoza JM, Amante D, Smith TR, McCoy JR, Sardesai NY, Broderick KE. 
Electroporation mediated DNA vaccination directly to a mucosal surface results in 
improved immune responses. Human vaccines & immunotherapeutics 2013; 9:2041-8. 
338. Koblish HK, Hunter CA, Wysocka M, Trinchieri G, Lee WM. Immune suppression by 
recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide 
synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 
vaccine adjuvant effect. The Journal of experimental medicine 1998; 188:1603-10. 
339. Welden B, Gates G, Mallari R, Garrett N. Effects of anesthetics and analgesics on natural 
killer cell activity. AANA journal 2009; 77:287-92. 
340. Desai BB, Quinn PM, Wolitzky AG, Mongini PK, Chizzonite R, Gately MK. IL-12 
receptor. II. Distribution and regulation of receptor expression. Journal of immunology 
1992; 148:3125-32. 
341. Nutku E, Zhuang Q, Soussi-Gounni A, Aris F, Mazer BD, Hamid Q. Functional 
expression of IL-12 receptor by human eosinophils: IL-12 promotes eosinophil apoptosis. 
Journal of immunology 2001; 167:1039-46. 
342. Yamaguchi T, Kimura H, Kurabayashi M, Kozawa K, Kato M. Interferon-gamma 
enhances human eosinophil effector functions induced by granulocyte-macrophage 
colony-stimulating factor or interleukin-5. Immunology letters 2008; 118:88-95. 
343. Means RT, Jr., Dessypris EN, Krantz SB. Inhibition of human erythroid colony-forming 
units by interleukin-1 is mediated by gamma interferon. Journal of cellular physiology 
1992; 150:59-64. 
344. Mullarky IK, Szaba FM, Kummer LW, Wilhelm LB, Parent MA, Johnson LL, Smiley ST. 
Gamma interferon suppresses erythropoiesis via interleukin-15. Infection and immunity 
2007; 75:2630-3. 
345. Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, Schild HH. 
Dynamic breast MR imaging: are signal intensity time course data useful for differential 
diagnosis of enhancing lesions? Radiology 1999; 211:101-10. 
References 
239 
346. Paprottka PM, Rosspunt S, Ingrisch M, Cyran CC, Nikolaou K, Reiser MF, Mack B, Gires 
O, Clevert DA, Zengel P. Reducing tumor growth and angiogenesis using a triple therapy 
measured with Contrast-enhanced ultrasound (CEUS). BMC cancer 2015; 15:373. 
347. Li S, Zhang X, Xia X. Regression of tumor growth and induction of long-term antitumor 
memory by interleukin 12 electro-gene therapy. Journal of the National Cancer Institute 
2002; 94:762-8. 
348. Shibata MA, Ito Y, Morimoto J, Kusakabe K, Yoshinaka R, Otsuki Y. In vivo electrogene 
transfer of interleukin-12 inhibits tumor growth and lymph node and lung metastases in 
mouse mammary carcinomas. The journal of gene medicine 2006; 8:335-52. 
349. Buttner M, Belke-Louis G, Rziha HJ, McInnes C, Kaaden OR. Detection, cDNA cloning 
and sequencing of canine interleukin 12. Cytokine 1998; 10:241-8. 
350. Mine B, Delpierre I, Hassid S, De Witte O, Lubicz B. The role of interventional 
neuroradiology in the management of skull base tumours and related surgical 
complications. B-Ent 2011; 7 Suppl 17:61-6. 
351. Raison CL, Miller AH. Depression in cancer: new developments regarding diagnosis and 
treatment. Biological psychiatry 2003; 54:283-94. 
352. Elenkov IJ, Iezzoni DG, Daly A, Harris AG, Chrousos GP. Cytokine dysregulation, 
inflammation and well-being. Neuroimmunomodulation 2005; 12:255-69. 
353. Maverakis E, Goodarzi H, Wehrli LN, Ono Y, Garcia MS. The etiology of paraneoplastic 
autoimmunity. Clinical reviews in allergy & immunology 2012; 42:135-44. 
354. Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Advances in 
genetics 2005; 54:3-20. 
355. Blackburn GL. Metabolic considerations in management of surgical patients. The 
Surgical clinics of North America 2011; 91:467-80. 
356. Kalli C, Teoh WC, Leen E. Introduction of genes via sonoporation and electroporation. 
Advances in experimental medicine and biology 2014; 818:231-54. 
357. Qin L, Ding Y, Pahud DR, Chang E, Imperiale MJ, Bromberg JS. Promoter attenuation in 
gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene 
expression. Human gene therapy 1997; 8:2019-29. 
358. Gu T, Rowswell-Turner RB, Kilinc MO, Egilmez NK. Central role of IFNgamma-
indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor 
immunity. Cancer research 2010; 70:129-38. 
359. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic 
therapy. Science 2005; 307:58-62. 
360. Clarke JM, Hurwitz HI. Understanding and targeting resistance to anti-angiogenic 
therapies. Journal of gastrointestinal oncology 2013; 4:253-63. 
361. Sevko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, Umansky L, Ramacher M, 
Kato M, Schadendorf D, Baniyash M, et al. Cyclophosphamide promotes chronic 
References 
240 
inflammation-dependent immunosuppression and prevents antitumor response in 
melanoma. The Journal of investigative dermatology 2013; 133:1610-9. 
362. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, 
Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes 
CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage 
cancer patients. Cancer immunology, immunotherapy : CII 2007; 56:641-8. 
363. Bajetta E, Del Vecchio M, Mortarini R, Nadeau R, Rakhit A, Rimassa L, Fowst C, Borri A, 
Anichini A, Parmiani G. Pilot study of subcutaneous recombinant human interleukin 12 
in metastatic melanoma. Clinical cancer research : an official journal of the American 
Association for Cancer Research 1998; 4:75-85. 
364. Kitamiya E, Iwasaki T, Momoi Y. Molecular cloning of interleukin-12 receptor beta2 
chain and its expression in dogs. Vet Immunol Immunopathol 2005; 106:221-8. 
365. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of 
the vasculature for treatment of cancer and other diseases. Physiological reviews 2011; 
91:1071-121. 
366. Ganss R, Arnold B, Hammerling GJ. Mini-review: overcoming tumor-intrinsic resistance 
to immune effector function. European journal of immunology 2004; 34:2635-41. 
367. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ. Scheduling 
of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic 
outcome via vessel normalization. Clinical cancer research : an official journal of the 
American Association for Cancer Research 2007; 13:3395-402. 
368. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, 
Fukumura D, di Tomaso E, et al. Kinetics of vascular normalization by VEGFR2 blockade 
governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and 
matrix metalloproteinases. Cancer Cell 2004; 6:553-63. 
369. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of 
inhibition of vascular endothelial growth factor signaling on distribution of extravasated 
antibodies in tumors. Cancer research 2006; 66:1434-45. 
370. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, 
Kalluri R. Thrombospondin-1 associated with tumor microenvironment contributes to 
low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth 
suppression. Cancer research 2004; 64:1570-4. 
371. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the 
antiangiogenic effects of low-dose metronomic chemotherapy. Proceedings of the 
National Academy of Sciences of the United States of America 2003; 100:12917-22. 
372. Lawler J. The functions of thrombospondin-1 and-2. Current opinion in cell biology 
2000; 12:634-40. 
373. Weng TY, Huang SS, Yen MC, Lin CC, Chen YL, Lin CM, Chen WC, Wang CY, Chang 
JY, Lai MD. A novel cancer therapeutic using thrombospondin 1 in dendritic cells. 
References 
241 
Molecular therapy : the journal of the American Society of Gene Therapy 2014; 22:292-
302. 
374. Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet 
D, Demarzo AM, Netto GJ, et al. Cyclophosphamide augments antitumor immunity: 
studies in an autochthonous prostate cancer model. Cancer research 2009; 69:4309-18. 
375. Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, 
Simmons AD, Jooss K. Vascular endothelial growth factor blockade reduces intratumoral 
regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer 
immunotherapy. Clinical cancer research : an official journal of the American 
Association for Cancer Research 2006; 12:6808-16. 
376. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, Ferrara 
N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid 
cells. Nature biotechnology 2007; 25:911-20. 
377. Saraç F.  SF. Causes of High Bone Alkaline Phosphatase. Biotechnology & 
Biotechnological Equipment 2014; 21:194-7. 
378. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma 
generation and wound healing. The New England journal of medicine 1986; 315:1650-9. 
379. Iwasaki M, Yu WG, Uekusa Y, Nakajima C, Yang YF, Gao P, Wijesuriya R, Fujiwara H, 
Hamaoka T. Differential IL-12 responsiveness of T cells but not of NK cells from tumor-
bearing mice in IL-12-responsive versus -unresponsive tumor models. International 
immunology 2000; 12:701-9. 
380. Rogge L, Sinigaglia F. Early events controlling T-helper cell differentiation: the role of the 
IL-12 receptor. Chemical immunology 1997; 68:38-53. 
381. Szabo SJ, Dighe AS, Gubler U, Murphy KM. Regulation of the interleukin (IL)-12R beta 2 
subunit expression in developing T helper 1 (Th1) and Th2 cells. The Journal of 
experimental medicine 1997; 185:817-24. 
382. Sinigaglia F, D'Ambrosio D, Panina-Bordignon P, Rogge L. Regulation of the IL-12/IL-
12R axis: a critical step in T-helper cell differentiation and effector function. 
Immunological reviews 1999; 170:65-72. 
383. Zhao Z, Yu S, Fitzgerald DC, Elbehi M, Ciric B, Rostami AM, Zhang GX. IL-12R beta 2 
promotes the development of CD4+CD25+ regulatory T cells. Journal of immunology 
2008; 181:3870-6. 
384. Huang X, Wong MK, Yi H, Watkins S, Laird AD, Wolf SF, Gorelik E. Combined therapy 
of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of 
angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion 
protein. Cancer research 2002; 62:5727-35. 
385. Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, 
Hicklin DJ, Jaffee EM, Emens LA. A vascular endothelial growth factor receptor-2 
inhibitor enhances antitumor immunity through an immune-based mechanism. Clinical 
References 
242 
cancer research : an official journal of the American Association for Cancer Research 
2007; 13:3951-9. 
386. Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH, Rabie T, Kaden S, 
Grone HJ, Hammerling GJ, et al. Vascular normalization in Rgs5-deficient tumours 
promotes immune destruction. Nature 2008; 453:410-4. 
387. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. 
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the 
effectiveness of adoptive immunotherapy of cancer. Cancer research 2010; 70:6171-80. 
388. Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, Kerbel RS. Tumors that 
acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to 
maximum tolerated dose cyclophosphamide. Neoplasia 2011; 13:40-8. 
389. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor 
response to antiangiogenic therapy. Science 2002; 295:1526-8. 
390. Chambers JD, Neumann PJ. Listening to Provenge--what a costly cancer treatment says 
about future Medicare policy. The New England journal of medicine 2011; 364:1687-9. 
391. Company page Pet Biocell. http://www.petbiocell.de/en/pets/health-insurances-pay-
dendritic-cell-therapy. Accessed 2015/12/11.  
392. Cameron C. Cancer jab saves Scottie dog Flora from tumour. Edinburgh: Edinburgh 
News, 2015. http://www.edinburghnews.scotsman.com/news/cancer-jab-saves-scottie-
dog-flora-from-tumour-1-3925599. Accessed 2016/01/23. 
393. Aasi J, Abbott BP, Abbott R, Abbott T, Abernathy MR, Accadia T, Acernese F, Ackley K, 
Adams C, Adams T, et al. Improved upper limits on the stochastic gravitational-wave 
background from 2009-2010 LIGO and Virgo data. Physical review letters 2014; 
113:231101. 
394. Company page Affymetrix. 
http://www.affymetrix.com/catalog/prod660071/USB/Cancer+Cell+Isolation+Kit#1_1. 
Accessed 2015/12/11  
395. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, 
Dutcher JP, Vogelzang NJ, Ryan JL. Effects of single-dose interleukin-12 exposure on 
interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 
90:2541-8. 
396. Bergman PJ. Paraneoplastic syndromes. In: Withrow SJ, Vail D.M., Page L.P., ed. Small 
Animal Clinical Oncology. St. Louis, Missouri: Elsevier, 2013:83-9. 
397. Gaynor JS, Dunlop CI, Wagner AE, Wertz EM, Golden AE, Demme WC. Complications 
and mortality associated with anesthesia in dogs and cats. Journal of the American 
Animal Hospital Association 1999; 35:13-7. 
398. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le 
D, Sugar E, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting 
tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic 
References 
243 
pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clinical 
cancer research : an official journal of the American Association for Cancer Research 
2008; 14:1455-63. 
399. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary 
MM, Biedrzycki B, Wolff AC, et al. Timed sequential treatment with cyclophosphamide, 
doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-
secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and 
immune activation. Journal of clinical oncology : official journal of the American Society 
of Clinical Oncology 2009; 27:5911-8. 
400. Kirner A, Mayer-Mokler A, Reinhardt C. IMA901: a multi-peptide cancer vaccine for 
treatment of renal cell cancer. Human vaccines & immunotherapeutics 2014; 10:3179-89. 
401. Wehland M, Bauer J, Magnusson NE, Infanger M, Grimm D. Biomarkers for anti-
angiogenic therapy in cancer. International journal of molecular sciences 2013; 14:9338-
64. 
402. van Duikeren S, Fransen MF, Redeker A, Wieles B, Platenburg G, Krebber WJ, 
Ossendorp F, Melief CJ, Arens R. Vaccine-induced effector-memory CD8+ T cell 
responses predict therapeutic efficacy against tumors. Journal of immunology 2012; 
189:3397-403. 
403. Otrock ZK, Hatoum HA, Musallam KM, Awada AH, Shamseddine AI. Is VEGF a 
predictive biomarker to anti-angiogenic therapy? Critical reviews in 
oncology/hematology 2011; 79:103-11. 
404. Cetin B, Kaplan MA, Berk V, Ozturk SC, Benekli M, Isikdogan A, Ozkan M, Coskun U, 
Buyukberber S. Prognostic factors for overall survival in patients with metastatic 
colorectal carcinoma treated with vascular endothelial growth factor-targeting agents. 
Asian Pacific journal of cancer prevention : APJCP 2012; 13:1059-63. 
405. Rejec A BJ, Pilla T, Henriques J, Benoit J. Diagnostic and prognostic significance of 
complete blood count indices (N/L, P/L, MPV/PLT, PLCRi) in canine cancer patients.  
ESVONC. Krakow - Poland, 2015. 
406. Azvolinsky A. Nivolumab Trumps Ipilimumab as First-Line Melanoma Therapy. 2015. 
407. Gordon I, Paoloni M, Mazcko C, Khanna C. The Comparative Oncology Trials 
Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug 
development pathway. PLoS medicine 2009; 6:e1000161. 
408. den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE. The 
tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, 
but full functional capacity is regained in an antigen-free environment. Journal of 
immunology 2004; 172:6074-9. 
409. Drake CG. Combination immunotherapy approaches. Annals of oncology : official 
journal of the European Society for Medical Oncology / ESMO 2012; 23 Suppl 8:viii41-6. 
References 
244 
410. Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, Hsieh SL. Combination of conformal 
radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in 
refractory hepatoma. Journal of immunotherapy 2005; 28:129-35. 
411. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, 
Lu H, Cuillerot JM, et al. Ipilimumab in combination with paclitaxel and carboplatin as 
first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a 
randomized, double-blind, multicenter phase II study. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology 2012; 30:2046-54. 
412. Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA. Simultaneous blockade of multiple 
immune system inhibitory checkpoints enhances antitumor activity mediated by 
interleukin-15 in a murine metastatic colon carcinoma model. Clinical cancer research : 
an official journal of the American Association for Cancer Research 2010; 16:6019-28. 
413. Postow MW, J. Toxicities associated with checkpoint inhibitor immunotherapy. 
UpToDate 2016. 
414. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, 
Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid 
tumours: revised RECIST guideline (version 1.1). European journal of cancer 2009; 
45:228-47. 
415. Kayashima H, Toshima T, Okano S, Taketomi A, Harada N, Yamashita Y, Tomita Y, 
Shirabe K, Maehara Y. Intratumoral neoadjuvant immunotherapy using IL-12 and 
dendritic cells is an effective strategy to control recurrence of murine hepatocellular 
carcinoma in immunosuppressed mice. Journal of immunology 2010; 185:698-708. 
416. Chiang CL, Coukos G, Kandalaft LE. Whole Tumor Antigen Vaccines: Where Are We? 
Vaccines 2015; 3:344-72. 
417. Lee MJ, Cho SS, Jang HS, Lim YS, You JR, Park J, Suh H, Kim JA, Park JS, Kim DK. 
Optimal salt concentration of vehicle for plasmid DNA enhances gene transfer mediated 
by electroporation. Experimental & molecular medicine 2002; 34:265-72. 
418. Ohse M, Takahashi K, Kadowaki Y, Kusaoke H. Effects of plasmid DNA sizes and several 
other factors on transformation of Bacillus subtilis ISW1214 with plasmid DNA by 
electroporation. Bioscience, biotechnology, and biochemistry 1995; 59:1433-7. 
419. Hu J, Cutrera J, Li S. The impact of non-electrical factors on electrical gene transfer. 
Methods in molecular biology 2014; 1121:47-54. 
420. McLenachan S, Sarsero JP, Ioannou PA. Flow-cytometric analysis of mouse embryonic 
stem cell lipofection using small and large DNA constructs. Genomics 2007; 89:708-20. 
421. Wells JM, Li LH, Sen A, Jahreis GP, Hui SW. Electroporation-enhanced gene delivery in 
mammary tumors. Gene therapy 2000; 7:541-7. 
422. Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. Journal of 
clinical and diagnostic research : JCDR 2015; 9:GE01-6. 
References 
245 
423. Andersen BL, Farrar WB, Golden-Kreutz D, Kutz LA, MacCallum R, Courtney ME, 
Glaser R. Stress and immune responses after surgical treatment for regional breast cancer. 
Journal of the National Cancer Institute 1998; 90:30-6. 
424. Prosen L, Markelc B, Dolinsek T, Music B, Cemazar M, Sersa G. Mcam Silencing With 
RNA Interference Using Magnetofection has Antitumor Effect in Murine Melanoma. 
Molecular therapy Nucleic acids 2014; 3:e205. 
425. Newman CM, Bettinger T. Gene therapy progress and prospects: ultrasound for gene 
transfer. Gene therapy 2007; 14:465-75. 
426. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and 
treatment. Mayo Clinic proceedings 2010; 85:838-54. 
427. Colacchio TA, Yeager MP, Hildebrandt LW. Perioperative immunomodulation in cancer 
surgery. American journal of surgery 1994; 167:174-9. 
428. Capasso LL. Antiquity of cancer. International journal of cancer Journal international du 
cancer 2005; 113:2-13. 
429. Sudhakar A. History of Cancer, Ancient and Modern Treatment Methods. Journal of 
cancer science & therapy 2009; 1:1-4. 
430. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA. 
CD56bright natural killer cells are present in human lymph nodes and are activated by T 
cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 
2003; 101:3052-7. 

  
CURRICULUM VITAE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Curriculum Vitae 
249 
Laetitia Cicchelero werd geboren op 15 mei 1985 in Laken. Ze behaalde haar diploma 
secundair onderwijs (Latijn-Wetenschappen) aan het Sint-Jozefsinstituut in Ternat en 
startte hierna in 2003 met de studies Diergeneeskunde aan de UGent. In 2009 behaalde 
ze het diploma van dierenarts met onderscheiding, evenals het FELASA C-statuut voor 
proefdierwetenschappen.  
In het daaropvolgende 2,5 jaar werkte zij als voltijds dierenarts in een eerstelijnspraktijk 
voor gezelschapsdieren. Geboeid door het wetenschappelijk onderzoek, startte zij in juli 
2012 een doctoraatstudie bij de vakgroep Voeding, Genetica en Ethologie, waar zij 
gedurende 3,5 jaar onderzoek verrichtte aangaande immunotherapie tegen kanker. 
Daarnaast was ze ook actief als lid van de Dierenwelzijnscel. De eerste 3,5 jaren werden 
gefinancieerd door een beurs van het Fundamenteel Wetenschappelijk Onderzoek 
(FWO). De laatste onderzoeksmaand werd betaald via een beurs van de Facultaire 
Commissie Wetenschappelijk Onderzoek (FCWO). 
Laetitia Cicchelero is auteur en mede-auteur van verschillende wetenschappelijke 
publicaties in nationale en internationale tijdschriften. Ze nam deel aan verschillende 
nationale en internationale congressen en behaalde in 2014 een prijs voor beste 
stormsessiepresentatie op Oncopoint. 

  
BIBLIOGRAPHY 
 
 
 
 
 
 
 
 

Bibliography 
253 
Publications in Journals 
x Cicchelero L, Huyghe S, Chiers K, Volckaert V, Melis S, Paepe D, Furcas A, de 
Rooster H. Paraprostatic cyst with urothelial lining in a dog. Vlaams 
Diergeneeskundig Tijdschrift 2012; 81 (6): 364-372. Impact factor: 0.23 / 
Ranking: Q4  
 
x Cicchelero L, de Rooster H, Sanders NN. Various ways to improve whole cancer 
cell vaccines. Expert Review of vaccines 2014; 14 (6): 721-735. Impact factor: 
4.22 / Ranking: Q1 
 
x Denies S, Cicchelero L, Van Audenhove I, Sanders NN. Combination of 
interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer 
vaccination directs all arms of the immune system towards tumor eradication. 
Journal of Controlled Release 2014; 187: 175-182. Impact factor: 7.26 / Ranking: 
Q1 
 
x Cicchelero L, de Rooster H, Sanders NN. Kankercelvaccinaties op basis van 
volledige cellen: mogelijkheden en hindernissen. Oncohemato 2014; 8 (5): 20-25.  
 
x Cicchelero L, Denies S, Devriendt B, de Rooster H, Sanders NN. Can dendritic 
cells improve whole cancer cell vaccines based on immunogenically killed cancer 
cells? OncoImmunology 2015; 4 (12): e1048413-1-9. Impact factor: 6.27 / 
Ranking: Q1 
 
x Remaut K, De Clercq E, Andries O, Rombouts K, Gils M,  Cicchelero L, 
Vandenbussche I, Praet S, Benito JM, Fernandéz JMG, Sanders NN, Vanrompay 
D. Aerosolized Non-viral Nucleic Acid Delivery in the Vaginal Tract of Pigs. 
Pharmaceutical Research 2015. Epub ahead of print. Impact factor: 3.42 / 
Ranking: Q1 
 
Bibliography 
254 
x Denies S, Cicchelero L, Polis I, Sanders NN. Immunogenicity and safety of 
xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in 
mice and dogs. Oncotarget 2016. Epub ahead of print. Impact factor: 6.37 / 
Ranking: Q1 
 
x Denies S, Cicchelero L, de Rooster H, Daminet S, Polis I, Van de Maele I, 
Sanders NN. Evaluation of regulatory T cells and angiogenic markers in canine 
cancer patients compared to a healthy control group and during metronomic 
chemotherapy. Veterinary and Comparative Oncology (Accepted for 
publication). Impact factor: 2.73 / Ranking: Q1 
 
x Cicchelero L, Denies S, Haers H, Vanderperren K,  Stock E, Van Brantegem L, de 
Rooster H*, Sanders NN*. Intratumoral interleukin 12 gene therapy stimulates 
the immune system and decreases angiogenesis in dogs with spontaneous 
cancer. Veterinary and Comparative Oncology 
*Co-last and co-corresponding authors 
Conference Contributions 
x Cicchelero L, de Rooster H, Denies S, Sanders NN. Preparation and 
characterization of a cancer vaccine composed of immunogenically killed tumor 
cells and dendritic cells. Second Oncopoint meeting, Ghent (Belgium) 2014, 33-
33. Oral presentation.  
 
x Denies S, Cicchelero L, Sanders NN. Combination of interleukin-12 gene 
therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all 
arms of the immune system towards tumor eradication. Second Oncopoint 
meeting, Ghent (Belgium) 2014, 50-50. Oral presentation.  
 
Bibliography 
255 
x Denies S, Cicchelero L, Sanders NN. Evaluation of a combinatorial cancer 
immunotherapy approach. Cancer Immunotherapy 12th annual meeting, Mainz 
(Germany) 2014, 75-75. Poster presentation.  
 
x Cicchelero L, Denies S, Devriendt B, de Rooster H, Sanders NN. Whole cancer 
cell vaccines based on immunogenically killed cancer cells and dendritic cells. 
Cancer Immunotherapy 13th annual meeting, Mainz (Germany) 2015, 137-137. 
Poster presentation. 
 
x Denies S, Cicchelero L, Sanders NN. Immunological and angiogenic markers 
during metronomic chemotherapy in spontaneous arising cancers in dogs. 
Cancer Immunotherapy 13th annual meeting, Mainz (Germany) 2015, 275-275. 
Poster presentation. 
 
x Denies S, Cicchelero L, de Rooster H, Daminet S, Polis I, Van de Maele I, 
Sanders NN. Immunological and angiogenic markers during metronomic 
chemotherapy. ESVONC annual congress, Krakow (Poland) 2015, 54-54. Oral 
presentation. 
 
x Cicchelero L, Vanderperren K, Denies S, Stock E, Haers H, Van Brantegem L, 
de Rooster H*, Sanders NN*. Contrast-enhanced ultrasound imaging of the anti-
angiogenic effects of interleukin 12 in pet dogs with spontaneous malignant 
tumors. The 21th European Symposium on Ultrasound Contrast Imaging, 
Rotterdam (The Netherlands) 2016, 35-39. Oral presentation.  
*Co-last and co-corresponding authors 

  
DANKWOORD 
 

Dankwoord 
259 
In de eerste plaats dank aan professor Sanders, mijn promoter, om mij de kans te geven 
me relevante ervaring te laten opdoen in een erg boeiend onderzoeksveld.  
Aan Hilde, mijn co- promotor, bedankt om zo vaak tijd voor me te maken in je drukke 
agenda, je enthousiasme, je onaflaatbare vertrouwen, zorgzaamheid, steun en precisie, 
evenals het plezierig samenwerken.  
Thank you prof. Agostinis, prof. Ducatelle, prof. Favoreel, dr. Van Brantegem, dr. 
Vandermeulen and prof. Vanderperren as members of the exam committee for your 
time and efforts to carefully evaluate this manuscript.  
 
Van de LGT-collega’s wil ik in het bijzonder Sofie bedanken voor de steun bij allerlei 
labotaken, de initiatie in praktische statistiek, de vele interessante gesprekken al dan 
niet over immunotherapie, het even enthousiast als ik verwelkomen van de honden die 
deelnamen aan de studies in onze bureau, ... het maakte dat ik met plezier ons hok 
binnenkwam. 
Aan Marina, Wenwen, Mario, Ruben, Sara, Eline C, Domi, Linda, Jana, Donna, Bregje, 
Hanne, Francis, Sean: bedankt voor de hulp en/of animatie over de middag. De 
ontspannen sfeer die van jullie uitging zorgde voor aangename 
ontspanningsmomenten. En Mario, bedankt voor de lessen en het voorbeeld in 
labonetheid en het organiseren van het badminton op maandagmiddag. Ruben, mister 
pc-held, bedankt voor het regelen van alle mogelijke administratieve problemen.  
 
Een ongelooflijke dankuwel aan Tom, Dante en Elly van het Belgisch Kankerfonds voor 
Dieren voor het inzamelen van het benodigde geld voor de IL-12 studies. Bedankt ook 
aan Sofie om de samenwerking op te zetten.  
Ook de eigenaars van de deelnemende honden en de honden zelf kunnen niet genoeg 
bedankt worden voor hun inzet en medewerking: bedankt Monique en Beaux, Marleen, 
Patric, Natasja en Biondo, Ludo, Lieve en Roxy, Barbara et Bouddha, Marc, Annique en 
Faja, Patrick en Lady, Roger, Annemie en Duvel, Emiel en Snoopy, Kirsten, Thierry en 
Casper, Jos, Janice en Aimy, Jeannice en Roefke, Angelo, Lindsay en Darco, Linda en 
Fille, Jenny en Isis, Anne en Georgia, Marleen, Sara en Toby. 
 
Dankwoord 
260 
Ook de fantastische collega’s in de kliniek mogen uiteraard niet ontbreken: bedankt Liz 
voor de uitleg, de hulp bij de bloedmetingen en de metingen onder de microscoop. 
Voor alle vragen en hulp ivm anesthesie kon ik terecht bij Tim, Ilaria, Annika, Virginie, 
Alix, Inge, Anna, Diego en professor Polis. De collega’s van chirurgie, in het bijzonder 
Marianne en Nausikaa, bedankt voor de hulp en het advies bij patiënten die 
wondverzorging nodig hadden. Uiteraard een grote dank u aan de collega’s van 
medische beeldvorming, met in het bijzonder de immer onvermoeibare, behulpzame en 
enthousiaste Emmelie, Elke en Katrien. Ook dank u aan Hendrik voor de eerste 
analyses van de contrastechobeelden. Bedankt aan de collega’s van inwendige 
geneeskunde Sofie, Annelies, Isabel, Pieter, Dominique en professor Daminet dat ik 
steeds even mocht binnenwippen met vragen. Ook een zeer grote dank u aan Peggy en 
de interns Sarah, Anouk, Melania, Arianne, Britt, Britt, Saskia, Michelle voor alle hulp 
bij het bloed nemen en katheters steken. Op de dienst pathologie wil ik graag Leen, 
Koen, Leslie, Joachim en Delphine bedanken voor hun snelle hulp bij de 
weefselverwerking.  
 
Bedankt aan Isabel Vanaudenhove voor het luminescent maken van de EO771-cellen, 
Evelien en Isabel voor het delen van scheidingskits en aan Jo Vanginderachter en Elio 
Schouppe voor het delen van de cellijn. Bedankt aan Bert Devriendt voor het geven van 
advies en de voortreffelijke leendienst van magneten. Eline A, bedankt voor je 
arendsogen die zo precies teksten kunnen nalezen en Nathalie voor de praktische 
template. 
Mark, bedankt voor de algemene overlevingstips op de trein en het doorgeven van je 
template om posters te maken. Lotte, bedankt om me te herinneren aan de dingen die 
er echt toe doen.  
 
Merci à mes parents, pour me donner l’opportunité d’étudier. Sans eux, je n’aurais pas 
pu devenir vétérinaire et entamer ce doctorat. Bedankt aan Florence en Maarten voor 
de oprechte interesse in mijn werk en aan Elise en Casper om geduldig mee de honden 
uit de studie in het weekend te bezoeken.  
Dankwoord 
261 
Een dikke dank u uiteraard ook aan Jeroen, de tofste smizmar van het heelal en 
omstreken. Voor je uitstekende vaardigheden als geduldige praatpaal, steun en je 
meesterschap in zowel het lay-outen als het gelukkig maken van een zekere Laetitia.  
 
En tot slot, Felix en Onktvos, bedankt voor de inspiratie om de studies aan te vatten en 
de motivatie om bij te dragen aan de verdere ontwikkeling van veterinaire oncologie. 
